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Abstract 
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common 
arthropathies in people, causing limited mobility, pain and subsequent reduction in 
quality of life, resulting in a substantial impact on human society. Conditions 
affecting articular joints are also common in horses, including OA, osteochondrosis 
(OC) and synovial sepsis. Despite their high prevalence and clinical relevance, 
diagnosis, staging, monitoring and determining an accurate prognosis remain a 
challenge. Thus, there is a need to identify reliable biomarkers of disease. The 
development of ‘omics’ technologies, such as metabolomics and proteomics, has 
provided global analysis of biological tissues and fluids, enabling discovery of 
disease biomarkers and providing a greater understanding of their underlying 
pathogeneses. Within this thesis, protocols for collection and processing of synovial 
fluid (SF) for nuclear magnetic resonance (NMR) metabolomic and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) proteomic analysis have 
been optimised. Lys-C endopeptidase pre-digestion greatly improved on-bead 
tryptic SF protein digestion when used in conjunction with randomised hexapeptide 
ProteoMinerTM beads for low abundant protein enrichment. Equine OA was 
stratified using metabolomic and proteomic SF profiles, identifying a panel of 
markers which may be applicable to grading OA severity. This is the first study to 
undertake computational integration of NMR metabolomic and LC-MS/MS 
proteomic datasets of any biological system. This thesis is also the first study to use 
a multi ‘omics’ approach to simultaneously investigate the metabolomic profile of 
ex-vivo cartilage and metabolomic/proteomic profiles of culture media using the 
TNF-α/IL-1β ex-vivo cartilage OA model. A panel of metabolites, proteins and 
neopeptides were identified which were differentially abundant within an early 
phase of this OA model and may provide further information on the underlying 
disease pathogenesis. Comparing human OA and RA SF identified that the metabolic 
pathways that differed most were glycolysis, amino acid biosynthesis and taurine 
and hypotaurine metabolism. This thesis has also identified a panel of metabolites 
and proteins within equine SF which can distinguish synovial sepsis from nonseptic 
joint pathologies, with glucose the principal metabolite discriminator. 
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1. Introduction 
1.1. Arthropathies 
Arthropathies encompass all joint diseases, with these conditions commonly leading 
to limited mobility, pain and subsequent reduction in quality of life (Aşkın et al., 
2017; Ji et al., 2017). Arthritis is a generic term for inflammatory joint disease, 
comprising the majority of arthropathies, with osteoarthritis (OA) and rheumatoid 
arthritis (RA) having the largest impact on human society (Fusco et al., 2017). One-
third of people in the UK aged over 45 (approximately 8.75 million) require 
treatment for OA with an estimated prevalence for RA of 0.5-1% of the adult 
population within developed countries (Davis and Matteson, 2012; Reynard and 
Loughlin, 2012; Scott et al., 2010). Conditions affecting the articular joints are also 
common in horses, resulting in loss of function, pain and/or subsequent inability to 
work, all of which represent economic and welfare concerns (Anderson, Phelan, et 
al., 2018). These pathologies include OA, accounting for 60% of lameness seen in 
horses, osteochondrosis (OC) and synovial sepsis, which can be life-threatening 
(Caron and Genovese, 2003; Summerhays, 2000). Despite their high prevalence and 
clinical relevance, diagnosis, staging, monitoring and determination of an accurate 
prognosis remain a challenge and thus there is a need to identify reliable 
biomarkers of disease (Anderson, Phelan, et al., 2018). The development of ‘omics’ 
technologies, such as metabolomics and proteomics, has provided global analysis of 
biological tissues and fluids, enabling discovery of potential disease biomarkers as 
well as providing a greater understanding of their underlying pathogenesis (Carlyle 
et al., 2018; Wang, Zhang, et al., 2012). 
1.1.1. Synovial Fluid 
The synovial membrane, which lines the inner layer of the joint capsule, consists of 
a one-cell thick layer of synoviocytes, within a hyaluronic acid and collagen matrix, 
and is responsible for the production of synovial fluid (SF) (Gibson and Rooney, 
2007; Mahendran et al., 2017). Although primarily acting as a lubricant within the 
joint, containing molecules with low-friction and low-wear properties to hyaline 
articular cartilage surfaces, SF also provides a pool of nutrients for surrounding 
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tissues and a medium of cellular communication with the semi-permeable synovial 
membrane allowing passive protein transfer and synoviocytes secreting regulatory 
cytokines and growth factors (Blewis et al., 2007; Gibson and Rooney, 2007; 
Mahendran et al., 2017; Tamer, 2013). Given this passive movement of proteins, 
below a certain size, across the synovial membrane, SF can be considered a 
dialysate of plasma (Sundblad, 1950). Due to the close relationship, both in terms of 
location and biological communication, that SF holds with surrounding tissues 
which are primarily altered during orthopaedic pathologies, SF provides a unique 
source of chemical information and holds great promise for biomarker discovery 
(Anderson, Phelan, et al., 2018; Mateos et al., 2012). SF can also be sampled from 
conscious horses with relative ease, meaning that SF analysis has the potential to 
translate to a clinical setting as a diagnostic aid. 
1.1.2. Osteoarthritis (OA) 
OA is an age-related degenerative musculoskeletal disease characterised by a loss 
of articular cartilage, abnormal bone proliferation, synovial membrane dysfunction, 
subchondral bone sclerosis and altered biochemical and biomechanical properties 
(Figure 1) (Kramer, Tsang, et al., 2014; Truong et al., 2006). Despite a high 
prevalence within humans and numerous mammal species, OA aetiology and 
pathophysiology remains poorly understood with an inability to achieve early 
diagnosis. A clinical human study of OA has identified distinct patterns of protein 
expression suggesting separate subgroups of disease which are independent of the 
duration of OA, highlighting the complexity of this condition (Gobezie et al., 2007). 
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Figure 1. Characteristic gross pathologic joint changes associated with osteoarthritis 
(OA). Adapted from Wluka et al., 2013.  
 
For horses in the UK, OA is one of the leading welfare issues, resulting in substantial 
morbidity and mortality (Ireland et al., 2011, 2012). Although recent advances in 
diagnostic imaging have improved identification of the condition, the slow onset of 
OA often leads to substantial pathology of the joint and articular cartilage prior to 
diagnosis (Brommer et al., 2003). There is therefore a need to develop diagnostic 
tests which are sensitive and specific to the early stages of OA, with the ability to 
achieve a diagnosis, which are repeatable and reproducible, as well as enabling a 
greater understanding of the underlying pathogenesis (Hunter et al., 2014; 
McIlwraith et al., 2018). Although non-steroidal anti-inflammatory drugs and 
corticosteroids are often utilised to reduce inflammation and pain associated with 
OA, these pharmaceutical agents are limited as to the extent they can slow OA 
progression (Caron and Genovese, 2003; Kramer, Tsang, et al., 2014). Thus, current 
management of OA is entirely symptomatic, with no treatments able to prevent or 
reverse the condition; in order to manage this debilitating condition more 
effectively it is hoped that ongoing interrogation of OA tissues at a molecular level 
will identify pathways and molecules which are altered during OA pathogenesis and 
thus develop novel therapeutic targets. 
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1.1.2.1. Osteoarthritis Pathogenesis 
OA pathology has previously been considered as resultant from repetitive joint 
overloading, leading to an excessive biomechanical joint stress (Silawal et al., 2018). 
Additionally, several risk factors have been identified including joint malalignment, 
ageing, genetic predisposition and obesity, although the underlying pathogenesis of 
OA remains largely unknown (Xia et al., 2014). Whilst obesity leads to increased 
joint loading, OA has also been identified within non-weight bearing joints in obese 
individuals, suggesting complex metabolic interactions are involved within the 
underlying disease pathogenesis (Griffin and Guilak, 2008; Oliveria et al., 1999; 
Pottie et al., 2006). 
1.1.2.1.1. Articular Cartilage 
Articular cartilage is a porous, highly hydrated connective tissue which lacks 
vascular, nervous and lymphatic structures (Bonassar et al., 1995). The extracellular 
matrix (ECM) consists of 15-20% (wet weight) collagen type II, 4-7% proteoglycans 
and < 5% collagen types V, VI, IX, X, XI, XII and XIV, perlecan, lumican, biglycan, 
epiphycan, fibromodulin and decorin (Xia et al., 2014). The ECM provides the 
unique mechanical properties of articular cartilage, generating elasticity and high 
tensile strength, enabling normal function (Buckwalter et al., 2005). Chondrocytes 
are the only cell type present within articular cartilage and are responsible for both 
the generation and maintenance of cartilaginous ECM (Heijink et al., 2012). 
Although repeated mechanical loading is essential for chondrocyte regulation of 
metabolic activity, excessive loading results in cartilage inflammation and 
degradation facilitated via the release of inflammatory and ECM-degrading factors 
including tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and matrix 
metalloproteinases (MMPs) (Silawal et al., 2018). In particular, MMP-13 
preferentially cleaves collagen type II, although it also degrades other ECM proteins 
including collagen types IV and IX, aggrecan and perlecan (Xia et al., 2014). As well 
as joint instability and overloading, the above mentioned OA risk factors disrupt 
whole joint homeostasis leading to the release of various catabolic and 
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inflammatory factors, in which cytokines TNF-α and IL-1β hold a central role, 
inducing a low grade inflammation and MMP activation (Silawal et al., 2018). 
1.1.2.2. Human Osteoarthritis Biomarkers 
Biomarkers associated with the musculoskeletal system are usually normal products 
or by-products of metabolic processes which can be used to assess abnormal 
turnover of skeletal tissue (Billinghurst, 2002; McIlwraith, 2005). Various markers of 
OA have been described in humans, identified in urine, serum and SF, including 
collagen type II, cartilage oligomeric matrix protein (COMP), tissue inhibitors of 
metalloproteinases (TIMPs) and MMPs (Rousseau and Delmas, 2007). However, to 
date few have been approved by regulatory authorities for OA diagnosis, prognosis 
or monitoring (Bay-Jensen et al., 2016). 
1.1.2.3. Equine Synovial Fluid Osteoarthritis Biomarkers 
Various studies have investigated potential OA biomarkers in SF, utilising both 
clinical samples and experimental OA models and identifying numerous potential 
equine OA markers (Table 1). These markers of interest include several proteins. 
Similarly to human OA studies, MMP activity/abundance within SF has shown 
diagnostic potential for equine OA (Ariza-Suárez et al., 2017; Brama et al., 1998, 
2004; Clegg et al., 1997; Fietz et al., 2008; Jouglin et al., 2000; Ma et al., 2017; 
Misumi et al., 2001; Zrimsek et al., 2007). However, studies investigating COMP 
levels have revealed conflicting results with SF COMP abundance unable to stage 
equine OA (Arai et al., 2005; Bertuglia et al., 2016; Clegg et al., 1997; Misumi et al., 
2001; Skiöldebrand et al., 2001; Taylor et al., 2006; Yamanokuchi et al., 2009; 
Zrimsek et al., 2007). Elevated levels of the neuropeptide substance P have been 
identified within OA SF and have been associated with joint pain (de Grauw, van de 
Lest, et al., 2006; de Grauw et al., 2009; Kirker-Head et al., 2000). Additionally, non-
protein molecules have been reported as potential OA biomarkers. Elevated SF 
levels of keratan sulphate, chondroitin sulphate and prostaglandin E2 have been 
associated with OA pathology (Alwan et al., 1990; Baccarin et al., 2014; Bertone et 
al., 2001; Frisbie et al., 2003, 2008; Gibson et al., 1996; de Grauw et al., 2009; 
Kirker-Head et al., 2000). However Brown et al. identified that SF chondroitin 
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sulphate levels were not indicative to that of cartilage (Brown et al., 1998). Results 
regarding glycosaminoglycan levels (GAG) have been contradictory, with both 
elevated and decreased levels identified within equine OA SF depending on the 
study (Alwan et al., 1991; van den Boom et al., 2005; Frisbie et al., 2003; Palmer et 
al., 1995).  
These markers are generated following significant joint pathology, including 
substantial articular cartilage degradation, and thus there is a need to identify 
markers at an earlier disease stage, when intervention would provide the most 
benefit. Presently, no biomarkers which are specific to equine OA have been 
identified and none used to aid earlier clinical diagnosis (Anderson, Phelan, et al., 
2018). There is therefore a need to identify markers and develop diagnostic tests 
which are sensitive and specific to the early stages of OA, which are repeatable and 
reproducible, as well as gaining a greater understanding of the underlying 
pathogenesis (Hunter et al., 2014; McIlwraith et al., 2018). 
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Table 1. Potential equine osteoarthritis biomarkers identified within studies investigating synovial fluid. 
Authors 
Clinical or 
Experimental 
OA 
Tissue Type Main Techniques Increased in OA Decreased in OA 
Alwan et al., 1990 Clinical SF and Serum ELISA SF: KS, Serum: KS   
Alwan et al., 1991 Clinical SF, Serum and Urine DMMB SF, Serum and Urine: GAG   
Arai et al., 2005 Clinical SF ELISA, Western Blotting COMP, COMP fragmentation   
Arai et al., 2008  Clinical SF, Serum and Urine Western Blotting, ELISA Urine: COMP/creatinine ratio   
Ariza-Suárez et al., 2017 Clinical SF ELISA MMP-3   
Baccarin et al., 2014 Clinical SF Gel Electrophoresis Chondroitin Sulphate (articular cartilage damage)   
Bertone et al., 2001 Clinical SF ELISA IL-6 and PGE2   
Bertuglia et al., 2016 Clinical SF and Serum ELISA 
SF: IL-1β, IL-6, TNF-α, CTX-II, COMP, TNF-α, 
Serum: CTX-II, COMP, TNF-α   
Brama et al., 1998 Clinical SF Fluorometric MMP activity assay MMP activity   
Brama et al., 2004 Clinical SF Fluorometric MMP activity assay MMP-1 activity   
Brown et al., 1998 Clinical  SF and Cartilage Capillary zone electrophoresis 
SF: CS not indicative of cartilage CS, Cartilage: 
Percentage of delta Di0S 
Cartilage: 6-sulfation of CS 
terminal residues 
Chiaradia et al., 2012 Clinical SF 
2D-gel electrophoresis, MALDI-TOF-MS, nano LC-
ESI-LIT-MS/MS 
Complement component C4A, Carboxylesterase 
D1, α-2-Macroglobulin, Ceruloplasmin, Inter-α-
trypsin inhibitor heavy chain H1-like, 
Serotransferrin, Vitamin D binding protein, 
Antithrombin III, Serum albumin, Haptoglobin, 
Apoliprotein A-I 
Plasminogen, Serum 
albumin, Afamin, α-1B-
glycoprotein, Ig γ 5 heavy 
chain constant region, 
Haptoglobin, 
Transthyretin 
Cleary et al., 2010  Experimental SF and Serum ELISA SF: CTX-II Serum: CTX-II 
Clegg et al., 1997 Clinical SF Gelatin zymography MMP-2, MMP-9 activity   
Dagleish et al., 2003  Clinical SF ELISA, Western Blotting ENE2A (Inflammation)   
de Grauw, van de Lest, et al., 2006  Clinical  SF Immunoassay Substance P (clinical joint pain)   
de Grauw et al., 2009  
Experimental 
(Inflammation) 
SF 
ELISA, fluorimetric assay, 1,9-
dimethylmethyleneblue assay 
PGE2, substance P, bradykinin and MMP activity, 
GAG, CS846 epitope, C2C, CPII, collagen II 
markers 
  
Fietz et al., 2008 Clinical SF 
Gelatin zymography and immunocapture activity 
assays 
MMP-2, MMP-9 activity   
Frisbie et al., 1999  Clinical  SF and Serum UNKNOWN 
SF: epitope 846 and total protein concentrations, 
linearly related to osteochondral fragmentation 
grade, Serum: epitope 846 and CPII 
concentrations  
  
Frisbie et al., 2002  Experimental SF and Serum UNKNOWN 
Serum: CS846, CPII, sGAG and CTXI. Serum 
osteocalcin and CS846 best predictors of pain 
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Frisbie et al., 2003 Experimental SF UNKNOWN 
CS-846, PGE2, sGAG, CPII, COL2–3/4Cshort, 
osteocalcin 
  
Frisbie et al., 2008 Experimental SF and Serum ELISA 
SF: CS846, CPII, Col CEQ, C1,2C, osteocalcin, Col I 
and PGE2, Serum: CS846, CPII, GAG and C1,2C 
  
Fuller et al., 2001   Clinical  SF ELISA, dimethylmethylene blue assay Bone specific alkaline phosphatase 
Hyaluronan, 5D4 epitope 
of keratan sulphate, 
KS:GAG ratio 
Gibson et al., 1996 Clinical SF ELISA, radioimunoassay PGE2   
Jouglin et al., 2000 Clinical SF Gelatin zymography MMP-9 monomer and dimer   
Kamm et al., 2013  Experimental 
SF, cartilage, 
synovial membrane, 
WBCs, Serum 
Microarray, PCR, ELISA WBCs: hUNC-93A mRNA 
WBCs: ADAMDEC1 mRNA, 
RRM2 mRNA 
Kawcak et al., 2008  Experimental SF ELISA Type I and Type II collagen   
Kirker-Head et al., 2000 Clinical SF Radioimmunoassay Substance P and prostaglandin E2   
Ley et al., 2007  Clinical SF 
Bioassay using proliferation of IL-6-dependent 
murine B9 hybridoma cells 
IL-6 (Osteochondral fragmentation)   
Ma et al., 2017  Experimental SF ELISA 
Before OA Symptoms: IL-1, IL-6, MMP-9, MMP-
13, ADAMTS-5, CS846, GAG, HA, CTX-II and 
COMP, After OA Symptoms: TNF-α, MMP-2 and 
MMP-3 
  
Misumi et al., 2001 Clinical SF ELISA, Western Blotting COMP fragments, MMP gelatinolytic activity COMP 
Misumi et al., 2002  Clinical SF and Serum ELISA   Serum: COMP, KS 
Nicholson et al., 2010  Clinical  SF and Serum ELISA SF: CPII, CTX-II, C1,2C, C2C, Serum: C1,2C SF: Serum: CTX-II, C2C 
Palmer et al., 1995 Clinical SF and Serum DMMB, colorimetric assay SF: GAG, CS, KS   
Peffers et al., 2015 Clinical SF LC-MS/MS 
S100-A10, CD109 antigen, Phospholipid transfer 
protein isoform 1, Complement component C8 
gamma chain 
Collagen alpha-1(I) chain, 
Calsyntenin-1, Integral 
membrane protein 2B, 
Mannan-binding lectin 
serine protease 2, Keratin, 
type II cytoskeletal 7, 
Cyclin D binding myb-like 
transcription factor 1 
isoform 1 
Reesink et al., 2017  
Experimental 
& Clinical 
SF, synovial 
membrane and 
cartilage 
ELISA, PCR SF: Lubricin, Synovial membrane: Proteoglycan 4 Cartilage: Proteoglycan 4 
Ribera et al., 2013  Clinical SF 
Quantitative immunoturbidimetric latex 
agglutination assay 
D-dimer (not statistically different)   
Skiöldebrand et al., 2001 Clinical SF and Serum ELISA 
Serum: COMP (Swedish Warmblood riding 
horses) 
SF: COMP, Aggrecan, 
Serum: COMP 
(Standardbred trotters) 
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Skiöldebrand et al., 2005  Clinical SF ELISA Fragmented COMP   
Skiöldebrand et al., 2017 Clinical SF LC-MS/MS, Neopeptide ELISA COMP neopeptide (SGPTHEGVC)   
Svala et al., 2017 Clinical SF 
Cartilage explants, ELISA, Western blotting, LC-
MS/MS 
Monosialylated Core 1 O-glycans 
Disialylated Core 1 O-
glycan 
Taylor et al., 2006 Clinical SF ELISA   COMP 
Trumble et al., 2008  Clinical  SF and Serum ELISA 
SF: BAP (Concentrations of BAP in the serum  
(< 30 U/L), SF (> 22 U/L) and a 0.5 ratio of SF to 
serum were predictive of OC injury) 
Serum: BAP 
Trumble et al., 2009  Clinical  SF ELISA 
Type II collagen degradation product (collagenase 
cleavage neoepitope commercially known as 
C2C) 
  
van den Boom et al., 2004 
Adult Horses - 
Clinical 
(Abattoir 
samples) 
SF HPLC, Hydroxyproline assay 
Hydroxyproline positively correlated with 
cartilage degeneration index and general MMP 
activity 
  
van den Boom et al., 2005  Clinical SF 
(HPLC) analysis following derivatisation with a 
fluorescent label of secondary amino acids, 1,9-
dimethylmethylene blue assay (DMMB), 
modified fluorometric assay 
Positive correlation between MMP activity and 
hydroxyproline 
GAG 
Yamanokuchi et al., 2009 Clinical SF and Serum ELISA SF: COMP, Serum: COMP   
Zrimsek et al., 2007 Clinical SF Gelatin zymography MMP-2 and MMP-9 activity   
 
Abbreviations: ADAMDEC1 = a metalloproteinase domain-like protein decysin-1, ADAMTS-5 = a disintegrin and metalloproteinase with thrombospondin motifs-5, BAP = bone 
alkaline phosphatase, C1, 2C = collagen type I and II cleavage, C2C = collagen type II cleavage, Col CEQ = collagen CEQ epitope, Col I = collagen type 1, COMP = cartilage 
oligomeric matrix protein, CPII = C-propeptide of type II collagen, CS = chondroitin sulphate, CS846 = chondroitin sulphate epitope 846, CTXI = C-terminal telopeptide of type 
1 collagen, CTX-II = C-telopeptide fragments of type II collagen, delta Di0S = delta-disaccharide 0S, DMMB = dimethylmethylene blue, ELISA = enzyme-linked immunosorbent 
assay, ENE2A = equine neutrophil elastase 2A, ESI-LIT = electrospray ionisation-linear ion trap, GAG = glycosaminoglycan, HA = hyaluronic acid, HPLC = high performance 
liquid chromatography, hUNC-93A = Unc-93 homolog A, IL = interleukin, KS = keratan sulphate, LC-MS/MS = liquid chromatography-tandem mass spectrometry, MALDI-TOF-
MS = matrix-assisted laser desorption/ionization-time of flight-mass spectrometry, MMP = matrix metalloproteinase protein, mRNA = messenger ribonucleic acid, OA = 
osteoarthritis, PCR = polymerase chain reaction, PGE2 = prostaglandin E2, RRM2 = ribonucleotide reductase M2 polypeptide, SF = synovial fluid, sGAG = sulphated 
glycosaminoglycans, TNF-α = tumour necrosis factor-α. 
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1.1.2.4. TNF-α/IL-1ß Osteoarthritis Model 
TNF-α and IL-1β are both pro-inflammatory cytokines which are central to OA 
pathogenesis (Wojdasiewicz et al., 2014). TNF-α and IL-1β, secreted by 
mononuclear cells, synoviocytes and articular cartilage, upregulate gene expression 
of MMPs, ADAMTS-4 and ADAMTS-5, leading to significant ECM degradation 
(Fernandes et al., 2002; Goldring and Goldring, 2004; Wang et al., 2011). Elevations 
in TNF-α and IL-1β are regularly identified within OA SF, including that of horses 
(Bertuglia et al., 2016; Ma et al., 2017; Westacott et al., 1990). TNF-α and IL-1β have 
therefore become established experimental treatments for modelling OA pathology 
within in vitro and ex-vivo studies (Williams, 2014). These two cytokines have been 
utilised in combination, and separately, to model OA using both chondrocyte 
cultures as well as cartilage explants (De Ceuninck et al., 2004; Pretzel et al., 2009; 
Stevens et al., 2008, 2009; Williams, 2014). 
1.1.2.5. Osteoarthritis Stratification 
The heterogeneous nature of OA suggests varying underlying aetiologies, with 
studies identifying different molecular subgroups which are independent of OA 
duration/severity (Gobezie et al., 2007; Soul et al., 2018). When grouping OA, 
current literature has applied the term ‘stratification’ to refer both to these 
subgroups, which are distinct from OA severity, as well as to groups which are able 
to stage OA according to severity (Berger et al., 2012; Schiphof et al., 2013; Soul et 
al., 2018; Turmezei et al., 2014). Within this thesis, the term ‘stratification’ has been 
used in reference to the identification of molecular profiles/markers which are able 
to grade OA severity. 
1.1.3. Osteochondrosis (OC) 
OC commonly affects growth cartilage of both humans and domesticated animals; 
including rats, cats, dogs, pigs, cows and horses (Ytrehus et al., 2007). Currently, the 
underlying aetiology and pathogenesis of OC is not fully understood (McCoy et al., 
2013). OC involves a focal disturbance of endochondral ossification within the 
epiphyseal-articular cartilage complex during bone growth (de Grauw et al., 2011; 
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Rejnö and Strömberg, 1978). An interrupted blood supply to epiphyseal cartilage 
channels leads to focal regions of chondronecrosis, resulting in clefts which extend 
through the articular cartilage and into subchondral bone (McCoy et al., 2013). In 
horses, OC is the most common developmental joint disorder, presenting clinically 
with lameness, joint distension, postural abnormalities, reduced activity levels, 
stiffness and a reluctance to get up (de Grauw et al., 2011; Wright and Minshall, 
2005). In equine OC, elevated levels of a C-propeptide of cartilage type II 
procollagen, osteocalcin, prostaglandin E2 and leukotriene B4 have shown potential 
as a diagnostic aid (Billinghurst et al., 2004; Donabedian et al., 2008; de Grauw, 
Brama, et al., 2006; Laverty et al., 2000). However, these markers have not 
translated to clinical practice. 
1.1.4. Synovial Sepsis 
In horses, synovial sepsis is most commonly caused by injuries penetrating synovial 
structures leading to bacterial contamination and subsequent infection (Haltmayer 
et al., 2017; Robinson et al., 2017). Although life threatening, early diagnosis and 
timely treatment intervention results in improved survival (Robinson et al., 2017). 
However, to date, no validated markers which are both sensitive and specific to 
synovial sepsis have been identified within veterinary medicine, making early 
diagnosis a challenge.  
1.1.4.1. Synovial Sepsis Diagnosis 
Together with clinical examination, synovial sepsis diagnosis is based on SF culture 
and intracellular bacteria identification (both low sensitivity) as well as total protein, 
total nucleated cell count and percentage of neutrophils whose results are open to 
interpretation and are affected by standard treatment protocols (Robinson et al., 
2017; Sanchez-Teran, Bracamonte, Hendrick, Burguess, et al., 2016; Sanchez-Teran, 
Bracamonte, Hendrick, Riddell, et al., 2016; Sanchez Teran et al., 2012). Reduced 
levels of glucose in human and equine SF, due to an increase in synovial and 
neutrophil cell glycolytic activity in severe inflammation or infection, have 
previously been identified, with a serum-synovial glucose difference of ˃ 2.2 
mmol/L considered supportive of a diagnosis of synovial sepsis (Krey and Bailen, 
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1979; Roberts et al., 1967). However, this parameter is non-specific and can be 
influenced by multiple variables, including synovial necrosis, diet, pain and white 
blood cell count. Elevations in lactate during the acute infection phase have 
previously been identified in SF of septic human, canine and equine joints, due to an 
increase in the consumption of glucose and subsequent production of lactate within 
an anaerobic environment (Gobelet and Gerster, 1984; Proot et al., 2015; Tulamo et 
al., 1989). However, other studies have not been able to differentiate septic and 
non-septic arthropathies based on lactate levels alone (Arthur et al., 1983; 
Washington, 1980). Synovial D-lactate (produced via bacterial fermentation and a 
stereoisomer of mammalian L-lactate) was recently found not to aid diagnosis of 
equine synovial sepsis (Robinson et al., 2017). 
1.1.5. Rheumatoid Arthritis (RA) 
Although not a condition diagnosed or considered to occur in horses, after OA, RA is 
the second most common form of arthritis in people and the most common 
autoimmune arthritis (American College of Rheumatology; Arthritis Research UK, 
2018). Despite both these chronic conditions being typically age-related with 
insidious onset, their underlying aetiologies are markedly different (Brouwers et al., 
2015; Majithia and Geraci, 2007). RA is a systemic, inflammatory autoimmune 
disease that primarily affects the synovium of joints, presenting as a symmetric 
polyarthritis (Bartok and Firestein, 2010; Davis and Matteson, 2012; Scott et al., 
2010). RA joints are marked by inflammation of the synovium and destruction of 
articular cartilage and underlying bone. The RA synovium becomes hyperplastic 
with infiltration by a variety of immunocompetent cells (activated neutrophils in 
particular) (Wright et al., 2014). RA SF is enriched with cytokines, inflammatory 
mediators such as leukotrienes, and proteases that degrade the ECM and hyaluronic 
acid (Wright et al., 2012, 2014). 
1.2. Metabolomics 
Metabolomics encompasses the comprehensive profiling of metabolic changes, 
including the study of metabolic pathways and quantification of unique biochemical 
molecules, within living systems (Wang, Zhang, et al., 2012). Small molecule 
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metabolites include metabolic intermediates, secondary metabolites, hormones 
and other signalling molecules (Jukarainen, 2009). Metabolomics studies are mainly 
carried out via two separate platforms, mass spectrometry (MS) or nuclear 
magnetic resonance (NMR) spectroscopy (Beltran et al., 2012). The major 
advantage of NMR spectroscopy is the analysis of native samples with a minimal 
level of sample preparation using a non-invasive and non-destructive method, 
subsequently producing results which are more reproducible and robust in 
comparison to those produced through alternative techniques (Keun and 
Athersuch, 2011). Additionally, unambiguous identification of metabolites 
compensates for its relatively low sensitivity (Nagana Gowda and Raftery, 2017). 
However, due to the separate physiochemical properties demonstrated by these 
different techniques, they can both be applied to the same sample to expand the 
coverage of identified metabolites and thus provide a wider metabolome 
interrogation (Beltran et al., 2012; Mickiewicz, Kelly, et al., 2015). 
1.2.1. NMR Spectroscopy 
NMR spectroscopy utilises magnetic moments of atomic nuclei to inform on 
molecular structure and dynamics (Blaum, 2010). Angular momentum nuclear spin 
is dependent upon the interactions between protons and neutrons within the 
nucleus (Figure 2) (Becker, 2000). With an odd total number of protons and 
neutrons, 1H nuclei exhibit a spin of ½. These nuclei can adopt two different 
orientations of equal energy. However, following the application of an external 
magnetic field (B0), these energy levels split into higher and lower energy planes (-½ 
and ½), denoted by a magnetic quantum number (m), whereby ½ is the most stable 
(Nuclear Magnetic Resonance Spectroscopy, Sheffield Hallam University). This 
change in energy state (ΔE) can be calculated using the following equation 
(Escalona, 2015): 
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ΔE = γhB0/2π 
ΔE = Change in energy state 
γ = Gyromagnetic ratio 
h = Planck’s constant 
B0 = External magnetic field 
 
Due to a difference between the nuclei populations within each energy state, a 
small net nuclear magnetisation is generated in the z plane (Mz) in which B0 is 
situated. The application of a short, intense pulse of radiofrequency radiation 
subsequently induces the movement of the nuclear magnetisation away from the z 
plane, rotating in the xy plane (Mxy), and termed precession. A wire coil detects this 
varying field, generating a current within the coil, oscillating at the frequency of Mxy. 
Following pulse removal and relaxation, this oscillation will decay to zero, termed 
the free induction decay (FID). Finally, a Fourier Transform is applied to the FID 
signal to produce an NMR spectrum, with signal intensities proportional to the 
number of nuclei (Escalona, 2015; Rattle, 1995). 
 
 
 
 
 
 
 
Figure 2. Theory of nuclear magnetic resonance (NMR) spectroscopy. (A) 
Alignment of 1H nuclear spins following the application of an external magnetic field 
(B0). (B) Transition between energy states following external magnetic field 
application. m = magnetic quantum number. Adapted from Hunt, University of 
Calgary. 
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1.2.1.1. Chemical Shift 
The magnetic field applied to the nucleus is partially shielded by the surrounding 
electron cloud which subsequently results in small differences in the magnetic field 
experienced by the nucleus compared to the applied B0 (Brink et al., 1988). On a 
final NMR spectrum, separate peaks are generated for each 1H chemical 
environment within a sample (Rattle, 1995). The chemical shift is usually expressed 
by the dimensionless parameter parts per million (ppm) from a reference standard, 
meaning that spectra can be compared irrespective of the field strength in which 
the spectra was acquired (Escalona, 2015). 
1.2.1.2. Spin-Spin Coupling Multiplicity 
NMR active nuclei, which are in close proximity, interact with each other via their 
associated orbiting electrons (Escalona, 2015; Rattle, 1995). Within a molecule 
consisting of two atoms, the orientation of the nuclear spin of the first nucleus will 
cause an alteration to the local magnetic environment experienced by the second 
via these electrons (Rattle, 1995). These spin-spin couplings, also known as J-
couplings, result in a splitting of the NMR signal into various groups, generating 
multiplicity. The number of peaks within these multiplets are dependent on the 
number of interacting adjacent nuclei, with relative peak intensities following a 
Pascal’s triangle distribution (Escalona, 2015). 
1.2.2. Metabolomic Studies of Synovial Fluid Investigating Osteoarthritis 
Various studies have used a metabolomics approach to investigate OA through SF 
analysis, using both MS and NMR platforms (Table 2). Although these studies have 
generally concentrated on clinical human SF (Hugle et al., 2012; Kang et al., 2015; 
Kim et al., 2017; Mickiewicz, Kelly, et al., 2015; Zheng et al., 2017), clinical equine SF 
(Lacitignola et al., 2008), experimental canine SF (Damyanovich et al., 1999) and 
experimental ovine SF (Mickiewicz, Heard, et al., 2015) have also been studied. 
Elevated levels of alanine have been identified within OA SF of both dogs and 
horses (Damyanovich et al., 1999; Lacitignola et al., 2008). As alanine is one of the 
main amino acid residues which constitutes collagen, it is likely that increased 
alanine abundance identified within OA SF is resultant of degradation of the 
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cartilage collagen framework, subsequently releasing alanine into the surrounding 
SF (Huster et al., 2004; Shet et al., 2012). Identified glucose abundances within OA 
SF have been contradictory, with two studies describing an elevation in OA 
(Lacitignola et al., 2008; Mickiewicz, Heard, et al., 2015) whilst another found 
decreased levels (Damyanovich et al., 1999). Kim et al. have previously undertaken 
an MS-led metabolomics approach to stratify OA in human SF, identifying 90 
metabolites differentially abundant between early- and late-OA (Kim et al., 2017). 
However, to date no studies have undertaken stratification of OA SF using NMR or 
equine OA SF samples.
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Table 2. Metabolomic studies undertaken on synovial fluid which include investigation of osteoarthritis. 
Authors 
Clinical or 
Experimental 
OA 
Species Study Groups Technique 
Total Number 
of Metabolites 
Identified 
Differentially Abundant Metabolites 
Damyanovich et al., 1999 Experimental Canine OA & Normal NMR Not Stated 
Increased in OA: acetamide, acetate, alanine, glycerol, hydroxybutyrate, 
hydroxyisobutyrate, isoleucine, lactate, lipoprotein-associated fatty acids, N-
acetylglycoprotcins, pyruvate; Decreased in OA: glucose 
Hügle et al., 2012 Clinical Human 
OA, RA, gout, calcium 
pyrophosphate disease, 
spondylarthritis & septic 
arthritis 
NMR 35 None Stated 
Kang et al., 2015 Clinical Human OA & RA UPLC-QTOF-MS 81 
Increased in OA: 11b-hydroxy-3,20-dioxopregn- 4-en-21-oic acid, 12,20-dioxoleukotriene 
B4, 3-hydroxymandelic acid, indoleacetaldehyde, indolelactic acid, kynurenine, L-
carnitine, lysoPC(18:1), N′-formylkynurenine, N6,N6,N6-trimethyl-L-lysine, phenylactic 
acid, trihydroxyeicosatrienoic acid/13,14-dihydrolipoxin A4; Decreased in OA: (S)-
ureidoglycolic acid, 5-L-glutamyltaurine, CE[24:1(15Z)], docosapentaenoic acid, 
galactosylceramide, methylguanine, taurine, trimethyltridecanoic acid 
Kim et al., 2017 Clinical Human Early OA & Late OA GC/TOF MS 114 
Increased in Late Stage OA: 86 metabolites, including malate, ethanolamine, glycerol, 
myristic acid, and oleic acid; Decreased in Late Stage OA: urate, arabitol, cysteine, and 
threitol 
Lacitignola et al., 2008 Clinical Equine OA & Normal NMR Not Stated 
Increased in OA: acetate, alanine, citrate, N-acetylglucosamine, creatine/creatinine, 
glycerol, HDL-choline, lactate, pyruvate, α-glucose 
Mickiewicz, Heard, et al., 2015 Experimental Ovine 
ACL reconstruction 
(early OA) & Sham-
surgical Control 
NMR 65 
Increased in early OA: isobutyrate, glucose; Decreased in early OA: uridine, serine, 
asparagine, hydroxyproline 
Mickiewicz, Kelly, et al., 2015 Clinical Human OA & Normal NMR & GC-MS 90 
Increased in OA: citrate, fructose; Decreased in OA: malate, methionine, N-
phenylacetylglycine, O-acetylcarnitine, hexanoylcarnitine, creatine, ethanol, 
athanolamine, 3-Hydroxybutyrate 
Zheng et al., 2017 Clinical Human OA, RA & Normal 
GC-TOF/MS & 
LC-MS/MS 
81 
Increased in OA compared to normal: threonine, 1,5-anhydroglucitol & gluconic lactone; 
Decreased in OA compared to normal: tyramine, 8-aminocaprylic acid & glutamine; 
Decreased in RA compared to normal: tyramine, 8-aminocaprylic acid & gluconic lactone; 
Increased in OA compared to RA: threonine, 1,5-anhydroglucitol & gluconic lactone; 
Decreased in OA compared to RA: glutamine 
 
Abbreviations: Groups, OA = osteoarthritis, RA = rheumatoid arthritis; Techniques, GC-MS = gas chromatography-mass spectrometry, GC/TOF MS = gas 
chromatography/time-of-flight mass spectrometry, LC-MS/MS = liquid chromatography-tandem mass spectrometry, NMR = nuclear magnetic resonance, UPLC-QTOF-MS = 
ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
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1.3. Proteomics 
The term ‘proteome’ can be defined as the complete complement of proteins and 
peptides, including modifications, expressed by an organism or cell. The proteome 
will vary over time and under the influence or various stresses, different conditions 
and disease states (Christians et al., 2017). Proteomics, first coined by Wilkins 
(1996), is the umbrella term for proteome study, obtaining information on protein 
quantities, structure, function, modifications and variations as well as 
associated/interacting proteins to improve understanding of cellular processes and 
networks (Wilkins et al., 1996). Clinical proteomics is a subgroup of proteomics, 
applying these same techniques to clinical specimens in order to discover 
biomarkers and biosignatures of disease that may be used to aid in diagnosis, 
prognosis and/or prediction of response to treatment (National Cancer Institute, 
2016). 
1.3.1. Mass Spectrometry 
Mass spectrometry (MS) is a sensitive platform, identifying as little as 10-15 moles of 
a 1 kDa compound, thus allowing compound identification within complex mixtures. 
MS ionises samples, producing a beam of gaseous ions which are separated 
according to their mass-to-charge ratio (m/z) and their abundances recorded (Kang, 
2012). Electrospray ionisation (ESI) and matrix-assisted laser desorption/ionization 
(MALDI) are the most common methods for ionisation of peptides/proteins prior to 
MS analysis, involving the addition or removal of a proton (Fenn et al., 1989; Karas 
and Hillenkamp, 1988). Coupling of ESI to liquid based separation tools allows for 
the analysis of complex biological samples, ionising the analyte out of solution, 
when integrated with liquid chromatography (LC) and LC-MS based systems 
(Peffers, 2013). Ions of a certain m/z are then usually isolated from the complex 
mixture as a preliminary step prior to ion fragmentation with greater 
characterisation via tandem MS (MS/MS) (Savaryn et al., 2016). 
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1.3.1.1. Clinical Proteomics 
Within the field of clinical proteomics, the discovery of protein biomarkers of 
disease is presently achieved through a ‘bottom-up’ approach, utilising MS-based 
systems which are coupled to either LC or gel electrophoresis methods (Fernandez-
Costa et al., 2012). Shotgun proteomics uses this ‘bottom-up’ approach whereby 
proteins are denatured, digested into constituent peptides, separated via LC and 
analysed using MS/MS (Figure 3). Peptide identification can then be inferred by 
matching the fragmentation spectra generated by MS/MS to theoretical peptide 
sequence spectra from a protein database and thus use peptides as a surrogate for 
protein quantification/identification (Klammer and MacCoss, 2006). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Workflow for label free quantification of protein abundances using a liquid 
chromatography-tandem mass spectrometry platform. 
 
1.3.1.2. Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer 
The Q ExactiveTM is a high performance benchtop quadrupole-orbitrap mass 
spectrometer which can be employed to analyse complex biological samples 
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(Michalski et al., 2011). Prior to Q ExactiveTM MS analysis, peptides are usually 
separated via reverse phase C18 high-performance liquid chromatography (HPLC) 
(Fanigliulo et al., 2011). The Q ExactiveTM consists of an atmospheric pressure ion 
source (API), a stacked-ring ion guide (S-lens), quadrupole mass filter, C-trap, 
higher-energy collisional dissociation (HCD) cell and an orbitrap mass analyser 
(Figure 4) (Michalski et al., 2011). 
Figure 4. Schematic of the Q ExactiveTM, a hybrid quadrupole-orbitrap mass 
spectrometer. Taken from Li et al., 2017. 
 
The S-lens comprises of a series of flat ring electrodes to which radio frequency 
voltages are applied, focusing the ions into a tight beam, within the central axis 
where the field is weakest, propelling the ions forward without the need for a direct 
current gradient (Guan and Marshall, 1996; ThermoFisher, n.d.). The quadrupole 
mass filter consists of four rods applied with alternate and direct current voltages 
which alter the transmission of ions, selecting a narrow m/z range, due to stabilities 
within the x-z and y-z planes, thus acting as a band-pass mass filter (Figure 5) 
(Savaryn et al., 2016). Ions are subsequently cooled and accumulate within a radio 
frequency only storage C-trap prior to injection via converging lines into an orbitrap 
for single Fourier transform acquisition (Makarov, 2012; Rosen et al., 2015). 
Coupling of the C-trap to an HCD cell enables fragmentation of ions, improving 
fragmentation in the low mass region when compared to traditional collision-
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induced dissociation (CID) (Demarque et al., 2016). Finally, within the orbitrap, ions 
oscillate both around a central spindle-like electrode as well as oscillating in the 
axial dimension (Figure 5). Electrodes detect this axial oscillation producing an ion 
oscillation frequency which is unique for each m/z. Ion oscillation frequencies are 
subsequently converted via Fourier transformation into the mass spectrum. Within 
the orbitrap, all m/z values are simultaneously detected (Savaryn et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematics of the (A) quadrupole and (B) orbitrap chamber components 
present within specific mass spectrometers. DC = direct current, RF = 
radiofrequency. Adapted from Savaryn et al., 2016. 
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1.3.2.1. Biofluid Protein Complexity 
The development of liquid chromatography tandem mass spectrometry (LC-MS/MS) 
has provided a fast and sensitive methodology to identify and quantify proteins 
within complex biological samples (Hsueh et al., 2014; Mahendran et al., 2017; 
Peffers et al., 2019). However, the complexity and variability of intensity of proteins 
within biofluids can lead to many challenges associated with proteome analysis 
(Puangpila et al., 2015). Similarly to serum, the SF proteome is dominated by highly 
abundant proteins, with an estimated substantial differential expression of 10x 
compared to the least abundant proteins, with 95% of the serum proteome 
consisting of approximately only 20 proteins, although representing just 0.1% of the 
total number of proteins (Anderson and Anderson, 2002; Fernandez-Costa et al., 
2012; Peffers, McDermott, et al., 2015; Roche et al., 2006; Seligner and Kellner, 
2006). These high abundant proteins can therefore mask and interfere with the 
detection of low abundant proteins, thus compromising potential biomarker 
discovery and understanding of pathogenesis pathways (Shen et al., 2004). This sub-
optimal identification of low abundant proteins is essentially due to a limited ion 
capacity restricting the isolation, fragmentation and detection of the least abundant 
peptide ions within ion trap mass spectrometers. Thus, until improvements within 
MS technology allow for increased coverage of the native biofluid proteome, at 
present, focusing on modifying the concentration dynamic range of biofluids to 
within the mass spectrometer’s detectable dynamic range is the preferred method 
to quantify low abundant protein biomarkers (Fonslow et al., 2011). However, 
within the field at this time there is no agreed method to achieve this compression 
of the protein concentration dynamic range (Fernandez-Costa et al., 2012). 
Numerous techniques have been applied including the use of immuno-affinity 
depletion through high performance liquid chromatography columns comprising 
antibodies to highly abundant proteins (Balakrishnan et al., 2014; Fernandez-Costa 
et al., 2012; Garner et al., 2013). However a fundamental flaw to this methodology 
is the resultant loss of low molecular weight proteins of interest that are closely 
associated with albumin and other highly abundant proteins (Peffers, McDermott, 
et al., 2015; Zhou et al., 2004). 
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1.3.2.2. ProteoMinerTM Protein Enrichment Columns 
An alternative approach to compress the protein concentration dynamic range 
involves the use of combinational ligand libraries to achieve peptide-based 
depletion but allowing preservation of the whole proteome (Furka et al., 1991; Lam 
et al., 1991). This methodology has recently been used in the development of 
ProteoMinerTM protein enrichment columns (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK). This technique was found to generate the largest increase in 
protein identifications compared to other protein depletion methods when applied 
to serum (Pisanu et al., 2018). The columns consist of an assortment of porous 
beads which are bound to combinations of randomised hexapeptides (oligopeptides 
containing six amino acids) generating 64 million combinations from 20 amino acids 
to which proteins can selectively bind (Figure 6) (Righetti and Boschetti, 2008). 
Following the introduction and overloading of a complex protein biofluid, ligands 
selecting for highly abundant proteins will become saturated with excess protein 
lost in the flow through from the column. Alternatively low abundant proteins will 
be completely bound to the column, with binding increasing proportionally to 
protein content of the biofluid introduced (Hartwig et al., 2009; Righetti and 
Boschetti, 2008). Thus this peptide-based approach produces a compressed protein 
concentration dynamic range, depleting highly abundant proteins and enriching 
those less abundant (Fonslow et al., 2011). This technique for quantifying low 
abundant proteins within a complex biofluid has previously been validated by 
Hartwig et al. (2009) in which human serum was supplemented with Escherichia coli 
lysate. However, the elution solution present within the kit is not compatible with 
LC-MS/MS analysis, due to the presence of 3-((3-cholamidopropyl) 
dimethylammonio)-1-propanesulfonate (CHAPS) (Williams, 2014). Although ‘clean-
up’ and alternative elution protocols are available, these introduce a further 
process in sample preparation and subsequently a source of variation. Peffers et al. 
have previously developed an on-bead trypsin digestion protocol for analysis of 
ProteoMinerTM processed SF (Davidson et al., 2017; Hulme et al., 2017; Peffers, 
McDermott, et al., 2015). However, although the reproducibility of ProteoMinerTM 
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beads when used in conjunction with serum has been examined, reproducibility 
with SF or on-bead digestions have yet to be investigated (Li et al., 2009).  
 
 
 
 
 
 
 
Figure 6. ProteoMinerTM Protein Enrichment Columns. Hexapeptide ligands 
specifically bind to proteins until saturation, enabling depletion of high abundant 
proteins and enrichment of low abundant proteins, compressing the protein 
concentration dynamic range. Taken from Freeby et al., 2010. 
 
1.3.1.2. Semi-Tryptic Peptides and Neopeptides 
Increased activity of MMP, ADAMTS, cathepsin and serine protease enzymes during 
OA leads to cartilage breakdown and the generation of OA-specific peptide 
degradation products (neopeptides) (Ben-Aderet et al., 2015; Peffers et al., 2016; 
Polur et al., 2010). During tryptic digestion of biological proteins for MS analysis, 
arginine and lysine are cleaved on the carboxyl side, unless followed directly by 
proline (Siepen et al., 2007). Thus non-tryptic peptide degradation sites may be 
resultant of this increased enzymatic activity during OA, with peptides with one 
tryptic and one non-tryptic cleavage site referred to as ‘semi-tryptic’ peptides 
(Peffers et al., 2016). Using MS, these neopeptides can be identified, quantified and 
thus utilised as potential molecular biomarkers of early OA. Additionally, a recent 
mouse study identified that a 32 amino acid peptide fragment, generated through 
degradation of aggrecan via increased ADAMTS-4/5 and MMP activity, drives OA 
pain through Toll-like receptor 2 (Miller et al., 2018). Thus, targeting neopeptides 
may provide analgesia and reduce significant pain associated with joint 
degeneration. Various studies have identified potential neopeptides associated with 
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OA in equine cartilage and SF (Peffers et al., 2014; Peffers, McDermott, et al., 2015; 
Peffers et al., 2016; Skiöldebrand et al., 2017). Subsequent development of 
neopeptide antibodies would allow for the detection and monitoring of cartilage 
degeneration as well as assessing response to therapeutics, in both laboratory and 
clinical settings (Peffers et al., 2017). In addition, identification of OA specific 
neopeptides may provide novel therapeutic targets. 
1.4. Multi ‘Omics’ Integration 
In recent years there has been a huge increase in the number of publications which 
are reporting results using ‘omics’ techniques, most highly represented by 
transcriptomics, genomics, metabolomics and proteomics (Cavill et al., 2016). 
Computational integration of these separate datasets can work synergistically, 
greatly enhancing the information that can be obtained opposed to analysing these 
datasets separately. In light of this, various software programs are now available 
which undertake pathway analysis and multi ‘omics’ data visualisation, generating 
joint pathway p- values (Eichner et al., 2014; García-Alcalde et al., 2011; van Iersel 
et al., 2008; Xia et al., 2013). In most cases, an optimal experimental design involves 
the splitting of samples which are subsequently used for appropriate ‘omics’ 
studies, termed a ‘split sample study’ design (Cavill et al., 2016).  
Recently, a study has used a multi ‘omics’ integration approach, utilising genomics, 
proteomics and miRNomics of human plasma for biomarker discovery in the study 
of the inherited cardiac disorder Brugada syndrome, providing further information 
on disease pathogenesis (Scumaci et al., 2018). Within musculoskeletal biology, 
Ritter et al. carried out MS proteomic analysis of early and late stage human OA SF 
and combined these results with transcriptomic results of articular tissues to inform 
on the source of differentially abundant synovial proteins (Ritter et al., 2013). Thus, 
a multi ‘omics’ approach can still yield more information and further 
support/validate a study even if the complementary ‘omics’ approaches are not 
performed on the same source material or data is drawn from publicly available 
data repositories. However, despite the growing field of multi ‘omics’ approaches, 
to date no studies have combined NMR metabolomics and MS proteomic datasets. 
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1.5. Hypothesis and Aims 
It is hypothesised that the synovial fluid metabolome and proteome can 
discriminate different articular pathologies and can stratify equine osteoarthritis 
according to severity. 
To answer this hypothesis, the aims and objectives of this study were to: 
1. Optimise collection and processing of synovial fluid for NMR metabolomic 
and LC-MS/MS proteomic analysis (Chapter 2). 
2. Compare the metabolite and protein profiles of equine synovial fluid 
associated with differing severities of osteoarthritis (Chapter 3). 
3. Undertake metabolomic and proteomic longitudinal analysis of an ex-vivo 
equine cartilage explant osteoarthritis model (Chapter 4). 
4. Compare the human synovial fluid metabolite profiles of osteoarthritis and 
rheumatoid arthritis (Chapter 5). 
5. Undertake metabolomic and proteomic analysis of equine synovial fluid 
diagnosed with septic and nonseptic articular pathologies (Chapters 6 and 
7).
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2.1. Abstract 
Synovial fluid (SF) is of great interest for the investigation of orthopaedic 
pathologies as it is in close proximity to various tissues which are primarily altered 
during these disease processes and can be collected using minimally invasive 
protocols. Therefore, SF has substantial potential for improved understanding of 
underlying disease pathogenesis and biomarker discovery. Nuclear magnetic 
resonance (NMR) metabolomics is a rapidly expanding field, providing 
comprehensive metabolite profiling of complex biological samples with high levels 
of technical reproducibility. However, currently there are no agreed standard 
protocols which are published for SF collection and processing for use with NMR 
metabolomic analysis. The development of liquid chromatography tandem mass 
spectrometry (LC-MS/MS) has provided a fast and sensitive methodology to identify 
and quantify proteins within complex biological samples. However, the large 
protein concentration dynamic range present within SF can mask the detection of 
low abundant proteins. Combinational ligand libraries (ProteoMinerTM columns) 
have been developed to reduce this dynamic range, achieving peptide-based 
depletion whilst allowing preservation of the whole proteome. However, the 
reproducibility of ProteoMinerTM columns when used in conjunction with SF or on-
bead protein digestion protocol reproducibility have yet to be investigated. During 
this study, protocols have been optimised for the collection, processing and storage 
of SF for NMR metabolite analysis. We have also optimised protocols for analysis of 
the SF proteome using LC-MS/MS, with the inclusion of a Lys-C endopeptidase 
digestion step prior to tryptic digestion found to increase the number of protein 
identifications and improve the reproducibility of on-bead ProteoMinerTM 
digestions. 
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2.2. Introduction 
Synovial fluid (SF) primarily acts as a biological lubricant, reducing friction between 
synovial joint articular cartilage surfaces, but also functions as a pool of nutrients 
for surrounding tissues and allows movement of regulatory cytokines (Blewis et al., 
2007; Tamer, 2013). SF is of great interest for the investigation of orthopaedic 
pathologies, including osteoarthritis (OA), osteochondrosis, rheumatoid arthritis 
and synovial sepsis, as it is in close proximity to various tissues which are primarily 
altered during these disease processes, with minimally invasive collection protocols 
(Anderson, Phelan, et al., 2018; Mateos et al., 2012). Therefore, SF has the potential 
for improved understanding of underlying disease pathogenesis and biomarker 
discovery. 
Nuclear magnetic resonance (NMR) metabolomics is a rapidly expanding field, 
providing comprehensive metabolite profiling of complex biological samples with 
high levels of technical reproducibility (Beckonert et al., 2007; Beltran et al., 2012). 
Numerous studies have utilised NMR to investigate the SF metabolome of 
orthopaedic diseases in various species, including humans, dogs, pigs and horses 
(Anderson, Phelan, et al., 2018; Damyanovich et al., 1999; Duffy et al., 1993; Hugle 
et al., 2012; Lacitignola et al., 2008; Meshitsuka et al., 1999; Mickiewicz, Heard, et 
al., 2015; Mickiewicz, Kelly, et al., 2015). Although the effect of freeze thaw cycles 
and long term low temperature storage have been investigated, no studies to date 
have investigated the impact of different freezing methods on NMR metabolite 
analysis (Damyanovich et al., 2000). Currently, there are no agreed standard 
protocols which are published for SF collection and processing for use with NMR 
metabolomic analysis. 
Various studies have used mass spectrometry (MS) based proteomics approaches to 
analyse SF, with the development of liquid chromatography tandem mass 
spectrometry (LC-MS/MS) providing a fast and sensitive methodology to identify 
and quantify proteins within complex biological samples (Hsueh et al., 2014; 
Mahendran et al., 2017). However, due to the multivariate nature of sample 
analysis, a large number of biological replicates are required in order to achieve an 
adequately powered study, which for LC-MS/MS, may be cost prohibitive. 
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Additionally, the large protein concentration dynamic range present within SF leads 
to various challenges associated with proteome analysis (Puangpila et al., 2015). A 
small number of highly abundant proteins, including albumin, can mask the 
detection of low abundant proteins, thus compromising potential biomarker 
discovery (Roche et al., 2006). Combinational ligand libraries have been developed 
to reduce this dynamic range, achieving peptide-based depletion whilst allowing 
preservation of the whole proteome (Furka et al., 1991; Lam et al., 1991). This 
methodology has recently been used in the development of ProteoMinerTM protein 
enrichment columns (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK), depleting 
highly abundant proteins and enriching those less abundant (Fonslow et al., 2011). 
This technique was found to generate the largest increase in protein identifications 
compared to other protein depletion methods when applied to serum (Pisanu et al., 
2018). However, the elution solution present within the kit is not compatible with 
LC-MS/MS analysis, due to the presence of 3-((3-cholamidopropyl) 
dimethylammonio)-1-propanesulfonate (CHAPS) (Williams, 2014). Although ‘clean-
up’ and alternative elution protocols are available, these introduce a further 
process in sample preparation and subsequently a source of variation. Peffers et al. 
have previously developed an on-bead trypsin digestion protocol for analysis of 
ProteoMinerTM processed SF (Davidson et al., 2017; Hulme et al., 2017; Peffers, 
McDermott, et al., 2015). However, although the reproducibility of ProteoMinerTM 
beads when used in conjunction with serum has been examined, reproducibility 
with SF or on-bead digestions have yet to be investigated (Li et al., 2009). 
Lys-C serine endopeptidase is the second most common enzyme used within 
bottom-up proteomics studies following trypsin, efficiently hydrolysing the peptide 
bond of lysine residues on the carboxyl side (Jekel et al., 1983; Wu et al., 2018). 
Whilst trypsin digests peptides at Arg-C or Lys-C residues, unless followed directly 
by proline, cleavage at the Lys-C site is comparatively poor when compared to Lys-C 
endopeptidase activity (Siepen et al., 2007; Wu et al., 2018). Thus, a combined 
digestion protocol can produce an overall improved digestion efficiency. When used 
within an in-solution protein digestion protocol, a Lys-C/trypsin protocol was found 
to produce significantly less missed cleavages and a more efficient digestion than a 
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tryptic digestion alone (Glatter et al., 2012). However, on-bead ProteoMinerTM 
digestion protocols to date have used trypsin alone, with the potential improved 
digestion of the addition of Lys-C endopeptidase into this protocol yet to be 
investigated. 
Cartilage breakdown products are generated during orthopaedic pathology, i.e. OA, 
due to elevations in enzymatic activity within synovial joints (Peffers et al., 2016). 
These products may be recognised via MS as semi-tryptic peptides. Identification 
and quantification of these semi-tryptic peptides within pathological groups has 
potential as an early OA biomarker as well as enabling disease stratification. 
However, the reproducibility of semi-tryptic peptide quantification is yet to be 
investigated following ProteoMinerTM processing. 
We hypothesise that refining SF collection and processing protocols for NMR 
metabolomic and LC-MS/MS proteomic analysis will maximise the number of 
molecule identifications as well as optimise technical reproducibility. 
2.3. Methods 
2.3.1. Study Overview 
Table 1 below summarises the main NMR and LC-MS/MS protocols investigated 
during this study for metabolite, protein and peptide identification and 
quantification. 
 
Table 1. Nuclear magnetic resonance and liquid chromatography-tandem mass 
spectrometry protocols investigated during this study for metabolite, protein and 
peptide identification and quantification. 
 
METABOLITES PROTEINS/PEPTIDES 
Nuclear Magnetic Resonance (NMR) 
Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS) 
Spun vs Unspun 
Hyaluronidase Treatment Protocol 
Optimisation 
Different Freezing Protocols ProteoMinerTM Bead Protein Loading 
Reproducibility of Separate Synovial Fluid 
Donors 
Gradient Length and Blank Acquisition 
  Protein Digestion Optimisation 
  Tryptic Peptide Reproducibility 
  Semi-Tryptic Peptide Reproducibility 
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2.3.2. Equine Synovial Fluid Collection 
All equine SF was collected post mortem from an abattoir within 8 hrs of 
euthanasia. Metacarpophalangeal (MCP) joints were opened aseptically and SF 
collected on ice using a 10 ml syringe. For NMR metabolomics analysis, SF was 
pooled from four MCP joints from four separate donors and vortexed for 1 min. SF 
was also collected from an additional three equine MCP joints from three donors 
and processed separately. For proteomic analysis SF was pooled from five MCP 
joints from five separate donors, pooled and vortexed for 1 min. All joints used for 
this study were considered to be macroscopically normal and were assigned a score 
of 0 according to the equine OARSI histopathology initiative scoring system 
(McIlwraith et al., 2010). 
2.3.3. Human Synovial Fluid Collection 
SF was collected, with ethical approval, from the acetabulofemoral joint of nine 
patients diagnosed with OA undergoing total hip replacement surgery at The Queen 
Elizabeth Hospital Birmingham and stored at -80°C. Further information on 
collection protocols is unavailable. 
2.3.4. NMR Metabolomics 
2.3.4.1. Sample Preparation - Spun vs Unspun 
150 μl of equine SF was aliquoted into nine eppendorfs which did not undergo 
centrifugation prior to freezing (unspun) and nine eppendorfs which were 
centrifuged (spun). In the spun group, SF was centrifuged at 2,540g and 4°C for 5 
min and the supernatant transferred to a new eppendorf. All samples were 
subsequently snap frozen in liquid nitrogen and stored at -80°C.  
2.3.4.2. Sample Preparation - Different Freezing Protocols 
150 μl of equine SF was aliquoted into 32 eppendorfs which were subsequently 
centrifuged at 2,540g and 4°C for 5 min and the supernatant removed. The samples 
were then divided into four separate groups (eight in each) and frozen either at  
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-20°C, -80°C, placed onto dry ice or snap frozen in liquid nitrogen. Following 
freezing, all samples were stored at -80°C. 
2.3.4.3. Sample Preparation - Reproducibility of Separate Synovial Fluid Donors 
Following collection, equine SF was separated into three separate 150 μl aliquots 
for each of the three separate donors, nine aliquots in total. SF was then 
centrifuged at 2,540g and 4°C for 5 min, supernatant removed, snap frozen in liquid 
nitrogen and stored at -80°C. 
2.3.4.4. Sample Preparation for NMR Spectrometry 
150 µl of each thawed SF sample was diluted to a final volume containing 50% (v/v) 
SF, 40% (v/v) dd 1H2O (18.2 MΩ), 10% (v/v) 1 M PO43- pH 7.4 buffer (Na2HPO4, VWR 
International Ltd., Radnor, Pennsylvania, USA and NaH2PO4, Sigma-Aldrich, 
Gillingham, UK) in deuterium oxide (2H2O, Sigma-Aldrich) and 0.0025% (v/v) sodium 
azide (NaN3, Sigma-Aldrich). Samples were vortexed for 1 min, centrifuged at 
13,000g and 4˚C for 2 min and 200 µl transferred (taking care not to disturb any 
pelleted material) into 3 mm outer diameter NMR tubes using a glass pipette. 
2.3.4.5. NMR Spectral Acquisition 
All SF samples were individually analysed. 1D 1H NMR spectra were acquired using a 
700 MHz NMR Bruker Avance III HD spectrometer with associated TCI cryoprobe 
and chilled Sample-Jet autosampler. A Carr-Purcell-Meiboom-Gill (CPMG) filter was 
used to attenuate macromolecule signals using a standard cpmgpr1d vendor pulse 
sequence. All CPMG spectra were acquired at 37˚C with a 15 ppm spectral width, a 
4 s interscan delay and 32 transients. Spectral acquisition and processing was 
carried out using Topsin 3.1 (Bruker Corporation, Billerica, Massachusetts, USA) and 
IconNMR 4.6.7 (Bruker). 
2.3.4.6. Spectral Bucketing 
All spectra were aligned to a single formate peak at 8.46 ppm. All peaks within each 
spectrum were then placed into ‘buckets’, excluding the peak generated by water, 
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with each bucket intensity divided by the width in order to negate intensity 
variance.  
2.3.5. LC-MS/MS Proteomics 
2.3.5.1. Hyaluronidase Treatment Protocol Optimisation 
750 µl aliquots of equine SF were supplemented with hyaluronidase (from bovine 
testes, Sigma-Aldrich) at a final concentration of 0, 0.05, 0.10, 0.25, 0.50, 0.75, 1.00, 
1.50 or 2.00 µg/ml and vortexed for 30 s. All samples (bar two 0 µg/ml treated 
samples) were then incubated at 37°C for 1 hr and rotated. All samples (bar two 0 
µg/ml and one 1.00 µg/ml treated samples) were then passed through 
polypropylene microcentrifuge tube filters with 0.22 µm pore cellulose acetate 
membranes (Costar Spin-X, Corning, Tokyo, Japan) for 15 min at 5,000g. 1 µl of each 
sample was analysed by one dimensional sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (1D SDS PAGE) and stained with Coomassie Blue (Bio-Rad). 
2.3.5.2. Standard Trypsin Protein Digestion Protocol 
During this study, previously developed standard trypsin digestion protocols were 
used for native SF protein digestion and on-bead ProteoMinerTM protein digestion, 
or a variation of this protocol as stated (Peffers, McDermott, et al., 2015) (Figure 1). 
160 µl of 25 mM ammonium bicarbonate (Fluka Chemicals Ltd., Gillingham, UK) 
containing 0.05% (w/v) RapiGest (Waters, Elstree, Hertfordshire, UK) was added to 
ProteoMinerTM columns. For native SF and ProteoMinerTM column flow-through, the 
appropriate volume containing 100 µg of protein was diluted to a final volume of 
160 µl 25 mM ammonium bicarbonate (Fluka) containing 0.05% (w/v) RapiGest. 
Samples were heated for 10 min at 80°C, 3 mM final concentration DL-Dithiothreitol 
(Sigma-Aldrich) added, heated at 60°C for 10 min and 9 mM final concentration 
iodoacetamide (Sigma-Aldrich) added and incubated at room temperature for 30 
min in the dark. Protein digestion was carried out through the addition of 2 µg of 
proteomics grade trypsin (Sigma-Aldrich), rotation at 37°C for 16 hrs with repeated 
trypsin supplementation for 2 hrs, again rotating at 37°C. Columns were centrifuged 
at 1,000g for 1 min, 0.5% (v/v) final concentration trifluoroacetic acid (TFA, Sigma-
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Aldrich) added, rotated at 37°C for 30 min, centrifuged at 13,000g and 4°C for 15 
min and the supernatant removed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Standard trypsin digestion protocol for on-bead ProteoMinerTM protein 
digestion, native synovial fluid (SF) and ProteoMinerTM column flow-through protein 
digestion. Red box indicates enzymatic protein digestion steps. AmBic = Ammonium 
Bicarbonate, DTT = DL-Dithiothreitol, IAA = Iodoacetamide, TFA = Trifluoroacetic 
acid. 
 
2.3.5.3. ProteoMinerTM Bead Protein Fractions 
Pooled equine SF was treated using the standard protocol of adding 1 µg/ml 
hyaluronidase, heating at 37°C for 1 hr, centrifuging at 1,000g for 5 min, removing 
the supernatant and passing through a 0.22 µm cellulose acetate filter at 5,000g for 
15 min. A ProteoMiner™ Small Capacity bead column (Bio-Rad) was loaded with 3.5 
mg of protein and processed according to manufacturer instructions. The sample 
was rotated at room temperature for 2 hrs, centrifuged at 1,000g for 1 min (flow-
through also collected), the beads washed in 200 µl phosphate buffered saline 
(PBS), rotated for 5 min and centrifuged for 1 min at 1,000g with the wash flow-
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through collected. The wash step was completed three further times with the final 
being completed using deionised water. 20 µl of elution buffer (8 M urea, 5% acetic 
acid and 2% CHAPS) was added to the column, vortexed several times over 15 min, 
centrifuged at 1,000g for 15 min and the elution collected. The elution step was 
repeated two further times. All fractions collected during the protocol were 
analysed to assess the protein profiles/abundant protein depletion and protein 
content via 1D SDS PAGE and stained with Coomassie Blue and a Pierce® 660 nm 
protein assay (Thermo Scientific, Waltham, Massachusetts, USA) respectively. 
2.3.5.4. ProteoMinerTM Bead Protein Loading 
Following the standard hyaluronidase treatment protocol, 1.0 mg, 2.5 mg and 5.0 
mg of a pooled SF sample and 5.0 mg and 10.0 mg of a separate pooled SF sample 
were loaded onto separate ProteoMinerTM columns. Sample incubation and wash 
steps were completed according to manufacturer instructions. However, instead of 
protein elution, a standard on-bead digestion protocol was undertaken as 
previously stated. 100 µg of native SF protein and 100 µg of protein column flow-
through were also digested using the same reduction, alkylation and digestion 
steps. Protein profiles were assessed using 1D SDS PAGE and stained with 
Coomassie Blue. Digests were individually analysed via LC-MS/MS with 120 min LC 
gradients. 
2.3.5.5. Gradient Length and Blank Acquisition 
SF protein digests used to assess ProteoMinerTM bead protein loading (100 µg 
native SF and 2.5 mg column loading) were both analysed using LC-MS/MS with 60, 
90 and 120 min LC gradients and the number of proteins and peptides identified for 
each protocol recorded. To assess peptide carry-over between successive samples, 
after each sample a ‘blank’ sample (containing only sample buffer (97% (v/v) high 
performance liquid chromatography (HPLC) grade H20 (VWR International), 2.9% 
acetonitrile (Thermo Scientific) and 0.1% TFA was run on a 30 min LC gradient and 
the spectra acquired. Following one SF sample a series of five successive blank 
samples were also run and again the spectra acquired. The abundance of each 
peptide identified within the blank sample was calculated as a percentage of the 
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abundance within the previous SF sample and the median of peptide percentage 
carry-overs recorded. 
2.3.5.6. Synovial Fluid Protein Digestion Profiles: Coomassie Brilliant Blue vs Silver 
Stain 
100 μg of protein of native human SF and 3 mg loaded ProteoMinerTM columns for 
the same nine separate human donors underwent a standard 16hr + 2hr trypsin 
digestion protocol. Digestion profiles were then analysed via 1D SDS PAGE and 
stained using both Coomassie Brilliant Blue and silver staining. 
2.3.5.7. Protein Digestion Optimisation 
Variations of the previously stated standard digestion protocols were used for 100 
µg and 2.5 mg loaded ProteoMinerTM columns using the 16hr + 2hr trypsin digestion 
method (Table 2). Native and ProteoMinerTM processed SF was digested using 4hr, 
16hr and 16hr + 2hr trypsin protocols. Additionally, for ProteoMinerTM processed 
SF, a 16hr + 16hr trypsin on-bead digestion protocol was also investigated as well as 
16hr trypsin digests centrifuged at 1,000g for 1 min and the second stage protein 
digestion (2hr or 16hr trypsin digestion) carried out on the resulting supernatant. 
Each of these ProteoMinerTM protocols was also analysed using a pre-digest step of 
Lys-C endopeptidase (FUJIFILM Wako Pure Chemical, Osaka, Japan). Prior to trypsin 
digestion, 2 µg of Lys-C (10 µg/ml final digest concentration) was added to the 
column and incubated at 37˚C for 4 hr. A longer 16hr Lys-C pre-digest was also 
investigated for the standard 16hr + 2hr trypsin digestion protocol. Different 
ProteoMinerTM column loading methods were also investigated. After an initial 2hr 
on-bead sample incubation and centrifugation, a second SF load of equal protein 
was added to the column and a second 2 hr incubation undertaken. Additionally to 
this, following a 2 hr on-bead sample incubation and centrifugation, the resultant 
flow-through was reloaded onto the column and a second 2 hr incubation carried 
out. As well as on-bead digestion protocols, one column did not undergo protein 
digestion with the intact proteins eluted using the manufacturer’s instructions and 
elution buffer, as previously described, to compare the protein bound protein 
profile to that of the digested protein profiles. Following processing, samples, and 
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ProteoMinerTM beads, were analysed by 1D SDS PAGE and silver staining. LC-MS/MS 
was undertaken with a 1hr LC gradient. 
Table 2. Different digestion protocols of native and ProteoMinerTM processed 
equine synovial fluid. 
 
2.3.5.8. Tryptic Peptide Reproducibility 
Using the same pooled equine SF, following hyaluronidase treatment and CoStar 
processing, 100 μg of protein and 2.5 mg loaded ProteoMinerTM columns (including 
ProteoMinerTM flow-throughs) underwent a standard 16hr + 2hr trypsin digestion 
protocol with three technical replicates of each. All samples were analysed using LC-
MS/MS with a 2 hr LC gradient. Additionally, for each sample type, the same vial 
was also analysed three times to investigate the reproducibility of LC-MS/MS alone. 
ProteoMinerTM columns loaded with 2.5 mg of pooled SF which underwent a 4hr 
Lys-C + 16hr + 2hr trypsin protocol were also analysed, although flow-through and 
repeated vial analysis was not undertaken. 
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2.3.5.9. Semi-Tryptic Peptide Reproducibility 
100 μg protein of native SF underwent 4hr trypsin and 16hr + 2hr trypsin protocols 
in technical triplicates. 2.5 mg loaded ProteoMinerTM columns underwent 4hr 
trypsin, 16hr + 2hr trypsin, 4hr Lys-C + 4hr trypsin and 4hr Lys-C + 16hr + 2hr trypsin 
digestion protocols, also in technical triplicate. All digests were analysed by LC-
MS/MS with using 1hr and 2hr LC gradients. 
2.3.5.10. 1D SDS PAGE 
1 μl of native SF, 5 μl of digested SF or 8 μl of ProteoMinerTM beads were used for 
1D SDS PAGE for optimal optimisation of protein bands. Samples were added to 
Laemmli loading buffer Novex™ (Thermo Scientific) with a final concentration of 
15% glycerine, 2.5% SDS, 2.5% Tris (hydroxymethyl) aminomethane, 2.5% HCL and 
4% β-mercaptoethanol at pH 6.8 and heated for 5 min at 95˚C. Samples were 
loaded onto a 4-12% Bis-Tris polyacrylamide electrophoresis gel (NuPAGE™ 
Novex™, Thermo Scientific) with protein separation undertaken at 200V for 30 min 
at room temperature.  
2.3.5.11. Coomassie Brilliant Blue Staining (Sensitivity = 100 ng of Protein) 
Following 1D SDS PAGE, gels were washed three times in ddH2O for 5 min, stained 
with Coomassie Brilliant Blue stain (R-250, Bio-Rad) for 1 hr, Coomassie stain 
removed and de-stained with Coomassie Brilliant Blue de-staining solution (R-250, 
Bio-Rad) for 16 hr. 
2.3.5.12. Silver Staining (Sensitivity = 1 ng of Protein) 
Following 1D SDS PAGE, gels were silver stained according to manufacturer 
instructions (Thermo Scientific). Gels were washed twice in ddH2O for 5 min, fixed in 
30% (v/v) ethanol (Sigma-Aldrich): 10% (v/v) acetic acid (Sigma-Aldrich): 60% (v/v) 
ddH20 for 15 min and the fixing step repeated. Gels were washed twice in 10% (v/v) 
ethanol: 90% (v/v) ddH20 for 5 min, twice in 100% ddH2O for 5 min, incubated in a 
sensitizer working solution for 1 min and washed twice in 100% ddH2O for 1 min. 
The gel was then incubated in a stain working solution for 30 min, washed twice in 
ddH2O for 20 s, incubated in developer working solution for 2-3 min until bands 
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appeared and finally 5% (v/v) acetic acid: 95% (v/v) ddH2O added and incubated for 
10 min. 
2.3.5.13. LC-MS/MS Spectral Acquisition 
All digests were individually analysed via LC-MS/MS on an UltiMate 3000 Nano LC 
System (Dionex/Thermo Scientific) coupled to a Q ExactiveTM Quadrupole-Orbitrap 
instrument (Thermo Scientific). Full LC-MS/MS instrument methods are described in 
chapter 7. Tryptic peptides (equivalent to 200 ng of protein) were loaded onto the 
column and run over a 30 min, 60 min, 90 min or 120 min LC gradient as stated. 
2.3.5.14. PEAKS® Search Parameters 
For peptide/protein database searches using PEAKS® Studio 8.5 (Bioinformatics 
Solutions Inc., Waterloo, Canada) the Equus caballus database was used with search 
parameters including: precursor mass error tolerance, 10.0 ppm; fragment mass 
error tolerance, 0.01 Da; precursor mass search type, monoisotopic; enzyme, 
trypsin; maximum missed cleavages, 1; non-specific cleavage, none; fixed 
modifications, carbamidomethylation; variable modifications, oxidation or 
hydroxylation and oxidation (methionine). A 1% false discovery rate (FDR) was set 
and a minimum of 2 unique peptides required for protein identification. No 
normalisation was undertaken. PEAKS® searches were used for all peptide and 
protein identifications except for protein digestion optimisation and semi-tryptic 
peptide analysis. 
2.3.5.15. Mascot Search Parameters 
For peptide/protein database searches using an in-house Mascot server Version 
2.6.2 (Perkins et al., 1999) the Equus caballus database was used with search 
parameters including: peptide mass tolerance, 10.0 ppm; fragment mass tolerance, 
0.01 Da; enzyme, trypsin; missed cleavages allowed, one; fixed modifications, 
carbamidomethylation (cysteine) and variable modifications; oxidation 
(methionine), oxidation (proline) and oxidation (lysine). Mascot database searches 
were used for protein digestion optimisation and semi-tryptic peptide analysis. 
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2.3.5.16. Semi-Tryptic Peptide Identification and Quantification 
Raw spectral files underwent spectral alignment, peak picking and peptide 
quantification in Progenesis™ QI 2.0 (Nonlinear Dynamics, Waters). No 
normalisation was undertaken. Peptide identifications were carried out for the top 
ten spectra of each feature with Mascot, using the same Equus caballus search 
parameters as for tryptic peptides, except a ‘semi-tryptic’ search was conducted 
opposed to ‘tryptic’. Peptides, with a 1% FDR correction, were exported from 
Progenesis™ and technical replicates of semi-tryptic peptide abundances compared 
using the online neopeptide tool (Peffers et al., 2017). 
2.3.6. Statistical Analysis 
Principal component analysis (PCA) plots were conducted using MetaboAnalyst 4.0 
(Chong et al., 2018). T tests were conducted in the software package R 
(https://cran.r-project.org/), box plots constructed using SPSS 24 and histograms 
drawn using Excel 2013. Peptide reproducibility was analysed using the coefficient 
of variation (CV) statistic on raw, non-normalised abundance values. 
2.4. Results 
2.4.1. NMR Metabolomics 
2.4.1.1. Spun vs Unspun 
Including a centrifugation step prior to freezing identified clear separation on a PCA 
plot (Figure 2a). Two distinct metabolomes can be discerned with separation 
determined by PC2. 
2.4.1.2. Different Freezing Protocols 
Unlike the centrifugation protocols, PCA of different SF freezing protocols did not 
generate separate metabolomic profiles with no distinct groupings identified 
according to the freezing method used (Figure 2b). However, the SF samples frozen 
by snap freezing in liquid nitrogen displayed the least variance between technical 
replicates and this protocol was therefore the most reproducible of those studied. 
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2.4.1.3. Reproducibility of Separate Synovial Fluid Donors 
The collection and processing protocol was identified to be reproducible with three 
technical replicates of three macroscopically normal MCP joints from three horses 
clustering separately on a PCA plot (Figure 2c). 
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Figure 2. Optimisation of equine synovial fluid processing for 1D 1H NMR 
metabolome analysis. The reproducibility of the metabolome for different 
processing protocols for equine synovial fluid (SF) was assessed using principal 
component analysis (PCA). These protocols included (A) with (n=6) and without 
(n=8) a centrifugation step (2,540g and 4°C for 5 min) prior to freezing and (B) the 
use of different freezing methods (-20˚C (n=7), -80˚C (n=6), dry ice (n=5) and liquid 
nitrogen (n=7)). (C) PCA showing reproducibility of the finalised SF processing 
method (including centrifugation and liquid nitrogen snap freezing) using three 
separate equine donors with three technical replicates for each donor. PCA shaded 
regions depict 95% confidence regions. 
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2.4.2. LC-MS/MS Proteomics 
2.4.2.1. Hyaluronidase Treatment Protocol Optimisation 
SF treated with hyaluraonidase at final concentrations of 0 - 0.50 µg/ml did not fully 
pass through cellulose acetate membrane filters due to incomplete hyaluraonidase 
degradation of hyaluronic acid, producing < 200 µl of flow-through (Figure 3a). 
Concentrations of 0.75 - 2.00 µg/ml however all yielded the same greater volume of 
flow-through (> 550 µl). No differences were identified between the global 
proteome profiles between the different hyaluraonidase treatment protocols 
(Figure 3b). 
  
Figure 3. Synovial fluid hyaluronidase treatment optimisation. (A) Synovial fluid 
flow-through via cellulose acetate membrane filters following heating at 37°C, for 0-
2 µg/ml hyaluronidase treatments and (B) 1D SDS PAGE of protein profiles using 
different hyaluronidase protocols. 
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2.4.2.2. ProteoMinerTM Bead Protein Fractions 
ProteoMinerTM columns were found to be effective in equalling the protein 
concentration dynamic range (Figure 4a). Most of the protein was removed within 
the initial flow-through with 0.9% attaching to the beads for further analysis of low 
abundant proteins (Figure 4b). 
 
Figure 4. Synovial Fluid Protein Fractions during ProteoMinerTM Column Processing. 
(A) 1D SDS PAGE of protein profiles at each stage of the low abundant protein 
enrichment process and (B) total protein within each fraction. 
 
2.4.2.3. ProteoMinerTM Bead Protein Loading 
ProteoMinerTM columns were found to increase the number of identified proteins 
within equine SF compared to native SF analysis, with 1 mg, 2.5 mg and 5 mg 
column loadings increasing protein identifications by 112%, 161% and 201% 
respectively (Figure 5b). Proteomic analysis of flow-through following 5 mg protein 
loading identified a similar number of proteins compared to native SF. For a 
separate pooled equine SF sample set, increasing the protein loading from 5 mg to 
10 mg only resulted in a small increase in protein identifications (21 proteins, 6%) 
(Figure 5c). At the level of Coomassie staining, tryptic digestion was sufficient for 
LC-MS/MS analysis for all protein loadings analysed (1-5 mg) (Figure 5a). Intensity of 
the highly abundant protein bands, 40-80 kDa, increased with increased protein 
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load. SF was loaded at equal concentration, thus indicating a higher proportion of 
these proteins within the flow-through with increasing protein load. 
 
 
Figure 5. ProteoMinerTM Column Loading of Synovial Fluid. (A) Protein profiles of 
on-bead digests and flow-through (FT) following 1 mg, 2.5 mg and 5 mg protein 
loading. (B) Number of proteins identified via LC-MS/MS following bead enrichment 
of depleted proteins and column flow-through for 1 mg, 2.5 mg and 5 mg protein 
loadings and (C) 5 mg and 10 mg protein loadings for another set of pooled synovial 
fluid. 
 
2.4.2.4. Gradient Length and Blank Acquisition 
For both native and ProteoMinerTM processed SF, longer LC gradient lengths 
resulted in increased numbers of identified proteins, with a higher number of 
proteins identified following ProteoMinerTM processing (Figure 6). All of the 
acquired blank samples, bar one, had a low carry-over of peptides from the 
previous test sample, all with a median percentage carry-over of less than 1 for 
 
47 
 
peptides identified within the blanks. Running a series of consecutive blanks did 
reduce the number of peptides identified and their peptide abundance carry-over 
percentage, although this effect was regarded as minimal. 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Number of peptides identified within native and ProteoMinerTM processed equine synovial fluid using LC-MS/MS for 60 min, 90 min 
and 120 min LC gradients. The number of peptides identified within blank samples run after synovial fluid samples were also recorded, with the 
median percentage carry of peptides identified within the blank compared to the previous synovial fluid sample stated above the relevant bar. 
Inset: Number of proteins identified for the same samples for 60 min, 90 min and 120 min LC gradients. 
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2.4.2.5. Synovial Fluid Protein Digestion Profiles: Coomassie Brilliant Blue vs Silver 
Stain 
At the level of protein sensitivity of Coomassie Brilliant Blue staining, the 16hr + 2hr 
trypsin digestion protocol indicated complete digestion of both native and 
ProteoMinerTM processed SF (Figure 7). However, the increased sensitivity of silver 
staining revealed that whilst native SF digestion was confirmed as complete, 
incomplete digestion was present on the ProteoMinerTM column. Additionally, the 
level of incomplete digestion was not uniform across different donors. 
 
Figure 7. Protein profiles of (A and C) native and (B and D) ProteoMinerTM processed 
human synovial fluid following trypsin digestion and (A and B) Coomassie Brilliant 
Blue or (C and D) silver staining. 
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2.4.2.6. Protein Digestion Optimisation 
Neither increased length of trypsin digestion nor an additional trypsin 
supplementation appeared to alter the protein profile of Native SF following 
digestion (Figure 8b). However, for on-bead ProteoMinerTM digestion, increased 
length of trypsin exposure and supplementation improved digestion efficiency, with 
clear protein bands present at 50-60 kDa and 260 kDa after 4hr trypsin digestion 
and near complete digestion following a 16hr + 2hr trypsin digestion protocol. Of 
the different on-bead tryptic digestion protocols investigated, protein profiles of the 
digested solutions of equine SF did not reveal as many undigested protein bands as 
identified previously for human SF (Figure 8a). However, a separate ProteoMinerTM 
16hr + 2hr tryptic digestion of equine SF has also previously led to a series of 
undigested protein bands, detected at the sensitivity of Coomassie Blue 
(Supplementary Figure 1). However, an undigested protein band was detected at > 
260 kDa for equine SF digests, which was not present for all protocols including the 
4hr Lys-C pre-digest. 
For protein profile analysis of the ProteoMinerTM beads, 4hr and 16hr trypsin 
digestions revealed significant levels of proteins were retained on the beads > 50 
kDa, indicating significant incomplete digestion (Figure 8c). A 16hr + 2hr tryptic 
digestion protocol revealed significant retention of undigested proteins bound to 
the beads, with molecular weights in the range of 3.5-20 kDa. However, the 
intensity of these bands was significantly reduced with the introduction of the 4hr 
Lys-C pre-digestion, and to a lesser extent a 16hr Lys-C pre-digestion step. The 
intensity of these same bands were less for a 16hr + 16hr trypsin digestion 
compared to the standard protocol, and were again reduced by the 4hr Lys-C pre-
digestion. Protocols in which the second trypsin digestion was completed in-
solution, following an on-bead 16hr trypsin digestion, revealed significant levels of 
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undigested proteins remaining on the beads. However, the 4hr Lys-C pre-digestion 
step resulted in complete digestion of these proteins. 
 
Figure 8. Protein profiles of native and ProteoMinerTM processed equine synovial 
fluid following protein digestion. (A) Different ProteoMinerTM loading and digestion 
protocols ± Lys-C endopeptidase pre-digestion (yellow boxes indicate profiles 
including Lys-C pre-digestion, arrow indicates a protein band not present following 
Lys-C pre-digestion protocols). (B) Trypsin digestion protocols for native and 
ProteoMinerTM processed synovial fluid. (C) ProteoMinerTM bead protein profiles 
following digestion protocols (red box indicates last stages of digestion were carried 
out in-solution, not on the beads). 
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Increased trypsin exposure time did not significantly increase the number of 
proteins identified for native SF (Figure 9). All ProteominerTM processed SF protocols 
resulted in an increased number of protein identifications compared to 
unprocessed native SF. Increased length in time of trypsin exposure increased the 
number of protein identifications for 4hr to 16hr + 2hr trypsin protocols, however a 
reduced number of proteins were identified following a 16hr + 16hr trypsin 
protocol. Neither repeated loading of native SF onto the column or reloading of 
flow-through increased the number of protein identifications, with both methods in 
fact leading to a reduction in the number of identifications. All trypsin digestion 
protocols in which Lys-C pre-digestion was included resulted in an increased 
number of protein identifications compared to the same protocol without a Lys-C 
pre-digest. Of all protocols examined, the 16hr Lys-C + 16hr + 2hr trypsin protocol 
resulted in the highest number of protein identifications. 
 
Figure 9. Number of Mascot protein identifications for native and ProteoMinerTM 
processed equine synovial fluid following different loading and protein digestion 
protocols involving trypsin ± Lys-C endopeptidase pre-digestion. Pilot study, 
n=1/digestion protocol. 
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2.4.2.7. Tryptic Peptide Reproducibility 
When the same trypsin digested sample vial was analysed via LC-MS/MS three 
times, reproducibility was high for all sample types, with 67-87% of identified 
peptides having a CV value of < 10% (Figure 10). Triplicate repeats of native SF 
digests provided a good level of reproducibility, with 78% of identified peptides 
having a CV value of < 20%. Following ProteoMinerTM processing and an on-bead 
digestion protocol, reproducibility was reduced to 57% of identified peptides having 
a CV value of < 20%. Analysis of flow-through tryptic peptides provided a 
reproducibility level between that of native SF and ProteoMinerTM processing and 
an on-bead digestion, with 61% of identified peptides having a CV value of < 20%. 
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Figure 10. (A) Technical reproducibility of tryptic peptide abundances following a 
16hr + 2hr trypsin digestion protocol of native equine SF with the same digested 
sample analysed three times and (B) digestion triplicates, (C) 2.5 mg protein loaded 
ProteoMinerTM columns with the same digested sample analysed three times and 
(D) digestion triplicates and (E) their subsequent flow-through, with the same 
digested sample analysed three times and (F) digestion triplicates. Peptide 
abundances were analysed via LC-MS/MS with a 2hr LC gradient and reproducibility 
calculated using peptide coefficient of variation (CV) values. 
 
A 4hr Lys-C pre-digestion prior to the standard on-bead 16hr + 2hr trypsin digestion 
protocol did not increase reproducibility in terms of CV values (Figure 11). However, 
Lys-C pre-digestion significantly reduced the average number of missed 
cleavages/peptide during the digestion protocol, with less variation in the number 
of missed cleavages per sample. Additionally, analysis using a non-supervised PCA 
approach, when applying a Lys-C pre-digestion step, reduced the variability 
between tryptic digestion protocols, providing a more consistent digestion. 
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Figure 11. Reproducibility of ProteoMinerTM processed synovial fluid protein digests 
with and without Lys-C endopeptidase pre-digestion. Tryptic peptide reproducibility 
of three technical replicates (A) with and (B) without a 4hr Lys-C pre-digestion prior 
to 16hr + 2hr on-bead trypsin digestion. (C) Average number of missed cleavages 
per peptide and (D) principal component analysis (PCA) of tryptic peptide profiles 
with (green) and without (red) Lys-C pre-digestion for a series of trypsin digestion 
protocols. Peptide abundances were analysed via LC-MS/MS with a 1hr LC gradient. 
CV = coefficient of variation. ** = p < 0.01. 
 
2.4.2.8. Semi-Tryptic Peptide Reproducibility 
For semi-tryptic peptide quantification, when using variations of a 4hr trypsin 
digestion protocol with a 1hr LC gradient, a 4hr on-bead trypsin digestion was by far 
the most reproducible, with 71% of peptides having a CV value of < 20% (Figure 12). 
A 4hr Lys-C pre-digestion substantially increased the number of identified peptides 
(38 to 265) although this was accompanied by a significant reduction in 
reproducibility, with only 29% of peptides having a CV value of < 20%. For 16hr + 
2hr trypsin digestion protocols with a 2hr gradient, digestion of native SF was the 
most reproducible, with 74% of peptides having a CV value of < 20%. Although 
ProteoMinerTM column processing increased the number of identified semi-tryptic 
peptides, both with and without a 4hr Lys-C pre-digestion step, reproducibility 
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dropped significantly, with 33% and 36% of peptides having a CV value of < 20% 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Reproducibility of semi-tryptic peptide abundances within equine 
synovial fluid analysed by technical triplicates. (A) Native synovial fluid, 4hr trypsin 
digestion, (B) Native synovial fluid, 16hr + 2hr trypsin digestion, (C) ProteoMinerTM 
processed synovial fluid, 4hr trypsin digestion, (D) ProteoMinerTM processed 
synovial fluid, 16hr + 2hr trypsin digestion, (E) ProteoMinerTM processed synovial 
fluid, 4hr Lys-C + 4hr trypsin digestion, (F) ProteoMinerTM processed synovial fluid, 
4hr Lys-C + 16hr + 2hr trypsin digestion. Native synovial fluid digestions were 
undertaken on 100 µg of protein and ProteoMinerTM columns were loaded with 2.5 
mg of protein. Protocols with a 4hr trypsin digestion component were analysed 
using a 1 hr liquid chromatography gradient whilst those containing a 16hr + 2hr 
trypsin digestion component were analysed via a 2 hr liquid chromatography 
gradient prior to tandem mass spectrometry analysis. CV = coefficient of variation. 
 
 
57 
 
2.5. Discussion 
In this study, protocols were optimised for collection and processing of SF for NMR 
metabolomic and LC-MS/MS proteomic analysis. Optimal NMR metabolome 
analysis required SF centrifugation followed by snap freezing in liquid nitrogen. 
Optimisation of LC-MS/MS proteomic analysis entailed treatment of SF with 1 µg/ml 
hyaluronidase and rotational incubation at 37°C for 1 hr with Lys-C endopeptidase 
pre-digestion greatly improving on-bead tryptic protein digestion when used in 
conjunction with small-capacity ProteoMinerTM column kits. For semi-tryptic 
peptide identification, a 16hr + 2hr tryptic digestion of native SF and a 4hr on-bead 
tryptic digestion were identified as the most reproducible protocols. 
SF is an important biofluid to further understand the pathogenesis of articular 
diseases, and identify specific biomarkers, as it is situated in close proximity to 
various tissues which are primarily altered by these pathologies (Anderson, Phelan, 
et al., 2018; Mateos et al., 2012). The use of global metabolite and protein profiling 
using systematic approaches, including NMR and LC-MS/MS, are becoming 
increasingly popular. However, to date, there are no agreed standardised published 
protocols available for collection and processing of SF for these platforms with 
reproducibility of on-bead digestions of ProteoMinerTM columns, used for peptide-
based depletion, yet to be investigated. 
Centrifugation of SF prior to freezing, removing cells and cellular debris, resulted in 
a distinct metabolome compared to SF which did not go through this processing 
step. It would therefore be recommended to undertake NMR metabolomic analysis 
on cellular-free SF, avoiding the variation and distinct changes that cell lysis and 
analysis of cellular contents that may incur on the SF metabolome. This current 
protocol is however unlikely to remove microvesicles, with a longer and faster 
centrifugation stage required to achieve this. Further work is required to investigate 
how the inclusion/exclusion of microvesicles would subsequently affect the SF 
metabolome. Different freezing method protocols did not result in distinct 
metabolic profiles, however snap freezing with liquid nitrogen was found to be the 
most consistent. Snap freezing with liquid nitrogen would therefore be the 
recommended gold standard freezing method for future studies. However, if SF has 
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been frozen using a different method, it may be acceptable to be included within 
the same study, provided that cellular material was removed prior to freezing. It 
should though be noted that freezing methods not involving liquid nitrogen will 
result in greater variation which may affect study results. It has also been found 
that storage of SF at low temperature for prolonged periods can alter the 
biochemical profile (Damyanovich et al., 2000). Therefore, to optimise study design 
when freezing is required, analysed SF should be stored for similar periods of time 
prior to analysis, with this time period kept to a minimum. Using the centrifugation 
and liquid nitrogen freezing protocol described in this study, we have also 
demonstrated this method to be reproducible in identifying consistent separate SF 
metabolite profiles for individual equine donors. 
Hyaluronidase breaks down hyaluronic acid and chondroitin sulphate through the 
cleavage of β-N-acetylhexosamine-(1,4)-glycosidic bonds, causing extracellular 
matrix breakdown and reduced SF viscosity, resulting in an increased number of 
protein identifications during LC-MS/MS analysis (Catterall et al., 2006; Stern and 
Jedrzejas, 2006). During this study, treatment with 0.75 µg/ml hyaluronidase 
resulted in sufficient digestion of hyaluronic acid, enabling efficient centrifugation 
through a 0.22 µm pore cellulose acetate membrane. In order to ensure complete 
digestion however, a treatment protocol of 1 µg/ml hyaluronidase would be 
recommended. However, during this study the effect on the number of proteins 
identified for each hyaluronidase concentration was not investigated. This therefore 
may be a relevant area for future study. 
Small-capacity ProteoMinerTM column kits recommend a minimum protein loading 
of 10 mg. However, with a maximum loading capacity of 1 ml, as SF protein 
concentrations are often less than 10 mg/ml (particularly for post mortem samples) 
this threshold for protein loading can often not be met (Yahia and El-Hakiem, 2014). 
Neither initial loading of 5 mg of protein followed by a repeated 5 mg protein load 
nor reloading of the resultant column flow-through led to an elevation in the 
number of identified proteins. However, reduced protein loads of 1 mg, 2.5 mg and 
5 mg were all found to significantly increase the number of proteins identified, with 
a 2.5 mg load also shown to be of acceptable reproducibility when undergoing an 
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on-bead protein digestion protocol. Thus, the small-capacity ProteoMinerTM column 
kit is still compatible with SF to achieve protein concentration dynamic range 
reductions, despite there being sub-optimal protein loading. 
As expected, for both native and ProteoMinerTM processed SF, longer LC gradients 
resulted in an increased number of protein identifications (Hsieh et al., 2013). For 
native SF a 120 min LC gradient resulted in only a small increase in the number of 
proteins identified compared to a 90 min LC gradient, 166 compared to 153 
proteins. As this small increase in protein identifications is likely to include less 
abundant proteins, which will also be identified within the ProteoMinerTM 
processed samples, if native and ProteoMinerTM processed SF are to be analysed 
within the same study, a 90 min LC gradient is sufficient for native SF analysis. For 
ProteoMinerTM processed SF however, a 120 min gradient identified substantially 
more proteins than a 90 min gradient and thus this would be a recommended 
gradient length for this sample type. 
Quantitative proteomic study approaches have become an important methodology 
for biomarker discovery within complex biological samples (Li et al., 2017). 
However, due to the multivariate nature of sample analysis, a large number of 
biological replicates are required in order to achieve an adequately powered study. 
Thus, when undertaking LC-MS/MS, analysing sufficient samples to achieve 
adequate study power can be cost prohibitive. Within this study, peptide carry-over 
onto the following sample run was found to be minimal and resultant sample 
contamination can therefore be considered insignificant. Inclusion of a ‘blank’ 
sample prior to the following run did result in a reduced number of peptides carried 
over and a reduced carry-over percentage of those identified, although these 
decreases were minimal. Thus, a gold standard approach would be to include a 
‘blank’ sample in between acquired sample spectra. However, excluding inter-
sample blanks will have a minimal impact on experimental analysis and may allow 
for an increased n number within experimental groups and subsequently a higher 
powered study and more robust statistical analysis. 
For all parameters investigated during this study, pre-digestion with Lys-C prior to 
tryptic digestion resulted in improved on-bead digestion, irrelevant of the tryptic 
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digestion protocol involved. Lys-C digestion resulted in a reduction of undigested 
proteins bound to ProteoMinerTM beads, a reduction in the number of peptide 
missed cleavages, improved reproducibility of tryptic peptide quantification and an 
increased number of protein identifications. Any of the protocols investigated 
during this study which included a Lys-C pre-digestion step would be acceptable for 
SF proteome analysis. Although a 16hr Lys-C + 16hr + 2hr trypsin protocol produced 
the highest number of protein identifications, despite a longer Lys-C incubation 
time, undigested bound proteins remained bound to the beads which may 
introduce variability. Although the reason for increased binding of undigested 
proteins following a 16hr Lys-C digestion compared to 4hr is unknown. 4hr Lys-C + 
16hr trypsin on-bead digestion protocols followed by 2hr trypsin digestion (on-bead 
and in solution) or 16hr trypsin in solution digestion all resulted in minimal levels of 
undigested proteins remaining bound to the beads. A second 16hr in-solution 
digestion did not result in an overall increase in the number of identified proteins. 
Therefore, our recommended on-bead digestion protocol would be a 4hr Lys-C pre-
digestion + 16hr tryptic digestion followed by a 2hr trypsin supplementation, either 
on-bead or in-solution.  
Reproducibility of quantifying tryptic peptides following protein concentration 
dynamic range compression of SF via ProteoMinerTM on-bead digestion has not 
previously been investigated. Although reproducibility decreased compared to 
native SF, as expected given the additional selective processing stage, 
reproducibility was still sufficient to retain confidence in this processing step and is 
certainly advantageous for biomarker discovery given the increased number of 
peptides identified. As LC-MS/MS analysis of SF is primarily used for discovery 
investigations, validation of native SF using orthologous methodologies, including 
Western blotting and enzyme-linked immunosorbent assays, would also provide 
greater confidence in the results. 
Semi-tryptic peptides are of interest within SF as increased enzymatic activity and 
cartilage breakdown during arthropathies, such as OA, lead to peptide degradation 
products which have potential as a diagnostic aid and disease stratification tool 
(Lotz et al., 2013). Of the protocols investigated, a 16hr + 2hr tryptic digestion of 
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native SF and a 4hr on-bead tryptic digestion were found to be the most 
reproducible for semi-tryptic peptide quantification. Although these protocols 
resulted in the fewest semi-tryptic peptide identifications, increased confidence in 
the semi-tryptic peptides identified is more advantageous, particularly given the 
time, cost and technical difficulty involved in the development of monoclonal 
antibodies which might lead on from potential neopeptide discovery (Caterson et 
al., 1985). Of these two protocols, a shorter, 4hr trypsin protocol would be 
recommended as longer trypsin incubations can lead to a greater number of non-
specific cleavages which may potentially generate false positive biological semi-
tryptic peptide identifications (Loziuk et al., 2013). Further validation of semi-tryptic 
peptides of interest would always be recommended, using a multiple reaction 
monitoring targeted MS/MS approach or carrying out digestion protocols in H218O 
water to separate biological semi-tryptic peptides from those generated via 
miscleavages during tryptic digestion (Havliš and Shevchenko, 2004; Mirgorodskaya 
et al., 2000; Parker and Borchers, 2014). 
2.5.1. Conclusion 
During this study we have optimised collection and processing protocols for NMR 
metabolomic and LC-MS/MS proteomic analysis of SF. For optimal metabolomic 
NMR analysis reproducibility, SF should first be centrifuged then frozen via snap 
freezing in liquid nitrogen. For proteomic analysis, treatment of SF with 1 µg/ml 
hyaluronidase and rotational incubation at 37oC for 1 hr provided sufficient 
enzymatic activity to enable efficient centrifugation through a 0.22 µm pore 
cellulose acetate membrane. Lys-C endopeptidase pre-digestion was identified to 
greatly improve on-bead tryptic protein digestion when used in conjunction with 
small-capacity ProteoMinerTM column kits, resulting in a reduction of undigested 
proteins bound to ProteoMinerTM beads, a reduction in the number of peptide 
missed cleavages, improved reproducibility of tryptic peptide quantification and an 
increased number of protein identifications. To maximise protein identifications 
using ProteoMinerTM columns, a 4hr Lys-C pre-digestion + 16hr tryptic digestion 
followed by a 2hr trypsin supplementation would be recommended. For semi-
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tryptic peptide identification, a 16hr + 2hr tryptic digestion of native SF and a 4hr 
on-bead tryptic digestion were found to be the most reproducible. 
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2.9. Supplementary Information 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Undigested proteins within twelve equine synovial fluid 
samples following a 16hr + 2hr on-bead tryptic digestion protocol using 
ProteoMinerTM beads. Protein gel stained using Coomassie Brilliant Blue. 
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3.1. Abstract 
Osteoarthritis (OA) is characterised by loss of articular cartilage, synovial membrane 
dysfunction and subchondral sclerosis. Few studies have used a global approach to 
stratify equine synovial fluid (SF) molecular profiles according to OA severity. SF was 
collected from 58 metacarpophalangeal (MCP) and metatarsophalangeal joints of 
racing Thoroughbred horses (Hong Kong Jockey Club; HKJC) and 83 MCP joints of 
mixed breed horses from an abattoir (biobank). Joints were histologically and 
macroscopically assessed for OA severity. For proteomics, native SF and SF loaded 
onto ProteoMiner™ equalisation columns, to deplete high abundant proteins, were 
analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and 
label-free quantification. ELISA validation of selected differentially expressed 
proteins was undertaken with clinical SF collected during diagnostic investigation. 
Native SF metabolites were analysed using 1D 1H Nuclear Magnetic Resonance 
(NMR). 1, 834 proteins and 40 metabolites were identified in equine SF. Afamin 
levels decreased with synovitis severity and four uncharacterised proteins 
decreased with OA severity. Gelsolin and lipoprotein binding protein decreased with 
OA severity and apolipoprotein A1 levels increased for mild and moderate OA. 
Within the biobank, glutamate levels decreased with OA severity and for the HKJC, 
2-aminobutyrate, alanine and creatine increased with severity. Proteomic and 
metabolomic integration was undertaken using linear regression via Lasso 
penalisation modelling, incorporating 29 variables (R2 = 0.82) with PC2 able to 
discriminate advanced OA from earlier stages, predominantly driven by H9GZQ9, 
F6ZR63 and alanine. Combining biobank and HKJC datasets, DAPC model prediction 
was good for mild OA (90%). This study has stratified equine OA using both 
metabolomic and proteomic SF profiles and identified a panel of markers of interest 
which may be applicable to grading OA severity. This is also the first study to 
undertake computational integration of NMR metabolomic and LC-MS/MS 
proteomic datasets of any biological system.
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3.2. Introduction 
The age-related degenerative musculoskeletal condition osteoarthritis (OA) is 
mainly characterised by articular cartilage degradation, synovitis, subchondral bone 
sclerosis and abnormal bone proliferation (Kramer, Tsang, et al., 2014; Truong et al., 
2006). OA is an important welfare issue for equids, with up to 60% of lameness 
cases attributed to OA, leading to substantial morbidity and mortality (Caron and 
Genovese, 2003; Ireland et al., 2011, 2012). Although it is known that degradation 
of the extracellular matrix (ECM) is driven by increased enzymatic activity of 
multiple matrix metalloproteinases (MMPs) and a disintegrin and 
metalloproteinases with thrombospondin motifs (ADAMTSs), the underlying 
pathogenesis of OA is yet to be fully understood (Li et al., 2007; Marhardt and 
Muurahainen, 2015; Struglics et al., 2006). Currently, equine OA is predominantly 
diagnosed through radiography, however due to the slow onset of the condition 
this often leads to substantial pathology of the joint and articular cartilage 
degradation prior to diagnosis (Brommer et al., 2003). There is therefore a need to 
develop accurate biomarkers of early OA which can be applied to a clinical setting 
and allow for timely intervention, as well as improving our understanding of OA 
pathogenesis and identifying potentially novel therapeutic targets. 
Currently, no equine OA-specific biomarkers have been identified to aid an early 
clinical diagnosis (Anderson, Phelan, et al., 2018). For human OA diagnosis, 
increased synovial fluid (SF) abundances of both matrix metalloproteinases (MMPs) 
and cartilage oligomeric matrix protein (COMP) have been identified as markers of 
interest (Balakrishnan et al., 2014). For horses, MMP activity has also shown OA 
diagnostic potential, however studies investigating COMP levels have shown 
conflicting results with SF COMP abundance unable to stage equine OA (Arai et al., 
2005; Bertuglia et al., 2016; Clegg et al., 1997; Misumi et al., 2001; Skiöldebrand et 
al., 2001; Taylor et al., 2006; Yamanokuchi et al., 2009; Zrimsek et al., 2007). 
However, these markers are generated following significant joint pathology, 
including substantial articular cartilage degradation, and thus there is a need to 
identify markers at an earlier disease stage, where intervention would provide the 
most benefit. 
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Palmar/plantar osteochondral disease (POD), located at the distal condyles of 
metacarpal III and metatarsal III, is a highly prevalent pathology of racehorses, 
resultant of repetitive joint overload during cyclic locomotion at high-speed (Barr et 
al., 2009; Kawcak et al., 2000; Pinchbeck et al., 2013). POD lesions range in severity, 
from mild to end-stage disease, and as the disease originates within the 
subchondral bone, provides an effective model to investigate subchondral bone 
mediated OA (Barr, 2010). 
The inner layer of the joint capsule consists of a one-cell thick lining of synoviocytes 
within a hyaluronic acid and collagen matrix, called the synovial membrane, which 
produces SF (Gibson and Rooney, 2007; Mahendran et al., 2017). SF primarily acts 
as a lubricant within the joint, protecting hyaline articular cartilage surfaces (Hui et 
al., 2012). However, SF also provides a pool of nutrients for surrounding tissues and 
a medium of cellular communication with the semi-permeable synovial membrane 
allowing passive protein transfer and synoviocytes secreting regulatory cytokines 
and growth factors (Blewis et al., 2007; Gibson and Rooney, 2007; Hui et al., 2012; 
Mahendran et al., 2017; Tamer, 2013). Due to the close relationship, both in terms 
of location and biological communication that SF holds with surrounding tissues 
which are primarily altered during OA, and its accessibility, SF can provide a unique 
source of chemical information and holds great promise for biomarker discovery 
(Anderson, Phelan, et al., 2018; Mateos et al., 2012). 
Various studies have utilised 1H nuclear magnetic resonance (NMR) to investigate 
metabolite markers associated with OA in various species, including pigs, dogs, 
humans and horses (Anderson, Phelan, et al., 2018; Damyanovich et al., 1999; Hugle 
et al., 2012; Lacitignola et al., 2008; Mickiewicz, Heard, et al., 2015; Mickiewicz, 
Kelly, et al., 2015). Lacitignola et al. identified a panel of ten metabolites which 
were elevated in equine OA SF compared to a normal control group. This panel 
included alanine, acetate, N-acetyl glucosamine, pyruvate, citrate, 
creatine/creatinine, choline, glycerol, lactate and α-glucose. However, no studies to 
date have used 1H NMR to stratify OA to identify changes to the metabolite profile 
at different stages of OA severity. 
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Several studies have used mass spectrometry (MS) based methodologies to 
investigate equine OA SF (Chiaradia et al., 2012; Peffers, McDermott, et al., 2015; 
Skiöldebrand et al., 2017; Svala et al., 2017). The relatively recent development of 
liquid chromatography tandem mass spectrometry (LC-MS/MS) has enabled a 
method which can quickly, with high sensitivity, quantify proteins present within 
biological fluids of high complexity (Mahendran et al., 2017). Protein biomarker 
discovery is however hindered by the large protein concentration dynamic range 
exhibited by SF, meaning that highly abundant proteins can mask those of less 
abundance (Puangpila et al., 2015; Roche et al., 2006). ProteoMinerTM protein 
enrichment columns (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) have 
however been developed which utilise combinational ligand library technology, 
depleting highly abundant proteins and subsequently enriching low abundance 
proteins to reduce this dynamic range (Fonslow et al., 2011; Furka et al., 1991; Lam 
et al., 1991). This methodology has successfully been used to investigate OA in 
equine SF (Peffers, McDermott, et al., 2015). However, this technique has not yet 
been utilised with SF to enable OA stratification, analysing SF at different OA 
severities. 
Increased activity of MMPs, ADAMTSs, cathepsins and serine proteases during OA 
leads to cartilage breakdown and the generation of OA-specific peptide degradation 
products (neopeptides) (Ben-Aderet et al., 2015; Peffers et al., 2016; Polur et al., 
2010). Numerous studies investigating equine tissue have identified potential OA 
neopeptides of interest using ex-vivo cartilage and SF (Peffers et al., 2014; Peffers, 
McDermott, et al., 2015; Peffers et al., 2016; Skiöldebrand et al., 2017). As OA 
neopeptides have also been shown to be a driver of OA pain, identification and 
quantification of neopeptides has the potential to stratify OA, providing markers of 
early OA pathology and providing potential novel OA therapeutic and analgesic 
targets (Miller et al., 2018). 
Within this study we have interrogated equine SF from horses with naturally 
occurring OA and those exhibiting POD pathology, as a subchondral bone mediated 
OA model using both 1H NMR metabolomics and LC-MS/MS proteomics to stratify 
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equine OA. This is the first study to use both techniques on the same samples and 
the first to statistically integrate NMR-led metabolomics with MS-based proteomics. 
3.3. Methods 
3.3.1. Sample Collection and Processing 
Equine post mortem samples were collected from both a commercial abattoir and 
The Hong Kong Jockey Club (HKJC) Equine Hospital in Hong Kong. Abattoir samples 
were collected from horses of mixed breed and sex and represented naturally 
occurring OA disease. HKJC samples were exclusively from Thoroughbred 
racehorses (aged 3-10 years old) with a high prevalence of POD, providing a model 
for subchondral bone mediated OA. 
3.3.2. Biobank - University of Liverpool 
Following euthanasia at the abattoir (F Drury & Sons, Swindon, UK) distal equine 
forelimbs were transported to the University of Liverpool. Within 8 hr of euthanasia 
the metacarpophalangeal (MCP) joint was opened aseptically and the distal 
metacarpal III photographed. SF was removed using a 10 ml syringe, transferred to 
a plain eppendorf, centrifuged at 2,540g and 4˚C for 5 min, supernatant removed, 
snap frozen in liquid nitrogen and stored at -80˚C (Figure 1). SF was separated into 
separate 1 ml eppendorfs prior to snap freezing to optimise study design prior to 
multi ‘omics’ analysis and integration (Cavill et al., 2016). Wedge sections of 
articular cartilage/subchondral bone (measuring 4 cm x 1.5 cm x 0.5 cm) were also 
sampled from the distal condylar region of metacarpal III, lateral to the sagittal 
ridge, and placed into 4% paraformaldehyde (PFA, Sigma-Aldrich, Gillingham, UK) in 
phosphate buffered saline (PBS, Sigma-Aldrich) (Supplementary Figure 1). Following 
decalcification in ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich), these 
were then sectioned and stained with Haematoxylin and eosin (H & E) (TCS 
Biosciences Ltd, Buckingham, UK) and Safranin O (BDH Chemicals, Poole, UK). 
Decalcification, sectioning and staining were undertaken by Ms Valerie Tilston. 
As biobank samples were obtained from a commercial abattoir, horses sampled 
were of mixed breed and sex and represented naturally occurring OA disease.
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Figure 1. Protocol for synovial fluid (SF) collection and processing prior to NMR metabolomic and LC-MS/MS proteomic analysis. MCP = 
metacarpophalangeal, MTP = metatarsophalangeal.
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3.3.4. Hong Kong Jockey Club 
HKJC samples were collected using the same collection protocols as used for the 
University of Liverpool equine biobank. In addition, synovial membranes were also 
dissected, fixed in 4% PFA and processed to prepare H & E stained histology slides. 
For HKJC samples, both MCP and metatarsophalangeal (MTP) joints were sampled. 
Following snap freezing with liquid nitrogen, frozen SF samples were shipped to 
Liverpool on dry ice. 
3.3.5. Clinical Synovial Fluid Collection for ELISA 
During clinical diagnostic investigations of horses presenting to The Philip 
Leverhulme Equine Hospital, University of Liverpool between 2014 and 2017, excess 
aspirated SF was collected and subsequently processed using the same processing 
steps as used for biobank and HKJC SF samples. Clinical OA was diagnosed via 
clinical examination, radiography and/or arthroscopy. Healthy/control SF samples 
were collected during clinical examinations, including diagnostic analgesia, whereby 
the joint involved was not identified as the cause of the current lameness. However, 
underlying joint pathology, not leading to a clinical manifestation, could not be 
ruled out. These clinical SF samples were used for enzyme-linked immunosorbent 
assay (ELISA) validations of protein abundances. 
3.3.6. Osteoarthritis Pathology: Macroscopic and Microscopic Scoring 
Biobank distal metacarpal III articular surfaces were assessed for macroscopic OA 
pathology using the equine OARSI scoring scale by two independent scorers 
(McIlwraith et al., 2010). Histological sections were also assessed for microscopic 
OA related pathology using the microscopic aspect of the equine OARSI scoring 
scale by two independent scorers. Within the HKJC group, distal metacarpal III 
samples were assessed macroscopically and microscopically for OA related and POD 
pathology using separate published scoring scales (Barr et al., 2009; Little et al., 
2010). Marginal remodelling and dorsal impact injury categories were excluded 
from the macroscopic scoring scale as these could not be scored using the joint 
photographs which were provided. Synovial membrane histological sections were 
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also scored according to synovitis severity (Krenn et al., 2006). Macroscopic scoring 
was carried out by two independent scorers whilst microscopic OA and synovitis 
grading was carried out by one scorer only as scoring was conducted historically and 
histological sections were unavailable for repeated assessment. For synovitis 
scoring, three separate regions of each slide were scored and then averaged. 
3.3.7. Metabolomics 
3.3.7.1. Sample Preparation - NMR 
SF was thawed out over ice and centrifuged for 15 min at 13,000g and 4°C. 150 µl of 
supernatant was then diluted to produce a final volume containing 50% (v/v) SF, 
40% (v/v) dd 1H2O, 10% (v/v) 1M PO43- pH 7.4 buffer (Na2HPO4, VWR International 
Ltd., Radnor, Pennsylvania, USA and NaH2PO4, Sigma-Aldrich) in deuterium oxide 
(2H2O, Sigma-Aldrich) and 0.0025% (v/v) sodium azide (NaN3, Sigma-Aldrich). 
Prepared samples were then vortexed for 1 min, centrifuged for 2 min at 13,000g 
and 4˚C and, using a glass pipette, 195 µl transferred into 3 mm outer diameter 
NMR tubes. 
3.3.7.2. NMR Acquisition 
All SF samples were individually analysed. A 700 MHz NMR Bruker Avance III HD 
spectrometer with associated TCI cryoprobe and chilled Sample-Jet autosampler 
was used to acquire all spectra. 1D 1H NMR spectra, using a Carr-Purcell-Meiboom-
Gill (CPMG) filter to attenuate macromolecule (e.g. protein) signals, were acquired 
using a standard cpmgpr1d vendor pulse sequence. Spectral acquisition was carried 
out at 37˚C with a 4 s interscan delay, 32 transients and a 15 ppm spectral width. 
Software programmes Topsin 3.1 and IconNMR 4.6.7 were used for acquisition and 
processing, carrying out automated phasing, baseline correction and a standard 
vendor processing routine (exponential window function with 0.3 Hz line 
broadening). 
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3.3.7.3. Metabolite Annotation and Identification 
All 1D 1H NMR spectra were scrutinised to make sure that the minimum reporting 
standards were met, as outlined by the Metabolomics Society (Sumner et al., 2007). 
Spectra were aligned to a single formate peak at 8.46 ppm. Chenomx NMR Suite 8.2 
(330-mammalian metabolite library) software was used to carry out metabolite 
annotations and relative abundances. Metabolite identifications were confirmed 
where possible using in-house 1D 1H NMR metabolite spectral library standards. 
3.3.8. Proteomics 
3.3.8.1. Synovial Fluid Processing and Protein Assay  
SF was thawed on ice and centrifuged at 4°C at 14,000g for 10 min. The supernatant 
was treated with 1µg/ml of hyaluronidase (bovine origin, Sigma-Aldrich) at 37˚C for 
1 hr, centrifuged at 1,000g for 5 min, supernatant removed and 1 ml centrifuged 
through a polypropylene microcentrifuge tube filter with 0.22 µm pore cellulose 
acetate membrane (Costar Spin-X, Corning, Tokyo, Japan) at 5000g for 15 min to 
remove remaining insoluble particulates (Mateos et al., 2012). A Pierce® 660 nm 
protein assay (Thermo Scientific, Waltham, Massachusetts, USA) was used to 
determine SF protein concentrations. 
3.3.8.2. ProteoMinerTM Column Processing 
2 mg of protein was loaded onto ProteoMiner™ Small Capacity bead columns (Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK) to achieve peptide-based depletion 
of the most abundant proteins. SF samples were rotated for 2 hr at room 
temperature and centrifuged at 1,000g for 60 s. ProteoMinerTM beads were then 
washed in PBS, rotated for 5 min and centrifuged at 1,000g for 60 s. The wash step 
was repeated two further times. 
3.3.8.3. Protein Digestion 
To assess both high and low abundance synovial proteins, both native and 
ProteoMinerTM processed SF were analysed. For native SF, 100 µg of protein was 
used for each protein trypsin digestion. 25 mM ammonium bicarbonate (Fluka 
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Chemicals Ltd., Gillingham, UK) containing 0.05% (w/v) RapiGest (Waters, Elstree, 
Hertfordshire, UK) was added to both native SF and peptide bound ProteoMinerTM 
beads to produce a final volume of 160 µl and heated at 80°C for 10 min. DL-
Dithiothreitol (Sigma-Aldrich) was added (3 mM final concentration) and incubated 
at 60°C for 10 min. Iodoacetamide (Sigma-Aldrich) was added (9 mM final 
concentration) and incubated at room temperature for 30 min in the dark. 
ProteoMinerTM processed samples then underwent an additional step which 
entailed the addition of 2 µg of Lys-C endopeptidase (FUJIFILM Wako Pure 
Chemical, Osaka, Japan) and incubation at 37˚C for 4 hr (Chapter 1). 2 µg of 
proteomics grade trypsin (Sigma-Aldrich) was added to all samples and rotated for 
16 hr at 37°C, followed by a second trypsin supplementation for 2 hr incubation. 
Digests were centrifuged at 1,000g for 1 min, supernatant removed, trifluoroacetic 
acid (TFA, Sigma-Aldrich) added (0.5% (v/v) final concentration) and rotated for 30 
min at 37°C. Digests were then centrifuged at 13,000g for 15 min at 4°C and the 
supernatant removed and stored at -80°C. To ensure complete protein digestion, 5 
µl of each digest was analysed by 1D SDS PAGE and stained with either Coomassie 
Blue (Bio-Rad) or silver stain (Thermo Scientific) following manufacturer instructions 
(data not shown). 
3.3.8.4. Sample Processing for Neopeptide Analysis 
After 4 hr of the 16 hr tryptic digestion of ProteoMinerTM processed samples, 10 µl 
was removed and supplemented with TFA and stored at -80°C using the same 
protocol as mentioned above.  
3.3.8.5. Label Free LC-MS/MS 
All SF digest samples underwent randomisation and were individually analysed 
using LC-MS/MS on an UltiMate 3000 Nano LC System (Dionex/Thermo Scientific) 
coupled to a Q ExactiveTM Quadrupole-Orbitrap instrument (Thermo Scientific). Full 
LC-MS/MS instrument methods are described in chapter 7. Tryptic peptides, which 
were equivalent to 200 ng of protein, were loaded onto the column and run over 60 
min, 90 min and 120 min LC gradients for 4 hr Lys-C + 4 hr tryptic digest 
ProteoMinerTM samples, native SF and 4 hr Lys-C + 16 hr + 2 hr tryptic digest 
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ProteoMinerTM processed samples respectively. Representative ion chromatograms 
are shown in Supplementary Figure 2. 
3.3.8.6. LC-MS/MS Spectra Processing and Protein Identification 
Progenesis™ QI 2.0 (Nonlinear Dynamics, Waters) software was used to process raw 
spectral files and undertake spectral alignment, peak picking, total protein 
abundance normalisation and peptide/protein quantification. The top ten spectra 
for each feature were then exported with peptide and protein identifications 
carried out with PEAKS® Studio 8.5 (Bioinformatics Solutions Inc., Waterloo, 
Ontario, Canada) using the reviewed Equus caballus database. Search parameters 
included: precursor mass error tolerance, 10.0 ppm; fragment mass error tolerance, 
0.01 Da; precursor mass search type, monoisotopic; enzyme, trypsin; maximum 
missed cleavages, 1; non-specific cleavage, none; fixed modifications, 
carbamidomethylation; variable modifications, oxidation or hydroxylation and 
oxidation (methionine). The false discovery rate (FDR) was set to 1% with only 
proteins identified with > 2 unique peptides used for quantitation. 
3.3.8.7. Semi-Tryptic Peptide Identification 
A ‘semi-tryptic’ search was undertaken to identify potential synovial neopeptides. 
PEAKS® search parameters were kept the same as those used for protein 
identifications, apart from ‘Non-specific Cleavage’ which was changed from ‘none’ 
to ‘one’. The exported ‘peptide ion measurements’ file from Progenesis™ was then 
analysed using an online neopeptide analyser software tool to identify only semi-
tryptic peptides and perform normalisation (Peffers et al., 2017). 
3.3.9. Batch Corrections 
ProteoMinerTM processed samples for both the biobank and HKJC cohorts were run 
in three separate batches on the Q ExactiveTM for protein analysis. To eliminate 
batch effects on the final analysis, a COMBAT batch correction was applied 
(Supplementary Figure 3) (Johnson et al., 2007). Metabolomic spectra were also 
acquired over 3 batches for both biobank and HKJC cohorts and data also 
underwent COMBAT batch correction.  
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3.3.10. ELISA Protein Validations 
Differentially expressed proteins apolipoprotein A1 (ApoA1), gelsolin and 
lipopolysaccharide binding protein (LBP) were selected for ELISA as commercially 
available kits were compatible with equine samples. Equine ApoA1 (MBS034194, 
MyBioSource Inc., San Diego, California, USA) and equine LBP (MBS062216, 
MyBioSource) utilised sandwich ELISA technology using undiluted SF whilst equine 
gelsolin (CSB-EL009965HO, Cusabio Technology LLC, Houston, Texas, USA) was a 
competitive inhibition assay with SF diluted 1:1250. 3-6 dependent (and 
independent where stated) SF samples were analysed per group. Aliquots of 100 µl 
were analysed in duplicate for each sample with absorbance measured at 450 nm 
and protein concentrations calculated from assay standard curves. Protein 
concentrations were normalised to total protein. 
3.3.11. Separate Dataset Statistical Analysis 
SF metabolite abundances underwent median normalisation and protein 
abundances were normalised to the total ion current (TIC). Before multivariate 
analysis, both metabolite and protein datasets underwent Pareto scaling (Worley 
and Powers, 2013). All principal component analysis (PCA), ANOVA and t-tests of 
metabolite, protein and neopeptide abundances were conducted using 
MetaboAnalyst 4.0 (http://www.metaboanalyst.ca). ELISA t-tests and ANOVAs were 
performed using Minitab version 17. For protein analysis an additional filter of > 2 
fold abundance was implemented. A p value of < 0.05 was considered statistically 
significant following correction for multiple testing using the Benjamini-Hochberg 
false discovery rate method (Benjamini and Hochberg, 1995). All box plots were 
produced using SPSS 24. 
3.3.12. NMR metabolomics and LC-MS/MS Proteomics Integration 
Metabolomic and proteomic data integration was conducted by Dr Eva Caamaño-
Gutiérrez at the Computational Biology Facility, University of Liverpool. Only 
datasets for horses which had both metabolite and protein abundance values were 
used for integration. Proteomics datasets were again normalised to the TIC whilst 
NMR datasets were normalised via probabilistic quotient normalisation (PQN) (Kohl 
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et al., 2012). When combining ProteoMinerTM processed SF and native SF protein 
abundances for the same SF sample, in which the same protein had been identified 
in both datasets, the higher abundance was included for analysis. The Mahalanobis 
distance on principal components was calculated and Chi-squared testing 
undertaken to identify potential outliers. When combining metabolite and protein 
variables, categorisation was carried out in accordance to macroscopic OA scoring. 
A linear regression, using Lasso (least absolute shrinkage and selection operator) 
penalisation to select the most important variables, was applied to combined 
datasets for both the biobank and HKJC sample groups. Additionally, correlations of 
all variables (proteins and metabolites) with macroscopic OA score were calculated, 
with significant variables (p < 0.05) included for further analysis. Significant 
variables across all analyses were then applied to a collective dataset, combing both 
biobank and HKJC results. This dataset was stratified into healthy, mild OA and 
severe OA and a discriminant analysis of principal components (DAPC) applied. All 
integration analyses were undertaken using standard analytical routines within the 
software package R (https://cran.r-project.org/). 
3.3.13. Uncharacterised Proteins 
Within this study, proteins which were considered uncharacterised were also 
analysed using BLAST (Basic local alignment search tool) to assess similarity of their 
amino acid sequence to characterised proteins within the Equus caballus database 
as well as other species (Altschul et al., 1990). Search parameters included: Matrix, 
blosum62; threshold, 0.1 E; filtering, none; gapped, true. 
3.3.14. Pathway Analysis 
Pathway analysis was conducted on proteins and metabolites which were 
considered significant variables for DAPC when carrying out NMR metabolomic and 
LC-MS/MS proteomic dataset integration. Metabolite pathway analysis was 
conducted using the online tool KEGG for Equus caballus with protein pathways also 
analysed using KEGG, via the STRING database (Ogata et al., 1999; Szklarczyk et al., 
2015). A filter of a minimum of two metabolites or proteins was set for inclusion of 
the relevant biological pathway. 
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3.4. Results 
3.4.1. Stratification Groups 
Interrater reliability score assessment for microscopic and macroscopic OA 
pathology scores of biobank samples and macroscopic OA pathology scores of HKJC 
samples identified good agreement with Cohen’s kappa coefficient scores of 0.78, 
0.70 and 0.69 respectively (McHugh, 2012). HKJC microscopic OARSI and synovitis 
scores were unable to be assessed as these were only scored once as slides were 
unavailable for second scoring. Histological microscopic OA scores vs macroscopic 
scores for biobank and HKJC samples both showed a weak positive correlation with 
R2 coefficient values of 0.12 and 0.17 respectively (Supplementary Figure 4). Where 
grading was carried out by two scorers, if the grading scores differed by more than 
1, a third scorer was used. For final grade scores an average of both scores was 
taken and grouped according to microscopic OA pathology, macroscopic OA 
pathology and synovitis scores (Table 1). Examples of gross and histological scores 
are shown in Figures 2 and 3. Although scored using different scoring systems, 
overall the HKJC samples exhibited a more severe OA phenotype. Macroscopically, 
scores were on average 30% of the highest possible score, compared to 14% within 
the biobank and microscopic scores 31% compared to 15% within the biobank. All 
scoring is shown in Supplementary Tables 3-7. Overall, the HKJC dataset was a 
younger cohort than the biobank cohort, with average ages of 6.6 ± 1.9 years and 
14.3 ± 7.6 years respectively (Supplementary Table 2).
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Table 1. Stratification groups according to microscopic osteoarthritis, macroscopic osteoarthritis and synovitis pathology used for synovial fluid 
LC-MS/MS proteomic and NMR metabolomic analysis. 
 
Abbreviations: OA = Osteoarthritis; Joints, MCP = Metacarpophalangeal joint, MTP = Metatarsophalangeal joint; Sex, M = male, F = Female. 
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Figure 2. Examples of macroscopic and microscopic osteoarthritis related pathology scoring for the biobank group using the equine OARSI 
scoring scale (McIlwraith et al., 2010). Macroscopic scoring was conducted on the distal metacarpal III articular surface. (A) Group 0, normal; (B) 
Group 1, grade 1 erosions; (C) Group 2, grade 1 erosions, grade 1 wear lines; (D) Group 3, grade 1 erosions, grade 2 wear lines, grade 2 palmar 
arthrosis. Microscopic scoring was conducted on wedge sections of articular cartilage/subchondral bone stained with haematoxylin and eosin 
(H & E) or Safranin O (Saf O). (E) grade 0 fissuring, grade 0 focal cell loss, grade 0 chondrone formation; (F) grade 0 fissuring, grade 1 focal cell 
loss, grade 2 chondrone formation; (G) grade 4 fissuring, grade 4 Saf O uptake. 
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Figure 3. Examples of macroscopic and microscopic osteoarthritis pathology scoring for the Hong Kong Jockey Club group using osteoarthritis 
related and palmar/plantar osteochondral disease (POD) pathology using published scoring scales (Barr et al., 2009; Little et al., 2010). 
Macroscopic scoring was conducted on the distal metacarpal III and metatarsal III articular surfaces. (A) Group 0, normal; (B) Group 1, grade 1 
POD, grade 2 wear lines, grade 1 cartilage loss; (C) Group 2, grade 3 POD, grade 2 wear lines, grade 3 cartilage loss. Microscopic scoring was 
conducted on wedge sections of articular cartilage/subchondral bone stained with haematoxylin and eosin (H & E). (E) grade 3 structure, grade 
0 chondrocyte density, grade 2 cell cloning; (F) grade 0 structure, grade 2 chondrocyte density, grade 2 cell cloning; (G) grade 4 structure, grade 
1 chondrocyte density, grade 0 cell cloning. 
 
82 
 
3.4.2. NMR Metabolomics 
Overall, both the biobank and HKJC SF 1D 1H NMR spectra produced similar profiles, 
although quantile plots revealed the biobank group exhibited more variation 
between samples (Supplementary Figure 5). In total, 40 metabolites were identified 
within equine SF (Table 2). For the biobank cohort, unsupervised multivariate PCA 
did not identify separation between OA grades based on microscopic or 
macroscopic scoring (Figure 2). However, when stratified according to macroscopic 
grade, glutamate levels were found to be differentially abundant, with lower levels 
identified at grades 2 and 3 compared to 1. PCA also did not identify clear 
separation between severity grades of OA or synovitis for HKJC SF samples (Figure 
3). When stratified according to macroscopic OA pathology, three metabolites were 
found to be differentially abundant. 2-aminobutyrate levels were increased at 
grades 1 and 2 compared to 0 and alanine and creatine levels were increased with 
OA severity. 
 
Table 2. Synovial fluid metabolites identified using Chenomx software. Metabolites 
which had also undergone identification using a 1D 1H NMR in-house spectral library 
were assigned to Metabolomics Standards Initiative (MSI) level 1 (Salek et al., 2013). 
 
Database 
Identifier 
Metabolite 
Identification 
Reliability 
HMDB00650 2-Aminobutyrate MS Level 2 
HMDB00357 3-Hydroxybutyrate MS Level 2 
HMDB00754 3-Hydroxyisovalerate MS Level 2 
HMDB01149 5-Aminolevulinate MS Level 2 
HMDB00042 Acetate MS Level 1 
HMDB00194 Anserine MS Level 2 
HMDB00043 Betaine MS Level 1 
HMDB00097 Choline MS Level 1 
HMDB00094 Citrate MS Level 1 
HMDB00064 Creatine MS Level 1 
HMDB01511 Creatine phosphate MS Level 2 
HMDB00562 Creatinine MS Level 1 
HMDB00122 D-Glucose MS Level 1 
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HMDB04983 Dimethyl sulfone MS Level 2 
HMDB00142 Formate MS Level 2 
HMDB00123 Glycine MS Level 1 
HMDB00128 Guanidoacetate MS Level 2 
HMDB00172 Isoleucine MS Level 1 
HMDB00190 Lactate MS Level 1 
HMDB00161 L-Alanine MS Level 1 
HMDB00062 L-Carnitine MS Level 2 
HMDB00174 L-Fucose MS Level 2 
HMDB00148 L-Glutamate MS Level 1 
HMDB00641 L-Glutamine MS Level 1 
HMDB00177 L-Histidine MS Level 1 
HMDB00687 L-Leucine MS Level 1 
HMDB00159 L-Phenylalanine MS Level 1 
HMDB00158 L-Tyrosine MS Level 1 
HMDB00883 L-Valine MS Level 1 
HMDB00691 Malonate MS Level 2 
HMDB01844 Methylsuccinate MS Level 2 
HMDB31419 N-Nitrosodimethylamine MS Level 2 
HMDB00895 O-Acetylcholine MS Level 2 
HMDB00243 Pyruvate MS Level 1 
HMDB00254 Succinate MS Level 1 
HMDB00294 Urea MS Level 1 
HMDB00296 Uridine MS Level 1 
HMDB00292 Xanthine MS Level 2 
HMDB00001 π-Methylhistidine MS Level 2 
HMDB00001 τ-Methylhistidine MS Level 2 
 
Metabolomics Standards Initiative definitions: MS Level 1 = Identified metabolite 
using two or more orthogonal properties of an authentic chemical standard 
analysed in the researcher’s laboratory. MS Level 2 = Putatively annotated 
metabolite which does not require matching to data for authentic chemical 
standards acquired within the same laboratory. 
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Figure 2. Principal component analysis (PCA) of metabolite profiles of equine 
biobank synovial fluid grouped according to (A) OARSI microscopic (n=70) and (B) 
OARSI macroscopic (n=76) grading. (C) Glutamate abundances according to 
macroscopic osteoarthritis grading. ANOVA: ** = p < 0.01 and *** = p < 0.001. 
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Figure 3. Principal component analysis (PCA) of metabolite profiles of equine Hong 
Kong Jockey Club (HKJC) synovial fluid (SF) grouped according to (A) OARSI 
microscopic (n=50), (B) OARSI macroscopic (n=50) and (C) synovitis (n=56) grading. 
For OARSI macroscopic grading, (D) 2-aminobutyrate, (E) alanine and (F) creatine 
were identified as being differentially abundant between osteoarthritis severity 
grades. ANOVA: * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
3.4.3. LC-MS/MS Proteomics 
Within the biobank cohort, 74 native SF samples were analysed with 68 of these 
additionally processed using ProteoMinerTM columns. For the HKJC group, 56 native 
SF samples were analysed with 55 of these additionally having also undergone 
ProteoMinerTM processing. In total, across all samples 1, 834 proteins were 
identified (Figure 4). A combination of an increase in LC gradient length and 
ProteoMinerTM processing resulted in a 168% increase in the overall number of 
identified proteins compared to native SF analysis. 
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Figure 4. Number of proteins identified within native and ProteoMinerTM processed 
equine synovial fluid using liquid chromatography-tandem mass spectrometry. 
Search criteria included > 2 unique peptides with an FDR of 1%. LC = liquid 
chromatography. 
 
For biobank and HKJC groups, when categorised according to macroscopic OA 
severity, PCA identified that increased OA severity resulted in less variation 
between samples (Figure 5). However, this was not evident when categorised 
according to microscopic OA grading. For native SF biobank samples categorised 
according to macroscopic grading, the abundance of three uncharacterised proteins 
and immunoglobulin kappa constant decreased with increasing OA severity. An 
uncharacterised protein (a member of the superfamily containing a leucine-rich 
repeat) and ApoA1 abundances both increased initially with OA pathology but then 
returned towards baseline with greater OA severity. Microscopic OA categorisation 
for native SF biobank as well as macroscopic and microscopic OA categorisation of 
native SF HKJC samples did not identify any differentially abundant proteins. The 
proteomes of native SF HKJC samples, categorised according to synovitis grade, 
were not separated via PCA (Figure 6). However, the abundance of afamin was 
identified as differentially abundant between low and high grade synovitis, 
decreasing with synovitis severity. ProteoMinerTM processing of both biobank and 
HKJC SF did not identify any differentially abundant proteins or distinct proteome 
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clusters (PCA) for any OA or synovitis categorisations (Supplementary Figures 6 and 
7). However, LC-MS/MS analysis of ProteoMinerTM processed biobank SF identified 
trends in gelsolin and LBP abundance, decreasing with increasing OA severity 
(Figure 7). ELISA analysis of gelsolin using the same SF samples that were analysed 
by LC-MS/MS corroborated this finding and was additionally supported by an 
independent clinical cohort, with gelsolin abundance lower in clinical OA cases 
compared to controls. LBP ELISA analysis of both dependent and independent SF 
samples also supported the trend identified via LC-MS/MS, although statistical 
significance was not reached. For biobank native and ProteoMinerTM processed SF 
we identified a trend that ApoA1 increased initially with OA severity and 
subsequently decreased. This trend was supported by ApoA1 ELISA analysis using 
dependent SF samples; however statistical significance was not reached. 
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Figure 5. Principal component analysis (PCA) of the biobank native synovial fluid 
proteome categorised by (A) macroscopic osteoarthritis (OA) grade and (B) 
microscopic OA grade using LC-MS/MS. (C-H) Differentially expressed proteins when 
categorised according to macroscopic OA grade. ANOVA: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001. Macroscopic OA, n=66, Microscopic OA, n=70. 
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Figure 6. Principal component analysis (PCA) of the Hong Kong Jockey Club (HKJC) 
native synovial fluid proteome profile categorised by (A) macroscopic osteoarthritis 
(OA) grade (n=49), (B) microscopic OA grade (n=49) and (C) synovitis grade (n=53) 
using LC-MS/MS. (D) Differential expression of afamin identified between synovitis 
grade 1 and 2. t-test: * = p < 0.05. 
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Figure 7. Abundances of gelsolin, lipopolysaccharide binding protein (LBP) and 
apolipoprotein A1 (ApoA1) within equine synovial fluid via LC-MS/MS (A, D & G) and 
ELISA validation using dependent (B, E & H) and independent (C & F) synovial fluid 
samples according to osteoarthritis (OA) grade. LC-MS/MS; HKJC, n=47; Biobank, 
n=60; ELISA, n=3-6/group. ANOVA and t-tests: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001. LC-MS/MS p values corrected for multiple testing within sample, but not for 
entire dataset. 
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3.4.3.1. Semi-Tryptic Peptide Profiles 
No semi-tryptic peptides arising from ECM proteins were identified which were 
more highly abundant at more severe OA levels and thus no potential neopeptide 
biomarkers were identified. Neither for the biobank or HKJC groups were distinct 
profiles identified between severities of OA (Figure 8). For the HKJC group there was 
less intra-group variation identified with increased levels of OA and synovitis 
pathology. However, conversely for the biobank group, samples with no OA 
pathology showed the least variation. 
 
Figure 8. Principal component analysis (PCA) of equine synovial fluid semi-tryptic 
peptide profiles grouped according to (A) microscopic osteoarthritis (n=62) and (B) 
macroscopic osteoarthritis (n=59) severity for the biobank cohort and (C) 
microscopic osteoarthritis (n=46), (D) macroscopic osteoarthritis (n=46) and (E) 
synovitis (n=53) severity for the Hong Kong Jockey Club (HKJC). 
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3.4.4. NMR metabolomics and LC-MS/MS Proteomics Integration 
For the HKJC dataset, linear regression using Lasso penalisation modelling was 
unable to select a suitable number of parameters without overfitting the model. 
However, correlation analysis of all variables (proteins and metabolites) identified 
58 significant variables, with a range in correlation from -0.48 to 0.42 (Table 3). 
Using these selected variables, PCA identified less variation between samples with 
more severe macroscopic OA scores, although their grouping could not clearly be 
distinguished from lower scoring samples (Figure 9).  
  
Table 3. Correlation of each variable (proteins and metabolites) to macroscopic OA 
score for the Hong Kong Jockey Club synovial fluid integrated dataset. p < 0.05. 
 
Variable Correlation Permutation 
p value 
Characterisation 
P60708 -0.44 0 Actin, cytoplasmic 1 
HMDB00001 0.37 0 τ-Methylhistidine 
F6UL68 -0.45 0 Transthyretin 
F6VCB4 -0.36 0 Histone H3 
F6VS95 -0.48 0 Protein disulfide isomerase family A member 6 
F6W3T1 -0.38 0 L-lactate dehydrogenase 
F6YNM7 -0.36 0 Prolyl endopeptidase 
F6YRC5 -0.39 0 IQ motif containing GTPase activating protein 1 
F6YRE0 -0.36 0 Tubulin alpha chain 
F6ZMJ5 -0.40 0 ATPase H+ transporting V1 subunit E2 
F7ABC9 -0.38 0 Fibulin-1 
F7D8W6 -0.43 0 Guanylate binding protein 2 
F7DNT0 -0.42 0 Tubulin alpha chain 
F7DYV0 -0.43 0 Galectin 
A2Q0Z0 -0.28 0.01 Elongation factor 1-alpha 1 
Q28372 -0.35 0.01 Gelsolin 
F6T0P6 -0.36 0.01 GC, vitamin D binding protein 
F6UZI2 -0.35 0.01 Coagulation factor XIII A chain 
F6V6L8 -0.36 0.01 IQ motif containing GTPase activating protein 2 
F6YIU8 -0.39 0.01 Methylenetetrahydrofolate dehydrogenase, 
cyclohydrolase and formyltetrahydrofolate 
synthetase 1 
F6YXS1 0.37 0.01 Receptor protein-tyrosine kinase 
F6ZFH9 -0.39 0.01 Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein gamma 
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F7AYC1 -0.31 0.01 Secreted phosphoprotein 1 
F7BNQ2 -0.36 0.01 Complement component 4 binding protein 
alpha 
F7BQD6 0.35 0.01 Complement C1s 
F7CYG2 -0.38 0.01 Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein eta 
HMDB00062 0.35 0.02 Carnitine 
HMDB00190 -0.33 0.02 Lactate 
F6QXN5 -0.34 0.02 Transgelin 
F6S0P5 -0.34 0.02 ADP ribosylation factor 4 
F6S2C3 -0.33 0.02 Cathepsin Z 
F6UN85 -0.40 0.02 Carboxylic ester hydrolase 
F6Y0G5 0.42 0.02 Periostin 
F6Y4J0 -0.31 0.02 ATPase H+ transporting V1 subunit B2 
F6Z8W0 -0.36 0.02 WD repeat domain 1 
F7APS1 -0.27 0.02 Uncharacterised 
F7BM69 -0.31 0.02 Uncharacterised 
F7BTK9 -0.36 0.02 Family with sequence similarity 129 member A 
F7DA17 -0.39 0.02 Transglutaminase 2 
F7DEW5 -0.31 0.02 Coronin 
F7DXM5 0.32 0.02 Uncharacterised 
HMDB00161 0.29 0.03 L-Alanine 
F6PKE1 -0.33 0.03 Uncharacterised 
F6QKR7 -0.38 0.03 Myocilin 
F6RCA8 -0.34 0.03 Peroxiredoxin 5 
F6YV40 -0.31 0.03 Glyceraldehyde-3-phosphate dehydrogenase 
F6YV53 -0.31 0.03 Actinin alpha 4 
HMDB00122 0.30 0.04 D-Glucose 
Q95182 -0.34 0.04 Major allergen Equ c 1 
F6RMN2 -0.34 0.04 Drebrin like 
F6SN52 -0.34 0.04 Eukaryotic translation initiation factor 5A 
F6SP02 -0.33 0.04 Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein theta 
F6T201 -0.29 0.04 Chondroitin sulfate proteoglycan 4 
F6UF75 -0.33 0.04 Protein S100 
F6WWW7 -0.32 0.04 Capping actin protein of muscle Z-line alpha 
subunit 1 
F6XEB4 -0.36 0.04 Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta 
F7B320 -0.32 0.04 Dihydropyrimidinase like 2 
H9GZU9 -0.30 0.04 Uncharacterised 
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Figure 9. Principal component analysis (PCA) using 58 selected variables (proteins 
and metabolites) for the Hong Kong Jockey Club synovial fluid combined datasets 
(n=43) following batch correction, grouped according to macroscopic osteoarthritis 
score. OA = osteoarthritis. 
 
For the biobank dataset, Lasso penalisation produced a model incorporating 29 
variables (Supplementary Table 1). This produced a good model (R2 = 0.82) with PC2 
able to discriminate more advanced stages of OA from the earlier stages (Figure 10). 
This model was predominantly driven by two uncharacterised proteins (H9GZQ9 
and F6ZR63) and alanine. Correlation analysis of all variables (proteins and 
metabolites) identified 32 significant variables, with a range in correlation from -
0.44 to 0.49 (Table 4). 
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Figure 10. (A) Principal component analysis (PCA) following Lasso model selection 
using the top 29 variables of influence for biobank synovial fluid, integrating 
metabolite and protein abundances and grouped according to macroscopic 
osteoarthritis scoring. (B) Top 14 variables of influence contributing to the model. 
n=60. 
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Table 4. Correlation of each variable (proteins and metabolites) to macroscopic OA 
score for the biobank synovial fluid integrated dataset. p < 0.05. 
Variable Correlation Permutation 
p value 
Characterisation 
H9GZS6 -0.44 0 Uncharacterised 
F7BFT1 -0.43 0 Peroxiredoxin 2 
F6Q4N3 -0.41 0 Neural EGFL like 2 
F6WCB7 -0.40 0 Cytokine like 1 
F6ZR63 -0.38 0 Uncharacterised 
H9GZU9 -0.37 0 Uncharacterised 
F6RRV1 -0.35 0 Fetuin B 
P35747 0.33 0 Serum albumin 
Q28369 0.34 0 Retinol-binding protein 4 
F6X667 0.34 0 Vitamin K-dependent protein C 
F7A1W7 0.49 0 Apolipoprotein C2 
H9GZV0 -0.34 0.01 Uncharacterised 
F6SP11 -0.32 0.01 Uncharacterised 
F6ZRF6 -0.31 0.01 Serpin family A member 7 
F6QF58 -0.31 0.01 60S ribosomal protein L6 
H9GZQ9 -0.29 0.01 Uncharacterised 
F7ASE1 0.32 0.01 Interleukin 1 receptor accessory protein 
F6RM73 0.36 0.01 Apolipoprotein A-II 
F7DRS2 -0.33 0.02 Serpin family A member 6 
F6WLX9 -0.29 0.02 tRNA-splicing ligase RtcB homolog 
F6XPL9 -0.27 0.02 Obg-like ATPase 1 
F6XI92 -0.27 0.02 Bridging integrator 2 
F6YV40 0.21 0.02 Glyceraldehyde-3-phosphate dehydrogenase 
F7DBT2 0.27 0.02 Complement C1q C chain 
F6PRI5 0.28 0.02 Carboxylic ester hydrolase 
F6T0P6 0.32 0.02 GC, vitamin D binding protein 
F6UCZ2 -0.24 0.03 Translin 
HMDB00562 0.30 0.03 Creatinine 
F6XWJ6 -0.32 0.04 RUN and FYVE domain containing 1 
F6V1V8 -0.27 0.04 Cluster of differentiation 109 
F7BA94 -0.20 0.04 40S ribosomal protein S3 
F7AS57 0.24 0.04 Proteasome activator subunit 2 
 
Combining both the biobank and HKJC datasets, including significant protein and 
metabolite variables, DAPC analysis produced a model whereby OA severity 
prediction was good for mild OA (90%) although this was reduced significantly for 
healthy (57%) and severe OA (35%) classifications (Figure 11). Linear discriminant 1 
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was driven predominantly by neural EGFL like 2, serum albumin and alanine whilst 
linear discriminant 2 was driven by periostin, gelsolin and myocilin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. (A) Discriminant analysis of principal components (DAPC) of selected 
variables (proteins and metabolites) for a combined biobank and Hong Kong Jockey 
Club synovial fluid dataset (n=103), built using 20 principal components and two 
linear discriminants. (B) Top 25% of variables for the DAPC model contributing to 
linear discriminant 1 and (C) linear discriminant 2. Macroscopic osteoarthritis (OA) 
scoring; Healthy = 0, Mild OA = 1-3, Severe OA = 4-8. 
 
3.4.5. Uncharacterised Proteins 
BLAST analysis of amino acid sequences of 12 uncharacterised proteins included 
within this study identified various related characterised proteins. The characterised 
protein with the highest percentage amino acid sequence similarity for each 
uncharacterised protein is shown in Table 5.
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Table 5.  BLAST analysis of amino acid sequences of uncharacterised proteins included within this study, identifying the characterised protein 
with the highest percentage amino acid sequence similarity for each uncharacterised protein. 
 
Accession 
Number of 
Uncharacterised 
Protein 
Analysis Present In 
Accession 
Number of 
Similar Protein 
Similar Protein Species E-Value 
Similarity 
(%) 
F6PKE1 
HKJC Macroscopic OA Correlation 
A0A340XC13 Inhibitor of carbonic anhydrase-like isoform X1  Lipotes vexillifer 0 77.2 
DAPC Linear Discriminant 2 
F6S2I3 Biobank Lasso Model A0A1U7U041 Glutathione S-transferase  Tarsius syrichta 4.60 e-144 88.5 
F6SP11 Biobank Macroscopic OA Correlation A0A0A1E4I0 Immunoglobulin lambda light chain variable region Equus caballus 8.10 e-60 100.0 
F6TED1 
Native (Macroscopic OA) 
A0A091E338 Immunoglobulin kappa chain V-III region MOPC 63  Fukomys damarensis 2.20 e-44 70.1 
Biobank Lasso Model 
F6ZR63 
Biobank Macroscopic OA Correlation 
A0A383YWT8 Complement factor H-like isoform X1 
Balaenoptera 
acutorostrata scammoni 
0 68.6 DAPC Linear Discriminant 1 
Biobank Lasso Model 
F7APS1 HKJC Macroscopic OA Correlation Q862Z5 Cystatin-B  Macaca fuscata fuscata 2.30 e-57 87.8 
F7BM69 HKJC Macroscopic OA Correlation A0A337SQC1 Immunoglobulin kappa variable 4-1  Felis catus 1.50 e-56 77.4 
F7DXM5 HKJC Macroscopic OA Correlation B5BV10 Alpha-1-antitrypsin  Equus caballus 0 98.1 
H9GZQ9 
Biobank Macroscopic OA Correlation 
Q95M34 Immunoglobulin gamma 1 heavy chain constant region Equus caballus 0 99.7 
Biobank Lasso Model 
H9GZS6 
Native (Macroscopic OA) 
Q95M34 Immunoglobulin gamma 1 heavy chain constant region Equus caballus 7.40 e-173 70.1 
Biobank Macroscopic OA Correlation 
H9GZU9 
Native (Macroscopic OA) 
Q95M34 Immunoglobulin gamma 1 heavy chain constant region  Equus caballus 1.10 e-159 67.9 HKJC Macroscopic OA Correlation 
Biobank Macroscopic OA Correlation 
H9GZV0 Biobank Macroscopic OA Correlation L5JR68 Immunoglobulin epsilon chain C region  Pteropus alecto 0 65.0 
 
Abbreviations: DAPC, Discriminant analysis of principal components; HKJC, Hong Kong Jockey Club; OA, Osteoarthritis
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3.4.6. Pathway Analysis 
Pathway analysis conducted on proteins and metabolites which were considered 
significant variables during DAPC modelling, when carrying out NMR metabolomic 
and LC-MS/MS proteomic dataset integration, identified the complement and 
coagulation cascades pathway and ABC transporters pathway to be the most 
represented (Tables 6 and 7). These pathways consisted of 7/96 proteins and 4/9 
metabolites included within the pathway analysis respectively. 
 
Table 6. Pathway analysis conducted on proteins which were considered significant 
variables during DAPC modelling, when carrying out NMR metabolomic and LC-
MS/MS proteomic dataset integration. 
 
Pathway 
ID 
Pathway Description 
Number of 
Proteins in 
Pathway 
False 
Discovery 
Rate 
4610 Complement and coagulation cascades 7 0.00000573 
4145 Phagosome 6 0.00498 
4390 Hippo signalling pathway 5 0.0188 
 
Table 7. Pathway analysis conducted on metabolites which were considered 
significant variables during DAPC modelling, when carrying out NMR metabolomic 
and LC-MS/MS proteomic dataset integration. 
 
Pathway ID Pathway Description 
Number of 
Metabolites in 
Pathway 
2010 ABC transporters  4 
4978 Mineral absorption  3 
10 Glycolysis / Gluconeogenesis 2 
4974 Protein digestion and absorption 2 
340 Histidine metabolism 2 
4066 HIF-1 signalling pathway 2 
4976 Bile secretion 2 
4922 Glucagon signalling pathway 2 
970 Aminoacyl-tRNA biosynthesis 2 
1230 Biosynthesis of amino acids 2 
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3.5. Discussion 
Equine OA is currently predominantly diagnosed through radiography and clinical 
examination, however, due to the slow onset of the condition this often leads to 
substantial pathology of the joint and articular cartilage degradation prior to 
diagnosis (Brommer et al., 2003). Presently, no equine OA-specific biomarkers have 
been identified which are able to accurately diagnose and stratify OA with none 
used to aid an earlier clinical diagnosis (Anderson, Phelan, et al., 2018). Within this 
study we have investigated equine SF of varying severities of associated OA 
pathology using both NMR-led metabolomics and MS-based proteomics 
approaches. 
Although both the biobank and HKJC datasets produced a degree of OA 
stratification, markers of interest were generally distinct. This may be reflective of 
the more severe OA phenotype demonstrated by the HKJC horses, whilst markers 
identified within the biobank represent a subtler grade of OA. Alternatively, the 
differences in markers identified may be due to the varying OA aetiologies, with the 
biobank representing a naturally occurring OA whilst the HKJC horses demonstrate 
a POD model for subchondral bone mediated OA, which is associated with trauma 
and overload (Barr, 2010). Additionally, the biobank cohort is on average an older 
donor group than the HKJC cohort which may also account for differences between 
the datasets. 1H NMR SF spectra were more variable between biobank donors 
compared to the HKJC donors. This is likely because the biobank is a more 
heterogeneous population, including age, breed, work done and diet. The HKJC 
group is a much more controlled sample set, with all horses housed together, all 
Thoroughbred racehorses, generally fed and trained similarly and all of a similar age 
at euthanasia. These differentials may also reflect the different markers of interest 
identified between the biobank and HKJC groups. 
Proteomic analysis of biobank samples identified several proteins which were able 
to discriminate a healthy phenotype from early OA changes. Although these 
proteins were largely uncharacterised, BLAST analysis of the amino acid sequences 
of three uncharacterised proteins, decreasing in abundance with OA severity, 
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identified high levels of similarity to immunoglobulin gamma 1 heavy chain constant 
region and immunoglobulin kappa chain V-III region MOPC 63 proteins. However, 
abundances of these uncharacterised proteins could not be validated using 
antibody methodologies. Recently, a study investigating the SF proteome of a 
surgery-induced OA model in rabbits identified reduced levels of immunoglobulin 
heavy chain protein compared to sham controls (Luo et al., 2018). Immunoglobulins 
have previously been identified within superficial articular cartilage layers of a 
proportion of OA patients as well as elevated levels found within the synovial 
membrane of dogs diagnosed with cranial cruciate ligament rupture (Cooke et al., 
1975; Lawrence et al., 1998). Thus, reduction of these immunoglobulins within the 
SF may be reflective of their translocation to surrounding articular tissues. 
3.5.1. Glutamate 
Glutamate is an excitatory amino acid neurotransmitter within the central nervous 
system, although evidence also suggests glutamate operates through intercellular 
signally cascades, as an autocrine/paracrine factor, in non-neuronal tissues (Wen et 
al., 2015). A self-sufficient glutamate signalling machinery has been identified 
within chondrocytes with a peripheral NMDA receptor proposed to have a role 
within inflammation and cartilage degradation (Piepoli et al., 2009). Within our 
study, the biobank group showed a reduction in synovial glutamate levels at higher 
OA severities. Previously, elevated levels of glutamate have been identified within 
OA SF of humans and within an OA rat models (Jean et al., 2005; Lawand et al., 
2000; McNearney et al., 2000). However, no increase in glutamate was identified 
with equine OA SF using 1H NMR, although it is not clear whether glutamate was 
identified during this study (Lacitignola et al., 2008). The disparity between the 
lower glutamate levels identified within the biobank group and elevated levels 
within the literature may be reflective of the subtler OA phenotype exhibited by the 
biobank samples, and they may be indicative of glutamate levels at an earlier OA 
severity. However, the HKJC dataset, reflective of a higher grade OA, did not 
identify differential abundance. Therefore, at this stage the relationship between 
synovial glutamate abundance and equine OA remains inconclusive.  
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3.5.2. Creatine 
Creatine is a nonessential amino acid involved in cellular energy metabolism, 
maintaining cellular adenosine triphosphate (ATP) levels, in particular within the 
muscle and brain (da Silva et al., 2014). Creatine SF levels increased with OA 
severity, which is supported by previous human and equine studies which also 
identified elevated SF creatine in OA SF (Ciurtin et al., 2006; Lacitignola et al., 2008). 
Approximately 95% of stored creatine is located within skeletal muscle (Snow and 
Murphy, 2001). Thus, given the association of muscle atrophy with OA, this 
elevation in synovial creatine may be reflective of an associated muscle mass loss 
(Porter, 2005). 
3.5.3. Alanine 
Within this study, alanine levels were identified to be increasing in SF in accordance 
with OA severity, which was also observed by Lacitignolia et al. (Lacitignola et al., 
2008). Previously, depleted alanine abundance has been identified within human 
OA cartilage using high resolution magic angle spinning NMR spectroscopy (Shet et 
al., 2012). As alanine is one of the main amino acid residues which constitutes 
collagen, it may be that the reduction in alanine abundance identified with OA 
cartilage is resultant of degradation of the cartilage collagen framework, which are 
subsequently released into the SF resulting in the elevated synovial abundance 
within this study (Huster et al., 2004; Shet et al., 2012).  
3.5.4. Gelsolin 
Gelsolin (82-84 kDa) is a multifunctional, calcium ion-regulated actin filament 
severing, capping, and nucleating protein which is involved in the determination of 
cell shape, secretion and chemotaxis (Kaneva et al., 2017; Yin et al., 1984). Previous 
studies of gelsolin on different biological systems have identified gelsolin as a 
potential predictor of both inflammation and tissue injury (DiNubile et al., 2002; Ito 
et al., 1992; Piktel et al., 2018). Within rheumatoid arthritis patients, reduced 
circulating levels of plasma gelsolin have been identified (Osborn et al., 2008). The 
authors propose this may be due to gelsolin redistribution to the affected joint 
space, binding to a plasma factor, reduced production or increased degradation. 
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Within this study, SF gelsolin abundance was identified as decreasing with OA 
severity. Gelsolin was also identified as having a significant correlation with OA 
severity and was found to be a highly influential factor when a model combining 
both biobank and HKJC datasets was developed. These results are supported by a 
mouse model whereby gelsolin knockout mice resulted in arthritis exacerbation 
(Aidinis et al., 2005). Additionally, within a mouse model of pain and acute 
inflammation, exogenous delivery of gelsolin was identified to have effective 
analgesic and anti-inflammatory properties (Gupta et al., 2015). Exogenous gelsolin 
administration has also been shown to have chondroprotective properties, 
nullifying the effect of interleukin-1β and OA SF on anabolic gene expression and 
increased glycosaminoglycan deposition in chondrocytes and protection of the 
integrity of murine cartilage following intra-articular injection (Kaneva et al., 2017). 
Therefore, gelsolin has potential as a biomarker of equine OA as well as an OA 
therapeutic target, and potential analgesic. 
3.5.5. Lipopolysaccharide Binding Protein (LBP) 
LBP is an endogenous protein which binds to lipopolysaccharides and catalytically 
delivers monomeric liposaccharides to cluster of differentiation 14 (CD14) protein 
(Citronberg et al., 2016; Ranoa et al., 2013). Previously, serum and synovial levels of 
LBP were not identified to be differentially expressed between human degenerative 
arthropathy patients and control samples (Heumann et al., 1995). However, 
increased plasma LBP levels have recently been described to predict knee OA 
progression (Huang et al., 2018). Within this current study, the trends identified 
suggest a decreasing SF abundance of LBP with increasing OA severity. It has 
previously been identified that mononuclear cell activation, induced by 
lipopolysaccharides, is enhanced by low LBP concentrations (Lamping et al., 1998). 
Activation of monocytes and macrophages by lipopolysaccharides leads to the 
secretion of tumour necrosis factor alpha and interleukin-1 beta, two pro-
inflammatory cytokines which are central to OA pathogenesis (Schumann et al., 
1994; Wojdasiewicz et al., 2014). Thus, decreasing synovial LBP levels may have a 
role in OA development. With CD14 also identified as a key variable within the 
104 
 
biobank and HKJC combined model, this provides further support that this pathway 
is involved in equine OA pathogenesis. 
3.5.6. Apolipoproteins 
Elevations in synovial ApoA1 were identified in mild and moderate OA within the 
biobank group although abundance decreased for severe OA. Elevations in OA SF 
have previously been identified in horses and dogs (Chiaradia et al., 2012; Shahid, 
2018). ApoA1 is the primary protein component of high density lipoproteins (HDLs) 
and involved in HDL binding to ATP-binding cassette (ABC) transporters as well as 
being a lecithin cholesterol acyl transferase cofactor (Luc et al., 1996; Rader, 2003; 
Ramella et al., 2018; Silver et al., 2001). ApoA1 has previously been found to induce 
the expression of interleukin-6, MMP-1 and MMP-3 in chondrocytes and 
synoviocytes through toll-like receptor 4 with the same study identifying a 
dissociation between the relationship of ApoA1 and HDLs in OA SF (de Seny et al., 
2015). When combining datasets within this study, apolipoprotein A-II (ApoA2) was 
also found to be an important variable. ApoA2 has previously been identified to be 
involved in the acute phase response which is associated with reactive amyloid A 
amyloidosis, via lipoprotein conformational changes, an associated complication of 
rheumatoid arthritis (Yang et al., 2018). Thus, this study provides further evidence 
that OA is a metabolic syndrome with disruption of lipid homeostasis due to 
alterations to apolipoprotein activity (de Seny et al., 2015). 
3.5.7. Synovitis - Afamin 
Synovitis has previously been identified as an important aspect of OA pathogenesis 
(Berenbaum, 2013; Mathiessen and Conaghan, 2017; Sellam and Berenbaum, 
2010). This study identified reduced synovial abundance of afamin in high grade 
synovitis compared to low grade. Similarly, reduced afamin levels have been 
recorded in equine OA SF compared to healthy joints (Chiaradia et al., 2012). In a 
previous study however, elevated levels of afamin were identified within human 
knee OA SF (Ritter et al., 2014). Afamin is a vitamin E binding glycoprotein and a 
member of the albumin gene family (Dieplinger and Dieplinger, 2015). Afamin forms 
a 1:1 complex with various hydrophobic Wnt proteins, solubilising the proteins and 
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producing a biologically active complex (Mihara et al., 2016). A growing body of 
evidence has identified that the Wnt/β-catenin signalling cascade is likely to have a 
central role within OA pathogenesis (Zhou et al., 2017). Thus, a reduction in synovial 
abundance of afamin may be reflective of a translocation following Wnt 
solubilisation to surrounding articular tissues, i.e. the synovium. However, it should 
be noted that a differential abundance of afamin was not identified when 
categorised according to OA severity. 
3.5.8. Semi-Tryptic Peptide Profiles 
For the HKJC the semi-tryptic profile was most consistent between samples in the 
groups with the most severe OA and synovitis pathology. This suggests, as expected, 
the OA phenotype is driving the semi-tryptic peptide profile, most likely due to an 
increase in enzymatic activity leading to ECM degradation fragments (Lotz et al., 
2013). However, this was not evident within the biobank SF sample set. This may be 
because the OA pathology identified within this group was far subtler than that 
identified within the HKJC samples and thus the level of pathology present was not 
severe enough to drive a global change within the semi-tryptic peptide profile.  
3.5.9. Metabolomic and Proteomic Integration 
Computational integration of separate ‘omics’ datasets can work synergistically, 
greatly enhancing the information that can be obtained from separate analyses. 
However, this poses the challenge of developing multi ‘omic’ integration 
techniques. Previously, a study carried out MS proteomic analysis comparing early 
and late stage human OA SF and combined this with transcriptomics of articular 
tissues to identify the source of differentially abundant synovial proteins (Ritter et 
al., 2013). However, no previous studies have combined NMR metabolomics and 
MS proteomic datasets. 
Integrating the metabolomic and proteomic datasets separately for the biobank and 
HKJC both identified groupings associated with OA severity. Although correlation 
values of variables to OA severity were generally low for the HKJC samples, 
stratification was still evident. Modelling was most robust for the biobank dataset, 
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with the application of a Lasso model, with the model’s strength being the 
separation of more severe OA grades. However, within this sample set there were 
relatively few samples which were assigned to the higher OA severity grades 
compared to lower and is therefore a limitation of the model. Combining all results 
from both the biobank and HKJC datasets produced a model which was found to be 
highly accurate in correctly assigning samples within the mild OA group based on 
their integrated metabolomic and proteomic profiles. This is promising as mild OA 
recognition is the current unmet clinical need, aiding in early diagnosis and allowing 
for timely OA interventional management. However, the model is dominated by 
predominantly mild OA graded samples, and thus this will inevitably introduce bias 
into the model and make a correct reclassification of mild OA more likely. 
3.5.9.1. Periostin 
Within the combined dataset DAPC model, periostin was the principal driver of 
linear discriminant 2. Periostin is a 90 kDa matricellular protein which has 
regulatory functions in cell differentiation, cell adhesion and ECM organisation 
(Kudo and Kii, 2018; Li et al., 2015). In human medicine, a positive correlation has 
been identified between both plasma and SF periostin abundance and knee OA 
severity (Honsawek et al., 2015). In-vivo results have identified that interleukin-13 
may induce the production of periostin during OA, with periostin subsequently 
stimulating the production of MMPs within synoviocytes (Tajika et al., 2017). In 
women, serum periostin levels were found to be associated with both prevalence 
and the risk of development/progression of knee OA (Rousseau et al., 2015). Thus 
for equids, periostin may also provide a potential therapeutic target and prognostic 
indicator. 
3.5.10. Pathway Analysis 
Protein pathway analysis identified the ‘complement and coagulation cascades’ 
pathway to be altered during OA pathology. Additionally, the uncharacterised 
protein F6ZR63, the second most important variable of influence driving the 
biobank Lasso model, was found to have a high level of amino acid sequence 
similarity to complement factor H-like isoform X1. The complement system is an 
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important component of the innate immune response, encompassing various roles 
including opsonisation initiation, pathogen phagocytosis, the inflammatory 
response and terminating within cell lysis (Horwitz et al., 2019; Silawal et al., 2018). 
However, a growing body of evidence has identified a role of complement 
activation within OA pathogenesis, which is further supported by this study (Silawal 
et al., 2018). Complement has been identified to have a role in the degradation of 
cartilage ECM, synovitis and osteophyte formation, with complement split fragment 
C3a found to upregulate gene expression of tumour necrosis factor-α and 
Interleukin-1β, pro-inflammatory cytokines central to OA pathogenesis (Silawal et 
al., 2018; Wojdasiewicz et al., 2014). Therefore, targeting the complement cascade 
may provide a novel therapeutic target for OA treatment. 
Within experimental arthritis models, coagulation and fibrinolysis pathways are 
known to play a role within disease pathogenesis, with these cascades also found to 
be activated within both the joint and circulation of degenerative and inflammatory 
arthropathies (So et al., 2003). Within the synovium of patients diagnosed with OA, 
the coagulation factor fibrinogen is present throughout the tissue with elevations in 
tissue factor, a coagulation initiator, identified near endothelial cells (Weinberg et 
al., 1991). Previously, fibrinogen has been identified as a potential target for 
arthritis therapy, with removal of fibrinogen-leukocyte integrin receptor αMβ2 
interactions limiting inflammatory processes whilst maintaining normal fibrinogen 
coagulation function (Raghu and Flick, 2011). Thus these pathways may also hold 
potential as a novel target for OA therapy. 
Metabolite pathway analysis identified the ‘ABC transporters’ pathway to be altered 
during OA pathology. ABC transporters utilise ATP hydrolysis to import or export 
molecules across cell membranes (Rees et al., 2009). ABC exporters have an 
important role in the export of cholesterol, fatty acid and lipids from cells, with 
dysregulation of this pathway underlying numerous diseases. The Wnt/β-catenin 
signalling cascade, with a proposed central role within OA pathogenesis, has 
previously been identified as a regulator of ABC transporters (Takamatsu et al., 
2014). Additionally, the ABC transporter MRP5 has been found to be the principal 
exporter of hyaluronan from its site of synthesis within the cell to the ECM (Schulz 
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et al., 2007). However, as only four key metabolites were identified within this 
pathway, caution should be applied when analysing these results to avoid over 
interpretation. 
3.5.11. Further Work 
Several proteins of interest identified within this study were uncharacterised. BLAST 
amino acid sequence analysis of similar proteins provided further information on 
their potential function, however this could be taken further by conducting 3D 
modelling of these proteins to help confirm function and potential interactions with 
other proteins/molecules. Additionally, developing monoclonal antibodies which 
are specific to these uncharacterised proteins would allow this methodology to 
provide an orthologous method to confirm protein abundances. Within the cohorts 
used in this study, there was an over-representation of mild OA diagnoses opposed 
to more severe phenotypes. Although this is advantageous in terms of identifying 
early OA markers, in order to fully stratify OA, the addition of a greater number of 
donors with higher grade OA would provide a more comprehensive synovial profile 
of the metabolite and protein profiles at differing OA grades and provide more 
robust models. As this study adopted a cross-sectional approach, further work of 
interest would be to conduct repeated measures within a longitudinal study to 
discover whether the identified markers of interest validate this study’s findings. 
Also, given the differential abundance of ApoA1 and LBP identified within this study, 
it would be of interest to further interrogate SF, using both NMR and MS based 
approaches, to investigate the lipid profile and identify changes during OA 
progression. 
3.5.12. Conclusions 
In conclusion, this study has stratified equine OA using both metabolomic and 
proteomic SF profiles and identified a panel of markers of interest which may be 
applicable to grading OA severity. This is also the first study to undertake 
computational integration of NMR metabolomic and LC-MS/MS proteomic datasets 
of any biological system. 
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3.9. Supplementary Information 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Subchondral bone/cartilage wedge taken at post mortem 
from the distal articular condylar surface of metacarpal III, lateral to the sagittal 
ridge. 
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Supplementary Figure 2. Representative ion chromatograms for native synovial 
fluid (SF) using (A) a 90 min liquid chromatography (LC) gradient, (B) ProteoMinerTM 
processed SF following a 4hr Lys-C + 4hr trypsin digestion using a 60 min LC gradient 
and (C) ProteoMinerTM processed SF following a 4hr Lys-C + 16hr + 2hr trypsin 
digestion using a 120 min LC gradient. 
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Supplementary Figure 3. Principal component analyses of biobank and Hong Kong 
Jockey Club (HKJC) equine synovial fluid NMR metabolomes and LC-MS/MS 
proteomes before and after application of a COMBAT batch correction. biobank; 
metabolomics, n=76, proteomics, n=70, HKJC; metabolomics, n=56, proteomics, 
n=53. 
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Supplementary Figure 4. Correlation between microscopic and macroscopic 
osteoarthritis (OA) grading scores for biobank (n=41) and Hong Kong Jockey Club 
(HKJC, n=41) cohorts. 
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Supplementary Figure 5. Quantile plots of (A) biobank (n=83) and (B) Hong Kong 
Jockey Club (HKJC, n=52) synovial fluid (SF) NMR spectra. The median spectra are 
depicted by a black line, with variation from the median spectral plot depicted by a 
yellow to red scale. The full spectral range is shown (8.56-0 ppm) with a more 
detailed region inset (4-3.1 ppm). Spectral regions 3.681-3.643 ppm and 1.201-
1.162 ppm have been removed due to ethanol contamination. 
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Supplementary Figure 6. Principal component analysis of biobank ProteoMinerTM 
processed (16hr + 2hr trypsin digestion) synovial fluid proteome categorised by (A) 
macroscopic OA grade (n=60) and (B) microscopic OA grade (n=64) using LC-MS/MS. 
 
 
Supplementary Figure 7. Principal component analysis of the Hong Kong Jockey 
Club (HKJC) ProteoMinerTM processed (16hr + 2hr trypsin digestion) synovial fluid 
proteome categorised by (A) macroscopic OA grade (n=47), (B) microscopic OA 
grade (n=45) and (C) synovitis grade (n=53) using LC-MS/MS. 
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Supplementary Table 1. Selected variables (proteins and metabolites) used to 
produce Lasso model for biobank synovial fluid. 
 
Variable Description 
HMDB00194 Anserine 
F7A1W7 Apolipoprotein C2 
F6XUJ2 ATP synthase subunit alpha 
HMDB00043 Betaine 
F6TK05 Chaperonin containing TCP1 subunit 2 
F6VK89 Cluster of differentiation 14 
F6ZNX3 Collagen type XIV alpha 1 chain 
F7DBT2 Complement C1q C chain 
F7BQD6 Complement C1s 
F6WCB7 Cytokine like 1 
F6W2Y1 Fibrinogen gamma chain 
F7DHW2 Galactokinase 1 
F7BKK5 Glutathione S-transferase 
F6XWM5 Haptoglobin 
HMDB00161 L-Alanine 
HMDB00883 L-Valine 
F6X485 Myosin heavy chain 9 
F7BJV0 Myosin IC 
F7BFT1 Peroxiredoxin 2 
F7AS57 Proteasome activator subunit 2 
F6XWJ6 RUN and FYVE domain containing 1 
Q2QLB2 Testin 
F7CS04 Tropomyosin 1 
F6S2I3 Uncharacterised 
F6TED1 Uncharacterised 
F6ZR63 Uncharacterised 
H9GZQ9 Uncharacterised 
F6RYX0 Vacuolar protein sorting-associated protein 29 
F6X667 Vitamin K-dependent protein C 
 
Supplementary Table 2. Age comparison between the biobank and Hong Kong 
Jockey Club (HKJC) cohorts. 
 Biobank HKJC 
Number of donors 83 58 
Mean age (years) 14.3 6.6 
Median age (years) 16 7 
Standard deviation (years) 7.6 1.9 
t-test (mean age) p = 6.22 e-12 
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Supplementary Table 3. Macroscopic osteoarthritis scoring of distal metacarpal III for the University of Liverpool equine biobank. 
 
 Scorer 1  Scorer 2  Scorer 3    
Horse 
Wear 
Lines 
(0-3) 
Erosions 
(0-3) 
Palmar 
Arthrosis 
(0-3) 
Total  
Wear 
Lines 
(0-3) 
Erosions 
(0-3) 
Palmar 
Arthrosis 
(0-3) 
Total  
Wear 
Lines 
(0-3) 
Erosions 
(0-3) 
Palmar 
Arthrosis 
(0-3) 
Total  
Average 
TOTAL 
Macroscopic 
OA Grade 
1 Not Scored  Not Scored               
2 0 2 0 2  1 2 0 3           3 3 
3 0 0 0 0  0 0 0 0           0 0 
4 Not Scored  Not Scored               
5 Not Scored  Not Scored               
6 Not Scored  Not Scored               
7 0 1 0 1  0 0 0 0           1 1 
8 1 0 2 3  2 1 1 4           4 3 
9 0 1 0 1  0 0 0 0           1 1 
10 0 0 0 0  0 1 1 2  0 1 0 1  2 2 
11 0 1 0 1  1 1 0 2           2 2 
12 0 0 1 1  1 1 0 2           2 2 
13 1 2 1 4  1 1 3 5           5 3 
14 0 0 0 0  1 0 1 2  1 0 0 1  2 2 
15 Not Scored  Not Scored               
16 0 0 1 1  1 0 2 3  1 0 0 1 
 1 1 
17 Not Scored  Not Scored               
18 0 0 0 0  0 0 0 0           0 0 
19 0 2 2 4  0 0 0 0  0 0 0 0  0 0 
20 0 0 0 0  0 0 0 0           0 0 
21 0 2 0 2  1 1 0 2           2 2 
22 0 0 0 0  0 0 0 0           0 0 
23 0 1 0 1  0 1 0 1           1 1 
24 0 1 0 1  0 1 0 1           1 1 
25 0 1 0 1  0 1 0 1           1 1 
26 0 1 0 1  0 0 1 1           1 1 
118 
 
27 1 2 0 3  0 1 0 1  0 1 0 1  1 1 
28 2 0 0 2  1 0 0 1           2 2 
29 0 1 1 2  0 2 0 2           2 2 
30 2 2 0 4  3 2 1 6  3 2 1 6  6 3 
31 0 2 0 2  0 2 0 2           2 2 
32 3 1 0 4  2 1 0 3           4 3 
33 1 1 0 2  0 0 1 1           2 2 
34 1 1 0 2  0 1 0 1           2 2 
35 2 2 0 4  3 2 2 7  2 1 2 5  5 3 
36 0 0 1 1  0 0 1 1           1 1 
37 0 0 0 0  0 0 1 1           1 1 
38 0 1 0 1  0 2 0 2           2 2 
39 0 2 1 3  1 2 1 4           4 3 
40 0 1 0 1  0 2 0 2           2 2 
41 0 2 0 2  0 1 0 1           2 2 
42 Not Scored  Not Scored               
43 0 1 0 1  0 0 1 1           1 1 
44 0 0 0 0  0 1 0 1           1 1 
45 1 0 0 1  0 0 0 0           1 1 
46 0 0 0 0  0 0 0 0           0 0 
47 0 0 1 1  1 2 0 3  0 0 1 1  1 1 
48 2 2 0 4  2 3 0 5           5 3 
49 1 2 0 3  0 2 0 2           3 3 
50 0 0 0 0  0 1 0 1           1 1 
51 1 2 0 3  0 2 0 2           3 3 
52 0 0 0 0  0 0 0 0           0 0 
53 0 2 0 2  0 1 0 1           2 2 
54 0 0 0 0  0 0 0 0           0 0 
55 0 0 0 0  0 1 0 1           1 1 
56 1 0 0 1  0 1 0 1           1 1 
57 0 0 0 0  0 0 0 0           0 0 
58 0 0 1 1  0 2 0 2           2 2 
59 0 0 0 0  0 1 0 1           1 1 
60 0 1 0 1  0 1 0 1           1 1 
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61 0 0 0 0  0 1 0 1           1 1 
62 0 0 0 0  0 1 0 1           1 1 
63 0 0 0 0  0 0 0 0           0 0 
64 0 0 0 0  0 1 0 1           1 1 
65 0 2 0 2  0 1 0 1           2 2 
66 0 1 0 1  0 1 0 1           1 1 
67 0 0 0 0  0 0 0 0           0 0 
68 1 2 0 3  1 1 1 3           3 3 
69 1 0 0 1  0 1 0 1           1 1 
70 0 1 0 1  0 2 0 2           2 2 
71 3 0 0 3  3 0 0 3           3 3 
72 0 0 2 2  1 1 2 4  0 0 2 2  2 2 
73 0 0 0 0  0 1 0 1           1 1 
132 0 0 2 2  0 0 0 0  0 0 0 0  0 0 
133 0 0 0 0  0 0 0 0           0 0 
134 0 2 0 2  0 1 0 1           2 2 
135 0 2 1 3  0 1 0 1  0 1 0 1  1 1 
136 1 0 1 2  1 1 0 2           2 2 
137 0 0 1 1  1 2 1 4  1 2 0 3  4 3 
138 0 0 0 0  0 0 0 0           0 0 
139 3 0 1 4  3 0 0 3           4 3 
140 1 1 0 2  0 1 0 1           2 2 
141 0 0 1 1  0 0 0 0           1 1 
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Supplementary Table 4. Microscopic osteoarthritis scoring of distal metacarpal III for the University of Liverpool equine biobank. 
 
 Scorer 1  Scorer 2   Scorer 3    
Horse 
Fissuring 
(0-4) 
Focal 
Cell 
Loss 
(0-4) 
Chond. 
Nec. 
(0-4) 
Chon. 
Form. 
(0-4) 
Saff 
O 
Stain 
(0-4) 
Total  
Fissuring 
(0-4) 
Focal 
Cell 
Loss 
(0-4) 
Chond. 
Nec. 
(0-4) 
Chon. 
Form. 
(0-4) 
Saff 
O 
Stain 
(0-4) 
Total   
Fissuring 
(0-4) 
Focal 
Cell 
Loss 
(0-4) 
Chond. 
Nec. 
(0-4) 
Chon. 
Form. 
(0-4) 
Saff 
O 
Stain 
(0-4) 
Total  
Average 
TOTAL 
Microscopic 
OA Grade 
1 0 1 1 0 0 2  1 1 0 0 0 2               2 1 
2 2 1 0 1 0 4  2 0 1 1 0 4               4 2 
3 0 1 0 0 0 1  0 0 0 0 0 0               1 0 
4 0 0 1 0 0 1  0 1 1 0 0 2               2 1 
5 1 1 0 0 0 2  1 1 0 1 0 3               3 1 
6 0 0 0 0 0 0  0 2 1 0 0 3  0 0 0 0 0 0  0 0 
7 1 1 0 0 0 2  1 0 1 0 1 3               3 1 
8 1 0 1 1 0 3  2 1 1 1 0 5  2 1 0 1 0 4  5 2 
9 1 0 0 0 1 2  0 2 2 0 1 5  0 1 0 0 0 1  2 1 
10 0 0 0 1 0 1  1 1 0 0 0 2               2 1 
11 1 2 0 0 0 3  1 0 0 0 0 1  1 0 0 0 0 1  1 0 
12 2 2 1 0 0 5  2 1 2 0 0 5               5 2 
13 1 1 0 0 0 2  1 1 0 0 0 2               2 1 
14 1 1 1 2 0 5  1 3 0 1 0 5               5 2 
15 1 1 0 0 0 2  1 1 0 0 0 2               2 1 
16 0 2 0 1 0 3  0 1 0 1 0 2               3 1 
17 Not Scored  Not Scored                   
18 0 0 0 0 0 0  0 1 0 0 0 1  0 1 0 0 0 1  1 0 
19 1 2 0 1 0 4  0 1 0 0 0 1  1 0 0 0 0 1  1 0 
20 0 2 0 0 0 2  0 2 0 0 0 2               2 1 
21 2 0 1 2 1 6  3 1 1 1 2 8  1 3 0 1 2 7  8 2 
22 0 1 0 0 0 1  0 0 1 0 0 1               1 0 
23 1 0 2 0 0 3  0 0 0 0 0 0  2 1 0 0 0 3  3 1 
24 0 0 0 1 0 1  1 0 0 1 0 2               2 1 
25 0 1 1 0 0 2  0 1 1 1 0 3               3 1 
26 0 1 0 0 0 1  0 1 1 0 0 2               2 1 
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27 0 0 0 0 0 0  0 0 0 0 0 0               0 0 
28 1 0 0 1 0 2  1 3 0 0 0 4  1 2 1 0 0 4  4 2 
29 1 1 0 0 0 2  0 0 0 1 0 1               2 1 
30 2 1 1 1 0 5  1 0 0 2 0 3  0 1 0 3 0 4  5 2 
31 2 1 1 1 4 9  1 0 1 1 0 3  1 2 0 0 0 3  3 1 
32 0 1 1 1 0 3  1 0 0 2 0 3               3 1 
33 2 2 1 1 1 7  2 1 1 1 0 5  2 1 2 1 0 6  7 2 
34 0 1 2 1 0 4  0 2 1 1 0 4               4 2 
35 1 0 1 2 1 5  1 1 1 2 1 6               6 2 
36 1 1 0 1 0 3  1 0 0 0 1 2               3 1 
37 0 1 1 1 1 4  0 2 1 0 0 3               4 2 
38 1 0 1 1 0 3  1 1 2 1 0 5  2 1 2 1 0 6  6 2 
39 0 1 0 1 2 4  0 0 1 0 1 2  0 1 0 0 2 3  4 2 
40 1 0 1 2 2 6  1 0 0 1 1 3  2 0 1 2 2 7  7 2 
41 2 1 1 2 0 6  1 2 2 3 0 8  2 2 0 1 0 5  6 2 
42 0 2 1 0 1 4  0 1 1 0 0 2  0 2 0 1 1 4  4 2 
43 1 0 1 1 0 3  1 0 1 0 0 2               3 1 
44 0 1 1 2 1 5  1 0 1 1 1 4               5 2 
45 0 1 1 0 0 2  0 1 1 0 0 2               2 1 
46 0 0 0 1 0 1  0 1 1 0 0 2               2 1 
47 0 1 0 1 1 3  1 0 0 0 1 2               3 1 
48 0 1 1 0 0 2  0 1 1 2 0 4  1 1 0 0 0 2  2 1 
49 1 1 0 1 1 4  0 0 0 1 0 1  0 1 1 1 1 4  4 2 
50 1 1 2 0 0 4  2 0 1 0 0 3               4 2 
51 0 1 1 0 1 3  1 0 1 2 1 5  0 0 0 2 0 2  3 1 
52 Not Scored  Not Scored                   
53 1 0 0 2 1 4  2 0 0 1 0 3               4 2 
54 0 1 1 0 0 2  0 2 0 0 0 2               2 1 
55 0 1 1 0 1 3  0 0 0 0 0 0  0 1 0 0 1 2  3 1 
56 1 1 0 0 2 4  0 1 0 0 1 2  1 1 0 0 2 4  4 2 
57 0 1 0 0 1 2  0 2 1 0 1 4  1 1 0 0 0 2  2 1 
58 0 1 0 2 0 3  0 1 2 0 0 3               3 1 
59 0 0 0 0 0 0  0 1 0 1 1 3  1 1 0 1 1 4  4 2 
60 1 0 0 1 0 2  2 0 0 2 0 4  0 2 0 2 0 4  4 2 
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61 0 1 1 1 0 3  0 0 1 0 2 3               3 1 
62 0 1 0 0 1 2  1 1 1 0 1 4  0 1 0 1 0 2  2 1 
63 0 2 1 1 0 4  0 1 1 0 2 4               4 2 
64 1 1 0 2 1 5  0 1 0 1 0 2  1 1 0 0 0 2  2 1 
65 1 2 0 1 0 4  0 1 0 1 0 2  0 1 0 2 0 3  4 2 
66 1 2 1 0 1 5  1 0 0 1 0 2  0 2 0 0 0 2  2 1 
67 0 1 1 1 0 3  0 0 0 1 1 2               3 1 
68 1 1 0 0 0 2  2 0 0 0 0 2               2 1 
69 2 0 1 1 0 4  1 0 1 1 0 3               4 2 
70 3 1 1 1 2 8  2 0 1 1 2 6  3 2 0 0 2 7  8 2 
71 2 2 1 1 0 6  1 1 0 1 0 3  1 2 0 3 0 6  6 2 
72 Not Scored  Not Scored                   
73 2 1 1 0 0 4  0 0 0 0 0 0  1 0 0 0 0 1  1 0 
132 Not Scored  Not Scored                   
133 Not Scored  Not Scored                   
134 Not Scored  Not Scored                   
135 Not Scored  Not Scored                   
136 Not Scored  Not Scored                   
137 Not Scored  Not Scored                   
138 Not Scored  Not Scored                   
139 Not Scored  Not Scored                   
140 Not Scored  Not Scored                   
141 Not Scored  Not Scored                   
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Supplementary Table 5. Macroscopic osteoarthritis scoring of distal metacarpal III or metatarsal III for the Hong Kong Jockey Club sample set. 
 
  Scorer 1  Scorer 2  Scorer 3    
Horse Joint POD (0-3) 
Wear 
lines 
(0-2) 
Cart. 
loss 
(0-3) 
Linear 
fissures 
(0-3) 
TOTAL 
 
POD (0-3) 
Wear 
lines 
(0-2) 
Cart. 
loss 
(0-3) 
Linear 
fissures 
(0-3) 
TOTAL 
 
POD (0-3) 
Wear 
lines 
(0-2) 
Cart. 
loss 
(0-3) 
Linear 
fissures 
(0-3) 
TOTAL  
Average 
TOTAL 
Macroscopic 
OA Grade 
74 MCP Not Scored   Not Scored                  
75 MCP 2 0 3 0 5  1 0 1 0 2  2 0 2 0 4  5 2 
76 MCP 0 2 2 1 5  2 2 1 0 5             5 2 
77 MCP 3 2 3 1 9  3 2 3 0 8             9 2 
78 MCP 0 2 0 2 4  0 1 0 0 1  0 1 0 1 2  2 0 
79 MCP 0 1 0 2 3  0 1 1 0 2             3 1 
80 MCP 3 2 1 0 6  3 2 1 0 6             6 2 
81 MCP Not Scored   Not Scored                  
82 MCP 2 1 0 0 3  2 1 1 0 4             4 1 
83 MCP 1 2 1 0 4  1 2 1 0 4             4 1 
84 MCP 0 0 3 1 4  0 0 1 1 2  0 1 1 1 3  4 1 
85 MCP 0 2 3 0 5  0 2 1 0 3  0 2 1 0 3  3 1 
86 MCP 2 2 3 0 7  2 1 1 0 4  1 1 1 0 3  4 1 
87 MCP 3 2 3 0 8  3 2 1 0 6  2 1 2 0 5  6 2 
88 MCP 1 0 0 0 1  1 0 0 2 3  1 1 0 1 3  3 1 
89 MCP 3 2 3 0 8  3 2 1 0 6  3 2 3 0 8  8 2 
90 MCP 1 0 3 0 4  1 0 1 0 2  1 1 1 0 3  4 1 
91 MCP 1 1 2 0 4  1 1 1 0 3             4 1 
92 MCP 3 2 3 0 8  1 1 1 0 3             6 2 
93 MCP 2 0 3 0 5  2 0 2 1 5             5 2 
94 MCP 0 0 2 0 2  1 1 1 0 3             3 1 
95 MCP 2 1 3 3 9  1 1 1 3 6  2 1 2 1 6  6 2 
96 MCP 2 0 3 0 5  2 0 1 1 4             5 2 
97 MCP 2 2 1 0 5  2 1 0 0 3  1 2 1 0 4  5 2 
98 MCP 0 0 0 1 1  0 0 0 1 1             1 0 
99 MCP 0 0 0 0 0  0 1 0 1 2  0 0 0 0 0  0 0 
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100 MCP 0 1 0 2 3  1 1 0 1 3             3 1 
101 MCP 1 0 0 0 1  0 0 1 1 2             2 0 
102 MCP 1 1 2 0 4  1 1 2 1 5             5 2 
103 MCP 0 0 0 1 1  0 0 1 1 2             2 0 
104 MCP Not Scored   Not Scored                  
105 MTP Not Scored   Not Scored                  
106 MTP 0 0 2 2 4  0 0 1 1 2  0 0 0 1 1  2 0 
107 MTP Not Scored   Not Scored                  
108 MTP 0 0 1 2 3  1 0 1 1 3             3 1 
109 MTP 2 0 1 2 5  2 0 1 2 5             5 2 
110 MTP 3 2 3 0 8  0 0 0 1 1  0 1 1 0 2  2 0 
111 MTP 0 2 2 0 4  1 1 0 1 3             4 1 
112 MTP Not Scored   Not Scored                  
113 MTP 0 1 3 1 5  1 1 0 1 3  0 1 0 2 3  3 1 
114 MTP 1 0 1 0 2  1 0 1 1 3             3 1 
115 MTP 0 1 0 3 4  1 1 0 2 4             4 1 
116 MTP 0 0 0 3 3  0 0 0 2 2             3 1 
117 MTP 0 0 0 3 3  0 1 0 1 2             3 1 
118 MTP 0 0 0 2 2  1 0 0 2 3             3 1 
119 MTP 0 0 1 2 3  0 0 0 2 2             3 1 
120 MTP 1 1 0 0 2  0 1 0 2 3             3 1 
121 MTP 0 0 0 1 1  0 0 0 1 1             1 0 
122 MTP 0 0 0 3 3  0 0 0 1 1             2 0 
123 MTP 1 1 0 0 2  1 0 0 2 3             3 1 
124 MTP Not Scored   Not Scored                  
125 MTP 2 0 0 2 4  1 0 0 1 2             3 1 
126 MTP Not Scored   Not Scored                  
127 MTP 0 0 0 1 1  0 0 0 2 2             2 0 
128 MTP 0 0 0 2 2  0 0 0 2 2             2 0 
129 MTP 1 0 0 1 2  1 0 0 2 3             3 1 
130 MTP 0 0 0 2 2  0 0 0 1 1             2 0 
131 MCP 0 1 3 1 5  1 1 1 0 3             4 1 
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Supplementary Table 6. Microscopic osteoarthritis scoring of distal metacarpal III or 
metatarsal III for the Hong Kong Jockey Club sample set. 
 
Horse Joint 
Structure 
(0-10) 
Cell 
Density 
(0-4) 
Cell 
Cloning 
(0-4) 
Staining 
(0-4) 
Tidemark 
(0-3) 
TOTAL 
Microscopic 
OA Grade 
74 MCP Not Scored  
75 MCP 1 0 2 2 3 8 1 
76 MCP 8 1 4 4 3 20 2 
77 MCP 1 0 1 1 2 5 1 
78 MCP 2 0 0 1 1 4 0 
79 MCP 1 1 1 0 0 3 0 
80 MCP Not Scored  
81 MCP Not Scored  
82 MCP 8 4 4 2 1 19 2 
83 MCP 6 2 3 4 1 16 2 
84 MCP 0 1 1 0 0 2 0 
85 MCP 1 1 1 2 1 6 1 
86 MCP 1 2 2 1 2 8 1 
87 MCP 0 0 0 0 0 0 0 
88 MCP 3 0 2 2 3 10 1 
89 MCP 2 1 1 3 2 9 1 
90 MCP 7 1 0 3 3 14 2 
91 MCP 7 1 1 4 3 16 2 
92 MCP 10 1 0 4 3 18 2 
93 MCP 4 2 0 2 3 11 2 
94 MCP 2 1 2 1 3 9 1 
95 MCP 10 1 2 2 3 18 2 
96 MCP Not Scored  
97 MCP 1 0 1 0 1 3 0 
98 MCP 0 0 1 0 0 1 0 
99 MCP 2 1 0 0 0 3 0 
100 MCP Not Scored  
101 MCP 3 0 0 2 2 7 1 
102 MCP 10 2 0 3 3 18 2 
103 MCP 1 0 0 1 2 4 0 
104 MCP 2 0 2 0 0 4 0 
105 MTP Not Scored  
106 MTP 1 0 0 1 0 2 0 
107 MTP 2 0 1 2 2 7 1 
108 MTP 5 0 0 2 3 10 1 
109 MTP 2 1 1 1 0 5 1 
110 MTP 4 2 0 4 2 12 2 
111 MTP 5 1 1 3 2 12 2 
112 MTP Not Scored  
113 MTP 2 0 1 1 1 5 1 
114 MTP 2 1 3 4 2 12 2 
115 MTP 3 3 4 1 1 12 2 
116 MTP 2 0 1 0 0 3 0 
117 MTP 1 1 1 2 2 7 1 
118 MTP 3 0 1 3 1 8 1 
119 MTP 1 0 0 1 0 2 0 
120 MTP 1 0 1 1 0 3 0 
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121 MTP 1 1 1 2 3 8 1 
122 MTP 1 1 1 0 0 3 0 
123 MTP 1 0 0 3 3 7 1 
124 MTP Not Scored  
125 MTP 2 1 1 2 0 6 1 
126 MTP 2 0 0 1 2 5 1 
127 MTP 2 1 1 2 2 8 1 
128 MTP 1 0 1 1 3 6 1 
129 MTP 1 0 0 1 2 4 0 
130 MTP 1 1 1 1 0 4 0 
131 MCP 0 1 1 1 0 3 0 
 
 
Supplementary Table 7. Synovitis scoring of distal metacarpal III or metatarsal III for 
the Hong Kong Jockey Club sample set. 
 
 
 Lining Cell Layer (0-3)  Resident Cells (0-3)  
Inflammatory 
infiltrate (0-3) 
   
Horse Joint 1 2 3 Average  1 2 3 Average  1 2 3 Average  Total 
Synovitis 
Grade 
74 MCP 1 1 0 0.7  2 2 0 1.3  2 2 1 1.7  4 1 
75 MCP 1 1 1 1.0  1 2 1 1.3  0 0 1 0.3  3 1 
76 MCP 2 2 1 1.7  1 1 1 1.0  1 2 1 1.3  4 1 
77 MCP 2 1 3 2.0  2 2 1 1.7  1 1 1 1.0  5 2 
78 MCP 2 1 1 1.3  1 1 1 1.0  1 1 1 1.0  3 1 
79 MCP 1 2 2 1.7  1 1 1 1.0  1 1 1 1.0  4 1 
80 MCP 1 2 2 1.7  1 1 1 1.0  1 1 1 1.0  4 1 
81 MCP 0 1 1 0.7  1 2 2 1.7  0 3 3 2.0  4 1 
82 MCP 1 1 3 1.7  1 2 2 1.7  2 2 3 2.3  6 2 
83 MCP 2 1 2 1.7  1 1 1 1.0  1 1 1 1.0  4 1 
84 MCP 1 1 2 1.3  1 1 1 1.0  1 1 1 1.0  3 1 
85 MCP 2 2 2 2.0  2 1 1 1.3  1 1 1 1.0  4 1 
86 MCP 2 2 1 1.7  1 1 1 1.0  1 1 1 1.0  4 1 
87 MCP 2 3 1 2.0  3 2 3 2.7  0 1 0 0.3  5 2 
88 MCP 2 2 2 2.0  1 1 1 1.0  2 1 1 1.3  4 1 
89 MCP 2 3 2 2.3  2 2 2 2.0  2 2 2 2.0  6 2 
90 MCP 3 2 3 2.7  3 3 3 3.0  2 2 2 2.0  8 2 
91 MCP 1 2 2 1.7  1 2 1 1.3  1 1 2 1.3  4 1 
92 MCP 2 3 3 2.7  1 1 2 1.3  1 1 2 1.3  5 2 
93 MCP 3 2 2 2.3  2 1 3 2.0  1 2 1 1.3  6 2 
94 MCP 0 1 1 0.7  1 2 1 1.3  1 1 2 1.3  3 1 
95 MCP 2 2 3 2.3  3 2 3 2.7  2 2 2 2.0  7 2 
96 MCP 1 1 3 1.7  2 2 2 2.0  1 1 1 1.0  5 2 
97 MCP 1 2 3 2.0  1 1 1 1.0  1 1 1 1.0  4 1 
98 MCP 2 1 1 1.3  1 1 1 1.0  1 1 1 1.0  3 1 
99 MCP 1 1 1 1.0  1 1 1 1.0  1 1 1 1.0  3 1 
100 MCP 0 1 1 0.7  1 1 1 1.0  0 1 1 0.7  2 1 
101 MCP 0 0 0 0.0  1 1 1 1.0  1 1 1 1.0  2 1 
102 MCP 3 3 3 3.0  2 2 3 2.3  2 2 1 1.7  7 2 
103 MCP 1 0 2 1.0  1 1 1 1.0  2 2 1 1.7  4 1 
104 MCP 0 1 2 1.0  0 1 1 0.7  1 1 1 1.0  3 1 
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105 MTP 1 2 2 1.7  1 3 3 2.3  2 2 2 2.0  6 2 
106 MTP 2 1 2 1.7  1 1 1 1.0  1 1 1 1.0  4 1 
107 MTP 1 2 1 1.3  1 1 1 1.0  1 1 1 1.0  3 1 
108 MTP 1 1 0 0.7  0 1 0 0.3  1 1 1 1.0  2 1 
109 MTP 2 2 3 2.3  1 1 1 1.0  1 1 1 1.0  4 1 
110 MTP 3 1 0 1.3  1 1 0 0.7  1 2 1 1.3  3 1 
111 MTP 2 2 0 1.3  1 1 1 1.0  1 1 1 1.0  3 1 
112 MTP 2 2 1 1.7  1 1 1 1.0  2 1 2 1.7  4 1 
113 MTP 2 3 1 2.0  1 2 0 1.0  1 3 0 1.3  4 1 
114 MTP 1 1 1 1.0  1 1 1 1.0  1 1 1 1.0  3 1 
115 MTP 0 0 1 0.3  0 0 0 0.0  1 1 1 1.0  1 0 
116 MTP 2 3 3 2.7  1 1 1 1.0  1 1 1 1.0  5 2 
117 MTP 1 1 2 1.3  0 1 1 0.7  1 1 1 1.0  3 1 
118 MTP 3 2 2 2.3  2 1 2 1.7  1 1 1 1.0  5 2 
119 MTP 2 2 2 2.0  2 3 1 2.0  2 2 2 2.0  6 2 
120 MTP 1 1 1 1.0  1 1 1 1.0  1 1 1 1.0  3 1 
121 MTP 0 2 2 1.3  1 1 3 1.7  2 2 3 2.3  5 2 
122 MTP 2 1 3 2.0  1 1 1 1.0  1 1 2 1.3  4 1 
123 MTP 2 2 1 1.7  1 1 1 1.0  2 1 1 1.3  4 1 
124 MTP 2 2 2 2.0  1 2 1 1.3  1 1 1 1.0  4 1 
125 MTP 2 2 2 2.0  1 1 0 0.7  1 1 1 1.0  4 1 
126 MTP 1 2 1 1.3  1 1 1 1.0  1 1 1 1.0  3 1 
127 MTP 0 2 2 1.3  1 2 2 1.7  1 2 2 1.7  5 2 
128 MTP 1 3 3 2.3  1 1 2 1.3  1 3 3 2.3  6 2 
129 MTP 2 2 1 1.7  2 2 1 1.7  1 2 1 1.3  5 2 
130 MTP 3 3 2 2.7  1 1 1 1.0  1 1 1 1.0  5 2 
131 MCP 1 3 2 2.0  1 1 1 1.0  1 1 1 1.0  4 1 
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A.3.10. Appendix to Manuscript 2 
Synovial Fluid Osmolality and Serum Metabolomic Analysis in Equine 
Osteoarthritis 
A.3.10.1. Introduction 
Presently, no equine osteoarthritis (OA)-specific biomarkers have been identified 
which are able to accurately diagnose and stratify OA with none in current clinical 
use to aid an earlier diagnosis (Anderson, Phelan, et al., 2018). A previous study in 
human synovial fluid (SF) identified that OA SF has a reduced osmolality compared 
to healthy samples (Shanfield et al., 1988). However, no studies have investigated 
equine OA SF osmolality. Previous studies have identified various molecules of 
interest which were found to be differentially abundant in OA equine serum 
compared to normal, including keratan sulphate (Alwan et al., 1990), 
glycosaminoglycan (Alwan et al., 1991), C-telopeptide fragments of type II collagen 
(Cleary et al., 2010), cartilage oligomeric matrix protein, tumour necrosis factor-α 
(Bertuglia et al., 2016) and bone alkaline phosphatase (Trumble et al., 2008). 
However, although nuclear magnetic resonance (NMR) spectroscopy has previously 
been used to investigate equine serum to study osteochondrosis, synovitis and an 
acute fracture, NMR has not been utilised to study serum of horses diagnosed with 
OA (Ralston et al., 2011; Turlo et al., 2018). 
Within this study we have investigated equine SF osmolality and the equine serum 
metabolome, using 1H NMR, to identify potential OA markers. 
A.3.10.2. Methods 
A.3.10.2.1. Sample Collection 
A.3.10.2.1.1. Equine Synovial Fluid Collection 
SF was collected from 86 horses within the Biobank and 36 horses at the Hong Jong 
Jockey Club at post mortem from the metacarpophalangeal, metatarsophalangeal 
and carpal joints. For collection protocols see manuscript 2. 
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A.3.10.2.1.2. Equine Serum Collection 
Equine serum was collected from 34 horses at the Hong Kong Jockey Club (HKJC) via 
venepuncture following euthanasia and stored at -80°C. Further information on 
serum collection is unavailable. 
A.3.10.2.2. Osteoarthritis Grading/Diagnosis 
3.10.2.2.1. Osteoarthritis and Synovitis Grading - Synovial Fluid Samples 
Macroscopic and microscopic OA grading was conducted on articular 
cartilage/subchondral bone wedge sections and microscopic synovitis scoring on 
synovial membrane collected at post mortem. For further details see manuscript 2. 
A.3.10.2.2.2. Clinical Osteoarthritis diagnosis - Serum 
Horses were assigned into their appropriate group according to their veterinary 
clinical records. Horses with a clear clinical diagnosis of OA were assigned into the 
OA group, with OA identified in one or more of the metacarpophalangeal, 
metatarsophalangeal or carpal joints. Where no clinical OA had been diagnosed, 
these horses were assigned to the healthy group. Samples from OA donors were all 
Thoroughbred racehorses. 
A.3.10.2.3. Measurement of Synovial Fluid Osmolality 
SF osmolality was measured with 100 µl of SF via freezing point depression, using an 
osmometer (MOD200Plus, Löser Messtechnik, Berlin, Germany). 
A.3.10.2.4. NMR 
A.3.10.2.4.1. NMR Sample Preparation 
See manuscript 2. 
A.3.10.2.4.2. NMR Acquisition 
See manuscript 2. 
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A.3.10.2.4.3. Metabolite Annotation and Identification 
See manuscript 2. 
A.3.10.2.5. Statistical Analysis 
Serum metabolite peak abundances underwent median normalisation and Pareto 
scaling prior to multivariate analysis (Worley and Powers, 2013). All principal 
component analysis (PCA) and t-tests of metabolite abundances were conducted 
using MetaboAnalyst 4.0 (http://www.metaboanalyst.ca). SF osmolality t-tests and 
ANOVAs were performed using Minitab version 17. All box plots were produced 
using SPSS 24. 
A.3.10.3. Results 
A.3.10.3.1. Synovial Fluid Osmolality 
No difference in SF osmolality was identified within either the Biobank or HKJC 
groups when stratified according to microscopic OA pathology, macroscopic OA 
pathology or synovitis grade (Figure A1).  
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Figure A1. Equine synovial fluid osmolalities for the Biobank, stratified according to 
(A) cartilage microscopic osteoarthritis pathology and (B) cartilage macroscopic 
osteoarthritis pathology and the Hong Kong Jockey Club, stratified according to (C) 
synovitis grade, (D) cartilage microscopic osteoarthritis pathology and (E) cartilage 
macroscopic osteoarthritis pathology. HKJC = Hong Kong Jockey Club. 
 
A.3.10.3.2. Equine Serum Metabolomics 
PCA was unable to discriminate between the healthy and clinical OA groups with no 
differentially abundant metabolites identified (Figure A2). Additionally, no 
differences were observed between the global 1D 1H NMR spectra of the two 
groups (Figure A3). 
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Figure A2. Principal component analysis of metabolite peaks identified within 
equine serum collected from the Hong Jong Jockey Club, categorised as healthy or 
clinically diagnosed with osteoarthritis (OA), using 1D 1H NMR. Healthy; n=19, OA; 
n=15. 
 
 
 
 
 
 
 
 
 
 
133 
 
Figure A3. Quantile plots of serum collected from (A) healthy horses (n=21) and (B) 
horses diagnosed with osteoarthritis (n=15) from the Hong Kong Jockey Club. The 
median spectra are depicted by a black line, with variation from the median spectral 
plot depicted by a yellow to red scale. The full spectral range is shown (9.0-0.7 ppm) 
with a more detailed region inset (4.2-3.0 ppm).  
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A.3.10.4. Discussion 
Presently, no equine OA-specific biomarkers have been identified which are able to 
accurately diagnose and stratify OA with none used to aid an earlier clinical 
diagnosis (Anderson, Phelan, et al., 2018). Within this study we have investigated 
equine SF osmolality and the equine serum metabolome, using 1H NMR, to identify 
potential OA markers. However, equine SF osmolality was unable to discriminate 
different grades of equine OA or synovitis. 1H NMR metabolomics of equine serum 
was unable to discriminate healthy horses from those clinically diagnosed with OA. 
A.3.10.4.1. Study Limitations 
SF which was analysed during this study had previously undergone numerous 
freeze-thaw cycles prior to osmolality analysis. Previously, a study identified that 
osmolality values of human plasma following freeze-thawing produced significantly 
less reliable results than fresh samples analysed within 30 min of collection (Bohnen 
et al., 1992). The study also identified differences in osmolality between plasma 
samples stored at 4°C or ambient temperature (21-24°C) prior to analysis. 
Therefore, given the susceptibility of biofluid osmolality to temperature changes, 
this may have affected the final osmolality readings collected and thus reduced 
experimental result reliability. Additionally, despite hyaluronidase treatment of SF, 
SF samples were more viscous than osmolality standards used for osmometer 
calibration, which might mean absolute osmolality values may be inaccurate. 
However, this should not have affected relative osmolality comparisons between 
samples. 
Study constraints did not allow for collection of serum as advised by the 
Metabolomics Society (glucose fasted with a restricted diet) as all samples obtained 
were collected at euthanasia and not from an experimental study designed for this 
purpose. Therefore, influences from variations within these factors may have 
affected the metabolite analysis.  
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A.3.10.4.2. Conclusion 
Equine SF osmolality was unable to discriminate different grades of equine OA or 
synovitis. 1H NMR metabolomics of equine serum was unable to discriminate 
healthy horses from those clinically diagnosed with OA. However, limitations to the 
experimental methods led to a reduced reliability in the results and thus further 
experimentation with improved protocols is required to confirm these findings.
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4.1. Abstract 
Osteoarthritis (OA) is an age-related degenerative musculoskeletal disease 
characterised by loss of articular cartilage, abnormal bone proliferation and 
subchondral bone sclerosis. The underlying pathogenesis of OA is yet to be fully 
elucidated with no OA specific biomarkers identified. Nuclear magnetic resonance 
(NMR) spectroscopy and mass spectrometry (MS) allow analysis of the global 
metabolome and proteome respectively. During this study, ex-vivo equine cartilage 
explants (n=5) were incubated in TNF-α/IL-1β supplemented culture media for 8 
days, with media removed and replaced at 2, 5 and 8 days. Acetonitrile metabolite 
extractions of 8 day cartilage explants and media samples at all time points 
underwent 1H NMR metabolic analysis with media samples also undergoing MS 
proteomic analysis. Within the cartilage, metabolites glucose and lysine levels were 
elevated following TNF-α/IL-1β treatment whilst adenosine, alanine, betaine, 
creatine, myo-inositol and uridine levels decreased. Within the culture media, four, 
four and six metabolites were identified as being differentially abundant between 
control and treatment groups for 1-2 day, 3-5 day and 6-8 day time points 
respectively. Culture media proteomics identified 154, 138 and 72 proteins were 
differentially abundant, with > 2 fold change, between control and treatment 
groups for 1-2 day, 3-5 day and 6-8 day time points respectively. Nine potential 
novel OA neopeptides were elevated in treated media. This is the first study to use 
a multi ‘omics’ approach to simultaneously investigate the metabolomic profile of 
ex-vivo cartilage and metabolomic/proteomic profiles of culture media using the 
TNF-α/IL-1β ex-vivo OA cartilage model. This study has identified a panel of 
metabolites, proteins and extracellular matrix derived neopeptides which are 
differentially abundant within an early phase of the OA model which may provide 
further information on underlying disease pathogenesis, allow potential translation 
for clinical markers and possible novel therapeutic targets.
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4.2. Introduction 
Osteoarthritis (OA) is an age-related degenerative musculoskeletal disease 
characterised by loss of articular cartilage, synovial membrane dysfunction, 
abnormal bone proliferation, subchondral bone sclerosis and altered biochemical 
and biomechanical properties (Kramer, Tsang, et al., 2014; Truong et al., 2006). For 
horses in the UK, OA is one of the leading welfare issues, resulting in substantial 
morbidity and mortality (Ireland et al., 2011, 2012). It is estimated that OA accounts 
for 60% of lameness seen in horses (Caron and Genovese, 2003). Within OA, 
extracellular matrix (ECM) degradation is driven by multiple matrix 
metalloproteinases (MMPs) and a disintegrin and metalloproteinases with 
thrombospondin motifs (ADAMTSs) (Struglics et al., 2006). However, the underlying 
pathogenesis of OA is yet to be fully elucidated with no licensed disease-modifying 
treatments currently available (Li et al., 2007; Marhardt and Muurahainen, 2015). 
No OA specific biomarkers have been identified for OA in the horse with none 
currently used within clinical practice (Anderson, Phelan, et al., 2018). Presently, 
equine OA is predominantly diagnosed through diagnostic imaging and clinical 
examination. However, due to the slow onset of the condition, this often leads to 
substantial pathology of the joint, particularly to articular cartilage prior to 
diagnosis (Brommer et al., 2003). There is therefore a need to develop diagnostic 
tests which are sensitive and specific to the early stages of OA, which are repeatable 
and reproducible, as well as gaining a greater understanding of the underlying 
pathogenesis (Hunter et al., 2014; McIlwraith et al., 2018). Early detection of OA 
could allow for timely management interventions which could potentially slow the 
progression of the disease. 
Tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are both pro-
inflammatory cytokines which are central in OA pathogenesis (Wojdasiewicz et al., 
2014). TNF-α and IL-1β are secreted by mononuclear cells, synoviocytes and 
articular cartilage and upregulate gene expression of MMPs, ADAMTS-4 and 
ADAMTS-5, leading to significant ECM degradation (Fernandes et al., 2002; Goldring 
and Goldring, 2004; Wang et al., 2011). Elevations in TNF-α and IL-1β are regularly 
identified within OA synovial fluid, including that of horses (Bertuglia et al., 2016; 
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Ma et al., 2017; Westacott et al., 1990). TNF-α and IL-1β have therefore become 
established experimental treatments for modelling OA pathology within in vitro and 
ex-vivo studies, having been used both independently and as a combined treatment 
(Barksby et al., 2006; De Ceuninck et al., 2004; Cillero-Pastor et al., 2010; Pretzel et 
al., 2009; Stevens et al., 2008, 2009; Williams, 2014). 
Proteomics is the systematic, large scale study of proteins within biological systems 
to assess quantities, isoforms, modifications, structure and function (de Hoog and 
Mann, 2004). Previous studies have undertaken mass spectrometry (MS) based 
proteomics using TNF-α and IL-1β OA models for secretome analysis of 
chondrocytes in vitro and ex-vivo cartilage explants (Cillero-Pastor et al., 2010; 
Stevens et al., 2008, 2009; Williams, 2014). Results from these studies included 
increased media levels of MMPs, cartilage oligomeric matrix protein (COMP), 
aggrecan and collagen VI. 
During OA pathology, disease-associated peptide fragments (neopeptides) are 
generated from cartilage breakdown due to increased enzymatic 
activity/abundance of MMPs, ADAMTSs, cathepsins and serine proteases (Ben-
Aderet et al., 2015; Peffers et al., 2016; Polur et al., 2010). Using MS, neopeptides 
can be identified and quantified and thus utilised as potential molecular biomarkers 
of early OA. Additionally, a recent mouse study identified that a 32 amino acid 
peptide fragment, generated through degradation of aggrecan via increased 
ADAMTS-4/5 and MMP activity, drives OA pain through Toll-like receptor 2 (Miller 
et al., 2018). Thus, targeting neopeptides may provide analgesia and reduce 
significant pain associated with joint degeneration. Various studies have identified 
potential neopeptides associated with OA in equine cartilage and synovial fluid (SF) 
(Peffers et al., 2014; Peffers, McDermott, et al., 2015; Peffers et al., 2016; 
Skiöldebrand et al., 2017). Subsequent development of neopeptide antibodies 
would allow for the detection and monitoring of cartilage degeneration as well as 
assessing response to therapeutics, in both laboratory and clinical settings (Peffers 
et al., 2017). In addition, identification of OA specific neopeptides may provide 
novel therapeutic targets.  
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Metabolomics uses a systematic methodology to comprehensively identify and 
quantify the metabolic profiles of biological samples (Beckonert et al., 2007). 1H 
Nuclear magnetic resonance (NMR) metabolomics analysis provides a high level of 
technical reproducibility with a minimal level of sample preparation (Beltran et al., 
2012). 1H NMR analysis has previously been used to investigate OA in the SF of 
humans, horses, pigs and dogs (Anderson, Chokesuwattanaskul, et al., 2018; 
Anderson, Phelan, et al., 2018; Damyanovich et al., 1999; Hugle et al., 2012; 
Lacitignola et al., 2008; Mickiewicz, Heard, et al., 2015; Mickiewicz, Kelly, et al., 
2015). Synovial metabolites alanine, choline, creatine and glucose have been 
identified as differentially abundant in OA across multiple studies (Anderson, 
Chokesuwattanaskul, et al., 2018; Anderson, Phelan, et al., 2018; Damyanovich et 
al., 1999; Lacitignola et al., 2008; Mickiewicz, Heard, et al., 2015; Mickiewicz, Kelly, 
et al., 2015). NMR techniques have also previously been used to characterise 
cartilage with high resolution magical angle spinning (HRMAS) NMR utilised to 
assess enzymatic degradation of bovine cartilage (Ling et al., 2008; Schiller et al., 
2001, 2004). A guinea pig OA model using HRMAS NMR identified elevations in 
methylene resonances associated with chondrocyte membrane lipids and an 
increase in mobile methyl groups of collagen (Borel et al., 2009). Another HRMAS 
NMR study of human OA cartilage identified a reduction in alanine, choline, glycine, 
lactate methyne and N-acetyl compared to healthy control cartilage (Shet et al., 
2012). However, no NMR studies to date have investigated the metabolic profile of 
culture media following the incubation of ex-vivo cartilage within an OA model. 
This is the first study to carry out 1H NMR metabolomic analysis of extracted 
cartilage metabolites and the first to undertake 1H NMR analysis of culture media 
using the TNF-α/IL-1β ex-vivo OA cartilage model. Additionally, this is also the first 
study to use a multi ‘omics’ approach to simultaneously investigate the 
metabolomic profile of ex-vivo cartilage and metabolomic/proteomic profiles of 
culture media using this OA model. It was hypothesised that following TNF-α/IL-1β 
treatment of ex vivo equine cartilage, 1H NMR metabolomic and MS proteomic 
platforms would identify a panel of cartilage metabolites which were able to 
differentiate control from treated cartilage and a panel of metabolites, proteins and 
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neopeptides within the associated culture media which were differentially 
abundant at each tested time point of the OA model. 
4.3. Methods 
4.3.1 Equine Ex-Vivo Cartilage Collection 
Full thickness cartilage was removed from all articular surfaces within five separate 
metacarpophalangeal joints of five nine-year-old mares of unknown breed within 24 
hr of slaughter (F Drury and Sons, Swindon, UK). Cartilage collected from all joints 
was considered macroscopically normal with a score of 0 according to the OARSI 
histopathology initiative scoring system for horses (McIlwraith et al., 2010) 
(Supplementary Figure 1). Cartilage was washed in complete media containing 
Dulbecco’s modified Eagle’s medium (DMEM, 31885-023, Life Technologies, Paisley, 
UK) supplemented with 10% (v/v) foetal calf serum (FCS, Life Technologies), 5 μg/ml 
Amphotericin B (Life Technologies), 100 U/ml Streptomycin and 100 U/ml Penicillin 
(Sigma-Aldrich, Gillingham, UK) (Figure 1). 
Cartilage was dissected into 3 mm2 sections and divided into two for each donor 
(control and treatment wells) on a twelve well plate (Greiner Bio-One Ltd., 
Stonehouse, UK). Explants were incubated for 24 hr in complete media within a 
humidified atmosphere of 5% (v/v) CO2 at 37°C. Culture media was removed, 
explants washed in phosphate buffered saline (PBS, Sigma-Aldrich) and replaced 
with serum free media (control) or serum free media supplemented with 10 ng/ml 
TNF-α (PeproTech EC Ltd., London, UK) and 10 ng/ml IL-1β (R&D Systems Inc., 
Minneapolis, Minnesota, USA) (treatment). After 48 hr, media was removed, 
centrifuged at 13,000g, 4°C for 10 min, supernatant removed and 
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (Roche, 
Lewes, UK) added to cell-free media. Supernatant was then snap frozen in liquid 
nitrogen and stored at -80°C. Cartilage was washed in PBS and control/treatment 
culture media replaced as appropriate. Media collection was repeated at five and 
eight days. After day eight, cartilage was washed in PBS, weighed, snap frozen in 
liquid nitrogen and stored at -80°C. 
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Figure 1. Experimental design for ex-vivo equine cartilage culture +/- TNF-α/IL-1β treatment. MCP = metacarpophalangeal.
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4.3.2. NMR Metabolomics 
4.3.2.1. Cartilage - Metabolite Extraction 
Equal masses of cultured cartilage explants (in addition to three macroscopically 
normal equine cartilage samples, each divided into three to assess metabolite 
extraction reproducibility) were thawed out over ice and added to 500 µl of 50:50 
(v/v) ice cold acetonitrile (ThermoFisher Scientific, Massachusetts, USA):dd 1H2O 
and incubated on ice for 10 min (Figure 2). Samples were then sonicated for three 
30 s periods, interspersed with 30 s rests, vortexed for 1 min, centrifuged at 
12,000g for 10 min at 4°C, supernatant removed, snap frozen in liquid nitrogen, 
lyophilised and stored at -80°C (Beckonert et al., 2007). 
 
 
 
 
 
Figure 2. Protocol for cartilage metabolite extraction. 
 
4.3.2.2. Cartilage - NMR Sample Preparation 
Each lyophilised sample was dissolved through the addition of 178 µl of 100% 
deuterium oxide (2H2O, Sigma-Aldrich), 20 µl of 1M PO43- pH 7.4 buffer (Na2HPO4, 
VWR International Ltd., Radnor, Pennsylvania, USA and NaH2PO4, Sigma-Aldrich), 
0.2 µl of 100 mM d4 trimethylsilyl propionate (TSP, Sigma-Aldrich) and 0.2 µl of 1.2 
mM sodium azide (NaN3, Sigma-Aldrich). Samples were vortexed for 1 min, 
centrifuged at 12,000g for 2 min, 190 µl of supernatant removed and transferred 
into 3 mm outer diameter NMR tubes using a glass pipette. 
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4.3.2.3. Culture Media - NMR Sample Preparation 
Culture media was thawed over ice and centrifuged for 5 min at 21,000g and 4°C. 
150 µl of thawed culture media was diluted to a final volume containing 50% (v/v) 
culture media, 40% (v/v) dd 1H2O, 10% 2H2O and 0.0025% (v/v) NaN3, within an 
overall concentration of 500 mM PO43- pH 7.4 buffer. Samples were vortexed for 1 
min, centrifuged at 13,000g for 2 min at 4°C, 250 µl supernatant removed and 
transferred to 3 mm outer diameter NMR tubes using a glass pipette. 
4.3.2.4. NMR Acquisition 
For each individual sample, 1D 1H NMR spectra, with the application of a Carr-
Purcell-Meiboom-Gill (CPMG) filter to attenuate macromolecule (e.g. proteins) 
signals, were acquired using the standard vendor pulse sequence cpmgpr1d on a 
700 MHz NMR Bruker Avance III HD spectrometer with associated TCI cryoprobe 
and chilled Sample-Jet autosampler. All spectra were acquired at 25°C, with a 4 s 
interscan delay, 256 transients for cartilage spectra and 128 transients for media 
spectra, with a spectral width of 15 ppm. Topsin 3.1 and IconNMR 4.6.7 software 
programmes were used for acquisition and processing undertaking automated 
phasing, baseline correction and a standard vendor processing routine (exponential 
window function with 0.3 Hz line broadening). In addition to all cartilage extract and 
culture media samples, protease inhibitor cocktail and treatment cytokines TNF-α 
and IL-1β were also analysed separately to evaluate their metabolite profiles. 
4.3.2.5. Metabolite Annotation and Identification 
All acquired spectra were assessed to determine whether they met minimum 
reporting standards (as outlined by the Metabolomics Society) prior to inclusion for 
statistical analysis (Sumner et al., 2007). These included appropriate water 
suppression, flat spectral baseline and consistent linewidths. Metabolite 
annotations and relative abundances were carried out using Chenomx NMR Suite 
8.2 (330-mammalian metabolite library). Where possible, metabolite identifications 
were confirmed using 1D 1H NMR in-house spectral libraries of metabolite 
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standards. Quantile plots of 1D 1H NMR spectra are shown in Supplementary Figure 
2. 
4.3.3. Culture Media Proteomics 
4.3.3.1. Protein Assay and StrataCleanTM Resin Processing 
Culture media was thawed over ice and centrifuged for 5 min at 21,000g and 4°C. 
Media sample concentrations were determined using a Pierce® 660 nm protein 
assay (Thermo Scientific, Waltham, Massachusetts, USA). 50 µg of protein for each 
sample was diluted with dd H2O, producing a final volume of 1 ml. 10 µl of 
StrataCleanTM resin (Agilent, Santa Clara, California, USA) was added to each 
sample, rotated for 15 min, centrifuged at 400g for 1 min and the supernatant 
removed and discarded. Samples were then washed through the addition of 1 ml of 
ddH2O, vortexed for 1 min, centrifuged at 400g for 1 min and the supernatant 
removed and discarded. The wash step was repeated two further times. 
4.3.3.2. Protein Digestion 
160 µl of 25 mM ammonium bicarbonate (Fluka Chemicals Ltd., Gillingham, UK) 
containing 0.05% (w/v) RapiGest (Waters, Elstree, Hertfordshire, UK) was added to 
each sample and heated at 80°C for 10 min. DL-Dithiothreitol (Sigma-Aldrich) was 
added to produce a final concentration of 3 mM, incubated at 60°C for 10 min then 
iodoacetamide (Sigma-Aldrich) added (9 mM final concentration) and incubated at 
room temperature in the dark for 30 min. 2 µg of proteomics grade trypsin (Sigma-
Aldrich) was added to each sample, rotated at 37°C for 16 hr and trypsin treatment 
then repeated for a 2 hr incubation. Samples were centrifuged at 1,000g for 1 min, 
digest removed, trifluoroacetic acid (TFA, Sigma-Aldrich) added (0.5% (v/v) final 
concentration) and rotated at 37°C for 30 min. Finally, digests were centrifuged at 
13,000g and 4°C for 15 min and the supernatant removed and stored at 4°C. 
4.3.3.3. Label Free LC-MS/MS 
All media digests were randomised and individually analysed using LC-MS/MS on an 
UltiMate 3000 Nano LC System (Dionex/Thermo Scientific) coupled to a Q 
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ExactiveTM Quadrupole-Orbitrap instrument (Thermo Scientific). Full LC-MS/MS 
instrument methods are described in chapter 7. Tryptic peptides, equivalent to 250 
ng of protein, were loaded onto the column and run over a 1 hr gradient, 
interspersed with 30 min blanks (97% (v/v) high performance liquid 
chromatography grade H20 (VWR International), 2.9% acetonitrile (Thermo 
Scientific) and 0.1% TFA. In addition to Individual time points, pooled samples for 
control and treatment groups were also analysed to investigate differences in the 
overall secretome. Representative ion chromatograms are shown in Supplementary 
Figure 3. 
4.3.3.4. LC-MS/MS spectra processing and protein identification 
Spectral alignment, peak picking, total protein abundance normalisation and 
peptide/protein quantification were undertaken using Progenesis™ QI 2.0 
(Nonlinear Dynamics, Waters). The exported top ten spectra for each feature were 
then searched against the Equus caballus database for peptide and protein 
identification using PEAKS® Studio 8.5 (Bioinformatics Solutions Inc., Waterloo, 
Ontario, Canada) software. Search parameters were: precursor mass error 
tolerance, 10.0 ppm; fragment mass error tolerance, 0.01 Da; precursor mass 
search type, monoisotopic; enzyme, trypsin; maximum missed cleavages, 1; non-
specific cleavage, none; fixed modifications, carbamidomethylation; variable 
modifications, oxidation or hydroxylation and oxidation (methionine). A filter of a 
minimum of 2 unique peptides was set for protein identification and quantitation 
with a false discovery rate (FDR) of 1%.  
4.3.3.5. 1D SDS PAGE 
Media samples for each donor were combined for all time points and analysed via 
one dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis (1D 
SDS PAGE). 1 μg of each sample was added to Laemmli loading buffer Novex™ 
(Thermo Scientific) producing a final concentration of 15% glycerine, 2.5% SDS, 2.5% 
Tris (hydroxymethyl) aminomethane, 2.5% HCL and 4% β-mercaptoethanol at pH 
6.8 and heated at 95°C for 5 min. Samples were loaded onto a 4-12% Bis-Tris 
polyacrylamide electrophoresis gel (NuPAGE™ Novex™, Thermo Scientific) and 
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protein separation carried out at 200 V for 30 min at room temperature. Protein 
bands were visualised via silver staining (Thermo Scientific) following manufacturer 
instructions. Gel images were converted to 8 bit grey scale and protein band 
intensities analysed using densitometry with the software Image J (NIH, Bethesda, 
Maryland). 
4.3.3.6. Semi-Tryptic Peptide Identification 
To identify potential neopeptides a ‘semi-tryptic’ search was carried out. The same 
PEAKS® search parameters were used as for protein identification, with the 
exception that ‘non-specific cleavage’ was altered from ‘none’ to ‘one’. The ‘peptide 
ion measurements’ file was then exported and analysed using the online 
neopeptide analyser software tool (Peffers et al., 2017). 
4.3.4. Statistical Analysis 
Cartilage metabolite profiles were normalised using probabilistic quotient 
normalisation (PQN) (Dieterle et al., 2006). Media metabolites were normalised to 
TSP concentration and protein profiles normalised to total ion current (TIC). Prior to 
multivariate analysis, metabolite and protein profiles were Pareto scaled (Worley 
and Powers, 2013). MetaboAnalyst 3.5 (http://www.metaboanalyst.ca) was used to 
produce principal component analysis (PCA) and partial-least-squares discriminant 
analysis (PLS-DA) plots. t-tests were carried out using MetaboAnalyst 3.5 (protein 
and metabolite abundances) and the neopeptide analyser (neopeptides) with p < 
0.05 (and a fold change of > 2 for proteins) considered statistically significant. The 
Benjamini-Hochberg false discovery rate method was applied for correction of 
multiple testing (Benjamini and Hochberg, 1995). The SPSS 24 software package was 
used to produce all box plots. 
4.3.5. Pathway Analysis 
Pathway analysis was conducted for differentially abundant metabolites using the 
online tool KEGG for Equus caballus (Ogata et al., 1999). Differentially abundant 
proteins (> 2 fold change) were also analysed using KEGG via the STRING database 
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(Szklarczyk et al., 2015). A filter of a minimum of two metabolites/proteins was set 
for each sample set for inclusion of the relevant biological pathway. 
4.4. Results 
4.4.1. NMR Metabolomics 
4.4.1.1. Protease inhibitor cocktail, TNF-α and IL-1ß metabolite profiles 
Protease inhibitor cocktail was found to have high levels of mannitol and thus this 
metabolite was removed from all analyses. Within the spectral profiles of TNF-α and 
IL-1β acquired separately, the metabolites acetate, acetone, ethanol, formate, 
lactate, methanol and succinate were identified. These metabolites were therefore 
also removed from further analyses. 
4.4.1.2 Cartilage - Metabolites 
Acetonitrile metabolite extraction was identified to be highly reproducible with 
technical replicates clustering within a PCA plot for three separate macroscopically 
normal cartilage samples (Figure 3). In total 35 metabolites were identified within 
equine cartilage (Table 1). Of these, following the removal of metabolites previously 
mentioned, eight were identified as being differentially abundant between control 
and treatment groups (Figure 4). Glucose and lysine levels were elevated following 
TNF-α/IL-1β treatment whilst adenosine, alanine, betaine, creatine, myo-inositol 
and uridine levels decreased. PCA identified that metabolite profiles separated into 
two distinct clusters, separating control and treatment groups (Figure 4a). PLS-DA 
(supervised multivariate discriminant analysis) produced a model comprising one 
component with a good predictive power (R2 = 0.89, Q2 = 0.82) (Figure 5b). Of the 
top 25 variables of influence (VIP), myo-inositol was found to be the most influential 
cartilage metabolite in separating control and treated samples, followed by glucose, 
betaine and alanine (Figure 5c). 
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Figure 3. Principal component analysis scores plot identifying high reproducibility of 
acetonitrile cartilage metabolite extraction (three separate equine donors, technical 
triplicate for each donor) using 1D 1H NMR metabolome analysis. Shaded regions 
depict 95% confidence regions. 
 
Table 1. Metabolites annotated within cartilage and culture media using Chenomx. 
Metabolites additionally identified using a 1D 1H NMR in-house library have been 
assigned to Metabolomics Standards Initiative (MSI) level 1 (Salek et al., 2013). 
 
Database 
Identifier 
Metabolite Identification Cartilage 
Cartilage 
Reliability 
Media 
Media 
Reliability 
HMDB00695 2-Oxoisocaproate     Y MS Level 2 
HMDB00491 3-Methyl-2-oxovalerate     Y MS Level 2 
HMDB31645 Acetamide Y MS Level 2     
HMDB00042 Acetate * Y MS Level 1 Y MS Level 1 
HMDB01659 Acetone *     Y MS Level 2 
HMDB00050 Adenosine Y MS Level 2     
HMDB00517 Arginine     Y MS Level 2 
HMDB00191 Aspartate Y MS Level 1     
HMDB00043 Betaine Y MS Level 1     
HMDB00097 Choline     Y MS Level 1 
HMDB00094 Citrate Y MS Level 1 Y MS Level 1 
HMDB00064 Creatine Y MS Level 1     
HMDB00562 Creatinine Y MS Level 1 Y MS Level 1 
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HMDB00192 Cystine     Y MS Level 2 
HMDB00122 D-Glucose Y MS Level 1     
HMDB04983 Dimethyl sulfone Y MS Level 2     
HMDB00108 Ethanol *     Y MS Level 1 
HMDB00142 Formate * Y MS Level 2 Y MS Level 2 
HMDB00123 Glycine Y MS Level 1 Y MS Level 1 
HMDB00870 Histamine     Y MS Level 2 
HMDB00172 Isoleucine Y MS Level 1 Y MS Level 1 
HMDB00863 Isopropanol *     Y MS Level 2 
HMDB00190 Lactate * Y MS Level 1 Y MS Level 1 
HMDB00161 L-Alanine Y MS Level 1 Y MS Level 1 
HMDB00062 L-Carnitine     Y MS Level 2 
HMDB00148 L-Glutamate Y MS Level 1 Y MS Level 1 
HMDB00641 L-Glutamine Y MS Level 1 Y MS Level 1 
HMDB00177 L-Histidine     Y MS Level 1 
HMDB00687 L-Leucine Y MS Level 1 Y MS Level 1 
HMDB00159 L-Phenylalanine Y MS Level 1     
HMDB00167 L-Threonine Y MS Level 2 Y MS Level 2 
HMDB00158 L-Tyrosine Y MS Level 1 Y MS Level 1 
HMDB00883 L-Valine Y MS Level 1 Y MS Level 1 
HMDB00182 Lysine Y MS Level 1 Y MS Level 1 
HMDB00765 Mannitol *     Y MS Level 1 
HMDB01875 Methanol *     Y MS Level 2 
HMDB00696 Methionine Y MS Level 1 Y MS Level 1 
HMDB01844 Methylsuccinate Y MS Level 2     
HMDB00211 myo-Inositol Y MS Level 1     
HMDB03269 Nicotinurate Y MS Level 2 Y MS Level 2 
HMDB00895 O-Acetylcholine Y MS Level 2     
HMDB00210 Pantothenate Y MS Level 2 Y MS Level 2 
HMDB00267 Pyroglutamate     Y MS Level 2 
HMDB00243 Pyruvate Y MS Level 1     
HMDB00086 sn-Glycero-3-phosphocholine Y MS Level 2     
HMDB00254 Succinate * Y MS Level 1 Y MS Level 1 
HMDB00929 Tryptophan     Y MS Level 1 
HMDB00300 Uracil Y MS Level 2     
HMDB00296 Uridine Y MS Level 1     
HMDB00001 τ-Methylhistidine Y MS Level 2     
 
Y = Yes; * = Metabolite removed from subsequent analyses
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Figure 4. Boxplots of differentially abundant extracted ex-vivo equine cartilage metabolites for control (n=5) and following TNF-α/IL-1β 
treatment (n=5), shown as relative intensities. t-test: * = p < 0.05 and ** = p < 0.01.
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Figure 5. PCA (A, D and G), PLS-DA (B, E and H) plots and VIP scores (C, F and I) for 
the 25 most influential metabolites and proteins present in ex-vivo equine cartilage 
and culture media for combined time points over 8 days, comparing controls (red, 
n=5) to TNF-α/IL-1β treatment (green, n=5). It should be noted that 1, 5 and 4 
components were used to fit PLS-DA models in B, E and H respectively. 
 
4.4.1.3. Media - Metabolites 
Phosphate salt precipitated out of solution for three samples (a 0-2 day treated 
sample, a control sample and a treated 3-5 time point sample) producing poor 
quality spectra which were therefore removed from further analyses. Isopropanol 
was identified within all media samples. As this was considered a likely contaminant 
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during cartilage culture, together with metabolites previously mentioned, 
isopropanol was also removed from all analyses. In total, 34 metabolites were 
identified within the culture media (Table 1). Time points were analysed separately 
with four, four and six metabolites identified as being differentially abundant 
between control and treatment groups for 1-2 day, 3-5 day and 6-8 day time points 
respectively (Figure 6). Choline levels were increased in treated samples compared 
to controls for all three time points whilst alanine and citrate levels decreased. At 3-
5 days glutamate levels were reduced following treatment. At 6-8 days, following 
treatment, arginine and isoleucine levels were elevated whilst 2-oxoisocaproate and 
3-methyl-2-oxovalerate levels were found to decrease. PCA of combined and 
separated time points identified clear separation between the metabolite profiles of 
control and treated media samples (Figure 5d and Figure 7a, b and c). PLS-DA of 
combined samples produced an excellent predictive model (R2 = 0.999, Q2 = 0.908) 
with separation driven primarily by alanine and glutamate (Figure 5e and f). 
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Figure 6. Boxplots of differentially abundant metabolites within the culture media following incubation of ex-vivo equine cartilage for control 
samples (C, red) and following TNF-α/IL-1β treatment (T, green), at 0-2, 3-5 and 6-8 days (d). Metabolite abundances shown as relative 
intensities. t-test: * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. Control (n=5) and TNF-α/IL-1β treatment (n=5) for each separate time point.
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Figure 7. Principal component analysis (PCA) plots of media metabolite (A-C) and 
protein (D-F) profiles at 0-2, 3-5 and 6-8 days for controls (green, n=5) and TNF-α/IL-
1β treatment (red, n=5) of ex-vivo equine cartilage.  
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4.4.2. LC-MS/MS Proteomics 
4.4.2.1. Media - Proteomics 
In total, 352 proteins were identified within analysed culture media samples with an 
elevated number of identified proteins within treated compared to control samples 
(Figure 8 and Supplementary Table 1). Of all identified proteins, 131 were identified 
within TNF-α/IL-1β treated media samples only. When time points were analysed 
separately, 154, 138 and 72 proteins were identified as being differentially 
abundant, with > 2 fold change, between control and treatment groups for 1-2 day, 
3-5 day and 6-8 day time points respectively. Supervised PLS-DA analysis of 
combined protein profiles produced an excellent predictive model (R2 = 0.997, Q2 = 
0.944) with separation primarily driven through elevated COMP and decreased 
fibronectin following treatment (Figure 5h and 5i). Unsupervised PCA multivariate 
analysis identified clear discrimination between control and treatment groups at all 
three time points (Figure 7). At each separated time point the top 25 VIP scoring 
proteins were identified (Supplementary Figure 4). Box plots in Figure 9 represent 
proteins which were found to be represented within the top 25 most influential 
proteins at all three time points (coagulation factor XIII A chain, COMP, enolase 1, 
Lamin A/C and MMP-3) and extracellular matrix related proteins of interest 
represented at 2/3 time points (collagen type VI α 2 chain, collagen type X α 1 
chain, fibromodulin, fibronectin, matrix Gla protein, MMP1 and vimentin). 
Coagulation factor XIII A chain, enolase 1 and lamin A/C were elevated at all three 
time points following treatment. MMP-1 and MMP-3 levels were found to be 
statistically elevated at 0-2 days only. Fibromodulin and vimentin levels were 
increased following treatment at both 0-2 days and 3-5 day time points whilst 
COMP levels increased at 0-2 days and 6-8 days. Collagen type VI α 2 chain and 
matrix Gla protein levels decreased following treatment at 3-5 days and 6-8 days 
whilst collagen type X α 1 chain and fibronectin levels statistically decreased at 6-8 
days alone. 
Silver stain analysis of the media profiles for combined time points identified two 
protein bands which were decreased in abundance following TNF-α/IL-1β 
treatment, with molecular weights of 160-260 kDa and 260 kDa (Figure 10). 
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Figure 8. Number of proteins identified within culture media for (A) combined and 
(B) individual sample time points for controls and TNF-α/IL-1β treated ex-vivo 
equine cartilage. Combined time points, n=5/group, Individual time points, 
n=15/group.
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Figure 9. Boxplots of differentially abundant proteins within the culture media following incubation of ex-vivo equine cartilage for control 
samples (C, red) and following TNF-α/IL-1β treatment (T, green), at 0-2, 3-5 and 6-8 days (d). Protein abundances shown as relative intensities. 
t-test: * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. Control (n=5) and TNF-α/IL-1β treatment (n=5) for each separate time point. 
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Figure 10. (A) Silver stain identifying media protein profiles (combined for all time 
points) following incubation of ex-vivo equine cartilage for control and TNF-α/IL-1β 
treated samples. Arrows indicate differentially secreted proteins at approximately 
160-260 kDa and 260 kDa. Relative abundances of bands at (B) 160-260 kDa and (C) 
260 kDa calculated using densitometry, n=5/group. t-test: * = p < 0.05. 
 
4.4.2.2. Semi-Tryptic Peptides 
PCA of all identified semi-tryptic peptides within combined control and combined 
treated samples identified far less variation within the treatment group (Figure 11). 
This was also identified for all time points analysed individually (Supplementary 
Figure 5). In total, nine potential novel OA neopeptides were identified which were 
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elevated in treated media samples (Table 2). These included semi-tryptic peptides 
of extracellular matrix proteins aggrecan, cartilage intermediate layer protein, 
collagen type VI α 2 chain and vimentin. 
 
 
 
 
 
 
 
 
 
 
Figure 11. Principal component analysis (PCA) of semi-tryptic peptide profiles within 
culture media of control (red, n=5) and TNF-α/IL-1β treated (green, n=5) ex-vivo 
equine cartilage. Time points pooled for each individual donor. 
 
Table 2. Potential Osteoarthritis Neopeptides. Semi-tryptic peptides of 
extracellular matrix related and unknown proteins, identified within culture media, 
with an increased abundance following TNF-α/IL-1β treatment of ex-vivo equine 
cartilage. 
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4.4.2.3. Pathway Analysis 
In total, 36 biological pathways were identified which are potentially involved 
within OA pathogenesis (Table 3). The ‘biosynthesis of amino acids’ and ‘carbon 
metabolism’ pathways were both highly represented by metabolites and proteins 
across all three time points. Additionally, ‘ABC Transporters’, ‘alanine, aspartate and 
glutamate metabolism’ and ‘aminoacyl-tRNA biosynthesis’ were well represented 
by metabolites across all time points and ‘fructose and mannose metabolism’ and 
‘glycolysis/gluconeogenesis’ by proteins across all time points. 
 
Table 3. Pathway analysis for differentially abundant metabolites and proteins 
identified in cartilage and culture media following TNF-α/IL-1β treatment of ex-vivo 
equine cartilage. 
DA = differentially abundant 
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4.5. Discussion 
In this study TNF-α/IL-1β treatment of ex-vivo equine cartilage explants was used to 
model OA to gain a greater understanding of OA pathogenesis and identify potential 
OA markers. 1H NMR metabolomic analysis of extracted cartilage metabolites 
(following 8 days incubation) was undertaken in addition to 1H NMR metabolomic 
and LC-MS/MS proteomic analysis of culture media at 0-2, 3-5 and 6-8 days. 
4.5.1. MMPs, COMP and Fibronectin 
Within culture media, following TNF-α/IL-1β treatment, elevations in 
endopeptidases MMP-1 and MMP-3 at 0-2 days, with a similar trend at both other 
time points, were identified as expected (Mackay et al., 1992). Elevated MMP-1 
activity has previously been identified within equine OA SF with general MMP 
activity also found to be correlated to severity of cartilage damage (van den Boom 
et al., 2005; Brama et al., 2004). Also, as previously reported, elevations in the non-
collagenous ECM protein COMP were also identified within the TNF-α/IL-1β equine 
OA model, with COMP considered a marker of cartilage breakdown (Svala et al., 
2015; Tseng et al., 2009). Clinically, elevated COMP levels have been identified 
within human OA SF, although within equine OA, one study identified reduced 
levels with COMP unable to stage the disease (Balakrishnan et al., 2014; Taylor et 
al., 2006). Fibronectin was identified as a key discriminator between control and 
treatment groups with reduced secreted fibronectin identified within the media 
following TNF-α/IL-1β treatment. Additionally, a protein band of molecular weight 
160-260 kDa was identified as reduced in treated media compared to control 
samples via 1D SDS PAGE which may be representing fibronectin (250 kDa), 
although further techniques, i.e. Western blotting or MS/MS analysis of an in-gel 
tryptic digest, are required to confirm this (Peffers, 2013; Stashak and Theoret, 
2011). However, elevated levels of fibronectin have previously been identified 
within OA SF with fibronectin found to localise at sites of cartilage degeneration and 
subsequently secreted into the ECM by equine chondrocytes (Lust et al., 1987; 
Murray et al., 2000). The reasons for this possible discrepancy in results between 
this study and previous studies is currently not known and requires further 
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investigation. It may be that within this study fibronectin has undergone post 
translational modifications following treatment which may not have been identified 
via the PEAKS® identification algorithm or resulted in peptides which subsequently 
did not ‘fly’ well during MS analysis and thus were subsequently not identified. 
4.5.2. Glucose 
Following TNF-α/IL-1β treatment, elevations of glucose within the cartilage were 
identified. This is supported by a previous study which demonstrated that TNF-α 
and IL-1β upregulate glucose transport in chondrocytes through upregulation of 
glucose transporter (GLUT)1 and GLUT9 mRNA synthesis with increased levels of 
glycosylated GLUT1 incorporated into the plasma membrane (Shikhman et al., 
2001). This influx in glucose is likely, at least in part, to be due to the increased 
energy requirement following cytokine stimulation in the production of MMPs and 
secretion of Il-6, Il-8, hematopoietic colony-stimulating factor and prostaglandin E2 
(Hernvann et al., 1996). 
4.5.3. Alanine, Arginine, Choline and Citrate 
Alanine, arginine, choline and citrate were all identified to be differentially 
abundant within culture media following TNF-α/IL-1β treatment at the earliest time 
point, 0-2 days. 
Within this study, arginine levels were initially identified as being decreased 
following treatment at the earliest time point. A recent study of human plasma also 
identified arginine to be depleted in knee OA (Zhang et al., 2016). The authors 
proposed this is due to an increased activity of the conversion of arginine to 
ornithine resulting in an imbalance between cartilage repair and degradation. This is 
supported by a recent learning and network approach of OA associated metabolites 
in which arginine and ornithine appeared in about 30% and 25% of the generated 
models studied (Hu et al., 2018). In addition to this, a reduction in arginine may be 
reflective of an increased production of nitric oxide (L-arginine being converted to 
NOH-arginine and subsequently L-citrulline and nitric oxide) as identified in human 
OA cartilage (Abramson, 2008; Loeser et al., 2002). 
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A 1H NMR metabolomics study of equine SF also identified elevated levels of choline 
in OA (Lacitignola et al., 2008). However, elevated levels of alanine and citrate were 
also identified whilst these were found to be decreased within our study. 
Across the whole study, alanine was found to be a central component in 
discriminating control and treatment groups. Alanine levels were depleted in 
treated cartilage extracts compared to controls, with PLS-DA identifying alanine as 
the fourth most important component in discriminating control and treated 
cartilage samples. Reduced alanine levels were also identified in human OA 
cartilage using HRMAS NMR spectroscopy (Shet et al., 2012). Within culture media, 
at all three time points alanine was depleted in treated samples and KEGG pathway 
analysis revealed the ‘alanine, aspartate and glutamate metabolism’ pathway to be 
well represented by both metabolites and proteins. Alanine has previously been 
identified as a key component of the metabolic urinary OA profile of guinea pigs 
(Lamers et al., 2003). 
4.5.4. Collagen Degradation 
Isoleucine was elevated within media during the latter stages of the model (6-8 
days). Elevated isoleucine levels have previously been reported within SF of a canine 
OA model and human OA serum (Damyanovich et al., 1999; Zhai et al., 2010). Borel 
et al. previously identified elevations of peaks within 1H HRMAS NMR spectra of OA 
cartilage which could be attributed to isoleucine (Borel et al., 2009). Thus the 
elevations seen in isoleucine may be reflective of cartilage collagen breakdown 
(Zhai et al., 2010). However, within this study, although a higher abundance was 
recorded for isoleucine in treated compared to control cartilage, this did not reach 
statistical significance. However, elevations in glutamate were identified within 
culture media at 3-5 days, which may be resultant of the catabolism of collagenous 
proline through proline oxidase (Phang et al., 2015). Reduced levels of collagen type 
VI α 2 chain and collagen type X α 1 chain were identified at 3-5 and 6-8 days 
following cytokine treatment. This may reflect a reduction in collagen synthesis 
which has previously been identified within other collagen types following TNF-α/IL-
1β stimulation (Stevens et al., 2009). Therefore these results provide evidence of a 
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disruption in collagen homeostasis and suggest that collagens are being degraded 
within the model sooner than the 14-28 days previously reported within other ex-
vivo cartilage OA models (Milner et al., 2001, 2006). 
4.5.5. Coagulation Factor XIII A Chain, Enolase 1, Fibromodulin, Lamin A/C and 
Vimentin 
Coagulation factor XIII A chain, enolase 1, fibromodulin, lamin A/C and vimentin 
were all identified as being differentially abundant within the culture media at the 
earliest time point; 0-2 days. 
Coagulation factor XIII is a heterotetrameric protein complex which crosslinks fibrin 
polymers through covalent bonds (Gupta et al., 2016). Coagulation factor XIII A 
chain immunostaining was previously found to be elevated within human articular 
knee cartilage following IL-1β stimulation (Johnson et al., 2001). Sanchez et al. 
identified increased expression of coagulation factor XIII A chain in osteoblasts 
within the sclerotic zone of OA subchondral bone (Sanchez et al., 2008). Clinically, 
remodelling of the subchondral bone is likely to be closely related to cartilage 
degradation (Day et al., 2004). Within hypertrophic chondrocytes, Nurminkaya et al. 
concluded that cell death and lysis were responsible for the externalisation of the 
protein (Nurminkaya et al., 1998). However, coagulation factor XIII A chain has also 
been identified within articular cartilage vesicles, although the underlying 
externalisation mechanism remains unknown (Rosenthal et al., 2001). 
Enolase 1 is a multifunctional glycolytic enzyme which has previously been shown to 
have increased abundance within an equine articular cartilage model stimulated 
with IL-1β, as well as increased expression on the cell surface of immune cells 
during rheumatoid arthritis (RA) (Lee et al., 2018; Peffers, 2013). Lee et al. identified 
apolipoprotein B within RA SF to be a specific ligand to enolase 1, provoking an 
inflammatory response. Elevated levels of apolipoprotein B have also been 
associated with human knee OA (Sánchez-Enríquez et al., 2008). Thus lipid 
metabolism may operate through this mechanism to regulate chronic inflammation 
in OA as well as RA (Lee et al., 2018). 
166 
 
Fibromodulin is a small leucine-rich repeat proteoglycan which interacts with 
collagen fibrils and influences fibrillogenesis rate and fibril structure (Roughley et 
al., 1996). Experimental mice which lack biglycan and fibromodulin have been 
shown to develop OA in multiple joints (Ameye et al., 2002; Wadhwa et al., 2005). 
Neopeptides generated from fibromodulin degradation have also been identified as 
potential markers of equine articular cartilage degradation (Peffers et al., 2016). 
Within our study, higher levels of Lamin A/C (intermediate filament protein) were 
identified within treated media samples (Swift and Discher, 2014). Lamin A/C has 
also been identified as being upregulated in human OA cartilage and elevated levels 
have been implicated in dysregulation of chondrocyte autophagy in ageing and OA 
(Attur et al., 2012; de Figueroa et al., 2017). Thus our results support these studies, 
with chondrocyte autophagy targeting a potential novel therapeutic route. 
Vimentin is a multifunctional intermediate filament protein (Ivaska et al., 2007). 
Within chondrocytes it has been shown that vimentin is likely to be involved in 
mechanotransduction (Langelier et al., 2000). Our results are supported by a 
previous study which identified elevated levels of cleaved vimentin within human 
OA cartilage with distortion of the vimentin network evident (Lambrecht et al., 
2008). 
4.5.6. Semi-Tryptic Peptides and Neopeptides 
Due to an elevation in enzymatic activity and breakdown of cartilage during OA, 
potential biomarkers include ECM degradation fragments (Lotz et al., 2013). PCA 
identified that the semi-tryptic peptide profiles generated from treated equine 
cartilage was less variable than that of the controls, demonstrating the TNF-α/IL-1β 
treatment is driving the semi-tryptic peptide profile within the model. Within this 
study we have identified several semi-tryptic peptides (potential neopeptides) 
which were identified as being elevated following treatment compared to controls, 
including degradation products from ECM proteins aggrecan, cartilage intermediate 
layer protein, vimentin and collagen type VI. None of these potential neopeptides 
have previously been identified within the literature (Peffers, 2013; Peffers et al., 
2014; Peffers, McDermott, et al., 2015; Peffers et al., 2016). 
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4.5.7. Further Work 
Additional MS based metabolomics analysis of the culture media within this study 
may be beneficial as NMR and MS are complementary techniques and would 
therefore expand the number of identified/quantified metabolites, additionally 
identifying potential lipid and carbohydrate profiles of interest (Anderson, Phelan, 
et al., 2018; Beltran et al., 2012; Marshall and Powers, 2017; Mickiewicz, Kelly, et 
al., 2015). In order to confirm the differentially abundant proteins within this study, 
validation using an orthologous technique e.g. western blotting or enzyme-linked 
immunosorbent assays is required. Further validation of potential neopeptides 
could also be carried out through multiple reaction monitoring using a triple-
quadrupole mass spectrometer (Parker and Borchers, 2014). Following this, 
development of monoclonal antibodies specific to neopeptides of interest would 
enable simpler monitoring of neopeptide abundance in in vitro, ex-vivo and clinical 
environments (Caterson et al., 1985). Following validations, monitoring the 
differentially abundant metabolites, proteins and neopeptides within this study 
within longitudinal SF samples from OA horses would identify translation of these 
findings to a clinical setting and the eventual generation of ‘bedside’ tests.  
4.5.8. Conclusion 
In conclusion, this is the first study to use a multi ‘omics’ approach to 
simultaneously investigate the metabolomic profile of ex-vivo cartilage and 
metabolomic/proteomic profiles of culture media using the TNF-α/IL-1β ex-vivo OA 
cartilage model. We have identified a panel of metabolites and proteins which are 
differentially abundant within an early phase of the OA model, 0-2 days, which may 
provide further information on the underlying disease pathogenesis and well as 
potential to translate to clinical markers. This study has also identified a panel of 
potential, ECM derived, neopeptides which have potential to help enable OA 
stratification as well as provide potential novel therapeutic targets. 
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4.9. Supplementary Information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Five post mortem equine metacarpophalangeal joints 
used for ex-vivo cartilage culture. Cartilage collected from all joints was considered 
macroscopically normal with a score of 0 according to the OARSI histopathology 
initiative scoring system for horses. 
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Supplementary Figure 2. 1D 1H nuclear magnetic resonance spectral quantile plots of (A) cartilage, 8 days in control media (B) cartilage, 8 days 
in TNF-α/IL-1β treated media (C) control media (all time points combined) and (D) TNF-α/IL-1β treated media (all time points combined). The 
median spectral plot is depicted by a black line and variation from the median shown as a yellow to red scale for both the full spectral range 
(9.00-0.80 ppm) and more detailed regions (4.14-3.00 ppm for cartilage and 3.60-2.00 ppm for media). Control (n=5) and TNF-α/IL-1β 
treatment (n=5). 
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Supplementary Figure 3. Representative culture media ion chromatograms of 
combined time points for (A) control and (B) TNF-α/IL-1β treated equine ex-vivo 
cartilage explants using a 60 min liquid chromatography gradient. 
Supplementary Figure 4. Top 25 most influential differentially abundant proteins 
present within culture media at (A) 0-2 days, (B) 3-5 days and (C) 6-8 days following 
TNF-α/IL-1β treatment of ex-vivo equine cartilage. n=5 for each time point. 
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Supplementary Figure 5. Principal component analyses of semi-tryptic peptide 
profiles within culture media of control (red, n=5) and TNF-α/IL-1β treated (green, 
n=5) ex-vivo equine cartilage at (A) 0-2 days, (B) 3-5 days and (C) 6-8 days. 
 
Supplementary Table 1. Proteins identified within culture media of control and 
TNF-α/IL-1β treated ex-vivo equine cartilage. 
 
Media Samples 
Identified In 
Accession 
Number 
Family/Subfamily 
Control Only F6PLF6 2-Phosphoxylose Phosphatase 1  
Control Only F6R1X9 Actin, Alpha Cardiac Muscle 1  
Control Only F7CZ92 Actin, Alpha Skeletal Muscle  
Control Only F7CW82 Actin, Aortic Smooth Muscle  
Control Only F6Z8K0 Actin, Gamma-Enteric Smooth Muscle  
Control Only F7C2Y5 Adipocyte Enhancer-Binding Protein 1  
Control Only F6YRA8 ATP-Dependent rna Helicase Ddx60-Related  
Control Only F7CPZ3 Calsyntenin 1 
Control Only F6YQD9 Carboxypeptidase E  
Control Only F7CCP9 Cartilage Intermediate Layer Protein 2  
Control Only F6VF11 Chordin-Like Protein 2  
Control Only F6VP03 Collagen Type IX Alpha 3 Chain 
Control Only F6VBF7 Collagen Type XI Alpha 1 Chain 
Control Only F6U661 Collagen Type XI Alpha 1 Chain 
Control Only F6VAW6 Collagen Type XI Alpha 1 Chain 
Control Only F7BQD6 Complement C1S Subcomponent  
Control Only F6ZR63 Complement Factor H  
Control Only F7AU56 Complement Factor I  
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Control Only F6Z7T9 
Ectonucleotide 
Pyrophosphatase/Phosphodiesterase 2 
Control Only F6Z7X8 
Ectonucleotide 
Pyrophosphatase/Phosphodiesterase Family 
Member 2  
Control Only F6Q4R1 Elongation Factor 1-Alpha 2  
Control Only F6WD07 Fibulin 7 
Control Only F7DHZ1 Gelsolin 
Control Only F7E2D1 Gelsolin  
Control Only F7D7T6 Heat Shock 70 KDa Protein 1-Like  
Control Only F6TWM4 Histone H2B 
Control Only F6WFI8 Histone H2B Type 1-A  
Control Only F7ASE9 Histone H2B Type 1-C/E/F/G/I  
Control Only F6VUX0 Histone H2B Type 1-D  
Control Only F7CJ51 Histone H2B Type 1-D  
Control Only F7E1X9 Histone H2B Type 1-H  
Control Only F6VYH8 Histone H2B Type 1-M  
Control Only F7DLL0 Histone H2B Type 1-N  
Control Only F6PWV1 Histone H2B Type 2-F  
Control Only Q95LJ1 Insulin-Like Growth Factor-Binding Protein 7  
Control Only F6SSR0 Integrin Beta-Like Protein 1  
Control Only F6QBB1 Inter-Alpha-Trypsin Inhibitor Heavy Chain H5  
Control Only F6ZEQ3 Keratin, Type I Cytoskeletal 16  
Control Only F7AGY4 Keratin, Type Ii Cytoskeletal 6B-Related  
Control Only F6ST15 Keratin-87 Protein-Related  
Control Only F6WZ08 Laminin Subunit Gamma-2  
Control Only Q8HZI9 Laminin Subunit Gamma-2  
Control Only F6W6E8 
Latent Transforming Growth Factor Beta Binding 
Protein 1 
Control Only F6W6Y4 
Latent-Transforming Growth Factor Beta-Binding 
Protein 1  
Control Only F6Z0F8 
Latent-Transforming Growth Factor Beta-Binding 
Protein 3  
Control Only F6UXM7 Lysyl Oxidase Homolog 3  
Control Only O02722 Metalloproteinase Inhibitor 1  
Control Only F7BEE7 Metalloproteinase Inhibitor 2  
Control Only F7AEL9 Neuron Derived Neurotrophic Factor 
Control Only F7BQX4 Peptidylglycine Alpha-Amidating Monooxygenase 
Control Only F7BR00 Peptidylglycine Alpha-Amidating Monooxygenase 
Control Only F6ZCC8 Peptidyl-Glycine Alpha-Amidating Monooxygenase  
Control Only F7D1R1 Phosphoglycerate Kinase 1  
Control Only F6VTS1 Phospholipase A1 Member A  
Control Only F7CR03 Phospholipid Transfer Protein  
174 
 
Control Only F7BKE1 Pigment Epithelium-Derived Factor  
Control Only F6R5Y2 Plasma Serine Protease Inhibitor  
Control Only F6V2X7 Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1  
Control Only F6VTD3 Proteoglycan 4  
Control Only F6XL03 Scrapie-Responsive Protein 1  
Control Only F6XVP2 Sparc-Related Modular Calcium-Binding Protein 1  
Control Only F6WQ44 Sulfhydryl Oxidase 
Control Only F6WR95 Sulfhydryl Oxidase 1  
Control Only O19011 Transforming Growth Factor Beta-1  
Control Only F7APU2 Uncharacterized Protein 
Control Only F6XLT6 Vascular Endothelial Growth Factor A 
Control Only Q9GKR0 Vascular Endothelial Growth Factor A  
Control Only F7AZP8 Xylosyltransferase 1  
Treatment Only F6T0A6 10 KDa Heat Shock Protein, Mitochondrial  
Treatment Only F6SP02 14-3-3 Protein Theta  
Treatment Only F7BFM4 60S Ribosomal Protein L10A  
Treatment Only F6T1A4 60S Ribosomal Protein L12  
Treatment Only F6Z421 60S Ribosomal Protein L12  
Treatment Only F7D917 
6-Phosphogluconate Dehydrogenase, 
Decarboxylating  
Treatment Only F6YG82 78 KDa Glucose-Regulated Protein  
Treatment Only F6PH57 Actin-Related Protein 2/3 Complex Subunit 4  
Treatment Only F6W354 Actin-Related Protein 3  
Treatment Only F6UFV3 Adenosine Kinase  
Treatment Only F6TL52 Adenylate Kinase Isoenzyme 1  
Treatment Only F6SRP7 Adenylyl Cyclase-Associated Protein 1  
Treatment Only F7AJD4 AHNAK Nucleoprotein 
Treatment Only F7CBN0 Alcohol Dehydrogenase (NADP+)-Like Protein 
Treatment Only P19854 Alcohol Dehydrogenase Class-3  
Treatment Only F7DMQ3 Aldose Reductase  
Treatment Only F7E419 Annexin A8  
Treatment Only F6ZB53 
Apurinic Or Apyrimidinic Site) 
Lyase;Apex1;Ortholog 
Treatment Only F6ZXT0 Atpase Inhibitor, Mitochondrial  
Treatment Only F7C555 Bifunctional Purine Biosynthesis Protein Purh  
Treatment Only F6YIU8 C-1-Tetrahydrofolate Synthase, Cytoplasmic  
Treatment Only F7D854 Catalase  
Treatment Only F6YF95 Cellular Nucleic Acid-Binding Protein  
Treatment Only F7CR22 Coatomer Subunit Delta  
Treatment Only F7DXG8 Cofilin-1  
Treatment Only F6ZNX3 Collagen Alpha-1 
Treatment Only F7DEW5 Coronin-1C  
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Treatment Only F6S9Z1 C-X-C Motif Chemokine 5  
Treatment Only Q8MIN2 C-X-C Motif Chemokine 5  
Treatment Only F6XJR7 Cysteine And Glycine-Rich Protein 1  
Treatment Only F7B5P1 Cytosolic Non-Specific Dipeptidase  
Treatment Only F7B320 Dihydropyrimidinase-Related Protein 2  
Treatment Only A2Q127 Elongation Factor 1-Gamma  
Treatment Only F6XTN1 Eukaryotic Initiation Factor 4A-I  
Treatment Only F6YYS2 Eukaryotic Initiation Factor 4A-Ii  
Treatment Only F7BPT4 Ezrin  
Treatment Only F6ZYU6 Far Upstream Element-Binding Protein 1  
Treatment Only F7A984 Far Upstream Element-Binding Protein 2  
Treatment Only F7CS60 Fibronectin 
Treatment Only F7D2D9 Flavin Reductase  
Treatment Only F6RKC6 Four and A Half Lim Domains Protein 1  
Treatment Only F7CL92 
Glutamine--Fructose-6-Phosphate 
Aminotransferase [Isomerizing] 1  
Treatment Only F6VSN2 Glutathione S-Transferase P  
Treatment Only F7BU09 Glutathione S-Transferase Pi 3  
Treatment Only F7DZD2 Glutathione S-Transferase Theta-1  
Treatment Only F6RV94 Glycogen Phosphorylase, Liver Form  
Treatment Only B7UBT6 Growth-Regulated Alpha Protein  
Treatment Only F6R8V8 Growth-Regulated Alpha Protein  
Treatment Only A2Q0Z1 Heat Shock Cognate 71 Kda Protein  
Treatment Only F7AUW2 Heat Shock Cognate 71 Kda Protein  
Treatment Only F7E3Y7 Heat Shock Protein Beta-1  
Treatment Only F6TF34 Heme Oxygenase 1  
Treatment Only F7A868 Heterogeneous Nuclear Ribonucleoprotein A1  
Treatment Only F6YZ44 
Heterogeneous Nuclear Ribonucleoprotein A1-
Related  
Treatment Only F6Z0C6 Heterogeneous Nuclear Ribonucleoprotein D 
Treatment Only F6WHS3 Heterogeneous Nuclear Ribonucleoprotein D0  
Treatment Only F6UQU2 Heterogeneous Nuclear Ribonucleoprotein D-Like  
Treatment Only F6Q4Q1 Heterogeneous Nuclear Ribonucleoprotein K  
Treatment Only F6RTD6 Heterogeneous Nuclear Ribonucleoprotein L  
Treatment Only F7BA08 Heterogeneous Nuclear Ribonucleoprotein R  
Treatment Only F6VYB1 Heterogeneous Nuclear Ribonucleoproteins A2/B1  
Treatment Only F6S2F8 Histone H1.2  
Treatment Only F7BCH1 Inhibin Beta A Chain  
Treatment Only P55102 Inhibin Beta A Chain  
Treatment Only F6QJ27 Isochorismatase Domain-Containing Protein 1  
Treatment Only F6R7J2 Isocitrate Dehydrogenase [Nadp] Cytoplasmic  
Treatment Only F6ZTT5 Keratin 33B 
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Treatment Only F6PJX6 Keratin, Type I Cytoskeletal 13  
Treatment Only F6VNP6 Keratin, Type II Cuticular Hb5  
Treatment Only F6SHJ8 Keratin, Type II Cytoskeletal 2 Epidermal  
Treatment Only F7C7Y1 Keratin, Type II Cytoskeletal 73  
Treatment Only F7B232 Lambda-Crystallin Homolog  
Treatment Only F7DQB9 Lim and Cysteine-Rich Domains Protein 1  
Treatment Only F6PSB8 Lim and Sh3 Domain Protein 1  
Treatment Only C6L1J5 L-Lactate Dehydrogenase B Chain  
Treatment Only F7D144 Macrophage-Capping Protein  
Treatment Only F6SAI2 Matrilin-4  
Treatment Only F6WTM6 Matrix Metalloproteinase 1 
Treatment Only Q9XSZ5 Matrix Metalloproteinase 1 
Treatment Only F6U999 
Mesencephalic Astrocyte-Derived Neurotrophic 
Factor  
Treatment Only Q9TUL9 Metalloproteinase Inhibitor 3  
Treatment Only F7DM22 Metallothionein 
Treatment Only P02801 Metallothionein-1B 
Treatment Only F6VKN2 Metallothionein-2  
Treatment Only F6PVJ6 Mimecan  
Treatment Only F7D7Z9 Multifunctional Protein Ade2  
Treatment Only F6X3K0 Nucleolin  
Treatment Only F6X6A6 Peptidyl-Prolyl Cis-Trans Isomerase-Related  
Treatment Only F7AXI9 Peroxiredoxin-6  
Treatment Only F7DQS6 Phosphoglycerate Mutase 1  
Treatment Only F7AGA5 Plastin-3  
Treatment Only F6WPZ3 Plectin 
Treatment Only F6WQ73 Plectin 
Treatment Only F6WQF0 Plectin 
Treatment Only F6WQW5 Plectin 
Treatment Only F6WXR4 Plectin 
Treatment Only F6WRA4 Plectin  
Treatment Only F6TQ92 Polyadenylate-Binding Protein 1  
Treatment Only F6UGL6 Polypyrimidine Tract-Binding Protein 1  
Treatment Only F6TEI8 Profilin-1  
Treatment Only F6UJ33 Profilin-1  
Treatment Only F6VS95 Protein Disulfide-Isomerase A6  
Treatment Only F6WPB4 Protein Dj-1  
Treatment Only F6UNB9 Protein S100-A1  
Treatment Only F7BND9 Protein S100-A11  
Treatment Only F7CB04 Protein Transport Protein Sec23A  
Treatment Only F7C108 Protein-Lysine 6-Oxidase  
Treatment Only F6WB51 Quinone Oxidoreductase  
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Treatment Only F6Z4J4 Rab Gdp Dissociation Inhibitor Beta  
Treatment Only F6YRC5 Ras Gtpase-Activating-Like Protein Iqgap1  
Treatment Only F6XJB9 RNA-Binding Motif Protein, X Chromosome  
Treatment Only F7ASU6 Selenium Binding Protein 1 
Treatment Only F7CI32 Selenium Binding Protein 1 
Treatment Only F7DKR3 Selenium-Binding Protein 1  
Treatment Only F6XS05 S-Formylglutathione Hydrolase  
Treatment Only F6PZ47 
Staphylococcal Nuclease Domain-Containing 
Protein 1  
Treatment Only F7E1X2 Stress-Induced-Phosphoprotein 1  
Treatment Only F6XC16 Synaptic Vesicle Membrane Protein Vat-1 Homolog  
Treatment Only F6UMQ4 Transforming Growth Factor Beta Induced 
Treatment Only F6QXN5 Transgelin-2  
Treatment Only F6TZS9 Triosephosphate Isomerase  
Treatment Only F6SAV5 Tubulin alpha chain 
Treatment Only F6ZSB4 Tubulin Alpha-1A Chain  
Treatment Only F7ANC9 Tubulin Alpha-1B Chain  
Treatment Only F6YRE0 Tubulin Alpha-1C Chain  
Treatment Only F7D253 UDP-Glucose 6-Dehydrogenase  
Treatment Only F6WHI8 UDP-N-Acetylglucosamine Pyrophosphorylase 1 
Treatment Only F6WI21 UDP-N-Acetylhexosamine Pyrophosphorylase  
Treatment Only F6VDK7 Uncharacterized Protein 
Treatment Only F6Y4I1 UTP--Glucose-1-Phosphate Uridylyltransferase  
Treatment Only F6VSD4 X-prolyl aminopeptidase 1 
Control and Treatment F7AYK2 72 KDa Type IV Collagenase  
Control and Treatment P60708 Actin, Cytoplasmic 1  
Control and Treatment F7AAK7 Actin, Cytoplasmic 2  
Control and Treatment F6UJD4 Adseverin  
Control and Treatment F7C3C6 Aggrecan Core Protein  
Control and Treatment F7C450 Alpha-2-Hs-Glycoprotein  
Control and Treatment F6V7C1 Alpha-Enolase  
Control and Treatment Q5VI84 Angiogenin  
Control and Treatment F7A971 Angiopoietin-Related Protein 4  
Control and Treatment Q8HZM6 Annexin A1  
Control and Treatment F6ZI51 Annexin A2-Related  
Control and Treatment F7C0I7 
Basement Membrane-Specific Heparan Sulphate 
Proteoglycan Core Protein  
Control and Treatment Q0W9Q0 Beta-Defensin 4A  
Control and Treatment F6VYL8 Betaine--Homocysteine S-Methyltransferase 
Control and Treatment F6VUP8 Betaine--Homocysteine S-Methyltransferase 1  
Control and Treatment O46403 Biglycan  
Control and Treatment F7C2J3 Cartilage Intermediate Layer Protein 1  
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Control and Treatment F6U3D3 Cartilage Oligomeric Matrix Protein  
Control and Treatment F6PQ46 Ceruloplasmin  
Control and Treatment F7AJP3 Chitotriosidase-1  
Control and Treatment F6WD70 Chondroadherin  
Control and Treatment Q29482 Clusterin  
Control and Treatment F6UZI2 Coagulation Factor XIII A Chain  
Control and Treatment F7DE18 Coiled-Coil Domain-Containing Protein 80  
Control and Treatment F6R4Y3 Collagen Alpha-1 
Control and Treatment F6UW03 Collagen Alpha-1 
Control and Treatment F6WCC9 Collagen Alpha-1 
Control and Treatment F6Y8T1 Collagen Alpha-1 
Control and Treatment F7A3F7 Collagen Alpha-1 
Control and Treatment F6RTL6 Collagen Alpha-2 
Control and Treatment F7BRR9 Collagen Alpha-2 
Control and Treatment F7CGV8 Collagen Alpha-2 
Control and Treatment F6R735 Collagen Alpha-3 
Control and Treatment F6RVX8 Collagen Type I Alpha 1 Chain 
Control and Treatment F6SSG3 Collagen Type I Alpha 1 Chain 
Control and Treatment F7D939 Collagen Type I Alpha 1 Chain 
Control and Treatment F7D9C7 Collagen Type I Alpha 1 Chain 
Control and Treatment F6RTH9 Collagen Type I Alpha 2 Chain 
Control and Treatment F6RTI8 Collagen Type I Alpha 2 Chain 
Control and Treatment F6RTJ6 Collagen Type I Alpha 2 Chain 
Control and Treatment F6RTN7 Collagen Type I Alpha 2 Chain 
Control and Treatment F6RTP3 Collagen Type I Alpha 2 Chain 
Control and Treatment F6RUA6 Collagen Type I Alpha 2 Chain 
Control and Treatment F6R528 Collagen type III alpha 1 chain 
Control and Treatment F6QAT0 Collagen type VI alpha 3 chain 
Control and Treatment F6TIN6 Complement C1Q Subcomponent Subunit A  
Control and Treatment F7BUV8 Complement C1Q Subcomponent Subunit B  
Control and Treatment F7DBT2 Complement C1Q Subcomponent Subunit C  
Control and Treatment F7BTW7 Complement C3  
Control and Treatment F6XSF7 Complement C4-A-Related  
Control and Treatment F6RMD0 Complement Factor B-Related  
Control and Treatment F6X0K3 Connective Tissue Growth Factor  
Control and Treatment F7CAX0 C-Type Lectin Domain Family 3 Member A  
Control and Treatment F6WCB7 Cytokine-Like Protein 1  
Control and Treatment O46542 Decorin  
Control and Treatment F7BQJ6 Elongation Factor 1-Alpha  
Control and Treatment A2Q0Z0 Elongation Factor 1-Alpha 1 
Control and Treatment F6RRD0 Elongation Factor 1-Alpha 1  
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Control and Treatment F6UME7 Elongation Factor 1-Alpha 1  
Control and Treatment F6UUS3 Elongation Factor 2  
Control and Treatment F6QYS3 Extracellular Matrix Protein 1  
Control and Treatment F6W2Y1 Fibrinogen Gamma Chain  
Control and Treatment A2Q126 Fibromodulin  
Control and Treatment F7CN05 Fibronectin 
Control and Treatment F7CN11 Fibronectin 
Control and Treatment F7ABC9 Fibulin-1  
Control and Treatment F6SX98 Fructose-Bisphosphate Aldolase A  
Control and Treatment F6ZP69 Fructose-Bisphosphate Aldolase C  
Control and Treatment Q28372 Gelsolin  
Control and Treatment F6QIB2 Glia-Derived Nexin  
Control and Treatment F6YV40 Glyceraldehyde-3-Phosphate Dehydrogenase  
Control and Treatment F6ZD04 Glycogen Phosphorylase, Brain Form  
Control and Treatment F7AB03 Granulin Precursor 
Control and Treatment F7AS83 Granulins  
Control and Treatment F7DW69 Heat Shock 70 KDa Protein 1A-Related  
Control and Treatment F7DMY7 Heparan Sulfate Proteoglycan 2 
Control and Treatment F6TAH8 Hhip-Like Protein 2  
Control and Treatment F6SK17 Histone H2B Type 1-B  
Control and Treatment F6UGW9 Histone H2B Type 1-J  
Control and Treatment F7DIN7 Histone H2B Type 1-O  
Control and Treatment F7AHT9 Histone H2B Type 2-C-Related  
Control and Treatment F7AZR5 Histone H2B Type 2-E  
Control and Treatment F6PRL4 Histone H2B Type 3-B  
Control and Treatment F7A4V1 Histone H2B Type 3-B  
Control and Treatment F6VCB4 Histone H3 
Control and Treatment F6Y7V5 Histone H3.1  
Control and Treatment F7B238 Histone H3.1T  
Control and Treatment F6YXV8 Histone H3.3-Related  
Control and Treatment F7C964 Histone H3-Related  
Control and Treatment F6VFV9 Histone H4  
Control and Treatment Q28381 Hyaluronan And Proteoglycan Link Protein 1  
Control and Treatment F7DEB1 Insulin-Like Growth Factor-Binding Protein 6  
Control and Treatment F6TNR4 Keratin, Type I Cuticular Ha1  
Control and Treatment F6SS14 Keratin, Type I Cytoskeletal 10  
Control and Treatment F6WDW3 Keratin, Type I Cytoskeletal 10  
Control and Treatment F7ATL5 Keratin, Type I Cytoskeletal 14  
Control and Treatment F7B7X0 Keratin, Type II Cytoskeletal 1  
Control and Treatment F6W7V0 Keratin, Type II Cytoskeletal 5  
Control and Treatment F7D281 Keratin, Type II Cytoskeletal 6B-Related  
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Control and Treatment F6YZV8 Keratin-87 Protein-Related  
Control and Treatment F7B0S3 Lactadherin  
Control and Treatment F6ZDB7 
Latent-Transforming Growth Factor Beta-Binding 
Protein 2  
Control and Treatment F6VQL3 Leukocyte Cell-Derived Chemotaxin-2  
Control and Treatment F6W3T1 L-Lactate Dehydrogenase A Chain  
Control and Treatment F6SKT2 Lumican  
Control and Treatment F7CU94 Lysozyme C  
Control and Treatment F6S243 Macrophage Migration Inhibitory Factor  
Control and Treatment F6XSR3 Matrilin-3  
Control and Treatment F6R013 Matrix Gla Protein  
Control and Treatment F6T9W9 Matrix metalloproteinase 3 
Control and Treatment Q28397 Matrix metalloproteinase 3 
Control and Treatment F6VJF5 Melanoma-Derived Growth Regulatory Protein  
Control and Treatment F6QKR7 Myocilin  
Control and Treatment F6YY66 Nucleoside Diphosphate Kinase B  
Control and Treatment A5YBL8 Peptidyl-Prolyl Cis-Trans Isomerase B  
Control and Treatment F6S6J4 Peroxiredoxin-1  
Control and Treatment F6QXW2 Phosphatidylethanolamine-Binding Protein 1  
Control and Treatment F6X8Q2 Phosphoglucomutase-1  
Control and Treatment P00559 Phosphoglycerate Kinase 1  
Control and Treatment F6ZY40 Prelamin-A/C  
Control and Treatment F6WZ69 Procollagen C-Endopeptidase Enhancer 1  
Control and Treatment F6UP14 Procollagen C-Endopeptidase Enhancer 2  
Control and Treatment F6RZ46 Prolargin  
Control and Treatment F6VSN9 Protein Disulfide-Isomerase A3  
Control and Treatment F6W3M5 Pyruvate Kinase 
Control and Treatment F7C5F1 Retinoic Acid Receptor Responder Protein 2  
Control and Treatment F7ATC2 Ribonuclease 4  
Control and Treatment F6WNV3 Secreted Frizzled-Related Protein 3  
Control and Treatment F6T8U8 Semaphorin-3C  
Control and Treatment F7B812 Serine Protease Htra1  
Control and Treatment F6ZTA7 Serum Amyloid A Protein 
Control and Treatment F6ZL17 Serum amyloid A protein 
Control and Treatment F7DMJ7 Sushi Repeat-Containing Protein Srpx2  
Control and Treatment F6TVT0 Target of Nesh-Sh3  
Control and Treatment F6PN81 Tenascin  
Control and Treatment F7CCQ6 Tenascin-X  
Control and Treatment F6YR34 Thrombospondin-1  
Control and Treatment F7E0P3 Thrombospondin-4  
Control and Treatment F6U5V3 Transcobalamin-2  
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Control and Treatment F6VB94 
Transforming Growth Factor-Beta-Induced Protein 
Ig-H3  
Control and Treatment F7D9J2 Transketolase  
Control and Treatment F7DMU4 
Tumour Necrosis Factor Receptor Superfamily 
Member 11B  
Control and Treatment Q28396 Type II collagen 
Control and Treatment F6SJK9 Uncharacterized Protein 
Control and Treatment F6SQQ0 Uncharacterized Protein 
Control and Treatment F6TTN2 Uncharacterized Protein 
Control and Treatment F6XIM5 Uncharacterized Protein 
Control and Treatment F6Y2J1 Uncharacterized Protein 
Control and Treatment F7CJG3 Uncharacterized Protein 
Control and Treatment F7E454 Uncharacterized Protein 
Control and Treatment F7B5C4 Vimentin  
Control and Treatment F6QP96 Vitrin  
Control and Treatment F7D8I6 Xanthine Dehydrogenase/Oxidase  
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5.1. Abstract 
Despite osteoarthritis (OA) and rheumatoid arthritis (RA) being typically age-
related, their underlying aetiologies are markedly different. This study has used 1H 
nuclear magnetic resonance (NMR) spectroscopy to identify differences in 
metabolite profiles in low volumes of OA and RA synovial fluid (SF). SF was aspirated 
from knee joints of 10 OA and 14 RA patients. 100 µl of SF was analysed using a 700 
MHz Avance IIIHD Bruker NMR spectrometer with a TCI cryoprobe. Spectra were 
analysed by Chenomx, Bruker TopSpin and AMIX software. Statistical analysis was 
undertaken using Metaboanalyst. 50 metabolites were annotated, including amino 
acids, saccharides, nucleotides and soluble lipids. Discriminant analysis identified 
group separation between OA and RA cohorts, with 32 metabolites significantly 
different between OA and RA SF (false discovery rate < 0.05). Metabolites of 
glycolysis and the tricarboxylic acid cycle were lower in RA compared to OA; these 
results concur with higher levels of inflammation, synovial proliferation and hypoxia 
found in RA compared to OA. Elevated taurine in OA may indicate increased 
subchondral bone sclerosis. This study demonstrates that quantifiable differences in 
metabolite abundance can be measured in low volumes of SF by 1H NMR 
spectroscopy, which may be clinically useful to aid diagnosis and improve 
understanding of disease pathogenesis. 
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5.2. Introduction 
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common forms 
of arthritis, which lead to significant disability and substantial reduction in quality of 
life (Li et al., 2016; Sprangers et al., 2000). Despite both these chronic conditions 
being typically age-related with insidious onset, their underlying aetiologies are 
markedly different (Brouwers et al., 2015; Majithia and Geraci, 2007). OA is a 
degenerative joint condition, primarily affecting the hands, hips and knees, with 
one-third of people in the UK aged over 45 (approximately 8.75 million) requiring 
treatment (Reynard and Loughlin, 2012). This disease is characterised by articular 
cartilage loss, synovial membrane dysfunction, subchondral bone sclerosis and 
osteophyte formation with the depletion of matrix proteins driven by proteases 
including multiple matrix metalloproteinases (MMPs) and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTSs) (Poole, 1999; Struglics 
et al., 2006; Truong et al., 2006). We have previously identified OA synovial fluid 
(SF) to be enriched in a number of proteins including S100-A10, Collagen type I and 
CD109 (Peffers, McDermott, et al., 2015). RA is a systemic, inflammatory 
autoimmune disease that primarily affects the synovium of joints (Bartok and 
Firestein, 2010), presenting as a symmetric polyarthritis with an estimated 
prevalence of 0.5-1% of the adult population within developed countries (Davis and 
Matteson, 2012; Scott et al., 2010). RA joints are marked by inflammation of the 
synovium and destruction of articular cartilage and underlying bone. The RA 
synovium becomes hyperplastic with infiltration by a variety of immunocompetent 
cells (activated neutrophils in particular) (Wright et al., 2014). RA synovial fluid is 
enriched with cytokines, inflammatory mediators such as leukotrienes, and 
proteases that degrade the extracellular matrix (ECM) and hyaluronic acid (Wright 
et al., 2012, 2014). 
SF is located within the articular joint cavity, providing a pool of nutrients for 
surrounding tissues but primarily serving as a biological lubricant, containing 
molecules with low-friction and low-wear properties to articular surfaces (Blewis et 
al., 2007). As a serum filtrate, not only does SF contain systemic protein/metabolite 
markers of disease, but also due to its close contact and near proximity to 
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numerous tissues found to be primarily altered during joint pathology (including 
synovial membrane, cartilage and bone), this biofluid holds significant potential in 
the discovery of biomarkers whose levels are altered at early stages of disease 
progression (Ruiz-Romero and Blanco, 2010). 
Metabolomics systematically and comprehensively profiles metabolic changes 
within biological systems, including metabolic pathway analysis and abundance of 
unique biochemical molecules (Wang, Zhang, et al., 2012). The small molecules 
investigated include secondary metabolites, metabolic intermediates and 
hormones, as well as other molecules involved in cellular signalling (Jukarainen, 
2009). Few studies have investigated the whole profile of metabolites within human 
SF. A recent investigation analysing 10 ml of each SF sample by liquid 
chromatography coupled with mass spectrometry (MS) identified 21 differentially 
expressed metabolites between OA and RA SF (Kang et al., 2015). These included a 
generally elevated level of lipid metabolites and phospholipids in RA patients 
compared to OA patients, although decreased levels of the phospholipid 
lysophosphatidylcholine was observed in OA. Nuclear magnetic resonance (NMR) 
spectroscopy is complementary to MS analysis and may offer advantages over MS 
in the metabolomic analysis of native samples, with a minimal level of sample 
preparation using a noninvasive and nondestructive method, subsequently 
producing results which are more reproducible and robust (Markley et al., 2017). 
One limiting factor of NMR spectroscopy of SF has previously been the minimum 
volume required for analysis, with difficulties in analysing SF from normal human 
joints in which < 200 µl can be aspirated (Naughton et al., 1993). Using the methods 
described in this study, it has been proved that analysable and reproducible 1H NMR 
spectra can be produced from just 100 µl of SF, thus increasing the potential 
applications of this technique when sample volume is limited. 
The aim of this study was to apply 1H NMR to study human SF metabolomics, in 
order to provide novel insights on the underlying pathogenesis of OA and RA, and to 
optimise protocols for clinically relevant volumes of SF typically available in a clinical 
setting. This study describes protocols for human SF sampling and processing and 
presents a novel approach to inflammation analysis, carrying out full profile 
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metabolite NMR examination on low volumes (100 µl) of SF. This method of biofluid 
analysis enables further understanding of disease pathogenesis, inflammatory 
signatures and biomarkers, and may aid in both our comprehension of these 
conditions and progress toward an earlier diagnosis and/or prognostic indicators to 
stratify patients to treatment. 
5.3. Methods 
5.3.1. Sample Groups 
RA patients (mean age 65.4 years) fulfilled the 1987 American College of 
Rheumatology (ACR) criteria for RA and were seropositive for rheumatoid factor 
(RF). OA patients (mean age 67.4 years) were diagnosed by radiographs using 
Kellgren and Lawrence score, and general orthopaedic guidelines carried out by an 
experienced orthopaedic knee surgeon. A diagnosis of RA was excluded for all OA 
patients. OA and RA groups were sex and age-matched to within 5 years of age. RA 
patients were receiving multiple therapies including disease-modifying 
antirheumatic drugs (DMARDs, typically methotrexate), tumour necrosis factor 
(TNF) inhibitors and/or prednisolone and had a mean disease duration of 13 years 
(range 0-35 years). OA patients were typically receiving nonsteroidal anti-
inflammatory drugs (NSAIDs) and in end-stage disease.  
5.3.2. Sample Collection 
OA and RA SF from knee joints was aspirated into heparinized tubes and processed 
within 1 hr. Aliquots of whole SF were centrifuged at > 2000g for 5 min and cell-free 
SF decanted and frozen at -20°C.  
5.3.3. Sample Preparation for NMR 
100 µl of SF was thawed out over ice and diluted to a final volume containing 50% 
(v/v) SF, 40% (v/v) ddH2O (18.2 MΩ), 10% (v/v) 1 M PO43- pH 7.4 buffer (Na2HPO4, 
VWR, Pennsylvania, US; NaH2PO4, Sigma-Aldrich, Gillingham, UK) in deuterium oxide 
(2H2O) and 0.0025% (v/v) sodium azide (NaN3, Sigma-Aldrich). Samples were 
vortexed for 1 min, centrifuged at 13000g and 4˚C for 2 min and 190 µl transferred 
into 3 mm outer diameter NMR tubes using a glass pipette. 
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5.3.4. NMR Setup Acquisition and Processing 
SF samples were individually analysed using 1H NMR spectroscopy on a 700 MHz 
NMR spectrometer Bruker Avance III HD with a TCI cryoprobe and chilled Sample-
Jet autosampler. Software for acquisition and processing was carried out using 
Topsin 3.1 and IconNMR 4.6.7. 1D 1H standard Carr-Purcell-Meiboom-Gill (CPMG)-
type metabolomics experiments, with optimal water suppression via presaturation, 
were acquired with cpmgpr1d filters for small molecules via a CPMG sequence. 
Spectra were acquired at 37°C with 32 transients, a 15 ppm spectral width, 32 K 
points, 9.6 ms echo time and a 3.1 s interscan delay. 
5.3.5. Spectra Processing and Quality Control 
Spectra were assessed to conform to minimum reporting standards as outlined by 
the Metabolomics Society to ensure consistent line widths, baseline corrections and 
water suppression (Sumner et al., 2007). As commonly used internal standards 
(trimethylsilyl propionate and 4,4-dimethyl-4-silapentane-1-sulfonic acid) are 
known to bind to some proteins including albumins, common in protein-rich fluids 
such as SF, spectra were indirectly referenced via an intrinsic metabolite whose 
shifts are unaffected by protein presence (glucose) (Beckonert et al., 2007). All 
spectra passing appraisal were then divided into ‘buckets’ that were defined 
globally for all spectra by the peak limits using Amix software. Spectra were then 
prepared for statistical analysis by bucketing/binning according to spectral features 
or peaks; all peaks, both identified and unknown, were included in the bucket table.  
5.3.6. Metabolite Annotation and Identification 
Metabolites in the SF 1H NMR spectra were initially tentatively annotated using the 
metabolite discovery software Chenomx (Chenomx, Canada) and, where possible, 
their identities confirmed using an in-house library of metabolite spectra (further 
details in Supplementary Table 1) (Salek et al., 2013). 
5.3.7. Metabolomics Statistical Analysis 
Statistical analyses were performed using Metaboanalyst® 
(http://www.metaboanalyst.ca/) (Xia et al., 2016). The bucketed experimental data 
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were normalised by the median and additionally Pareto scaled (for multivariate 
analysis). Univariate analysis was by t-test with application of a false discovery rate 
(FDR) adjusted p value of 0.05. Multivariate analysis was via unsupervised principal 
component analysis (PCA) followed by partial least squares discriminant analysis 
(PLS-DA) validated via leave one out cross-validation to automatically determine the 
optimal number of components for the model. 
5.3.8. Metabolomics Pathway Analysis 
Pathway analysis was carried out using the list of significantly differentially 
abundant metabolites between OA and RA SF using Metaboanalyst and with 
reference to the KEGG (Kyoto Encyclopedia of Genes and Genomes) metabolic 
pathway database (http://www.kegg.jp/kegg/pathway.html) for human metabolic 
pathways (Xia et al., 2016). Pathway enrichment was determined by 
Hypergeometric test and reported with an FDR-adjusted p value. Pathway analysis 
was carried out by Dr Helen Wright. 
5.3.9. Availability of Data and Materials 
Metabolomics data have been deposited to the EMBL-EBI MetaboLights database 
and can be accessed at https://www.ebi.ac.uk/metabolights/MTBLS564. 
5.4. Results 
5.4.1 Metabolite Identification 
NMR spectra for all cohorts showed a consistent set of metabolite signals present. 
NMR spectra of extracts were divided into individual spectral bins accounting for 
one or more multiplets. The number of spectral bins in each extract was 171, of 
which 126 (73.6%) were assigned to 50 metabolites. Quantile plots identifying the 
global variation of metabolite abundances within each cohort demonstrated much 
less variation within the OA cohort than the RA cohort, indicating a more 
homogeneous OA population (Figure 1). Fifty metabolites were annotated in total, 
including amino acids, saccharides, nucleotides and soluble lipids (Table 1). 
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Figure 1. Quantile Plots of osteoarthritis (OA, n=10) and rheumatoid arthritis (RA, 
n=14) spectra depicting spectral variation within both pathological groups. The 
median spectral plot is depicted by a black line and variation from the median 
shown by a yellow to red scale for both the full spectral range (8.5 - 0.5 ppm) and a 
more detailed region (4.15 - 3.55 ppm). Peaks of interest are annotated as 
examples. Note multiple peaks for some metabolites, e.g. glucose. 
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Table 1. List of 50 Metabolites Detected in osteoarthritis and rheumatoid arthritis 
synovial fluid by 1H NMR Spectroscopy 
 
 
Amino Acids 
2-Aminobutyrate, 5-Aminolevulinate, Alanine, Asparagine, Creatine, Creatinine, 
Glutamine, Glycine, Guanidoacetate, Histidine, Isoleucine, Leucine, Lysine, 
Methionine, n-Acetylamino acid, Ornithine, Phenylalanine, Proline, Sarcosine, 
Threonine, Tyrosine, Valine 
Fatty and Organic Acids 
2-Hydroxybutyrate, 3-Hydroxybutyrate, 3-Hydroxyisovalerate, Acetate, 
Acetoacetate, Carnitine, Citrate, Formate, Lactate, Malonate, Pyruvate, Taurine 
Sugars 
Acetylated-saccharide, Glucose, Glycerol, Mannose, Myoinositol 
Other 
Acetylcholine, Adenosine, Choline, Dimethylamine, Ethanol, Isopropanol, Mobile-
lipid, o-Phosphocholine, Oxypurinol, sn-Glycero-3-phosphocholine, Xanthine 
 
5.4.2. Univariate Comparison of Osteoarthritis and Rheumatoid Arthritis Synovial 
Fluid 
Univariate analysis of the 171 spectral bins identified 91 significantly different bins 
(including 50 annotated) which corresponded to 32 metabolites which were 
significantly different (FDR < 0.05) between OA and RA SF. These included citrate, 
creatinine, glucose, glutamine, glycerol, pyruvate and taurine which were higher in 
OA (Table 2, Figure 2, Figure 3a). 3-hydroxybutyrate, acetate, isoleucine, leucine, 
sarcosine and threonine were higher in RA. Acetylated saccharides, an annotation 
that incorporates commonly acetylated molecules such as heparin and chondroitin 
sulphate, and monosaccharide subunits N-acetyl glucosamine and N-acetyl 
galactosamine, were also significantly higher in RA. No significant association was 
observed between metabolite profile or drug therapy in the RA patients, or with the 
length of disease activity. 
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5.4.3. Multivariate Analysis comparison of Osteoarthritis and Rheumatoid 
Arthritis Synovial Fluid 
PCA analysis exhibited separation between OA and RA cohorts (Figure 3b). 
Regression analysis (PLS-DA, partial least square discriminant analysis) correctly 
distinguished between the two groups in five components (Figure 3c, R2 = 0.99, Q2 = 
0.95).  
 
Table 2. List of 32 significantly altered metabolites between osteoarthritis (OA) and 
rheumatoid arthritis (RA) synovial fluid (FDR < 0.05). Y = yes 
 
Metabolite 
HMDB 
Annotation 
Higher 
in OA 
Higher 
in RA 
Fold 
Change 
OA vs RA 
-log10    
(p value) 
FDR 
2-Hydroxybutyrate HMDB00008 Y  1.19 3.2495 1.70x10-3 
3-Hydroxybutyrate HMDB00357 Y  1.59 2.3288 1.02x10-2 
3-Hydroxyisovalerate HMDB00754 Y  2.22 7.6958 6.85x10-7 
Acetate HMDB00042  Y -1.69 2.6401 5.56x10-3 
Acetylcholine HMDB00895 Y  1.57 3.9361 5.32x10-4 
Acetylated-saccharide None  Y -1.49 4.5038 1.97x10-4 
Adenosine HMDB00050 Y  1.94 1.6375 4.45x10-2 
Alanine HMDB00161 Y  1.42 2.79 4.18x10-3 
Asparagine HMDB00168 Y  1.31 3.8413 5.83x10-4 
Citrate HMDB00094 Y  1.67 5.972 1.65x10-5 
Creatinine HMDB00562 Y  1.43 4.0608 4.48x10-4 
Glucose HMDB00122 Y  1.82 4.2582 3.03x10-4 
Glutamine HMDB00641 Y  1.80 9.7868 9.26x10-9 
Glycerol HMDB00131 Y  1.42 2.6897 5.18x10-3 
Glycine HMDB00123  Y -1.64 3.9516 5.28x10-4 
Guanidoacetate HMDB00128 Y  1.19 3.283 1.61x10-3 
Histidine HMDB00177 Y  1.34 3.3713 1.36x10-3 
Isoleucine HMDB00172  Y -1.39 4.0006 4.88x10-4 
Leucine HMDB00687  Y -1.20 2.1407 1.52x10-2 
Mannose HMDB00169 Y  1.73 3.5567 9.85x10-4 
Methionine HMDB00696  Y -1.30 2.8572 3.69x10-3 
Mobile-lipid None Y  1.96 4.7317 1.42x10-4 
Myoinositol HMDB00211 Y  1.24 2.48 7.61x10-3 
n-Acetylamino acid None Y  1.11 2.5075 7.24x10-3 
Proline HMDB00162 Y  1.26 3.1978 1.85x10-3 
Pyruvate HMDB00243 Y  3.44 11.994 8.61x10-11 
Sarcosine HMDB00271  Y -1.56 4.6614 1.51x10-4 
sn-Glycero-3-phosphocholine HMDB00086 Y  1.49 3.0967 2.27x10-3 
Taurine HMDB00251 Y  1.26 2.2132 1.32x10-2 
Threonine HMDB00167  Y -1.22 1.6233 4.50x10-2 
Tyrosine HMDB00158 Y  1.40 2.9942 2.78x10-3 
Valine HMDB00883 Y  1.25 2.5638 6.45x10-3 
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Figure 2. Boxplots of representative metabolites identified from univariate analysis 
as significantly different between osteoarthritis (OA, n=10) and rheumatoid arthritis 
(RA, n=14) synovial fluid (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). Y-axis 
represents normalised peak intensity following median normalisation and Pareto 
scaling. 
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Figure 3. Comparison of NMR synovial fluid metabolomes between osteoarthritis 
(OA, n=10) and rheumatoid arthritis (RA, n=14). (A) Heatmap showing metabolites 
significantly different in OA and RA SF (p < 0.05). Blue = low, White = medium, Pink 
= high concentration. (B) Unsupervised PCA scores plot showing metabolite profile 
is more variable between RA (green) than OA synovial fluid (red). Shading 
represents 95% confidence region. (C) Supervised multivariate analysis by PLS-DA 
segregated RA (green) and OA (red) synovial fluid samples. Shading represents 95% 
confidence region. Scores plot is shown for components 1 and 2. (D) Pathway 
scheme depicting metabolite levels detected in RA and OA synovial fluid. Blue = 
higher in RA synovial fluid, Red = higher in OA synovial fluid.  
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5.4.4. Biological Context 
In order to determine the metabolic pathways that were differently regulated 
between OA and RA, the list of 32 significantly different metabolites was uploaded 
into Metaboanalyst for Pathway Analysis. The results of this analysis are shown in 
Table 3 and include pathways relating to amino acid synthesis and degradation, 
taurine and hypotaurine metabolism and glycolysis. With reference to current 
understanding of metabolic pathways, results of the pathway analysis were 
combined into a single metabolic flow diagram (Figure 3d) to enable interpretation 
of the interactions between the metabolites and the different metabolic pathways 
(Berg et al., 2012). 
 
Table 3. Pathway analysis using Metaboanalyst and with reference to the KEGG 
database predicted the most enriched pathways from the list of metabolites that 
were significantly different between osteoarthritis and rheumatoid arthritis synovial 
fluid (FDR ≤ 0.1). Pathway enrichment was determined by Hypergeometric test and 
reported with an FDR-adjusted p value. The number of metabolites enriched in our 
dataset (hits) is shown compared with the total number of metabolites in the KEGG 
pathway. 
 
 
Pathway Total Hits -log10 (p value) FDR 
Aminoacyl-tRNA biosynthesis 75 12 24.693 1.51x10-9 
Nitrogen metabolism 39 6 12.124 2.17x10-4 
Valine, leucine and isoleucine biosynthesis 27 5 11.165 3.78x10-4 
Taurine and hypotaurine metabolism 20 4 9.3989 1.66x10-3 
Alanine, aspartate and glutamate metabolism 24 4 8.6483 2.81x10-3 
Glycine, serine and threonine metabolism 48 5 8.2939 3.24x10-3 
Arginine and proline metabolism 77 6 8.1678 3.24x10-3 
Galactose metabolism 41 4 6.5415 1.44x10-2 
Glycolysis or Gluconeogenesis 31 3 5.0818 5.52x10-2 
Valine, leucine and isoleucine degradation 40 3 4.3697 1.02x10-1 
 
Normalised levels of acetylated saccharide in RA SF correlated positively with serum 
levels of inflammatory markers (Figure 4), including the acute-phase protein C-
related protein (CRP, g/L) (Pearson R2 = 0.78, p = 0.008, n = 10), erythrocyte 
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sedimentation rate (ESR, mm/hr) (Pearson R2 = 0.62, p = 0.02, n = 13) and 
rheumatoid factor (RF) titre (Pearson R2 = 0.618, p = 0.018, n = 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Correlation of acetylated saccharide with protein C-related protein (CRP), 
erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) titre in 
rheumatoid arthritis patients. Levels of acetylated saccharide (median normalised 
with Pareto scaling) in rheumatoid arthritis synovial fluid correlated positively with 
serum levels of CRP (Pearson R2 = 0.78, p = 0.008, n = 10), ESR (Pearson R2 = 0.62, p 
= 0.02, n = 14) and RF titre (Pearson R2 = 0.618, p = 0.018, n = 14). 
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5.5. Discussion 
In this study, OA and RA SF metabolomes were analysed using 1H NMR 
spectroscopy. This study differs from previous ones in that this study has 
investigated the metabolome of SF, the biofluid that is in contact with all the tissues 
and cells at the site of disease manifestation and joint damage, thereby allowing 
analysis of the pathophysiology of the whole joint. To date, metabolomic studies in 
OA and RA have focused on biofluids, including urine, serum and SF using a number 
of different platforms including gas chromatography-mass spectrometry (GC-MS), 
liquid chromatography-mass spectrometry (LC-MS) and 1H NMR spectroscopy 
(Cuppen et al., 2016; Giera et al., 2012; Hugle et al., 2012; Kang et al., 2015; Kapoor 
et al., 2013; Kim et al., 2017; Madsen et al., 2011; Mickiewicz, Kelly, et al., 2015; 
Priori et al., 2015; Sumner et al., 2007; Young et al., 2013; Zhang et al., 2014; Zhou 
et al., 2016). These studies have provided insight into the metabolites found within 
human arthritic SF, and the different underlying cellular pathology of OA and RA 
joints. The RA synovial environment is characterised by proliferation of synovial 
fibroblasts and angiogenesis. Infiltration of immune cells, including neutrophils, 
macrophages, and T and B cells, drives inflammation within the joint, releasing 
proteases, cytokines, chemokines and lipid mediators that perpetuate inflammation 
leading to growth of an invasive, inflammatory pannus across the surface of the 
cartilage. Further dysregulation of neutrophils and osteoclasts within the pannus 
leads to degradation of the underlying cartilage matrix and bone erosion (Wright et 
al., 2012, 2014). In contrast, while there is some evidence of mild to moderate 
inflammation and synovial hyperplasia within OA joints, this is markedly less than 
the levels observed in RA, with the population of infiltrating immune cells consisting 
mainly of T cells and macrophages (Berenbaum, 2013; de Lange-Brokaar et al., 
2012). Synovitis is not as common in OA, and the loss of articular cartilage and bone 
is caused by a dysregulation in proteases including MMPs leading to destruction of 
the cartilage ECM (Poole, 1999; Struglics et al., 2006). 
A common feature of previous studies investigating OA and RA SF metabolites is the 
activation of metabolic pathways controlling glycolysis and fatty acid metabolism; 
however most studies compare OA or RA serum metabolites to sera from healthy 
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individuals. This study presents a direct comparison of OA and RA metabolite 
profiles in SF using 1H NMR spectroscopy and provides a novel insight into the 
differences in metabolic activity within joints of patients with two common forms of 
arthritis. In this study, 50 metabolites were identified in OA and RA SF: 22 amino 
acids, 5 sugars, 12 fatty and organic acids and 11 others. Multivariate analysis 
separated patient SF metabolite profiles based on the levels of 32 metabolites that 
were significantly different between OA and RA SF. These metabolites were 
associated with metabolic pathways controlling amino acid synthesis, taurine 
metabolism, glycophospholipid metabolism, glycolysis and the tricarboxylic acid 
(TCA) cycle. OA SF had significantly higher levels of substrates for glycolysis and the 
TCA cycle, including glucose, mannose, pyruvate and citrate. In addition, many 
amino acids, which feed into glycolysis and the TCA cycle, were higher in OA, 
including tyrosine, glutamine, proline, histidine, asparagine, taurine and alanine. We 
have previously identified altered glycolysis pathways in early OA using NMR 
metabolomics (Peffers, Riggs, et al., 2015). Furthermore, several studies have 
identified altered status of glycolysis and glucose metabolism glycolytic proteins in 
OA. One study identified these changes in OA compared to normal cartilage (Guo et 
al., 2008). In another study of an in vitro model of OA using cartilage explants and 
label-free MS proteomics, 13.8% of up-regulated proteins were related to glycolysis 
(Peffers, 2013).  
A previous study of urine metabolomics found altered TCA cycle activity in OA (Li et 
al., 2010). The authors hypothesised this was due to changes in cartilage 
metabolism which resulted in elevations of aconitic acid, isocitric acid and citrate in 
the urine of OA patients. In addition, a reduction in excretion of glutamine was 
suggestive of altered energy metabolism in chondrocytes (Li et al., 2010). In our 
study we identified increased citrate and glutamine in OA SF compared to RA, 
suggestive of altered chondrocyte biology in OA joints. Chondrocytes are extremely 
dependent on glucose metabolism to drive the ECM biosynthetic machinery, 
requiring anaerobic glycolysis to generate ATP (Heywood et al., 2010). Indeed, 
glycolysis constitutes 95% of their energy production (Heywood et al., 2010). 
Adequate ATP is needed for chondrocytes to respond to stress thus, a high rate of 
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anaerobic glycolysis is essential for ATP generation. It is hypothesised that this 
increase in glycolysis is an attempt to increase ECM production in the face of MMP-
driven degradation. 
In this study, lower levels of substrates for glycolysis and the TCA cycle in RA SF 
were identified, suggesting even higher levels of anaerobic cellular metabolism 
within RA joints compared to OA. While the levels of lactate did not differ between 
OA and RA SF in this study, the ratio of lactate to glucose was significantly higher in 
RA, supporting this theory (Kramer, Ravi, et al., 2014; Wright et al., 2014). In RA 
sera, substrates of glycolysis including glucose, valine, alanine, glutamine and 
tyrosine increase in patients who respond to TNF-inhibitor therapy with etanercept, 
suggesting the levels of these metabolites increase when inflammation decreases 
(Priori et al., 2015). A decrease in 3-hydroxybutyrate levels in RA sera in response to 
etanercept has also been reported (Priori et al., 2015); again we observed lower 
levels of 3-hydroxybutyrate in RA SF compared to OA SF. Lower levels of glucose 
have been previously reported in RA serum compared to healthy individuals (Zhou 
et al., 2016). Within the joint, lower glucose levels may be as a consequence of the 
increase in cellular metabolism in resident SF fibroblasts and infiltrating immune 
cells, particularly neutrophils, as these cells rely solely on glycolysis for energy 
production (Kramer, Ravi, et al., 2014; Wright et al., 2014). Increased hypoxia within 
RA joints has also been shown to promote glycolysis, and is strongly associated with 
synovial proliferation, whereas in OA, no association between synovial proliferation 
and hypoxia is evident (Biniecka et al., 2016; Lee et al., 2007). Interestingly, taurine 
was higher in OA versus RA SF, while ‘taurine and hypotaurine metabolism’ was 
identified in our pathway analysis. Previous metabolomics studies in RA have 
demonstrated that taurine is increased in RA versus control serum, and in RA SF 
compared to OA SF (Kang et al., 2015; Young et al., 2013). Taurine is involved in the 
pathogenesis of subchondral bone sclerosis, a feature of both RA and OA (Li et al., 
2014; Yang et al., 2016). It is possible that the higher levels of taurine in OA SF 
identified in our study may be because of increased subchondral bone sclerosis in 
OA compared to RA samples, and in addition may be an indicator of the degree of 
subchondral bone sclerosis along with additional metabolites such as L-carnitine 
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and glycerophospholipids. Patients in our study were in end-stage OA and likely to 
have high levels of subchondral bone sclerosis associated with advanced disease, 
whereas in previous studies OA SF was collected from patients at an earlier stage of 
disease progression (Kang et al., 2015). 
A number of metabolites increased in RA SF indicated activation of ketosis, possibly 
due to the low glucose levels observed in RA. Metabolites including leucine, 
isoleucine and threonine were elevated in RA SF. Ketosis occurs via a shift in 
metabolism during glucose limitation: in the absence of glucose e.g. via dietary 
limitation or decreased mobilisation of glycogen stores, or during oxygen limitation, 
metabolism of stored lipids is stimulated to increase the supply of acetyl CoA. 3-
Hydroxybutyrate, a key metabolite in ketosis, was previously identified as being 
elevated in RA serum compared to healthy controls (Priori et al., 2015). Our study 
found levels of this metabolite to be lower in RA compared to OA SF. A number of 
lipid metabolites have previously been reported to be lower in RA biofluids, with a 
possible explanation being that lipids are a source of energy within the hypoxic joint 
(Young et al., 2013). Alteration of lipid metabolism is associated with changes in 
membrane composition/permeability, gene expression and protein distribution and 
function, as well as in cellular functions such as cell growth, proliferation, 
differentiation, survival, apoptosis, and chemotaxis, implicated in the RA disease 
process (Guma et al., 2016).  
Metabolomic analysis of urine from RA patients prior to commencement of anti-
TNF therapy identified higher histamine, glutamine and xanthurenic acid, along with 
lower levels of ethanolamine as biomarkers of a good response to therapy (Kapoor 
et al., 2013). Serum metabolite biomarkers can also distinguish responders and 
nonresponders to methotrexate (Wang, Chen, et al., 2012). A number of serum 
metabolites and metabolic pathways have been shown to correlate with markers of 
inflammation in RA, e.g. CRP, including metabolites associated with arginine 
metabolism (arginine and ornithine), tryptophan metabolism (serotonin and 
tryptophan) and branched-chain amino acids (isoleucine, leucine, and valine) 
(Cuppen et al., 2016). We did not find correlation of these metabolites with markers 
of inflammation in RA SF in our study; however, we observed significant correlation 
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of acetylated-saccharide with serum CRP levels, ESR and RF titre. The assignment of 
this metabolite as ‘acetylated saccharide’ was based on comparison of 2D 1H 13C 
spectra to our in-house library of common acetylated molecules including 
acetylated heparin and acetylated chondroitin sulphate, and to monosaccharide 
subunits N-acetyl glucosamine and N-acetyl galactosamine (data not shown). While 
the precise acetylated saccharide cannot be definitively identified from this analysis 
alone, we are confident in our assignment of the NMR resonances to this class of 
acetylate-saccharide metabolites. The presence of these metabolites concurs with 
previous observation of a significant elevation in the activities of exoglycosidases 
(including β-D-glucuronidase and β-D-N-acetyl-glucosaminidase) in RA compared to 
OA SF (Ortutay et al., 2003). These enzymes are responsible for the degradation of 
glycosaminoglycans (GAGs) such as heparan sulphate within the cartilage matrix, 
and of hyaluronic acid within SF, leading to the reduced viscosity of SF and 
irreversible damage to cartilage that is a hallmark of RA. Degradation of GAGs by β-
D-glucuronidase and β-D-N-acetyl-glucosaminidase liberates both N-acetyl 
glucosamine monosaccharide and chondroitin sulphate (disaccharide of N-acetyl 
glucosamine and glucoronic acid). The likely source of exoglycosidases in RA SF is 
activated neutrophils (Wright et al., 2014). Neutrophils are also the main source of 
SF myeloperoxidase, the enzyme responsible for the production of hypochlorous 
acid, which has also been implicated in the degradation of GAGs and the 
appearance of acetylated saccharides in SF (Schiller et al., 1996). Interestingly, a 
strong correlation between β-D-N-acetyl-glucosaminidase activity and RF titre was 
previously reported (Ortutay et al., 2003). Correlation of serum glycoprotein acetyls 
with CRP and disease activity has also been reported in RA sera (Kononoff et al., 
2015).  
One limitation of our study was the heterogeneous nature of the RA patient cohort, 
which included patients at different stages of disease (from early RA with < 1 year 
diagnosis up to long-standing RA > 35 years diagnosis), and on a variety of different 
treatments including DMARDs such as methotrexate, biologic therapies and 
glucocorticoids. The heterogeneous nature of RA SFs was evident in the spectral 
analysis. Despite this, regression analysis (PLS-DA) was able to segregate OA and RA 
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SF samples with a high degree of accuracy. In addition, we were unable to include 
‘normal’ SF samples from healthy donors in our study. Definition of normal SF, and 
in particular the ethical collection of such from living donors, is ambiguous and 
difficult. Post mortem SF cannot be defined as having a 'normal' metabolome due to 
the anaerobic changes that take place following death. It would be of great value 
for a future study of this kind to perform analysis of SF lipids in OA and RA; however 
this was outside the scope of our current study. Future studies should also correlate 
clinical markers of disease activity (e.g. tender and swollen joint counts, disease 
activity scores), radiographic changes and physical characteristics such as body mass 
index with SF metabolome profiles. 
5.5.1. Conclusion 
In summary, this study has made a direct comparison of SF from RA and OA and 
found that the metabolic pathways that differ most between the two forms of 
arthritis are glycolysis, amino acid biosynthesis and taurine and hypotaurine 
metabolism. In general, metabolites of glycolysis and the TCA cycle were higher in 
OA compared to RA; these results concur with higher level of inflammation, synovial 
proliferation and hypoxia found in RA compared to OA. Levels of taurine were also 
higher in OA indicating increased subchondral bone sclerosis compared to RA. The 
study has deepened our understanding of the metabolic differences (and hence 
pathophysiology) of these two forms of arthritis. This study also demonstrates the 
feasibility of performing 1H NMR metabolomics on small clinical samples (100 µl), 
hence widening the applicability of the technology within a clinical setting. We 
speculate that the discriminative power of our approach to analysis of 100 µl SF 
using 1H NMR spectroscopy may be sensitive enough to identify changes in disease 
progression that could inform the use of disease modifying therapies or measure 
the efficacy of future therapies on disease activity/progression in OA and RA. 
5.6. Ethics 
SF samples from patients with OA and RA were collected in accordance with the 
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law. The study that collected the RA SF was approved by Sefton Adult Ethics 
Committee; all patients gave written, informed consent. 
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5.9. Supplementary Information 
Supplementary Table 1. List of 50 metabolites detected in osteoarthritis and rheumatoid arthritis synovial fluid by 1H NMR spectroscopy, 
assignment levels according to the Metabolomics Society Initiative (Salek et al., 2013). 
  
Class Metabolite Name HMDB Assignment 
Level 
Chenomx 
Annotation 
(y/n) 
Confirmed by in-house 1H 
(n = no standard available; 
y = present) 
Observed in in-house 2D HSQC (n1 = no 
standard available; n2 = below level of 
detection; y = present) 
Amino Acids 2-Aminobutyrate HMDB00650 2 y n n1  
5-Aminolevulinate HMDB01149 2 y n n1  
Alanine HMDB00161 1 y y y  
Asparagine HMDB00168 2 y n n2  
Creatine HMDB00064 1 y y y  
Creatinine HMDB00562 1 y y n2  
Glutamine HMDB00641 1 y y y  
Glycine HMDB00123 1 y y y  
Guanidoacetate HMDB00128 2 y n n1  
Histidine HMDB00177 1 y y n2  
Isoleucine HMDB00172 1 y y y  
Leucine HMDB00687 1 y y y  
Lysine HMDB00182 1 y y y  
Methionine HMDB00696 1 y y n2  
n-acetylaminoacid - 3 y n n1  
Ornithine HMDB00214 1 y y n2  
Phenylalanine HMDB00159 1 y y y  
Proline HMDB00162 1 y y n2  
Sarcosine HMDB00271 2 y n n2  
Threonine HMDB00167 1 y y y  
Tyrosine HMDB00158 1 y y n2  
Valine HMDB00883 1 y y y 
Fatty and Organic Acids 2-Hydroxybutyrate HMDB00729 2 y n n1  
3-Hydroxybutyrate HMDB00357 2 y n n1 
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3-Hydroxyisovalerate HMDB00754 2 y n n1  
Acetate HMDB00042 1 y y y  
Acetoacetate HMDB00060 2 y n n1  
Carnitine HMDB00062 2 y n n1  
Citrate HMDB00094 1 y y n2  
Formate HMDB00142 2 y n n1  
Lactate HMDB00190 1 y y y  
Malonate HMDB00691 2 y n n2  
Pyruvate HMDB00243 1 y y n2  
Taurine HMDB00251 1 y y n2 
Sugars Acetylated-saccharide - 3 y y y  
Glucose HMDB00122 1 y y y  
Glycerol HMDB00131 1 y y y  
Mannose HMDB00169 1 y y y  
Myoinositol HMDB00211 1 y y n2 
Other Acetylcholine HMDB00895 2 y n n1 
  Adenosine HMDB00050 2 y n n1 
  Choline HMDB00097 1 y y y 
  Dimethylamine HMDB00087 1 y y y 
  Ethanol HMDB00108 1 y y y 
  Isopropanol HMDB00863 2 y n n1 
  Mobile-lipid - 3 y n n1 
  o-Phosphocholine HMDB01565 2 y n n2 
  Oxypurinol HMDB00086 2 y n n1 
  sn-Glycero-3-
phosphocholine 
HMDB00086 2 y n n1 
  Xanthine HMDB00292 2 y n n2 
 
Abbreviation: HSQC = Heteronuclear single quantum coherence
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6.1. Abstract 
Osteoarthritis (OA), osteochondrosis (OC) and synovial sepsis in horses cause loss of 
function and pain. Reliable biomarkers are required to achieve accurate and rapid 
diagnosis, with synovial fluid (SF) holding a unique source of biochemical 
information. Nuclear magnetic resonance (NMR) spectroscopy allows global 
metabolite analysis of a small volume of SF, with minimal sample preprocessing 
using a noninvasive and nondestructive method. Equine SF metabolic profiles from 
both nonseptic joints (OA and OC) and septic joints were analysed using 1D 1H NMR 
spectroscopy. Univariate and multivariate statistical analyses were used to identify 
differential metabolite abundance between groups. Metabolites were annotated 
via 1H NMR using 1D NMR identification software Chenomx, with identities 
confirmed using 1D 1H and 2D 1H 13C NMR (Supplementary Figure 1). Multivariate 
analysis identified separation between septic and nonseptic groups. Acetate, 
alanine, citrate, creatine phosphate, creatinine, glucose, glutamate, glutamine, 
glycine, phenylalanine, pyruvate and valine were higher in the nonseptic group, 
while glycylproline was higher in sepsis. Multivariate separation was primarily 
driven by glucose; however, partial-least-squares discriminant analysis plots with 
glucose excluded demonstrated the remaining metabolites were still able to 
discriminate the groups. This study demonstrates that a panel of synovial 
metabolites can distinguish between septic and nonseptic equine SF, with glucose 
the principal discriminator. 
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6.2. Introduction 
Conditions affecting the articular joints are common in horses resulting in loss of 
function, pain and/or subsequent inability to work, all of which represent economic 
and welfare concerns. These pathologies include osteoarthritis (OA), 
osteochondrosis (OC) and synovial sepsis, which can be life-threatening 
(Summerhays, 2000). Despite these conditions having a high prevalence and clinical 
relevance, diagnosis, staging, monitoring and determination of an accurate 
prognosis remain challenging for practising veterinarians. Therefore, in order to 
differentiate equine articular joint pathologies, there is a need to identify reliable 
biomarkers of disease. Synovial fluid (SF) is located within the articular joint cavity, 
providing a pool of nutrients for surrounding tissues but primarily serving as a 
biological lubricant, containing molecules with low-friction and low-wear properties 
to articular surfaces (Blewis et al., 2007). As SF is in close proximity to articular 
tissues primarily altered during joint pathology, this biofluid is an important source 
of biomarker discovery (Mateos et al., 2012; Ruiz-Romero and Blanco, 2010). 
To date, no validated markers that are both sensitive and specific to synovial sepsis 
have been identified within veterinary medicine, making early diagnosis a challenge. 
Together with clinical examination, diagnosis is based on SF culture and intracellular 
bacteria identification (both low sensitivity) as well as total protein, total nucleated 
cell count and percentage of neutrophils whose results are open to interpretation 
and are affected by standard treatment protocols (Robinson et al., 2017; Sanchez-
Teran, Bracamonte, Hendrick, Burguess, et al., 2016; Sanchez-Teran, Bracamonte, 
Hendrick, Riddell, et al., 2016; Sanchez Teran et al., 2012). Reduced levels of glucose 
in human and equine SF, due to an increase in synovial and neutrophil cell glycolytic 
activity in severe inflammation or infection, have previously been identified, with a 
serum-synovial glucose difference of ˃ 2.2 mmol/L considered supportive of a 
diagnosis of synovial sepsis (Krey and Bailen, 1979; Roberts et al., 1967). However, 
this parameter is nonspecific and can be influenced by multiple variables, including 
synovial necrosis, diet, pain and white blood cell count. Elevations in lactate during 
the acute infection phase have previously been identified in SF of septic human, 
canine and equine joints, due to an increase in the consumption of glucose and 
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subsequent production of lactate within an anaerobic environment (Gobelet and 
Gerster, 1984; Proot et al., 2015; Tulamo et al., 1989). However, other studies have 
not been able to differentiate septic and nonseptic arthropathies based on lactate 
levels alone (Arthur et al., 1983; Washington, 1980). Synovial D-lactate (produced 
via bacterial fermentation and a stereoisomer of mammalian L-lactate) was recently 
found to be unable to aid diagnosis of equine synovial sepsis (Robinson et al., 2017). 
At present, no specific biomarkers have been identified for equine OA with none 
currently used as a diagnostic aid in clinical practice. Potential OA markers of 
interest include cartilage oligomeric matrix protein (COMP) and matrix 
metalloproteinases (MMPs), which have both been identified as elevated in human 
OA SF (Balakrishnan et al., 2014). Although detection of active MMPs in horses has 
demonstrated important potential in diagnosis, conversely, decreased levels of 
COMP have been identified in equine OA and found unable to stage the disease 
(Taylor et al., 2006; Zrimsek et al., 2007). In equine OC, elevated levels of a C-
propeptide of cartilage type II procollagen and osteocalcin have shown potential as 
a diagnostic aid, although these markers have not translated to clinical practice 
(Billinghurst et al., 2004; Donabedian et al., 2008; Laverty et al., 2000). However, 
these protein markers identify pathology following significant cartilage degradation 
and bone remodelling opposed to an early disease state where potential 
intervention would prove most beneficial.  
Metabolomics encompasses the comprehensive profiling of metabolic changes, 
including the study of metabolic pathways and quantification of unique biochemical 
molecules, within living systems (Wang, Zhang, et al., 2012). These small molecule 
metabolites include metabolic intermediates, secondary metabolites, hormones 
and other signalling molecules (Jukarainen, 2009). A major advantage of nuclear 
magnetic resonance (NMR) spectroscopy over other techniques, that is, mass 
spectrometry, is the analysis of native samples with a minimal level of sample 
preparation using a noninvasive and nondestructive method, subsequently 
producing results which are more reproducible and robust (Keun and Athersuch, 
2011). Thus this methodology holds huge potential in the analysis of biofluids to 
characterise the global metabolic profiles of various pathologies (de Sousa et al., 
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2017). Hugle et al. previously carried out NMR spectroscopy using human SF, 
identifying that septic arthritis SF could be distinguished from nonseptic arthritis SF 
via principal component analysis (PCA), although they were unable to identify the 
specific metabolites responsible for this discrimination (Hugle et al., 2012). To date, 
only one peer reviewed publication has used NMR to investigate the whole 
metabolic profile of equine SF, comparing normal and osteoarthritic SF (Lacitignola 
et al., 2008). Lacitignola et al. identified ten differentially abundant metabolites 
which included elevated levels of glucose and lactate in OA. No studies have 
analysed equine SF using NMR to investigate synovial sepsis or OC, concurrently 
analysed the metabolic profiles of multiple equine articular pathologies or used 
multivariate analysis to investigate the metabolic profile as a whole. 
In this study we have used global metabolite identification using 1H NMR to identify 
potential metabolite biomarkers that allow differentiation between equine articular 
joint pathologies, potentially aiding accurate diagnosis. 
6.3. Methods 
6.3.1. Patient Groups and Synovial Fluid Collection 
Following ethical approval and owner consent, excess aspirated SF (collected during 
clinical diagnostic investigations) was analysed from joints of horses presenting to 
The Philip Leverhulme Equine Hospital, University of Liverpool between 2014 and 
2016. SF was aspirated for diagnostic purposes from the affected joints at the start 
of surgical arthroscopy under general anaesthesia with 500 µl of excess SF 
submitted for NMR metabolomic analysis. Pathological joints included the 
femorotibial, glenohumeral, metacarpophalangeal, metatarsophalangeal and 
tarsocrural joints. Horses were divided into two main groups of joint pathology, 
septic and nonseptic. The septic group was subdivided into six horses with synovial 
sepsis following a local penetrating wound and one foal diagnosed with synovial 
sepsis secondary to haematogenous spread. The nonseptic group consisted of four 
horses diagnosed with OA, two with meniscal tears and concurrent OA (MT) and six 
with OC. Diagnoses were determined via a combination of radiography, 
ultrasonography, arthroscopy and SF total protein, cytology and/or bacterial culture 
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as previously described (Robinson et al., 2017). SF was immediately placed into 
uncoated 1.5 ml collection tubes and processed within 1 hr of collection. Particulate 
and cells were removed from the SF by centrifugation (4oC, 2540g for 5 min) and 
then the cell-free supernatant transferred to a clean uncoated 1.5 ml collection 
tube, snap-frozen using liquid nitrogen and stored at -80oC. Samples were spun to 
ensure removal of cellular debris which was critical to eliminate variance due to 
bacterial contamination in septic joints. To ascertain the most reproducible and 
robust collection protocol, biologically identical SF underwent ± centrifugation and 
supernatant removal followed by freezing using various methods at different 
temperatures. Multivariate statistical analysis of these samples indicated that the 
above method was most robust at reducing variance due to sample 
handling/processing (Chapter 2). 
6.3.2. Sample Preparation 
NMR samples were prepared within 48 hrs of acquisition. A 300 µl sample of 
thawed SF was diluted to a final volume containing 50% (v/v) SF, 40% (v/v) dd 1H2O 
(18.2 MΩ), 10% (v/v) 1 M PO43- pH 7.4 buffer (Na2HPO4, VWR International Ltd., 
Radnor, Pennsylvania, USA and NaH2PO4, Sigma-Aldrich, Gillingham, UK) in 
deuterium oxide (2H2O, Sigma-Aldrich) and 0.0025% (v/v) sodium azide (NaN3, 
Sigma-Aldrich). Samples were vortexed for 1 min, centrifuged at 13,000g and 4˚C 
for 2 min and 590 µl transferred (taking care not to disturb any pelleted material) 
into 5 mm outer diameter NMR tubes using a glass pipette. 
6.3.3. NMR Acquisition  
All SF samples were analysed individually. One dimensional 1H NMR spectra, with 
Carr-Purcell-Meiboom-Gill (CPMG) filter to attenuate signals from macromolecules 
such as albumins, were acquired using a standard vendor pulse sequence 
(cpmgpr1d) on a 600 MHz NMR Bruker Avance III spectrometer with a TCI 
cryoprobe and chilled Sample-Jet autosampler. Spectra were acquired at 25˚C, with 
a 4 s interscan delay, 32 transients and a 15 ppm spectral width. Software for 
acquisition and processing was carried out using Topsin 3.1 and IconNMR 4.6.7 with 
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automated phasing and baseline correction and a standard vendor processing 
routine (exponential window function with 0.3 Hz line broadening).  
6.3.4. Metabolite Annotation and Identification 
All spectra were scrutinised to ensure spectra met community recommended 
quality control criteria prior to inclusion in statistical analysis (Sumner et al., 2007). 
Quality control criteria included a flat baseline, water signal less than 0.4 ppm wide 
and line-width half heights of representative beta anomeric glucose doublet all 
within one standard deviation. Spectra were then divided into spectral regions or 
‘buckets’ according to metabolite annotation from Chenomx NMR Suite 8.2 (330-
mammalian metabolite library) with buckets attributed to multiple metabolites 
where peaks were found to overlap. Each spectrum was divided into 306 buckets 
with the intensity of each bucket divided by the bucket width to negate the 
intensity variance. Buckets were normalised to the median and Pareto scaled prior 
to statistical treatment. Metabolites annotated in Chenomx were also confirmed by 
a mixture of 1H 1D NMR and, where possible, to in-house 2D 1H 13C Heteronuclear 
Single Quantum Coherence NMR standards. Spectra and metabolite assignments 
including HMDB IDs and annotation level are all available in the Metabolights 
repository (www.ebi.ac.uk/metabolights/MTBLS543) and shown in Table 2 (Salek et 
al., 2013). Among the metabolites identified was ethanol, likely through 
contamination during SF aspiration following surgical sterilisation. Therefore, for 
multivariate analysis the buckets attributed to ethanol were omitted. 
6.3.5. Statistical Analysis 
SF spectra were divided into two groups: nonseptic and septic. Further separation 
of the groups was not possible due to limited sample number in this study. t-tests 
and partial-least-squares discriminant analysis (PLS-DA) were carried out using 
MetaboAnalyst 3.5 (http://www.metaboanalyst.ca) which uses the R package of 
statistical computing software (Xia et al., 2016). For t-tests, p < 0.05 was considered 
statistically significant following correction for multiple testing using the Benjamini-
Hochberg false discovery rate method (Benjamini and Hochberg, 1995). Box plots 
were carried out using the software package SPSS 22. Quantile and PCA plots were 
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produced using standard analytical routines in the software package R 
(https://cran.r-project.org/). 
6.4. Results 
6.4.1. Group Limitations 
The patient groups were restricted to two main groups; septic or nonseptic (Table 
1) due to a lack of sufficient cases of differing subdiagnoses. The joints from which 
each sample was collected were noted, however, without a larger study size no 
separate grouping for differing joints was attempted. 
 
Table 1. Further clinical characteristics of group patients. 
Abbreviations: Groups, OA = Osteoarthritis, MT = Meniscal tear and concurrent OA, 
OC = Osteochrondrosis; Sex, M = Male, F = Female; Joints, GH = Glenohumeral, MCP 
= Metacarpophalangeal. FT = Femorotibial, MTP = Metatarsophalangeal and TC = 
Tarsocrural. 
6.4.2. Metabolite Annotation and Identification 
NMR spectra for all groups showed a consistent set of metabolite signals present 
with multiple metabolites identified from 1D multiplet pattern overlap (Figure 1). 
The metabolite abundances within the septic group were less variable than the 
nonseptic group, which is perhaps expected given the nonseptic group included 
samples from two separate diagnoses (OA and OC). Of the 306 spectral bins in each 
extract, 203 (66%) were annotated to 71 metabolites, with identification confirmed 
for 55 of these metabolites (Table 2). 
  Main Groups Subgroups 
  
Septic Nonseptic 
Septic Nonseptic 
  
Wound 
Sepsis 
Haematogenous 
Sepsis 
OA 
MT with 
OA 
OC 
Number 7 12 6 1 4 2 6 
Mean 
Age 
6 years 
10 months 
7 years 
7 months 
7 years 
11 months 
0 years 
2 months 
10 years 
6 months 
12 years 
 0 months 
4 years 
6 months 
Sex 7M 6F, 6M 6M 1M 1F, 3M 1F, 1M 4F, 2M 
Joint 
 
1 x GH 
1 x MCP 
1 x MTP 
4 x TC 
 
2 x GH 
3 x MCP 
4 x FT 
1 x MTP 
2 x TC 
1 x MCP 
1 x MTP 
4 x TC 
1 x GH 
2 x GH 
1 x FT 
1 x MTP 
2 x FT 
3 x MCP 
1 x FT 
2 x TC 
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Figure 1. Quantile plots of osteoarthritis (OA)/osteochondrosis (OC) (nonseptic, 
n=12), sepsis (n=7) and all spectra (n=19) depicting the median spectral plot (black 
line) and variation from the median within each group (yellow to red scale) for the 
full spectral range (9.0 - 0.5 ppm) and more detailed regions depicting selected 
peaks from three differentially abundant metabolites, glucose, glutamine and 
alanine. Variation within the full spectra can most clearly be seen at 0.8 ppm. 
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Table 2. Metabolites annotated in synovial fluid by Chenomx, metabolites 
subsequently identified using an in-house library are indicated by the Metabolomics 
Standards Initiative (MSI) level 1 (Salek et al., 2013). 
 
Database Identifier Metabolite Identification Reliability 
HMDB00001  1-Methylhistidine  MS Level 2 
HMDB59655  2-Hydroxyglutarate  MS Level 2 
HMDB11743  2-Phenylpropionate  MS Level 2 
HMDB00357  3-Hydroxybutyrate MS Level 2 
HMDB00355  3-Hydroxymethylglutarate  MS Level 2 
HMDB01149  5-Aminolevulinate MS Level 2 
HMDB00042  Acetate MS Level 1 
HMDB00060  Acetoacetate MS Level 2 
HMDB01890  Acetylcysteine  MS Level 2 
HMDB01432  Agmatine  MS Level 2 
HMDB00729  Alpha-Hydroxyisobutyrate MS Level 2 
HMDB00186  Alpha-Lactose  MS Level 2 
HMDB00043  Betaine  MS Level 1 
HMDB00030  Biotin  MS Level 1 
HMDB00094  Citrate MS Level 1 
HMDB00064  Creatine  MS Level 1 
HMDB00562  Creatinine  MS Level 1 
HMDB00143  D-Galactose  MS Level 2 
HMDB00122  D-Glucose  MS Level 1 
HMDB00108  Ethanol  MS Level 1 
HMDB00142  Formate MS Level 2 
HMDB00663  Glucarate MS Level 2 
HMDB01401  Glucose 6-phosphate  MS Level 2 
HMDB00131  Glycerol MS Level 1 
HMDB00123  Glycine  MS Level 1 
HMDB00721  Glycylproline  MS Level 2 
HMDB00128  Guanidoacetate MS Level 2 
HMDB00870  Histamine  MS Level 2 
HMDB00764  Hydrocinnamate MS Level 2 
HMDB00678  Isovalerylglycine  MS Level 2 
HMDB00190  Lactate MS Level 1 
HMDB00161  L-Alanine  MS Level 1 
HMDB00646  L-Arabinose  MS Level 2 
HMDB00062  L-Carnitine  MS Level 2 
HMDB00174  L-Fucose  MS Level 2 
HMDB00148  L-Glutamate MS Level 1 
HMDB00641  L-Glutamine MS Level 1 
HMDB00177  L-Histidine  MS Level 1 
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HMDB00687  L-Leucine  MS Level 1 
HMDB00159  L-Phenylalanine  MS Level 1 
HMDB00167  L-Threonine  MS Level 2 
HMDB00158  L-Tyrosine  MS Level 1 
HMDB00883  L-Valine  MS Level 1 
HMDB01389  Melatonin  MS Level 2 
HMDB01238  N-Acetylserotonin  MS Level 2 
HMDB02055  o-Cresol  MS Level 2 
HMDB00210  Pantothenic acid  MS Level 2 
HMDB00821  Phenylacetylglycine  MS Level 2 
HMDB01511  Phosphocreatine  MS Level 2 
HMDB00239  Pyridoxine  MS Level 2 
HMDB00243  Pyruvate MS Level 1 
HMDB00635  Succinylacetone  MS Level 2 
HMDB00262  Thymine  MS Level 1 
HMDB01878  Thymol  MS Level 2 
HMDB00294  Urea  MS Level 1 
 
6.4.3. Statistical Analysis and Differentially Abundant Metabolites 
Of the 306 identified peaks, 180 were found to be differentially abundant between 
septic and nonseptic groups when analysed using a univariate t-test, p < 0.05, with 
98 peaks assigned to 26 different metabolites (Supplementary Table 1). 
Unsupervised multivariate analysis (PCA) identified clear variance between spectra 
from septic and nonseptic joint pathologies, forming two distinct clusters (Figure 2). 
Ninety-five percent of the variance was explained by seven principal components 
(PCs) with PC1 and PC2 explaining a combined 71.89% of variance within the data. 
Although the analysis between groups was limited to a binary diagnosis (septic vs 
nonseptic) to explore the variance in metabolite profile for SF aspirated from horses 
with differing underlying conditions, the PCA score plots were coloured in terms of 
either main diagnosis (Binary) or subdiagnosis (five groups). Within the nonseptic 
group, samples obtained from joints with OA and associated meniscal tears were 
found to cluster together. In addition, despite a separate aetiology, SF obtained 
from a foal with haematogenous sepsis clustered with SF collected from joints 
diagnosed with sepsis subsequent to penetrating wounds.  
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Supervised multivariate discriminant analysis using PLS-DA plots of the known 
metabolites indicated that the variance was heavily influenced by glucose (Figure 3a 
and b), with 23 of the 25 most influential buckets attributed to glucose peaks. The 
optimal model comprised two components with reasonable predictive power (R2 = 
0.85, Q2 = 0.72). Omitting glucose signals from the analysis gave rise to a somewhat 
lower predictive model (R2 = 0.70, Q2 = 0.45, fit with 1 component) (Figure 3c). From 
the glucose free model, metabolites acetate, glycylproline, glycine, citrate, 
creatinine and alanine were among the most influential (Figure 3d). 
Both univariate and multivariate analysis were compared to identify differentially 
abundant metabolites. Metabolite peaks identified as either significantly different 
(p < 0.05) via t-test or in the top 25 variables of influence (VIP) via glucose excluded 
PLS-DA were then attributed to a genuine differentially abundant metabolite 
change if the individual metabolite peak changes correlated. In total a panel of 13 
metabolites were identified as being differentially abundant between septic and 
nonseptic groups. Acetate, alanine, citrate, creatine phosphate, creatinine, glucose, 
glutamate, glutamine, glycine, phenylalanine, pyruvate and valine were higher in 
the nonseptic group whilst glycylproline was higher in synovial sepsis (Figure 4). 
PCA analysis of OA and OC subgroups suggested that, bar one sample, they may 
cluster separately and may therefore demonstrate distinctive metabolomes. 
However, with this modest group size no significant differences in metabolites (p < 
0.05) were identified by univariate analysis (data not shown). 
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Figure 2. Principal component analysis (PCA) scores plot of septic (blue, n=7) and 
nonseptic (red, n=12) synovial fluid 1H NMR metabolomes. Samples with meniscal 
tear or haematogenous sepsis subdiagnoses for osteoarthritis (OA) and sepsis, 
respectively, are highlighted in each group with a thick black outline, 
osteochondrosis (OC) are distinguished from OA by highlight shade. 
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Figure 3. (a) PLS-DA plots of osteoarthritis (OA)/osteochondrosis (OC) (n=12) versus 
sepsis (n=7) using only metabolite annotated buckets: first two components shown 
out of a total of two components used to fit the model (R2 = 0.85, Q2 = 0.72). (b) VIP 
scores for the 25 most influential buckets of PLS-DA. (c) PLS-DA plots of OA/OC 
versus sepsis using only metabolite annotated/identified buckets with all glucose 
buckets excluded: first two components shown. It should be noted that only one 
component was used to fit the model (R2 = 0.70, Q2 = 0.45). (d) VIP scores for the 25 
most influential buckets of glucose-excluded PLS-DA.
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Figure 4. Boxplots of key synovial metabolites differentiating septic (n=7) and nonseptic (osteoarthritis (OA) and osteochondrosis (OC), n=12) 
articular pathologies, shown as relative intensities corresponding to the most representative peak for each metabolite. t-test: * = p < 0.05, ** = 
p < 0.01 and *** = p < 0.001.
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6.5. Discussion 
Despite OA, OC and synovial sepsis having a high prevalence and clinical relevance, 
diagnosis, staging, monitoring and determination of an accurate prognosis remain 
challenging for practising veterinarians. Therefore, to differentiate equine articular 
joint pathologies, there is a need to identify reliable biomarkers of disease. To aid 
equine synovial sepsis diagnosis, currently recognised markers of glucose and 
lactate are considered to be nonspecific and unreliable respectively (Arthur et al., 
1983; Tulamo et al., 1989). In addition, clinically assessing response to treatment of 
septic joints can be challenging, with differentiating horses with continued 
lameness from a nonresolving sepsis to those with a resolving sepsis but ongoing 
significant inflammation, difficult. Therefore, reliable metabolic markers of sepsis 
may aid as part of a longitudinal clinical assessment. 
In this study it has been shown that the metabolite profile of equine SF is able to 
discriminate between septic and nonseptic joint pathologies. A panel of 13 
metabolites was identified which were differentially abundant between these two 
groups. These metabolites may in turn prove beneficial in an equine clinical setting 
as a diagnostic aid as well as monitoring response to treatment and assessing 
prognosis. Ideally this could be carried out through field tests, similar to those 
produced and used for equine biofluids for metabolites glucose and lactate, 
urinalysis and the protein inflammatory marker serum amyloid A (Hackett and 
McCue, 2010; Kobayashi, 2007; Savage, 2008; Stack et al., 2014). No metabolite 
abundances were identified to be statistically different between OA and OC 
subgroups. However, the PCA analysis suggested that, bar one sample, OC and OA 
metabolite profiles were different and thus may demonstrate distinctive 
metabolomes sufficient to apply robust statistical models such as PLS-DA. This can 
only be tested with a larger sample size which was not possible on this modest 
subset of patients. 
The PLS-DA VIP scores revealed spectral peaks assigned to glucose were highly 
represented as a discriminant of joint sepsis (23/25 of the most influential peaks). 
Reduced levels of glucose in human and equine SF, due to an increase in synovial 
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and neutrophil cell glycolytic activity in severe inflammation or infection, have 
previously been identified, with a serum-synovial glucose difference of ˃2.2 mmol/L 
considered supportive of a diagnosis of synovial sepsis (Krey and Bailen, 1979; 
Roberts et al., 1967). Glucose is, however, a nonspecific parameter and can be 
influenced by multiple other variables (Tulamo et al., 1989). However, PLS-DA 
analysis with all glucose influenced spectral peaks omitted revealed there to still be 
a modest separation between the groups, thus indicating the differentiated 
metabolomes are driven by a panel of metabolites and potential septic markers, 
opposed to glucose alone. 
Previous studies have described mixed results as to whether elevated synovial 
lactate can be used to help distinguish synovial sepsis (Arthur et al., 1983; Gobelet 
and Gerster, 1984; Tulamo et al., 1989; Washington, 1980). In this study we did not 
identify lactate abundance to be different between the septic and nonseptic groups, 
therefore providing further evidence that lactate is an unreliable marker for 
synovial sepsis. 1H NMR spectroscopy is not able to distinguish D-lactate from L-
lactate and consequently we are unable to draw any conclusions on the specific 
levels of bacterially derived D-lactate within the groups. 
In this study the majority of differentially abundant metabolites were found to be 
reduced in sepsis compared to the nonseptic group. However, glycylproline was 
elevated in synovial sepsis. Glycylproline is a dipeptide end product of the 
catabolism of collagen (Le et al., 1999). Following synovial infection and an 
insufficient immunological response, collagen catabolism is upregulated through a 
high cytokine concentration increasing the release of matrix metalloproteinases and 
other collagen-degrading enzymes from within the host (Shirtliff and Mader, 2002). 
Elevated levels in markers of collagen destruction in synovial sepsis over nonseptic 
joint pathologies have been identified previously, with one study demonstrating 
increased synovial levels of the collagen degradation marker cross-linked C-
telopeptide fragments of type II collagen (CTX-II) in longitudinal samples of a patient 
with septic arthritis compared to osteoarthritic patients’ SF (Lohmander et al., 
2003). Thus glycylproline, in combination with other metabolite/protein derived 
markers of collagen catabolism, may aid clinical diagnosis of synovial sepsis. 
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Following on from this study, further investigation using mass spectrometry analysis 
would complement these results as the identified degradation of extracellular 
matrix may provide lipid and carbohydrate profiles of interest. 
All raw NMR spectral data and associated annotations that contributed to this study 
have been deposited with the open access online repository Metabolights, curated 
by the European Bioinformatics Institute (EBI), including acquisition and processing 
parameters with all metabolites identified clearly reported. The authors feel this 
transparent, gold standard approach to data submission to independent 
bioinformatics specialists, such as the EBI, should be further encouraged within the 
NMR metabolomics field, in line with other ‘omics’ journal submissions. 
6.5.1. Study Limitations 
Modest sample size prohibited further analysis of metabolome differences between 
OA and OC or between wound sepsis and haematogenous sepsis. Similarly, SF with 
OA and associated meniscal tears were found to cluster together although we are 
unable to conclude that SF collected from femorotibial joints with meniscal tears 
form a distinct metabolome as only two samples were available for inclusion within 
this study. This is of particular interest as a diagnostic aid for meniscal tears would 
have a practical clinical implication within veterinary medicine which could also 
translate to human medicine. It is our hope that additional studies will provide 
further information and enable more stringent analyses to be undertaken. 
Furthermore, because of limited sample size, SF was aspirated from a range of 
joints which may lead to variation in data due to biomechanical differences 
between joints. Again, a larger sample size would enable a greater understanding as 
to what influence joint location has on the metabolome and a stricter control of site 
of sample collection (if necessary) and thus enable further information to be 
extracted from the metabolic profiles. In addition, during the joint pathologies 
studied there are likely to be changes to management of the animal, particularly 
exercise and diet, which may alter the metabolome of SF, although this influence is 
likely to be minimal compared to the significant metabolic influence of the localised 
joint pathology. 
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During this study we were unable to compare the SF of the joint pathologies of 
interest to a normal group. In equine clinical practice only pathological joints are 
aspirated during diagnostic investigations. Post mortem SF cannot be defined as 
having a normal metabolome due to the anaerobic changes that take place 
following death, including artefactual changes in the abundance of glucose and 
lactate, two key metabolites of interest during sepsis. 
6.5.2. Conclusion 
This paper is the first to use NMR-led metabolomics to analyse equine SF with 
multiple pathologies and demonstrates that NMR-led metabolomics is an effective 
technique for analysis of equine SF collected within a clinical veterinary 
environment. Furthermore, this study demonstrates a panel of synovial metabolites 
that can distinguish between septic and nonseptic equine SF, with glucose the 
principal discriminator. To translate this into a diagnostic aid, a wider study with 
participants with less common diagnoses is required to improve the diagnostic 
power. 
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6.9. Supplementary Information 
 
Supplementary Figure 1. Equine synovial fluid 2D NMR 1H 13C Heteronuclear Single 
Quantum Coherence (HSQC) spectrum used for metabolite identifications. x axis = 
1H, y axis = 13C. n = 1. 
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Supplementary Table 1. Statistically significant differentially abundant peaks 
between septic and non-septic equine synovial fluid. t-test, p < 0.05. 
 
Metabolite 
Pattern 
File Peak 
Number 
Peak 
Number 
p value 
Fold 
Change 
Mean 
Fold 
Change 
Median 
Fold 
Change 
2-HYDROXYGLUTARATE 207 1 4.09E-06 0.61 0.61 0.61 
3-HYDROXY-3-
METHYLGLUTARATE 
183 1 0.00723 1.56 1.56 1.56 
3-HYDROXYBUTYRATE 188 1 0.00207 1.42 1.42 1.42 
ACETATE 236 1 0.01926 2.32 2.32 2.32 
AGMATINE 148 1 0.00388 1.26 1.26 1.26 
ALANINE 262 1 0.00510 1.74 
1.74 1.74 
ALANINE 263 2 0.00400 1.75 
BIOTIN 209 1 0.00005 0.57 
0.71 0.73 
BIOTIN 210 2 0.00390 0.77 
BIOTIN 211 3 0.02578 0.82 
BIOTIN 267 4 0.00244 0.70 
CITRATE 171 1 0.00051 1.88 
3.75 4.13 
CITRATE 172 2 0.00011 3.49 
CITRATE 175 3 0.00014 4.76 
CITRATE 176 4 0.00011 4.86 
CREATINE PHOSPHATE 60 1 0.02617 1.23 
1.26 1.26 
CREATINE PHOSPHATE 61 2 0.00196 1.29 
CREATININE 53 1 0.00598 1.35 
1.60 1.60 
CREATININE 149 2 5.75E-06 1.84 
GLUCOSE 39 1 0.00247 1.93 
1.88 1.91 
GLUCOSE 40 2 0.00109 2.04 
GLUCOSE 41 3 0.00313 1.97 
GLUCOSE 42 4 0.00800 1.93 
GLUCOSE 65 5 0.01642 1.69 
GLUCOSE 66 6 0.00436 1.82 
GLUCOSE 68 7 0.01392 1.69 
GLUCOSE 69 8 0.00466 1.84 
GLUCOSE 70 9 0.03247 1.49 
GLUCOSE 71 10 0.00210 1.70 
GLUCOSE 72 11 0.00173 1.64 
GLUCOSE 73 12 0.00149 1.89 
GLUCOSE 74 13 0.00303 1.80 
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GLUCOSE 75 14 0.00509 1.75 
GLUCOSE 80 15 0.00055 1.85 
GLUCOSE 81 16 0.00009 1.84 
GLUCOSE 83 17 0.00012 1.76 
GLUCOSE 84 18 0.00014 1.71 
GLUCOSE 85 19 0.00104 1.85 
GLUCOSE 86 20 0.00127 1.91 
GLUCOSE 87 21 0.00209 1.85 
GLUCOSE 88 22 0.00183 1.93 
GLUCOSE 89 23 0.00208 1.81 
GLUCOSE 102 24 0.00173 1.87 
GLUCOSE 103 25 0.00115 1.94 
GLUCOSE 104 26 0.00254 1.87 
GLUCOSE 105 27 0.00129 1.91 
GLUCOSE 106 28 0.00234 1.88 
GLUCOSE 107 29 0.00168 1.95 
GLUCOSE 108 30 0.00163 1.98 
GLUCOSE 109 31 0.00133 2.00 
GLUCOSE 110 32 0.00153 2.00 
GLUCOSE 111 33 0.00128 2.05 
GLUCOSE 112 34 0.00137 2.02 
GLUCOSE 113 35 0.00135 2.05 
GLUCOSE 114 36 0.00115 1.95 
GLUCOSE 115 37 0.00150 1.95 
GLUCOSE 116 38 0.00056 2.06 
GLUCOSE 117 39 0.00110 2.00 
GLUCOSE 118 40 0.00037 2.02 
GLUCOSE 119 41 0.00097 1.98 
GLUCOSE 132 42 0.00010 1.98 
GLUCOSE 133 43 0.00101 1.93 
GLUCOSE 134 44 0.00255 1.69 
GLUCOSE-6-PHOSPHATE 58 1 0.00119 1.37 
1.38 1.37 GLUCOSE-6-PHOSPHATE 129 2 0.00784 1.36 
GLUCOSE-6-PHOSPHATE 130 3 0.00227 1.41 
GLUTAMATE 197 1 0.01746 1.29 1.29 1.29 
GLUTAMINE 180 1 0.00037 1.66 
1.34 1.5 GLUTAMINE 181 2 0.00018 1.69 
GLUTAMINE 182 3 0.04998 1.33 
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GLUTAMINE 219 4 0.00001 0.66 
GLYCINE 101 1 0.00091 1.53 1.53 1.53 
GLYCYLPROLINE 232 1 0.00017 0.77 
0.66 0.66 
GLYCYLPROLINE 233 2 7.46E-06 0.54 
HISTIDINE 143 1 0.00353 1.31 
1.28 1.28 
HISTIDINE 144 2 0.00079 1.25 
LEUCINE 244 1 0.00824 1.27 
1.25 1.25 
LEUCINE 246 2 0.04653 1.23 
N-ACETYLCYSTEINE 222 1 0.00011 0.65 0.65 0.65 
N-ISOVALEROYLGLYCINE 304 1 0.00224 0.80 0.80 0.80 
N-PHENYLACETYLGLYCINE 10 1 0.00180 0.55 0.55 0.55 
PHENYLALANINE 4 1 0.00291 1.42 
1.46 1.49 PHENYLALANINE 5 2 0.00344 1.49 
PHENYLALANINE 6 3 0.00413 1.49 
PI-METHYLHISTIDINE 137 1 0.02448 0.74 
0.72 0.74 PI-METHYLHISTIDINE 139 2 0.02026 0.77 
PI-METHYLHISTIDINE 140 3 0.02210 0.66 
PYRUVATE 189 1 0.01229 1.53 1.53 1.53 
TYROSINE 21 1 0.01954 1.23 
1.45 1.49 
TYROSINE 22 2 0.00066 1.41 
TYROSINE 28 3 0.00001 1.58 
TYROSINE 29 4 0.00003 1.57 
VALINE 203 1 0.01526 0.83 
1.14 1.21 
VALINE 204 2 0.00804 0.82 
VALINE 295 3 0.00179 1.40 
VALINE 296 4 0.00143 1.40 
VALINE 299 5 0.03166 1.19 
VALINE 300 6 0.01854 1.23 
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7.1. Abstract 
Articular conditions are common in horses and can result in loss of function, pain 
and/or inability to work. Common conditions include osteoarthritis, 
osteochondrosis and synovial sepsis, which can be life-threatening, but despite the 
high clinical prevalence of these conditions, rapid and specific diagnosis, monitoring 
and prognostication remains a challenge for practicing veterinarians. Synovial fluid 
from a range of arthropathies was enriched for low abundance proteins using 
combinatorial peptide ligand ProteoMiner™ beads and analysed via liquid 
chromatography-tandem mass spectrometry. Changes in protein abundances were 
analysed using label-free quantification. Principal component analysis of 
differentially expressed proteins identified groupings associated with joint 
pathology. Findings were validated using ELISA. Lactotransferrin (LTF) abundance 
was increased in sepsis compared to all other groups and insulin-like growth factor-
binding protein 6 (IGFBP6) abundance decreased in sepsis compared to other 
disease groups. Pathway analysis identified upregulation of the complement system 
in synovial joint sepsis and the downregulation of eukaryotic translation initiation 
factors and mTOR signalling pathways in both osteoarthritis and osteochondrosis 
compared to the healthy group. Overall, we have identified a catalogue of proteins 
which we propose to be involved in osteoarthritis, osteochondrosis and synovial 
sepsis pathogenesis.  
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7.2. Introduction 
Articular conditions are common in horses and can result in loss of function, pain 
and/or inability to work, which are important welfare concerns. The most common 
conditions include osteoarthritis (OA), osteochondrosis (OC) and synovial sepsis, 
which can be life-threatening (Rubio-Martínez et al., 2012). Despite the high clinical 
prevalence of these conditions, rapid and specific diagnosis, monitoring and 
prognostication remains a challenge for practicing veterinarians, thus, identification 
of reliable biomarkers of disease is required. Synovial fluid (SF) is in direct contact 
with articular structures and represents an important source of biomarker 
discovery. SF is located within the articular joint cavity, providing a pool of nutrients 
for surrounding tissues but primarily serving as a biological lubricant, containing 
molecules including hyaluronan with low-friction and low-wear properties to 
articular surfaces (Dicker et al., 2014). As SF is in close proximity to articular tissues 
primarily altered during joint pathology, this biofluid is an important first approach 
source for biomarker discovery (Mateos et al., 2012; Ruiz-Romero and Blanco, 
2010). 
Total protein content in synovial fluid is associated with presence of articular 
pathology and is one of the parameters most commonly used in equine clinical 
practice to enable diagnosis and to monitor horses with synovial sepsis (Frisbie, 
2006). Problematically there are large overlaps in the ranges of SF total protein 
content among arthropathies, and total protein content is also affected by articular 
diagnostic procedures and treatments (Sanchez-Teran, Bracamonte, Hendrick, 
Riddell, et al., 2016). This situation can lead to erroneous interpretations and clinical 
decisions, representing an important welfare risk to the horse. More specific 
proteins such as the acute phase inflammatory protein serum amyloid A has been 
investigated as a potential biomarker of articular conditions in horses; however, it is 
easily affected by the systemic condition of the patient, and therefore, can be 
unreliable for specific diagnosis (Jacobsen, Thomsen, et al., 2006; Sinovich et al., 
2018). 
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Proteomics encompasses the comprehensive profiling of protein contents. The SF 
proteome is dependent upon articular disease and its characterization has allowed 
the differentiation of OA and rheumatoid arthritis (RA) in man (Mateos et al., 2012). 
A recent study has identified a subset of proteins differentially expressed in OA 
versus normal equine joints (Peffers, McDermott, et al., 2015). Although an increase 
in total protein is a well-known feature of synovial sepsis, the protein profile in 
synovial sepsis has not been investigated. Identification of a characteristic 
proteomic profile in synovial sepsis would increase the understanding of the 
molecular basis of the condition and enable the identification of potential 
biomarkers for early diagnosis and treatment of this disease.  
A previous study has investigated the equine SF profile in OA and OC compared to 
healthy donors using 2D-gel electrophoresis with subsequent mass spectrometry 
analysis of in-gel tryptic digests (Chiaradia et al., 2012). However, few studies have 
investigated the proteomic profile of equine SF using high mass resolution mass 
spectrometer of in-solution tryptic digestions and, to our knowledge, none have 
investigated protein profile changes in septic SF in any species (Jacobsen, Niewold, 
et al., 2006; Peffers, McDermott, et al., 2015). In this study we have used mass 
spectrometry and label-free quantification to identify potential protein biomarkers 
that allow differentiation between equine articular joint pathologies, potentially 
aiding accurate diagnosis and enabling increased understanding of the effect of 
septic synovitis on the joint environment. Identification of characteristic proteomic 
profiles in synovial sepsis would increase the understanding of the molecular basis 
of the condition and allow the determination of potential biomarkers for early 
diagnosis and treatment of the disease. We hypothesised that proteomic profile 
characteristics will distinguish septic from non-septic equine arthropathies and 
between the non-septic common arthropathies OC and OA. The objective of the 
study was to identify possible synovial biomarkers in equine arthropathies. 
7.3. Methods  
All chemicals were supplied by Sigma-Aldrich (Gillingham, UK) unless otherwise 
stated. 
  
233 
 
7.3.1. Sample Collection 
Following ethical approval and owner consent, excess aspirated SF (collected during 
clinical diagnostic investigations) was analysed from joints of horses presenting to 
The Philip Leverhulme Equine Hospital, University of Liverpool between 2014 and 
2016, diagnosed with clinical OA, OC and synovial sepsis. Clinical diagnoses were 
determined via a combination of radiography, ultrasonography, arthroscopy and SF 
analysis and/or bacterial culture as previously described (Robinson et al., 2017). SF 
was aspirated for diagnostic purposes from the affected joints during patient 
examinations or at the start of surgical arthroscopy under general anaesthesia. SF 
was immediately placed into EDTA-containing tubes (BD Vacutainer, Belliver 
Industrial Estate, Plymouth, UK) with particulate and cells removed from the SF by 
centrifugation (4oC, 2540g for 4 min). The cell-free supernatant was transferred to a 
clean uncoated 1.5 ml collection tube, snap-frozen using liquid nitrogen and stored 
at -80°C. SF was collected from the distal interphalangeal, femorotibial, 
glenohumeral, intercarpal, metacarpophalangeal, metatarsophalangeal, 
patellofemoral and tarsocrural joints.  
Eight healthy SF samples were obtained from the metacarpophalangeal joint of 
mixed breeds of horses from an abattoir with no gross joint changes, with a total 
score of 0 according to the Mcilwraith et al. gross scoring system, scored by two 
independent assessors (McIlwraith et al., 2010). Samples were collected as a by-
product of the agricultural industry and processed within 12 hours of euthanasia. 
The Animals (Scientific Procedures) Act 1986, Schedule 2, does not define collection 
from these sources as scientific procedures and ethical approval was therefore not 
required. Post mortem SF samples were processed using identical protocols as for 
clinically collected hospital samples. Final groups consisted of OA (n=4), OC (n=8), 
synovial sepsis (n=7) and healthy (n=8) (full details in Supplementary Table 1). 
7.3.2. Synovial Fluid Preparation 
SF was thawed and treated with 1 µg/ml hyaluronidase as previously described and 
centrifuged at 10000g for 10 min to remove any particulates (Peffers, McDermott, 
et al., 2015). Protein concentrations of SF were determined by Bradford assay 
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(Thermo Scientific, USA). A volume of sample equivalent to 5 mg of protein was 
added to 10 µl of beads (Peffers, McDermott, et al., 2015). SF samples were 
enriched for low abundance proteins using ProteoMiner™ beads (BioRad, UK) 
according to the manufacturer’s instructions. Beads were re-suspended in 80 µl of 
25 mM ammonium bicarbonate and 5 µl of 1% (w/v) Rapigest SF (Waters, UK) 
added and the sample heated at 80°C for 10 min. On-bead trypsin digestion was 
undertaken (Peffers, McDermott, et al., 2015). 
7.3.3. LC-MS/MS and Label-Free Quantification 
Tryptic digests (diluted 5-fold in 0.1% (v/v) trifluoroacetic acid (TFA) and 3% (v/v) 
acetonitrile) were subjected to liquid chromatography tandem mass spectrometry 
(LC-MS/MS) using a 2 hr gradient and analysed individually. Data-dependent LC-
MS/MS analyses were conducted on a Q ExactiveTM HF quadrupole-Orbitrap mass 
spectrometer (Thermo Scientific, Hemel Hempstead, UK) coupled to a Dionex 
Ultimate 3000 RSLC nano-liquid chromatograph (Thermo Scientific). Sample digests 
were loaded onto a trapping column (Acclaim PepMap 100 C18, 75 µm x 2 cm, 3 µm 
packing material, 100 Å) using a loading buffer of 0.1% (v/v) TFA and 2% (v/v) 
acetonitrile in water for 7 min at a flow rate of 12 µl min-1. The trapping column was 
then set in-line with an analytical column (EASY-Spray PepMap RSLC C18, 75 µm x 
50 cm, 2 µm packing material, 100 Å) and the peptides eluted using a linear 
gradient of 96.2% A (0.1% (v/v) formic acid):3.8% B (0.1 % (v/v) formic acid in 
water:acetonitrile (80:20) (v/v)) to 50% A:50% B over 90 min at a flow rate of 300 nl 
min-1, followed by washing at 1 % A:99% B for 5 min and re-equilibration of the 
column to starting conditions. The column was maintained at 40°C and the effluent 
introduced directly into the integrated nano-electrospray ionisation source 
operating in positive ion mode. The mass spectrometer was operated in data-
dependent acquisition (DDA) mode with survey scans between m/z 350-2000 
acquired at a mass resolution of 60,000 (full width at half maximum) at m/z 200. 
The maximum injection time was 100 ms, and the automatic gain control was set to 
3e6. The 12 most intense precursor ions with charge states of between 2+ and 5+ 
were selected for MS/MS with an isolation window of 2 m/z units. Fragmentation of 
the peptides was by higher-energy collisional dissociation using normalised collision 
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energy of 30%. Dynamic exclusion of m/z values to prevent repeated fragmentation 
of the same peptide was used with an exclusion time of 20 s. 
For label-free quantification, the raw files of the acquired spectra were analysed by 
ProgenesisQI™ software (Waters, Manchester, UK) which aligns the files and then 
peak picks for quantification by peptide abundance (Peffers, McDermott, et al., 
2015). Briefly, the top five spectra for each feature were exported from 
ProgenesisQI™ and utilised for peptide identification with our local Mascot server 
(Version 2.6.2), searching against the Unihorse database with carbamidomethyl 
cysteine as a fixed modification and methionine oxidation as a variable 
modification, peptide mass tolerance of 10 ppm and MS/MS tolerance of 0.01 Da. In 
this study, differentially expressed (DE) proteins are defined as those with a > 2 fold 
change in expression, with a false discovery rate (FDR) adjusted p value of < 0.05 
and identified with at least two unique peptides  
Proteomic data has been deposited in the PRIDE ProteomeXchange and can be 
accessed using the identifier PXD011276 (Vizcaíno et al., 2016). 
7.3.4. Pathway and Network Analysis Comparing Sepsis, OA or OC to Healthy 
Network analysis, canonical pathways and upregulated regulators were analysed 
using Ingenuity Pathway Analysis (IPA, Qiagen, USA). Proteins with an FDR adjusted 
p value of < 0.05 and with 2 or more unique peptides were used for analysis, 
uncharacterised proteins were not included to the analysis. Gene names from the 
lists generated by ProgenesisQI™ were uploaded to IPA, unmapped genes were 
converted manually to human orthologues. IPA analysis was conducted by Mr Aibek 
Smagul. 
7.3.5. Validation of Mass Spectrometry using ELISA 
The differentially expressed proteins lactotransferrin (LTF) and insulin-like growth 
factor-binding protein 6 (IGFBP6) were selected to validate mass spectrometry 
findings as they could be measured using available enzyme linked immunosorbent 
assays (ELISAs) that were compatible with equine samples. Commercially available 
kits were used for both equine LTF (MBS902183, MyBioSource Inc., San Diego, 
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California, USA) and equine IGFBP6 (abx574245, Abbexa Ltd, Cambridge, UK), using 
sandwich and competitive inhibition ELISA methodology respectively. For IGFBP6 
analysis, hyaluronidase treated/Costar processed native SF was diluted 1/10 
whereas for LTF analysis SF was undiluted. 5-6 dependent cohort SF samples were 
tested per group. 100 µl aliquots of each sample were analysed in duplicate, with 
the absorbance measured at 450 nm and protein concentrations calculated from 
standard curves.  
7.3.6. Additional Statistical Analyses 
Principal component analysis (PCA) plots and heat map analysis were produced 
using MetaboAnalyst 4.0 (Chong et al., 2018). The Venn diagram was produced 
using the online tool Venny 2.1 and box plots constructed using SPSS 24. Statistical 
analysis of SF protein concentration, LTF and IGFBP6 abundances were performed in 
Minitab version 17. These were conducted via ANOVA, using Tukey post hoc testing, 
with a p value of < 0.05 considered statistically significant, following correction for 
multiple testing.  
7.4. Results 
7.4.1. Protein Concentration of Synovial Fluid with Different Arthropathies 
The SF protein assay demonstrated that protein concentration was dependant on 
the type of arthropathy, with septic SF having the highest protein concentration 
(Figure 1). 
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Figure 1. Synovial fluid protein concentrations in equine arthropathies. Protein 
concentrations of synovial fluid were determined by Bradford assay. Healthy (n=8), 
osteoarthritis (OA, n=4), osteochondrosis (OC, n=8), sepsis (n=7). Significant 
changes are demonstrated following analysis using ANOVA with Tukey’s multiple 
comparison; ** p < 0.01, **** p < 0.0001. 
 
7.4.2. Differential Abundance of Proteins in Osteoarthritis, Osteochondrosis and 
Sepsis compared to Healthy Synovial Fluid 
From the aggregate data file produced from all samples 1,385 protein families, at a 
1% FDR, were identified. ProgenesisQI™ identified 750 proteins DE when all groups 
were compared using a 4-way analysis (> 2-fold change, FDR < 0.05 and identified 
with at least two unique peptides). The number of protein identifications in each 
analysed group are shown in Figure 2a. The number of DE proteins in 2-way 
contrasts is shown in Table 1 and multivariate 2-way comparisons of protein profiles 
shown in Figure 2b. Unsupervised multivariate analysis (PCA) demonstrated clear 
variance between groups in the 4-way analysis (Figure 3a). 
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Figure 2. (A) Venn diagram of protein identifications for each analysed group. A 
minimum of 2 unique peptides were required for protein identification, with a 1% 
FDR correction applied. (B) Principal component analysis plots of healthy versus 
osteoarthritis (OA), healthy versus osteochondrosis (OC) and healthy versus sepsis 
(FDR < 0.05, > 2-fold change and identified with at least two unique peptides). 
Healthy (n=8), osteoarthritis (OA, n=4), osteochondrosis (OC, n=8), sepsis (n=7). 
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Table 1. Number of differentially expressed (DE) proteins in two-way comparisons. 
Contrast Number of Proteins DE Increased Decreased 
Healthy versus Sepsis 386 205 181 
Healthy versus OA 430 331 99 
Healthy versus OC 539 474 65 
OA versus Sepsis 53 22 31 
OC versus Sepsis 454 75 379 
OA versus OC 0 0 0 
 
Differentially expressed proteins were filtered to include proteins identified with two 
or more peptides, q < 0.05 and > 2-fold change in expression. Osteoarthritis = OA, 
Osteochondrosis = OC. 
Figure 3. Principal component analysis (PCA) and heat map analysis of healthy 
(n=8), osteoarthritis (OA, n=4), osteochondrosis (OC, n=8) and sepsis (n=7) synovial 
fluid samples. (A) Principal component analysis of proteins (FDR < 0.05, > 2-fold 
change and identified with at least two unique peptides) revealed the greatest 
variability was due to the type of arthropathy distinguished by shading (healthy; 
red, OA; green, OC; blue, sepsis; turquoise). (B) Heat maps of the top 100 
differentially expressed proteins show distinguishable profiles based on arthropathy 
type. Each column indicates a different sample group. Each row indicates one 
protein. Red shading indicates increased expression and blue decreased expression. 
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7.4.3. Canonical Pathways and Network Analysis of Osteoarthritis, 
Osteochondrosis and Sepsis Synovial Fluid 
Canonical pathway analysis was undertaken on differentially abundant synovial 
proteins comparing either OA, OC or sepsis to healthy. When comparing sepsis and 
healthy samples, it revealed the predicted upregulation of coagulation system (p = 
7.94 x 10-23), acute phase response signalling (p = 3.98 x 10-19), LXR/RXR activation 
(p = 2.51 x 10-17), extrinsic and intrinsic prothrombin activation pathways (p = 2 x 10-
16 and p = 1 x 10-14), complement system (p = 3.16 x 10-11), neuroprotective role of 
THOP1 in Alzheimer’s disease (p = 1.55 x 10-6) and OA pathway (p = 7.08 x 10-6); and 
downregulation of inhibition of matrix metalloproteases (p = 2.51 x 10-15) (Figure 
4a). Pathway analysis of OA versus healthy demonstrated upregulation of the 
coagulation system (p = 5.01 x 10-17), complement system (p = 1.58 x 10-16), extrinsic 
and intrinsic prothrombin activation pathways (p = 5.01 x 10-12 and p = 2 x 10-11) 
(Figure 4b). Comparison of differentially abundant proteins in OC compared to 
healthy samples demonstrated an upregulation in complement system (p = 2 x 10-
16) and RhoGDI signalling (p = 5.62 x 10-9) (Figure 4c). Downregulated canonical 
pathways of OA and OC versus healthy had a substantial overlap including acute 
phase response (OA: p = 6.31 x 10-15, OC: p = 7.94 x 10-11), EIF2 signalling (OA: p = 
7.94 x 10-15, OC: p = 1.26 x 10-23), actin cytoskeleton signalling (OA: p = 7.94 x 10-13, 
OC: p = 1 x 10-12), regulation of eIF4 and p7056K signalling (OA: p = 7.94 x 10-13, OC: 
p = 3.98 x 10-15), mTOR signalling (OA: p = 1.58 x 10-11, OC: p = 3.16 x 10-13), 
leukocyte extravasation signalling (OA: p = 3.98 x 10-11, OC: p = 3.98 x 10-11), 
signalling by Rho family GTPases (OA: p = 2.82 x 10-10, OC: p = 1.82 x 10-9), p7056K 
signalling (OA: p = 8.91 x 10-9, OC: p = 1.15 x 10-9) and protein kinase A signalling 
(OA: p = 1.02 x 10-8, OC: p = 4.9 x 10-8). IGF-1 signalling (p = 3.16 x 10-11) and ephrin 
B signalling (p = 1.91 x 10-9) were downregulated pathways in OA only; and Fcy 
receptor-moderated phagocytosis in macrophages and monocytes (p = 1.91 x 10-10), 
production of nitric oxide and reactive oxygen species in macrophages (p = 2.88 x 
10-8) downregulated in OC only. 
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Figure 4. Canonical pathways of differentially abundant proteins in equine synovial fluid of (A) sepsis, (B) osteoarthritis and (C) osteochondrosis 
compared to healthy samples. Bars represent the significance of the canonical pathway, calculated by a right-sided Fisher’s exact test. The 
tallest bars represent the canonical pathways that are the least likely to have been identified due to random chance. Upregulated canonical 
pathways are shown in orange and downregulated pathways in blue. Ratio = number of proteins within the dataset mapping to the pathway 
divided by the total number of proteins within the pathway.
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Compared to healthy SF, septic SF exhibited upregulation in cellular movement, 
haematological system development, inflammatory response, cell-to-cell signalling 
and immune cell trafficking (Figure 5). This was in direct contrast to OA and OC in 
which these pathways were downregulated. Similarities between groupings of 
canonical pathways in OA and OC were identified. The groups of organismal injury 
and abnormalities, and cancer had the highest overlap in OA versus healthy and OC 
versus healthy. These were predicted to be upregulated in OA compared to healthy 
and further upregulated in OC versus healthy. 
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Figure 5. Heat map identifying canonical pathway groupings for molecular and cellular functions altered in equine synovial fluid of (A) sepsis, 
(B) osteoarthritis and (C) osteochondrosis compared to healthy. Squares are coloured according to their Z score, with orange upregulated in 
the disease state and blue downregulated, with the colour intensity indicating prediction strength. Z scores represent whether the up- or 
downregulation of the proteins within that function will lead to activation (positive Z score) or inhibition (negative Z score) of the function.  
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More detailed pathway analysis of differentially abundant proteins in healthy versus 
septic SF predicted the upregulation of immune response in cells (p = 1.45 x 10-3). 
The network of molecules included amyloid precursor protein (APP), 26s 
proteasome, LTF, DNM1L, HSP90, HSP90AA1, PIN1 and OTUB1 (Figure 6). 
Figure 6. Network involved in the immune response of cells mapped from the 
differential abundant proteins of septic equine synovial fluid. Red nodes represent 
greater protein abundance in sepsis; green nodes represent lower protein 
abundance in sepsis; and white nodes represent molecules mapped to this network 
but not present in the dataset. Orange arrows represent predicted activation, blue 
arrows predicted inhibition and yellow arrows indicate results inconsistent with the 
state of downstream molecules.    
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7.4.4. ELISA Validation of LTF and IGFBP6 
LTF ELISA assay results corroborated mass spectrometry findings with a statistically 
elevated abundance present within septic SF samples compared to all other groups 
(Figure 7). IGFBP6 ELISA results produced a similar trend to that identified via mass 
spectrometry; however, these results were not of statistical significance. 
 
 
Figure 7. ELISA validation of LC-MS/MS results for lactotransferrin (A and B) and 
insulin-like growth factor binding protein 6 (IGFBP6) (C and D). IGFBP6 normalised 
to total protein. LC-MS/MS, n=4-8/group, ELISA: n=5-6/group. * = p < 0.05, ** = p < 
0.01, *** = p < 0.001. OA = osteoarthritis, OC = osteochondrosis, n.s. = non-
significant. 
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7.5. Discussion 
Articular pathologies have an important clinical relevance in horses; however, to 
date the veterinary practitioner can find it difficult to achieve a timely diagnosis and 
prognostication of these conditions in horses affected by joint pathologies. This 
study has confirmed that SF protein concentration is associated with the type of 
arthropathy and has identified pathways and possible markers that may enable 
further understanding, together with rapid and accurate identification of these 
conditions in horses and potentially other species. For the first time the study of the 
proteomic profile of SF has identified potential SF markers of synovial sepsis. The 
proteomic profile can discriminate between septic and non-septic articular 
pathologies, and between non-septic conditions such as OC and OA. The 
implications highlighted by protein changes attributable to different pathways has 
increased our knowledge on articular pathophysiology.  
Within this study, elevated synovial levels of lactotransferrin (LTF) were identified 
within the sepsis group compared to the other pathologies. LTF, also known as 
lactoferrin, is an 80 kDa multifunctional glycoprotein, abundant in various biofluids, 
primarily transporting iron ions, but also exhibiting anti-microbial, anti-
inflammatory, and immune modulatory effects (Albar et al., 2014; Paramasivam et 
al., 2002; Ye et al., 2014). LTF provides anti-bacterial action against various bacterial 
species, inhibiting the growth of Staphylococcus epidermidis, antibiotic-resistant 
Klebseilla and Staphylococcus aureus in vitro and reducing blood and hepatic 
infection severity following Escherichia coli enteral infection in rats (Edde et al., 
2001; Nibbering et al., 2001; Pammi and Abrams, 2015; Valenti and Antonini, 2005). 
LTF is present within specific granules of neutrophils with elevations in LTF levels 
potentially representing a marker of neutrophil granulocyte activation (Afeltra et 
al., 1997). LTF levels within human SF have been found to be closely correlated to 
the level of SF neutrophilia, indicating the degree of inflammatory response 
(Bennett and Skosey, 1977). Various studies on SF from RA patients have identified 
increased synovial levels of LTF (Abbink et al., 1991; Caccavo et al., 2003; Decoteau 
et al., 1972). LTF has been found to activate expression of bone morphogenetic 
protein 7 (BMP7) within porcine articular chondrocytes, through the mitogen-
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activated protein kinase ERK pathway (Zhang et al., 2013). As BMP7 has an 
important role in maintaining homeostasis of articular cartilage, the authors 
propose LTF exhibits a protective function following inflammation within the joint. 
During synovial sepsis, there is an upregulation of collagen catabolism due to an 
increased cytokine concentration leading to the release of matrix 
metalloproteinases (Shirtliff and Mader, 2002). Thus, following synovial sepsis the 
release of LTF from neutrophil granulocytes may have a multi-functional role, both 
providing a direct antibacterial function and enabling a degree of 
chondroprotection. Clinically, LTF diet supplementation of neonates has 
demonstrated an ability to reduce the occurrence of late onset sepsis (Baveye et al., 
1999; Baynes and Bezwoda, 1994; Kruzel et al., 2002; Pammi and Abrams, 2015). 
However, elevations in synovial LTF levels have not previously been identified as a 
marker of synovial sepsis. 
In this study, reduced SF IGFBP6 was identified within the sepsis group compared to 
other joint pathologies. This protein is involved in cartilage and bone homeostasis 
but is also expressed in the synovium, particularly in RA versus OA in people 
(Alunno et al., 2017). IGFBP6 is a 30 kDa protein which is secreted into extracellular 
regions where it can subsequently interact with insulin growth factors (IGFs). 
IGFBP6, unlike other IGFBPs, binds to IGF2 with higher affinity than IGF1, inhibiting 
IGF2 activity (Aboalola and Han, 2017). IGFBP6 has previously been identified in 
human SF, with synovial levels decreased in RA compared to OA (Alunno et al., 
2017). Postoperative sepsis significantly alters the growth hormone/IGF axis, 
reducing GH-dependent molecule secretion (i.e. IGFBP3) and increasing GH-
independent molecule secretion (i.e. IGFBP6) (Nedic et al., 2013). However, 
decreased levels of synovial IGFBP6 have not previously been identified for synovial 
sepsis in horses. IGFBPs are known regulators of insulin resistance, with increased 
serum IGFBP6 levels identified within type 1 diabetes, and thus high systemic 
glucose (Lu et al., 2012). Reduced synovial glucose concentrations is a known 
clinical parameter associated with synovial sepsis (Anderson, Phelan, et al., 2018). 
Thus, the localised reduced abundance of IGFBP6 may be reflective or the 
decreased synovial glucose levels. 
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Protein differences were greatest between synovial sepsis and other groups, 
probably reflecting the more distant pathological pathways implicated. Pathway 
analysis of DE proteins in sepsis compared to healthy revealed upregulation of 
several canonical pathways including the coagulation system, acute phase response 
signalling and complement system. Systemic inflammation results in activation of 
coagulation, due to tissue factor-mediated thrombin generation, downregulation of 
physiological anticoagulant mechanisms, and inhibition of fibrinolysis (Levi et al., 
2003). In healthy SF, coagulation proteins have a low abundance with the elevated 
SF levels identified within sepsis in our study probably due to thrombin activation 
and coagulation, also reported in inflamed human joints (So et al., 2003). In an 
equine model of joint inflammation, changes in fibrinogen and 
thrombin/antithrombin have also been reported (Andreassen et al., 2017). The 
upregulation in sepsis of the acute phase response signalling pathway supports 
findings of our group, and others, that acute phase proteins such as serum amyloid 
A increase in equine joint sepsis (Jacobsen and Kjelgaard-Hansen, 2008; Robinson et 
al., 2017). 
The upregulation of the complement system in joint sepsis is not unexpected. The 
complement system is one of the key players in the defence against infections 
(Blom, 2017). Its activation during the innate immune response leads to the 
generation of several proteins that contribute to the lysis and opsonisation of 
microorganisms, regulate inflammatory reactions and bridge innate immunity with 
the subsequent adaptive immune response. Depletion in the complement system in 
animal models increases the severity of septic arthritis (Sakiniene et al., 1999). 
Interestingly, eukaryotic translation initiation factors (EIF2) and mTOR signalling 
were downregulated pathways in both OA and OC compared to healthy SF. OC is a 
juvenile osteoarticular disorder affecting several mammalian species. In horses, it is 
a multifactorial disease with focal disruption of endochondral ossification leading to 
the development of osteoarticular lesions (Olsson and Reiland, 1978). Nevertheless, 
OC pathophysiology is poorly understood. Protein synthesis requires cooperation 
among a large number of polypeptides including ribosomal proteins, modification 
enzymes and ribosome associated translation factors. The initiation phase of 
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protein synthesis requires a set of EIFs. A reduction in these proteins in OA and OC 
is interesting as in both conditions there is an imbalance between cartilage protein 
anabolism and catabolism leading to a net loss of cartilage. However, there is an 
increase in mTOR in end-stage OA with mTOR important in maintaining cartilage 
homeostasis (Zhang et al., 2015). Furthermore, signalling through mTOR is an 
important link between synovitis and structural damage in inflammatory arthritis 
(Cejka et al., 2010). In OA and OC, proteins in the SF in our study may be derived 
from cartilage, subchondral bone or synovium. Further studies are required to 
determine the relevance of these changes at the SF proteome level to the 
pathogenesis of these diseases since mTOR inhibition protects cartilage from 
experimental OA (Olsson and Reiland, 1978). 
Using IPA we have identified a number of proteins requiring further investigation as 
potential biomarkers of disease and/or therapeutic targets. For example, Nuclear 
factor (erythroid-derived 2) (NFE2L2) was identified as the most significantly 
inhibited upstream regulator in OC. Interestingly, although also identified as a 
potential upstream inhibitory regulator in OA, the effect in OC was much more 
significant. This master regulator of redox homeostasis regulates the expression of 
antioxidant proteins that protect against oxidative damage triggered by injury and 
inflammation. It has a potentially protective role in joint inflammation and 
degeneration (Maicas et al., 2011). We have therefore identified a catalogue of 
proteins for future studies. 
Healthy SF samples were collected following euthanasia whilst samples from the 
pathological groups were predominantly collected from live horses during clinical 
examination. Thus, it cannot be ruled out that differentially abundant proteins 
identified within the healthy group may be resultant of post mortem change. 
However, post mortem processing took place within 12 hours of euthanasia and 
therefore the impact on the synovial proteome is likely to be minimal. Due to the 
limited sample sizes included within this study, SF aspirated from various joints was 
included. However, despite the inclusion of analysis of SF from multiple sites, the 
clear separation identified in the proteomic profiles of different joint diseases 
strengthens the conclusion that the differentially expressed proteins are resultant 
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of the joint pathology opposed to joint location. Additionally, horses with different 
pathologies investigated within this study may experience changes in management, 
including diet and exercise, which may subsequently influence synovial protein 
composition. However, these systemic effects are likely to have a limited effect on 
the synovial proteome compared to the more significant impact of local joint 
pathology. 
Within this study, ELISA validations of LTF and IGFBP6 synovial abundances were 
undertaken on the same samples as those used for mass spectrometry analysis due 
to limited availability of additional SF samples. Thus, to confirm the results of this 
study identifying these as potential synovial sepsis markers, further validation needs 
to be undertaken using an independent cohort before these proteins are 
investigated further. 
7.5.1. Conclusion 
This study has identified that the equine SF proteome exhibits distinctive profile 
changes between OA, OC, synovial sepsis and healthy joints. Elevated synovial 
abundance of LTF and decreased IGFBP6 were both found to distinguish synovial 
sepsis from all other study groups. Thus, these protein markers may have a future 
role in clinical practice to enable an earlier and reliable diagnosis of synovial sepsis.  
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7.9. Supplementary Information 
Supplementary Table 1. Further Clinical Characteristics of Group Patients. 
 
Abbreviations: Joint, TC = Tarsocrural, IC = Intercarpal, DIP = Distal interphalageal, 
MCP = Metacarpophalangeal, MTP = Metatarsophalangeal, FP = Femoropatellar, 
MFT = Medial femorotibial (stifle - corresponds with the 'human knee'), Shoulder = 
Corresponds to the 'human' Glenohumeral joint, L = Left, R = Right, F = Forelimb, H = 
Hindlimb, U = Unknown; Sex, F = Female, M = Male, U = Unknown.
Group Left/Right  
Fore/Hind 
Limb 
Joint Age Sex Breed 
Sepsis 
R H TC 3 years 0 months F Thoroughbred 
R H TC 15 years 1 months M Thoroughbred 
L F IC 14 years 0 months M Arab 
L F DIP 16 years 0 months F Irish Sports 
L F DIP 19 years 11 months M Cob 
L H MTP 11 years 0 months M Thoroughbred 
R H TC 6 years 0 months M Irish Sports 
Osteochondrosis 
L H TC 5 years 3 months M Sports horse 
R H TC 8 years 0 months M Warmblood 
R H TC 5 years 5 months M Arab 
L H TC 6 years 2 months M Arab Cross 
L H FP 5 years 5 months F Apaloosa 
R H TC 7 years 0 months M Dutch Warmblood 
R F MCP 7 years 4 months M Warmblood 
L H MFT 6 years 0 months F Cob 
Osteoarthritis 
R F Shoulder 8 years 9 months M Welsh D 
R H TC 13 years 5 months F Irish Sports 
R H FP 9 years 7 months M Irish Sports 
R F MFT 8 years 0 months M Welsh D 
Healthy 
U F MCP 5 years 0 months M Thoroughbred 
U F MCP 16 years 0 months M Thoroughbred 
L F MCP 8 years 0 months U Thoroughbred 
L F MCP 3 years 0 months U Thoroughbred 
U F MCP 8 years 0 months U Unknown 
U F MCP 8 years 0 months U Unknown 
U F MCP 18 years 0 months U Unknown 
U F MCP 4 years 0 months U Unknown 
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8. General Discussion 
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common 
arthropathies in people, causing limited mobility, pain and subsequent reduction in 
quality of life, resulting in a substantial impact on human society (Fusco et al., 
2017). Conditions affecting articular joints are also common in horses, including OA, 
osteochondrosis (OC) and synovial sepsis (Caron and Genovese, 2003; Summerhays, 
2000). Despite their high prevalence and clinical relevance, diagnosis, staging, 
monitoring and determination of an accurate prognosis remain a challenge 
(Anderson, Phelan, et al., 2018). Thus, there is a need to identify reliable biomarkers 
of disease. The development of ‘omics’ technologies, such as metabolomics and 
proteomics, has provided global analysis of biological tissues and fluids, enabling 
discovery of potential disease biomarkers as well as providing a greater 
understanding of their underlying pathogenesis (Carlyle et al., 2018; Wang, Zhang, 
et al., 2012). This thesis has optimised collection and processing protocols for 
analysis of synovial fluid (SF) using nuclear magnetic resonance (NMR) led 
metabolomics and mass spectrometry (MS) led proteomics. Human OA and RA SF 
metabolomes were compared using NMR, equine OA stratified via NMR 
metabolomic and MS proteomic SF analysis, equine SF metabolite and protein 
profiles compared between septic and common nonseptic joint pathologies and 
NMR metabolomic and MS proteomic analysis undertaken on an ex-vivo equine 
cartilage OA explant model. 
8.1. Synovial Fluid Collection and Processing Optimisation 
NMR and MS approaches provide comprehensive metabolite and protein/peptide 
profiling of complex biological samples respectively (Beckonert et al., 2007; Beltran 
et al., 2012; Hsueh et al., 2014; Mahendran et al., 2017). However, the large protein 
concentration dynamic range present within SF leads to various challenges 
associated with proteome analysis (Puangpila et al., 2015). ProteoMinerTM protein 
enrichment columns contain beads bound to randomised hexapeptides which, 
following saturation, compress the protein concentration dynamic range of complex 
biological samples (Fonslow et al., 2011; Righetti and Boschetti, 2008). However, to 
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date, there are no agreed standardised published protocols available for collection 
and processing of SF for these platforms with reproducibility of on-bead digestions 
of ProteoMinerTM columns, yet to be investigated. 
This thesis has identified that for optimal reproducibility of SF NMR metabolomics 
analysis, SF should first be centrifuged at 2,540g and 4°C for 5 min and then snap 
frozen in liquid nitrogen. For proteomic analysis, treatment of SF with 1 µg/ml 
hyaluronidase and rotational incubation at 37°C for 1 hr provided sufficient 
enzymatic activity to enable efficient centrifugation through a 0.22 µm pore 
cellulose acetate membrane. Lys-C endopeptidase pre-digestion greatly improved 
on-bead tryptic protein digestion when used in conjunction with small-capacity 
ProteoMinerTM column kits for low abundant protein enrichment, resulting in a 
reduction of undigested proteins bound to ProteoMinerTM beads, a reduction in the 
number of peptide missed cleavages, improved reproducibility of tryptic peptide 
quantification and an increased number of protein identifications. To maximise 
protein identifications using ProteoMinerTM columns, a 4hr Lys-C pre-digestion + 
16hr tryptic digestion followed by a 2hr trypsin supplementation would be 
recommended. For semi-tryptic peptide identification, a 16hr + 2hr tryptic digestion 
of native SF and a 4hr on-bead tryptic digestion were found to be the most 
reproducible. The optimised protocols examined during this thesis can subsequently 
be used for future SF NMR-led metabolomics and LC-MS/MS-led proteomic studies 
to ensure high levels of technical reproducibility, enabling more reliable results and 
maximising the value of SF samples and instrument time available. 
Due to silver stain analysis of tryptic digests of native SF indicating complete protein 
digestion, the effect of Lys-C endopeptidase pre-digestion in conjunction with 
tryptic digestion of native SF was not investigated. Thus, following on from this 
work, it may be of interest to investigate this further as Lys-C pre-digestion may 
improve native SF digestion reproducibility and increase the number of protein 
identifications. Additionally, Lys-C pre-digestion may improve proteomic analysis of 
culture media e.g. when used in conjunction with ex-vivo cartilage cultures. 
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8.2. Osteoarthritis Stratification - Metabolomics and Proteomics 
To assess the stratification of OA according to the SF metabolome and proteome, 
two sample sets were analysed. The University of Liverpool biobank SF was 
obtained from a commercial abattoir with horses sampled of mixed breed and sex 
and representing naturally occurring OA. Hong Kong Jockey Club (HKJC) SF samples 
were exclusively from Thoroughbred racehorses with a high prevalence of 
palmar/plantar osteochondral disease (POD), providing a model for subchondral 
bone mediated OA. OA stratification of post mortem equine SF according to its 
metabolome was limited, with unsupervised multivariate analysis of biobank 
samples not indicating any separation according to microscopic or macroscopic OA 
scoring. However, when stratified according to macroscopic grade, glutamate levels 
were found to be differentially abundant, with lower levels identified at higher OA 
grades. For the HKJC cohort, when stratified according to macroscopic OA 
pathology, three metabolites were found to be differentially abundant, with 2-
aminobutyrate, alanine and creatine levels increasing with OA severity. 
When assessing the SF proteome, for both the biobank and HKJC groups, when 
categorised according to macroscopic OA severity, principal component analysis 
(PCA) identified that increased OA severity resulted in less variation between 
samples, indicating that OA is driving the SF OA proteome. For the biobank cohort, 
eight proteins discriminated between OA severities including immunoglobulin 
kappa constant and lipopolysaccharide binding protein (LBP) which decreased with 
increasing OA severity and apolipoprotein A1 which increased for mild and 
moderate OA grades.  
LBP is an endogenous protein which binds to lipopolysaccharides and catalytically 
delivers monomeric liposaccharides to cluster of differentiation 14 (CD14) protein 
(Citronberg et al., 2016; Ranoa et al., 2013). Recently, increased plasma LBP levels 
have been described to predict knee OA progression (Huang et al., 2018). It has 
previously been identified that mononuclear cell activation, induced by 
lipopolysaccharides, is enhanced by low LBP concentrations (Lamping et al., 1998). 
Activation of monocytes and macrophages by lipopolysaccharides leads to the 
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secretion of tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), two pro-
inflammatory cytokines which are central to OA pathogenesis (Schumann et al., 
1994; Wojdasiewicz et al., 2014). Thus, decreasing synovial LBP levels may have a 
role in OA development. With CD14 also identified as a key variable within the 
biobank and HKJC combined model, this provides further support that this pathway 
is involved in equine OA pathogenesis. 
Elevations of apolipoprotein A1 have previously been identified in OA SF of horses 
and dogs (Chiaradia et al., 2012; Shahid, 2018). Apolipoprotein A1 is the primary 
protein component of high density lipoproteins (HDLs) and involved in HDL binding 
to adenosine triphosphate (ATP)-binding cassette (ABC) transporters as well as 
being a lecithin cholesterol acyl transferase cofactor (Luc et al., 1996; Rader, 2003; 
Ramella et al., 2018; Silver et al., 2001). Apolipoprotein A1 has been found to 
induce the expression of interleukin-6, matrix metalloproteinase (MMP)-1 and 
MMP-3 in chondrocytes and synoviocytes through toll-like receptor 4 with the same 
study identifying a dissociation between the relationship of apolipoprotein A1 and 
HDLs in OA SF (de Seny et al., 2015). Thus, this study provides further evidence that 
OA is a metabolic syndrome with disruption of lipid homeostasis due to alterations 
to apolipoprotein activity (de Seny et al., 2015). 
Within the HKJC cohort, gelsolin abundance decreased with OA severity. This result 
is supported by a mouse model whereby gelsolin knockout mice resulted in arthritis 
exacerbation (Aidinis et al., 2005). Additionally, within a mouse model of pain and 
acute inflammation, exogenous delivery of gelsolin was identified to have effective 
analgesic and anti-inflammatory properties (Gupta et al., 2015). Exogenous gelsolin 
administration has also been shown to have chondroprotective properties, 
nullifying the effect of IL-1β and OA SF on anabolic gene expression and increased 
glycosaminoglycan deposition in chondrocytes and protection of the integrity of 
murine cartilage following intra-articular injection (Kaneva et al., 2017). Therefore, 
gelsolin has potential as a biomarker of equine OA as well as an OA therapeutic 
target, and potential analgesic. 
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Although both the biobank and HKJC datasets produced a degree of OA 
stratification, markers of interest were generally distinct. This may be reflective of 
the more severe OA phenotype demonstrated by the HKJC horses, whilst markers 
identified within the biobank represented a subtler grade of OA. Alternatively, the 
differences in markers identified may be due to the varying OA aetiologies, with the 
biobank representing a naturally occurring OA whilst the HKJC horses demonstrated 
a POD model for subchondral bone mediated OA, which is associated with trauma 
and overload (Barr, 2010). Additionally, the biobank cohort was on average an 
older, mixed breed donor group compared to the younger, Thoroughbred HKJC 
cohort which may also account for differences between the datasets. 
Both metabolomic and proteomic multivariate analysis of longitudinal culture 
media samples following TNF-α and IL-1β treatment of ex-vivo equine cartilage 
identified discrete groupings between control and treatment groups. This was 
evident for all analysed time points. Overall, the top five metabolites and proteins 
driving this discrimination were alanine, glutamate, pyroglutamate, citrate and 
glutamine and cartilage oligomeric matrix protein, fibronectin, enolase 1, 
thrombospondin and collagen X α 1 respectively. This model identified changes in 
the abundance of various molecules which were consistent with collagen 
degradation. Isoleucine was elevated within media during the latter stages of the 
model with elevated isoleucine levels previously reported within SF of a canine OA 
model and human OA serum (Damyanovich et al., 1999; Zhai et al., 2010). Borel et 
al. previously identified elevations of peaks within 1H High resolution magical angle 
spinning NMR spectra of OA cartilage which could be attributed to isoleucine (Borel 
et al., 2009). Thus the elevations seen in isoleucine may be reflective of cartilage 
collagen breakdown (Zhai et al., 2010). However, within this study, although a 
higher abundance was recorded for isoleucine in treated compared to control 
cartilage, this did not reach statistical significance. However, elevations in glutamate 
were identified within culture media at 3-5 days, which may be resultant of the 
catabolism of collagenous proline through proline oxidase (Phang et al., 2015). 
Reduced levels of collagen type VI α 2 chain and collagen type X α 1 chain were 
identified at 3-5 and 6-8 days following cytokine treatment. This may reflect a 
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reduction in collagen synthesis which has previously been identified within other 
collagen types following TNF-α/IL-1β stimulation (Stevens et al., 2009). Therefore 
these results provide evidence of a disruption in collagen homeostasis and suggest 
that collagens are being degraded within the model sooner than the 14-28 days 
previously reported within other ex-vivo cartilage OA models (Milner et al., 2001, 
2006). 
Although the TNF-α/IL-1β ex-vivo equine cartilage OA model identified a number of 
molecules of interest which were consistent with the equine OA SF samples, there 
were some discrepancies in the trends identified for these molecules between the 
experiments. The TNF-α/IL-1β model has become an established model for 
investigating OA pathology within ex-vivo studies, with elevations in TNF-α and IL-
1β regularly identified within OA SF, although this model requires further 
refinement (Westacott et al., 1990; Williams, 2014). Cartilage explant experiments 
allow investigation of chondrocytes in situ within their natural extracellular matrix 
(ECM) environment, although a limitation can be cell death at the edge of the 
explant (Johnson et al., 2016). As OA is a disease of the whole joint, an 
improvement to this model would be to replace ex-vivo cartilage explants with 
osteochondral (cartilage and bone) plugs, treated with TNF-α/IL-1β or OA SF, to 
retain subchdrondral bone/cartilage communication (Cope et al., 2019). 
8.3. Human Osteoarthritis and Rheumatoid Arthritis 
1D 1H NMR spectroscopy of human SF was able to discriminate between OA and RA 
according to their metabolome. The metabolic pathways that differed the most 
between these two forms of arthritis were glycolysis, amino acid biosynthesis and 
taurine and hypotaurine metabolism. In general, metabolites of glycolysis and the 
tricarboxylic acid (TCA) cycle were higher in OA compared to RA, concurring with 
the higher levels of inflammation, synovial proliferation and hypoxia identified in RA 
compared to OA. Levels of taurine were also higher in OA indicating increased 
subchondral bone sclerosis in comparison to RA. Previously, one limiting factor of 
NMR spectroscopy of SF has been the minimum volume required for analysis, with 
difficulties in analysing SF from normal human joints in which < 200 μl can be 
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aspirated (Naughton et al., 1993). Using the methods described within this thesis, it 
has been demonstrated that analysable and reproducible 1H NMR spectra can be 
produced from just 100 μl of SF, thus increasing the potential applications of this 
technique when sample volume is limited. 
8.4. Synovial Sepsis 
This thesis has identified a panel of metabolites and proteins within equine SF 
which are able to distinguish synovial sepsis from other joint pathologies. Although 
reduced glucose abundance was the principal metabolite discriminant, a partial 
least squares discriminant analysis (PLS-DA) model with glucose removed revealed 
there to still be a modest separation between septic and nonseptic disease groups, 
thus indicating the differentiated metabolomes are driven by a panel of metabolites 
(potential septic markers) opposed to glucose alone. 
Pathway analysis was not conducted on the metabolomic dataset as the number of 
differentially abundant metabolites was relatively small (thirteen) and subsequently 
this analysis was deemed unreliable. However, undertaking further computational 
analysis, combining the metabolomic and proteomic datasets (as in chapter 3) 
would complement the analysis already undertaken within this thesis, identifying a 
focused, combined synovial sepsis panel which is the most significant in 
discriminating disease groups as well as strengthening pathway analysis. 
Additionally, further ‘omics’ investigations, i.e. transcriptomics and lipidomics, of 
the same sample set would substantiate this work further. 
The identified metabolite and protein synovial sepsis panel may also have 
translational potential to aid diagnosis in human medicine. However, in people, as 
RA is a risk factor for septic arthritis, joint infections complicate RA with diagnosis 
often delayed, resulting in increased morbidity and mortality (Al-Ahaideb, 2008; 
Goldenberg, 1989). Thus, septic markers would need to be able to discriminate 
septic joint pathology from autoimmune disease. As autoimmune joint disease was 
not a comparative study group to equine synovial sepsis within this thesis, as this is 
not diagnosed or considered to occur in horses, and human sepsis SF was 
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unavailable for comparison to human OA and RA SF, it is currently unknown 
whether this panel of molecules would be able to discriminate RA from sepsis. Thus, 
further analysis would need to be carried out on human SF with these associated 
pathologies in order to qualify this. 
8.5. Alanine 
Elevated levels of alanine have previously been identified within OA SF of both dogs 
and horses (Damyanovich et al., 1999; Lacitignola et al., 2008). As alanine is one of 
the main amino acid residues which constitutes collagen, it is likely that increased 
alanine abundance identified within OA SF is resultant of degradation of the 
cartilage collagen framework, subsequently releasing alanine into the surrounding 
SF (Huster et al., 2004; Shet et al., 2012). This is supported by another study, using 
high resolution magic angle spinning NMR spectroscopy, identifying depleted 
alanine abundance within human OA cartilage (Shet et al., 2012). These results are 
supported by this thesis within chapters 3, 4, 5 and 6. 
8.5.1. Equine Osteoarthritis Stratification - Alanine 
Stratification of equine OA using SF for the HKJC dataset identified increasing 
alanine levels with increased severity. Although univariate analysis for the biobank 
dataset did not identify elevated levels of alanine with increasing OA severity, 
computational analysis integrating both proteomic and metabolomic datasets 
identified alanine to be the third most important variable driving the model. 
Additionally, combining metabolomic and proteomic datasets for both the biobank 
and HKJC datasets via discriminant analysis of principal components (DAPC) 
modelling identified alanine to be the third most important discriminant for linear 
discriminant 1. 
Metabolite extraction of ex-vivo equine cartilage following 8 day TNF-α and IL-1β 
treatment identified reduced levels of alanine compared to control samples, with 
alanine the fourth most influential variable during supervised multivariate analysis, 
supporting the previous work by Shet et al. (Shet et al., 2012). Over the same 
period, within associated culture media, alanine abundance was found to be the 
  
261 
 
most important variable in discriminating control from treated samples. However, 
unexpectedly, decreased alanine abundance was identified within treated culture 
media compared to control samples at all analysed time points. This may be due to 
the highly inflammatory environment of the TNF-α and IL-1β model leading to 
further degradation of alanine, particularly given the greater discrepancy between 
alanine abundances at later time points. It would therefore be of interest to repeat 
this study, applying TNF-α and IL-1β treatments separately to identify whether this 
has an effect on alanine media levels. 
8.5.2. Equine Synovial Sepsis vs Nonseptic Synovial Fluid - Alanine 
Elevated levels of alanine were identified within nonseptic articular pathology (OA 
and OC) SF compared to septic SF. Additionally, with the principal septic metabolite 
discriminator glucose removed from supervised multivariate analysis, alanine was 
identified as the sixth most important variable in discriminating between these two 
groups. However, this study was unable to separate OA and OC based on their 
synovial metabolome, restricted by the low sample number. Therefore, higher 
powered studies are required to identify whether the SF metabolome, in particular 
alanine, is able to distinguish OA from OC. 
8.5.3. Human Osteoarthritis vs Rheumatoid Arthritis Synovial Fluid - Alanine 
Elevated alanine levels were identified within human OA SF compared to RA with 
the ‘alanine, aspartate and glutamate metabolism’ pathway identified as 
differentially altered between the conditions. Additionally, many other amino acids 
which feed into glycolysis and the TCA cycle were higher in OA, including tyrosine, 
glutamine, proline, histidine, asparagine and taurine. Previously, a study of urine 
metabolomics identified altered TCA cycle activity in OA, hypothesising this was 
resultant of changes to cartilage metabolism, with glycolysis constituting 95% of 
chondrocyte energy production (Heywood et al., 2010; Li et al., 2010). 
Although degradation of articular cartilage is present within both OA and RA, with 
overlap in the molecular mechanistic steps leading to cartilage ECM destruction, 
different pathways are also involved (Pap and Korb-Pap, 2015). Within OA, cartilage 
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damage leads to and combines with inflammatory processes resulting in altered 
chondrocyte phenotype and expression of ECM-degrading enzymes. During RA, 
fibroblast-like synoviocytes are activated, invade and breakdown ECM with 
resultant inflammatory molecules stimulating further fibroblast-like synoviocyte 
activity. Thus, these different cartilage breakdown mechanisms may result in 
differences in which alanine is first released into the SF as well as subsequently 
degraded. Therefore, chapter 5 has provided further evidence that elevated alanine 
SF levels may aid OA diagnosis and differentiation from other articular pathologies. 
Overall, the results from this thesis have identified that alanine has potential as a 
diagnostic aid for OA and as a marker of OA severity to assist stratification. 
8.6. Neopeptides 
Increased activity of MMPs, a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS), cathepsins and serine proteases during OA leads 
to cartilage breakdown and the generation of OA-specific peptide degradation 
products (neopeptides) (Ben-Aderet et al., 2015; Peffers et al., 2016; Polur et al., 
2010). Proteomic analysis of culture media within the ex-vivo equine cartilage TNF-
α/IL-1β OA model identified various potential novel biomarkers of early OA, 
including neopeptides generated from aggrecan, cartilage intermediate layer 
protein, vimentin and collagen type VI α 2 chain. 
Although univariate analysis of equine SF did not identify any differentially 
abundant neopeptides, for the HKJC cohort, the semi-tryptic profile was most 
consistent between samples in the groups with the most severe OA and synovitis 
pathology. This suggests, as expected, the OA phenotype is driving the semi-tryptic 
peptide profile, most likely due to an increase in enzymatic activity leading to ECM 
degradation fragments (Lotz et al., 2013). However, this was not evident within the 
biobank SF sample set. This may be because OA pathology identified within this 
group was far subtler than that identified within the HKJC samples and thus the 
level of pathology present was not severe enough to drive a global change within 
the semi-tryptic peptide profile. 
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As the ex-vivo equine cartilage OA model neopeptides were not identified as 
differentially abundant within equine SF of different OA severity grades, it would be 
of interest to use a targeted MS approach to undertake absolute quantification via 
multiple reaction monitoring (MRM) using a triple-quadrupole mass spectrometer 
to validate these findings within the culture media (Parker and Borchers, 2014). 
Additionally, the more targeted MRM approach could also be applied to the SF 
samples, to quantify these semi-tryptic peptides of interest which may not have 
been quantified during analysis of the global proteome. 
8.7. Uncharacterised Proteins 
Proteomic analysis of equine SF identified several proteins which were able to 
discriminate a healthy phenotype from early OA changes. Although these proteins 
were largely uncharacterised, basic local alignment search tool (BLAST) analysis of 
the amino acid sequences of three uncharacterised proteins (F6TED1, H9GZU9 and 
H9GZS6), decreasing in abundance with OA severity, identified high levels of 
similarity to immunoglobulin gamma 1 heavy chain constant region and 
immunoglobulin kappa chain V-III region MOPC 63 proteins. However, this could be 
taken further by conducting 3D computational modelling of these proteins to help 
confirm function and potential interactions with other proteins/molecules, as well 
as undertaking solid-state NMR (Zhao, 2011). 
8.8. Equine Osteoarthritis Pathway Analysis 
8.8.1. Complement and Coagulation Cascades 
KEGG (Kyoto Encyclopedia of Genes and Genomes) protein pathway analysis, 
applied when stratifying equine OA using post mortem SF, identified the 
‘complement and coagulation cascades’ pathway to be altered during OA 
pathology. This was supported by Ingenuity Pathway Analysis of differentially 
abundant proteins between clinical OA and healthy equine SF collected from live 
horses in which the ‘coagulation system’ and ’complement system’ were the top 
two implemented pathways. Additionally, KEGG protein pathway analysis of culture 
media within the ex-vivo equine cartilage TNF-α/IL-1β OA model identified various 
proteins involved in the ‘complement and coagulation cascades’ pathway which 
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were differentially abundant between control and treatment groups. The 
complement system is an important component of the innate immune response, 
encompassing various roles including opsonisation initiation, pathogen 
phagocytosis, the inflammatory response and terminating within cell lysis (Horwitz 
et al., 2019; Silawal et al., 2018). However, there is a growing body of evidence 
which has identified a role of complement activation within OA pathogenesis, 
further supported by this thesis (Silawal et al., 2018). Complement has been 
identified to have a role in the degradation of cartilage ECM, synovitis and 
osteophyte formation, with complement split fragment C3a found to upregulate 
gene expression of TNF-α and IL-1β, pro-inflammatory cytokines central to OA 
pathogenesis (Silawal et al., 2018; Wojdasiewicz et al., 2014). Additionally, within 
this thesis, various equine synovial immunoglobulins were identified as being 
differentially abundant according to OA severity, with immunoglobulins known to 
regulate complement binding (Miletic and Frank, 1995). Therefore, targeting the 
complement cascade may provide a novel therapeutic target for OA treatment. 
Within experimental arthritis models, coagulation and fibrinolysis pathways are 
known to play a role within disease pathogenesis, with these cascades also found to 
be activated within both the joint and circulation of degenerative and inflammatory 
arthropathies (So et al., 2003). Within the synovium of patients diagnosed with OA, 
the coagulation factor fibrinogen is present throughout the tissue with elevations in 
tissue factor, a coagulation initiator, identified near endothelial cells (Weinberg et 
al., 1991). Previously, fibrinogen has been identified as a potential target for 
arthritis therapy, with removal of fibrinogen-leukocyte integrin receptor αMβ2 
interactions limiting inflammatory processes whilst maintaining normal fibrinogen 
coagulation function (Raghu and Flick, 2011). Thus, these pathways may also hold 
potential as a novel target for OA therapy.  
8.8.2. ABC Transporters 
Metabolite pathway analysis identified the ‘ABC transporters’ pathway to be altered 
during OA pathology when stratifying equine OA using post mortem SF and within 
the ex-vivo equine cartilage TNF-α/IL-1β OA model. ABC transporters utilise ATP 
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hydrolysis to import or export molecules across cell membranes (Rees et al., 2009). 
ABC exporters have an important role in the export of cholesterol, fatty acid and 
lipids from cells, with dysregulation of this pathway underlying numerous diseases. 
The Wnt/β-catenin signalling cascade, with a proposed central role within OA 
pathogenesis, has previously been identified as a regulator of ABC transporters 
(Takamatsu et al., 2014). Additionally, the ABC transporter MRP5 has been found to 
be the principal exporter of hyaluronan from its site of synthesis within the cell to 
the ECM (Schulz et al., 2007). 
8.9. Further Work 
8.9.1. Synovial Sepsis - Bacterial Species 
Whilst obtaining a diagnosis of synovial sepsis in horses, sensitivity of bacterial 
culture is low, with just 32% of septic SF samples resulting in a positive bacterial 
culture (Robinson et al., 2017; Taylor et al., 2010). Within this thesis, both 
metabolite and protein septic SF profiles were able to discriminate equine synovial 
sepsis from nonseptic articular pathologies. However, in order to take this work 
further, it would be of interest to identify whether the septic SF metabolome and 
proteome, when analysed either independently or collectively, are able to discern 
joint infections derived from separate microbiological species, their associated 
markers/molecular profiles and whether these profiles can be used to predict 
antimicrobial sensitivity. Thus, this may provide an additional diagnostic aid which is 
clinically applicable. 
8.9.2. Longitudinal Synovial Fluid Studies 
During this thesis, longitudinal culture media samples were analysed within the ex-
vivo equine cartilage TNF-α/IL-1β OA model. However, SF analysis was restricted to 
cross-sectional samples across each studied population with longitudinal SF samples 
unavailable. Therefore, in order to further the analysis of SF markers identified 
within this thesis, longitudinal samples taken at set time points during disease 
progression would confirm differential abundance of these markers during OA or 
synovial sepsis within individual horses. For OA stratification, these longitudinal SF 
samples could be aspirated during naturally occurring OA in addition to an 
  
266 
 
experimental OA model i.e. following carpal groove-defect surgery (Maninchedda et 
al., 2015). For synovial sepsis, longitudinal analysis may provide further information 
as to what stage of disease the identified septic markers’ abundances change. 
Additionally, longitudinal synovial sepsis SF samples may identify whether these 
markers can differentiate horses with continued lameness from a nonresolving 
sepsis compared to those with a resolving sepsis but ongoing significant 
inflammation, whether they can assess effectiveness of novel therapeutics and 
whether they have a role as a prognostic indicator. 
8.9.3. Monoclonal Antibodies 
Following MRM validation of OA-specific neopeptides of interest identified within 
the ex-vivo equine cartilage OA model, and additional MRM validation within 
stratified equine OA SF, the next step would be to develop/produce monoclonal 
antibodies using the methodology developed by Professor Bruce Caterson 
(Caterson et al., 1985). Additionally, monoclonal antibodies could also be developed 
for proteins/unique peptides of proteins which this thesis has identified as 
candidates for aids in equine OA stratification, e.g. immunoglobulin kappa constant 
and uncharacterised proteins F6TED1, H9GZU9 and H9GZS6. The production of 
these antibodies would subsequently have the potential to develop clinical 
‘bedside’ tests to assess OA severity, allowing a potentially more bespoke, timely 
and appropriate management protocol. 
8.9.4. Clinical Trials 
Before their potential use in clinical trials, markers of interest identified within this 
study, in particular for the stratification of equine OA and diagnosis of equine 
synovial sepsis, would need to undergo further validation and subsequently have 
clinically applicable assays developed. The assays developed for these markers may 
then have a potential role in investigating response to novel therapeutics, providing 
an earlier diagnostic aid and have a role as a prognostic indicator. 
8.9.5. Lipid Analysis 
A growing body of evidence is supporting the theory that disruption of lipid 
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homeostasis has a role to play in OA pathogenesis (de Seny et al., 2015). Alteration 
of lipid metabolism is associated with changes in membrane 
composition/permeability, gene expression and protein distribution and function, 
as well as in cellular functions such as cell growth, proliferation, differentiation, 
survival, apoptosis, and chemotaxis (Guma et al., 2016). Additionally, differential 
biofluid abundance of lipids has been identified between RA and OA, as well as 
healthy controls (Kang et al., 2015; Young et al., 2013). Within this thesis, 
apolipoprotein A1, apolipoprotein A2, apolipoprotein C2, enolase 1 and lipoprotein 
binding protein were found to be key discriminants between OA severity grades 
with mobile-lipids and metabolites involved in glycophospholipid metabolism 
(acetylcholine, acetate and sn-glycero-3-phosphocholine) key in distinguishing OA 
from RA. Therefore, for both conditions it would be of interest to further 
interrogate SF and serum, using both NMR and MS based approaches, to undertake 
lipidomic studies to further investigate lipid profiles. Additionally, with obesity a 
known risk factor for OA, it would also complement the work carried out within this 
thesis to undertake metabolomic, proteomic and lipidomic analysis of SF and serum 
of obese individuals and those with a healthy body mass index in order to further 
understand the underlying pathogenesis (Xia et al., 2014). 
8.9.6. Pain Markers 
Within SF proteomics, the identification of early biomarkers for orthopaedic 
pathologies has been a key objective, with markers which can predict clinical 
prognosis and monitor therapeutic effects growing areas of interest. In addition, an 
exciting potential area of research is the identification of protein biomarkers of 
musculoskeletal pain within SF (Peffers et al., 2019). Factors of interest include 
nerve growth factor, a neuromediator, which is likely to be a key regulator involved 
in inflammatory and neuropathic pain, and the neurotransmitter substance P, which 
has been suggested as a potential biomarker for pain in chronic equine OA joints 
(de Grauw, van de Lest, et al., 2006; Isola et al., 2011). This is an exciting area of 
research, which will undoubtedly develop over the coming years, potentially 
providing a panel of pain markers which may have potential to deliver a more 
bespoke, clinical analgesic therapeutic plan, identifying pain pathways implicated 
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for individuals, generating novel therapeutic targets for the next generation of 
analgesics, and a potential pain panel to quantifiably monitor the effectiveness of 
future analgesics. Additionally, within the equine field, this research area may play 
an important role in an earlier recognition of pain, identification of subclinical pain 
and subsequent improvements in quality of life and performance. 
8.10. Conclusion 
Within this thesis, protocols for collection and processing of SF for NMR 
metabolomic and LC-MS/MS proteomic analysis have been optimised. Lys-C 
endopeptidase pre-digestion was identified to greatly improve on-bead tryptic 
protein digestion when used in conjunction with small-capacity ProteoMinerTM 
column kits for low abundant protein enrichment. Equine OA was stratified using 
both metabolomic and proteomic SF profiles, identifying a panel of markers of 
interest which may be applicable to grading OA severity. This is the first study to 
undertake computational integration of NMR metabolomic and LC-MS/MS 
proteomic datasets. This thesis is also the first study to use a multi ‘omics’ approach 
to simultaneously investigate the metabolomic profile of ex-vivo cartilage and 
metabolomic/proteomic profiles of culture media using the TNF-α/IL-1β ex-vivo 
cartilage OA model. A panel of metabolites, proteins and neopeptides were 
identified which were differentially abundant within an early phase of this OA 
model and may provide further information on the underlying disease 
pathogenesis. A direct comparison of human SF from RA and OA identified that the 
metabolic pathways that differ most between these two forms of arthritis are 
glycolysis, amino acid biosynthesis and taurine and hypotaurine metabolism. This 
thesis has also identified a panel of metabolites and proteins within equine SF 
which are able to distinguish synovial sepsis from nonseptic joint pathologies, with 
glucose the principal metabolite discriminator.
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The synovial ﬂuid proteome diﬀerentiates between septic and nonseptic
articular pathologies
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A B S T R A C T
Articular conditions are common in horses and can result in loss of function, chronic pain and/or inability to
work. Common conditions include osteoarthritis, osteochondrosis and synovial sepsis, which can be life-threa-
tening, but despite the high clinical prevalence of these conditions, rapid and speciﬁc diagnosis, monitoring and
prognostication remains a challenge for practicing veterinarians. Synovial ﬂuid from a range of arthropathies
was enriched for low abundance proteins using combinatorial peptide ligand ProteoMiner™ beads and analysed
via liquid chromatography-tandem mass spectrometry. Changes in protein abundances were analysed using
label-free quantiﬁcation. Principle component analysis of diﬀerentially expressed proteins identiﬁed groupings
associated with joint pathology. Findings were validated using ELISA. Lactotransferrin (LTF) abundance was
increased in sepsis compared to all other groups and insulin-like growth factor-binding protein 6 (IGFBP6)
abundance decreased in sepsis compared to other disease groups. Pathway analysis identiﬁed upregulation of the
complement system in synovial joint sepsis and the downregulation of eukaryotic translation initiation factors
and mTOR signalling pathways in both OA and OC compared to the healthy group. Overall, we have identiﬁed a
catalogue of proteins which we propose to be involved in osteoarthritis, osteochondrosis and synovial sepsis
pathogenesis.
Signiﬁcance: Osteoarthritis, osteochondrosis and synovial sepsis, which can be life-threatening, are common
articular conditions in which rapid and speciﬁc diagnosis, monitoring and prognostication remains a challenge
for practicing veterinarians. This study has identiﬁed that the equine synovial ﬂuid proteome exhibits distinctive
proﬁle changes between osteoarthritis, osteochondrosis, synovial sepsis and healthy joints. Elevated synovial
abundance of lactotransferrin and decreased insulin-like growth factor-binding protein 6 were both found to
distinguish synovial sepsis from all other study groups. Thus, these protein markers may have a future role in
clinical practice to enable an earlier and reliable diagnosis of synovial sepsis.
1. Introduction
Articular conditions are common in horses and can result in loss of
function, chronic pain and/or inability to work, which are important
welfare concerns. The most common conditions include osteoarthritis
(OA), osteochondrosis (OC) and synovial sepsis, which can be life-
threatening [1]. Despite the high clinical prevalence of these condi-
tions, rapid and speciﬁc diagnosis, monitoring and prognostication re-
mains a challenge for practicing veterinarians, thus, identiﬁcation of
reliable biomarkers of disease is required. Synovial ﬂuid (SF) is in direct
contact with articular structures and represents an important source of
biomarker discovery. SF is located within the articular joint cavity,
providing a pool of nutrients for surrounding tissues but primarily
serving as a biological lubricant, containing molecules including hya-
luronan with low-friction and low-wear properties to articular surfaces
[2]. As SF is in close proximity to articular tissues primarily altered
during joint pathology, this bioﬂuid is an important ﬁrst approach
source for biomarker discovery [3,4].
Total protein content in synovial ﬂuid is associated with presence of
articular pathology and is one of the parameters most commonly used
https://doi.org/10.1016/j.jprot.2019.04.020
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1H NMR Metabolomics Identiﬁes Underlying Inﬂammatory
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Joints
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ABSTRACT: Despite osteoarthritis (OA) and rheumatoid arthritis (RA) being typically age-related, their underlying etiologies
are markedly diﬀerent. We used 1H nuclear magnetic resonance (NMR) spectroscopy to identify diﬀerences in metabolite
proﬁles in low volumes of OA and RA synovial ﬂuid (SF). SF was aspirated from knee joints of 10 OA and 14 RA patients.
100 μL SF was analyzed using a 700 MHz Avance IIIHD Bruker NMR spectrometer with a TCI cryoprobe. Spectra were
analyzed by Chenomx, Bruker TopSpin and AMIX software. Statistical analysis was undertaken using Metaboanalyst.
50 metabolites were annotated, including amino acids, saccharides, nucleotides and soluble lipids. Discriminant analysis
identiﬁed group separation between OA and RA cohorts, with 32 metabolites signiﬁcantly diﬀerent between OA and RA SF
(false discovery rate (FDR) < 0.05). Metabolites of glycolysis and the tricarboxylic acid cycle were lower in RA compared
to OA; these results concur with higher levels of inﬂammation, synovial proliferation and hypoxia found in RA compared to OA.
Elevated taurine in OA may indicate increased subchondral bone sclerosis. We demonstrate that quantiﬁable diﬀerences in
metabolite abundance can be measured in low volumes of SF by 1H NMR spectroscopy, which may be clinically useful to aid
diagnosis and improve understanding of disease pathogenesis.
KEYWORDS: synovial ﬂuid, metabolomics, osteoarthritis, rheumatoid arthritis, nuclear magnetic resonance
■ INTRODUCTION
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two
most common forms of arthritis, which lead to signiﬁcant
disability and substantial reduction in quality of life.1,2 Despite
both these chronic conditions being typically age-related with
insidious onset, their underlying etiologies are markedly dif-
ferent.3,4 OA is a degenerative joint condition, primarily
aﬀecting the hands, hips and knees, with one-third of people in
the UK aged over 45 (approximately 8.75 million) requiring
treatment.5 This disease is characterized by articular cartilage
loss, synovial membrane dysfunction, subchondral bone scle-
rosis and osteophyte formation with the depletion of matrix
proteins driven by proteases including multiple matrix metallo-
proteinases (MMPs) and a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTSs6−8). We have
identiﬁed OA synovial ﬂuid (SF) to be enriched in a number
of proteins including S100-A10, Collagen type I and CD109.9
RA is a systemic, inﬂammatory autoimmune disease that pri-
marily aﬀects the synovium of joints,10 presenting as a sym-
metric polyarthritis with an estimated prevalence of 0.5−1% of
the adult population within developed countries.11,12 RA joints
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ABSTRACT: Osteoarthritis (OA), osteochondrosis (OC), and
synovial sepsis in horses cause loss of function and pain. Reliable
biomarkers are required to achieve accurate and rapid diagnosis, with
synovial ﬂuid (SF) holding a unique source of biochemical infor-
mation. Nuclear magnetic resonance (NMR) spectroscopy allows
global metabolite analysis of a small volume of SF, with minimal sample
preprocessing using a noninvasive and nondestructive method. Equine
SF metabolic proﬁles from both nonseptic joints (OA and OC) and
septic joints were analyzed using 1D 1H NMR spectroscopy. Univariate
and multivariate statistical analyses were used to identify diﬀerential
metabolite abundance between groups. Metabolites were annotated
via 1H NMR using 1D NMR identiﬁcation software Chenomx, with
identities conﬁrmed using 1D 1H and 2D 1H 13C NMR. Multivariate
analysis identiﬁed separation between septic and nonseptic groups.
Acetate, alanine, citrate, creatine phosphate, creatinine, glucose, glutamate, glutamine, glycine, phenylalanine, pyruvate, and
valine were higher in the nonseptic group, while glycylproline was higher in sepsis. Multivariate separation was primarily driven
by glucose; however, partial-least-squares discriminant analysis plots with glucose excluded demonstrated the remaining metab-
olites were still able to discriminate the groups. This study demonstrates that a panel of synovial metabolites can distinguish
between septic and nonseptic equine SF, with glucose the principal discriminator.
KEYWORDS: metabolomics, equine, synovial ﬂuid, osteoarthritis, osteochondrosis, sepsis, nuclear magnetic resonance
■ INTRODUCTION
Conditions aﬀecting the articular joints are common in horses
resulting in loss of function, chronic pain, or subsequent inability
to work, all of which represent economic and welfare concerns.
These pathologies include osteoarthritis (OA), osteochondrosis
(OC), and synovial sepsis, which can be life-threatening.1
Despite these conditions having a high prevalence and clinical
relevance, diagnosis, staging, monitoring, and determination
of an accurate prognosis remain challenging for practising
veterinarians. Therefore, to diﬀerentiate equine articular joint
pathologies, there is a need to identify reliable biomarkers of
disease. Synovial ﬂuid (SF) is located within the articular joint
cavity, providing a pool of nutrients for surrounding tissues but
primarily serving as a biological lubricant, containing molecules
with low-friction and low-wear properties to articular surfaces.2
As SF is in close proximity to articular tissues primarily altered
during joint pathology, this bioﬂuid is an important source of
biomarker discovery.3,4
To date, no validated markers that are both sensitive and
speciﬁc to synovial sepsis have been identiﬁed within veterinary
medicine, making early diagnosis a challenge. Together with
clinical examination, diagnosis is based on SF culture and
intracellular bacteria identiﬁcation (both low sensitivity) as well
as total protein, total nucleated cell count, and percentage of
neutrophils whose results are open to interpretation and are
aﬀected by standard treatment protocols.5−8 Reduced levels of
glucose in human and equine SF, due to an increase in synovial
and neutrophil cell glycolytic activity in severe inﬂammation or
infection, have previously been identiﬁed, with a serum-synovial
glucose diﬀerence of >2.2 mmol/L considered supportive of a
diagnosis of synovial sepsis.9,10 However, this parameter is
nonspeciﬁc and can be inﬂuenced by multiple variables including
synovial necrosis, diet, pain and white blood cell count. Elevations
in lactate during the acute infection phase have previously been
identiﬁed in SF of septic human, canine, and equine joints due
to an increase in the consumption of glucose and subsequent
production of lactate within an anaerobic environment.11−13
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Abstract
Experiments involving mass spectrometry (MS)-based proteomics are widely
used for analyses of connective tissues. Common examples include the use of
relative quantification to identify differentially expressed peptides and proteins
in cartilage and tendon. We are working on characterising so-called
‘neopeptides’, i.e. peptides formed due to native cleavage of proteins, for
example under pathological conditions. Unlike peptides typically quantified in
MS workflows due to the  use of an enzyme such as trypsin, ain vitro 
neopeptide has at least one terminus that was not due to the use of trypsin in
the workflow. The identification of neopeptides within these datasets is
important in understanding disease pathology, and the development of
antibodies that could be utilised as diagnostic biomarkers for diseases, such as
osteoarthritis, and targets for novel treatments. Our previously described
neopeptide data analysis workflow was laborious and was not amenable to
robust statistical analysis, which reduced confidence in the neopeptides
identified. To overcome this, we developed ‘Neopeptide Analyser’, a user
friendly neopeptide analysis tool used in conjunction with label-free MS
quantification tool Progenesis QIP for proteomics. Neopeptide Analyser filters
data sourced from Progenesis QIP output to identify neopeptide sequences, as
well as give the residues that are adjacent to the peptide in its corresponding
protein sequence. It also produces normalised values for the neopeptide
quantification values and uses these to perform statistical tests, which are also
included in the output. Neopeptide Analyser is available as a Java application
for Mac, Windows and Linux. The analysis features and ease of use
encourages data exploration, which could aid the discovery of novel pathways
in extracellular matrix degradation, the identification of potential biomarkers and
as a tool to investigate matrix turnover. Neopeptide Analyser is available from 
.https://github.com/PGB-LIV/neo-pep-tool/releases/
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